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ABSTRACT
Spinal muscular atrophy (SMA) is a devastating, autosomal-recessive neurodegenerative disease.
It is characterized by the loss of alpha motor neurons (MNs) located in the ventral horn of the
spinal cord. Degeneration of lower MNs leads to proximal muscle weakness and can ultimately
result in respiratory failure. Accordingly, SMA is among the most common genetic causes
of infant death. Causative for SMA is a reduced survival motor neuron (SMN) protein level.
The reduction of ubiquitously expressed SMN results mainly from biallelic deletions or partially
from point mutations in the SMN1 gene. Solely an almost identical copy of SMN1 - SMN2 -
prevents embryonic lethality in SMA patients. A plethora of molecular defects, including RNA
processing, protein synthesis, metabolic defects, and mitochondrial function, contribute to
SMA pathology. Furthermore, reduced SMN levels delay maturation of acetylcholine receptor
subunits and morphological and functional abnormalities at the neuromuscular junction.
Neurons highly depend on energy production via oxidative phosphorylation (OXPHOS) by
mitochondria. Dysfunctional mitochondria in SMA produce fewer ATP molecules and generate
massive amounts of reactive oxygen species (ROS), resulting in oxidative stress. Oxidative
stress challenges the cells with DNA damage, protein carbonylation, and impaired protein
synthesis. Based on these findings, we hypothesized that defective mitochondria contribute to
impaired protein synthesis in SMA. Another central question is whether increasing ATP and
reducing oxidative stress ameliorates SMA pathology.
We performed a whole proteome analysis of cultured primary MNs, derived from SMA
and WT embryos. Using mass spectrometry (MS), we confirmed previously known molecular
mechanisms altered by SMN deficiency and contributing to SMA pathology. Particularly, a
tendency of altered proteins localized to mitochondria was determined. In detail, complex I
of the respiratory chain was identified as the major disturbed complex in SMA mitochondria.
Besides alterations in mitochondrial protein abundance, immunostainings showed a decreased
number and altered mitochondrial shape in the axon of SMA MNs. However, results from
the whole proteome analysis and immunochemical results reveal an increase of mitochondrial
proteins in whole-cell lysates, suggesting an accumulation of dysfunctional mitochondria in the
soma.
Biochemical assays revealed functional impairments such as reduced ATP, impaired respira-
tory complex I activity, and increased ROS production. Additionally, a reduced glucose uptake
suggested no compensation of energy deprivation by glycolysis. Previous studies implicated a
reduced protein synthesis in SMA. We confirmed those findings with this study and further
linked reduced protein synthesis to protein carbonylation resulting from increased oxidative
stress. Moreover, we provide evidence that protein synthesis is also reduced in the axonal
compartment of SMA MNs. Protein carbonylation and protein synthesis were quantified using
immunochemical approaches. These findings prompted us to evaluate the mechanism of
impaired protein synthesis. To decipher the contribution of translation initiation and elongation
during impaired protein synthesis, we performed the SUnSET and SunRiSE assay, respectively.
Based on our results, impaired protein synthesis in SMA results from impaired translation
initiation and not elongation. While the SunRiSE assay shows a similar elongation speed in
XI
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WT and SMA MNs, the phosphorylation status of the eIF4E-binding protein (4E-BP) reveals
an impaired translation initiation in SMA MNs.
To increase ATP and decrease ROS, the cell culture medium of MNs and MN-like NSC-34
cells was supplied with lactate, pyruvate, and N-acetylcysteine (NAC). E!ects of substrate
supplementation on the whole proteome of MNs were determined by MS. Supplementation of
pyruvate was able to increase ATP levels in SMA MNs, measured biochemically. Furthermore,
pyruvate and NAC supplementation reduced excessive ROS and improved impaired protein
synthesis, including local translation in SMA MNs.
While the antioxidant NAC can enhance global mRNA translation, pyruvate could only
increase a subset of proteins. However, both pyruvate and NAC increased SMN in SMA
MNs. Downstream targets of the mTOR pathway were measured immunochemically after NAC
and pyruvate supplementation. Up-regulation of protein synthesis upon NAC and pyruvate
supplementation is due to increased translation initiation mediated by the mTOR pathway. The
mTOR-mediated increase of SMN after pyruvate supplementation was confirmed by pharmaco-
logical inhibition of the mTOR pathway.
In summary, we found that excessive ROS generated by defective complex I inhibits the
initiation of mRNA translation in SMA MNs. Our findings suggest a new molecular networking
system among dysfunctional mitochondria, excessive ROS production, and impaired protein
synthesis via the mTOR pathway. This study opens up new treatment possibilities concerning
SMA pathology by improving mitochondria, reducing ROS, and influencing impaired protein
synthesis. As many neuropathies display molecular defects in mitochondria, including excessive
ROS production, additional research fields despite SMA will benefit from our study.
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ZUSAMMENFASSUNG
Die Spinale Muskelatrophie (SMA) ist eine verheerende, autosomal-rezessive neurodegenerative
Erkrankung. Sie ist gekennzeichnet durch den Verlust von Alpha-Motorneuronen (MN), die
sich im ventralen Horn des Rückenmarks befinden. Die Degeneration der unteren MN führt
zu einer proximalen Muskelschwäche und kann schließlich zu einem Atemstillstand führen.
Dementsprechend gehört die SMA zu den häufigsten genetischen Ursachen des Kindstodes.
Ursächlich für die SMA ist ein verminderter Survival Motor Neuron (SMN) Proteinspiegel. Die
Reduktion des ubiquitär vorkommenden SMN resultiert hauptsächlich aus biallelischen Deletio-
nen oder teilweise aus Punktmutationen im SMN1 -Gen. Lediglich eine fast identische Kopie
von SMN1 - SMN2 - verhindert die embryonale Letalität bei SMA-Patienten. Eine Fülle von
molekularen Defekten, einschließlich RNA-Verarbeitung, Proteinsynthese, Sto!wechseldefekten
und mitochondrialen Funktionen, tragen zur SMA-Pathologie bei. Darüber hinaus verzögern
reduzierte SMN-Spiegel die Reifung von Acetylcholinrezeptor-Untereinheiten und führen zu
morphologischen und funktionellen Anomalien an der neuromuskulären Endplatte.
Neuronen sind in hohem Maße von der Energieproduktion über oxidative Phosphorylierung
(OXPHOS) durch Mitochondrien abhängig. Dysfunktionale Mitochondrien in SMA produzieren
weniger ATP-Moleküle und erzeugen massive Mengen an reaktiven Sauersto!spezies (ROS),
was zu oxidativem Stress führt. Oxidativer Stress belastet die Zellen mit DNA-Schäden, Protein-
Carbonylierung und beeinträchtigter Proteinsynthese. Basierend auf diesen Erkenntnissen
stellten wir die Hypothese auf, dass defekte Mitochondrien zu einer gestörten Proteinsynthese
bei SMA beitragen. Eine weitere zentrale Frage ist, ob die Erhöhung von ATP und die Re-
duzierung von oxidativem Stress die SMA-Pathologie verbessert.
Wir führten eine Analyse des gesamten Proteoms von kultivierten primären MN, die von
SMA- und WT-Embryonen stamen, durch. Mittels Massenspektrometrie (MS) konnten wir
bereits bekannte molekulare Mechanismen bestätigen, die durch SMN-Mangel verändert wer-
den und zur SMA-Pathologie beitragen. Insbesondere zeichnete sich eine Tendenz ab von
veränderten Proteinen, die in Mitochondrien lokalisiert sind. Der Komplex I der Atmungskette
wurde als der am meisten gestörte Komplex in SMA-Mitochondrien identifiziert. Neben Verän-
derungen in der mitochondrialen Proteinhäufigkeit zeigten Immunfärbungen eine verminderte
Anzahl und veränderte Form der Mitochondrien im Axon von SMA-MN. Die Ergebnisse der
Gesamtproteomanalyse sowie immunochemische Versuche zeigen jedoch einen Anstieg der
mitochondrialen Proteine in Lysaten ganzer Zellen, was auf eine Anhäufung von dysfunktionalen
Mitochondrien im Soma hindeutet.
Biochemische Versuche zeigten funktionelle Beeinträchtigungen wie reduziertes ATP, beein-
trächtigte Aktivität des Atmungskomplexes I und erhöhte ROS-Produktion. Zusätzlich deutete
eine reduzierte Glukoseaufnahme auf eine fehlende Kompensation des Energiemangels durch
die Glykolyse hin. Frühere Studien deuteten auf eine reduzierte Proteinsynthese bei SMA
hin. Wir bestätigten diese Ergebnisse mit dieser Studie und brachten die reduzierte Protein-
synthese mit der Proteincarbonylierung in Verbindung, die durch erhöhten oxidativen Stress
entsteht. Außerdem konnten wir nachweisen, dass die Proteinsynthese auch im axonalen
Kompartiment von SMA-MN reduziert ist. Die Protein-Carbonylierung und die Proteinsynthese
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wurden mit immunochemischen Ansätzen quantifiziert. Diese Ergebnisse veranlassten uns, den
Mechanismus der gestörten Proteinsynthese zu untersuchen. Um den Beitrag der Translation-
sinitiation und -elongation während der gestörten Proteinsynthese zu entschlüsseln, führten wir
den SUnSET- bzw. SunRiSE-Assay durch. Basierend auf unseren Ergebnissen resultiert die
gestörte Proteinsynthese bei SMA aus einer gestörten Translationsinitiation und nicht aus der
Elongation. Während der SunRiSE-Assay eine ähnliche Elongationsgeschwindigkeit in WT- und
SMA-MN zeigt, o!enbart der Phosphorylierungsstatus des eIF4E-bindenden Proteins (4E-BP)
eine gestörte Translationsinitiation in SMA-MN.
Um ATP zu erhöhen und ROS zu verringern, wurde das Zellkulturmedium von MN und
MN-ähnlichen NSC-34-Zellen mit Laktat, Pyruvat und N-Acetylcystein (NAC) zugesetzt. Die
Auswirkungen der Substratsupplementierung auf das gesamte Proteom der MN wurden mittels
MS bestimmt. Die Supplementierung von Pyruvat war in der Lage, den ATP-Gehalt in SMA-
MN zu erhöhen, was biochemisch gemessen wurde. Außerdem reduzierte die Pyruvat- und
NAC-Supplementierung exzessive ROS und verbesserte die beeinträchtigte Proteinsynthese,
einschließlich der lokalen Translation in SMA-MN.
Während das Antioxidant NAC die globale mRNA-Translation verbessern kann, konnte
Pyruvat nur eine Untergruppe von Proteinen erhöhen. Allerdings erhöhten sowohl Pyruvat
als auch NAC SMN in SMA-MN. Nachgeschaltete Ziele des mTOR-Wegs wurden nach NAC-
und Pyruvat-Supplementierung immunochemisch gemessen. Die Hochregulierung der Protein-
synthese nach NAC- und Pyruvat-Supplementierung ist auf eine erhöhte Translationsinitiation
zurückzuführen, die durch den mTOR-Signalweg vermittelt wird. Der mTOR-vermittelte
Anstieg von SMN nach Pyruvat-Supplementierung wurde durch pharmakologische Hemmung
des mTOR-Weges bestätigt.
Zusammenfassend fanden wir, dass exzessive ROS, die durch einen defekten Komplex I
erzeugt werden, die Initiation der mRNA-Translation in SMA MN hemmen. Unsere Ergeb-
nisse deuten auf eine neue molekulare Verbindung zwischen dysfunktionalen Mitochondrien,
exzessiver ROS-Produktion und gestörter Proteinsynthese über den mTOR-Weg hin. Diese
Studie erö!net neue Behandlungsmöglichkeiten bezüglich der SMA-Pathologie, indem sie die
Mitochondrien verbessert, ROS reduziert und die gestörte Proteinsynthese beeinflusst. Da viele
Neuropathien molekulare Defekte in Mitochondrien aufweisen, einschließlich einer übermäßigen
ROS-Produktion, werden weitere Forschungsfelder zusätzlich zur SMA von unserer Studie
profitieren.
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1.1 Spinal muscular atrophy (SMA)
Spinal muscular atrophy (SMA) is an inherited neuromuscular disease characterized by selective
loss of lower alpha motor neurons (MNs), which leads to proximal muscle weakness and atrophy.
SMA is caused by reduced levels of ubiquitously expressed survival of motor neuron protein
(SMN) due to biallelic deletions or mutations in the SMN1 gene at chromosome 5 and primarily
non-functional SMN2 gene copies, which each patient carries in the genome (Melki et al.,
1990). Besides the classical SMA linked to inheritance at chromosome 5 (5q-SMA), other
forms of SMA with a similar spectrum of symptoms can be classified. The classification is
based on their mode of inheritance (autosomal recessive, dominant, or X-linked) and a!ected
muscle weaknesses (i.e., proximal or distal) (Lefebvre et al., 1995; Kugelberg & Welander,
1956; Farrar & Kiernan, 2015; Kennedy et al., 1968). However, the majority (! 90%) of SMA
cases are autosomal recessive linked to chromosome 5 with a rate of 2% de novo mutations
(Lefebvre et al., 1995; Alías et al., 2009; Zerres, 1997; Wirth et al., 1997). The incidence varies
between 1 in 6.000- 10.000 live births, with a worldwide carrier frequency of 1:51 (Pearn, 1978;
Feldkötter et al., 2002; Melki et al., 1994; Verhaart et al., 2017; Wirth et al., 2020). However,
the carrier frequency varies in di!erent ethnic groups, with the lowest occurrence of 1:145
in the sub-Saharan African population and a frequency of 1:41 in the European population
(Sangaré et al., 2014; Wirth et al., 2020). With an increasing number of countries performing
SMN newborn screenings, the incidence can be determined more precisely (Vidal-Folch et al.,
2017; Vill et al., 2019).
When SMN levels fall under a certain threshold, a plethora of cellular pathways are disturbed.
SMA is one of the most common genetic causes of infant mortality caused by respiratory failure
(Lewelt et al., 2012). Overall, SMA is presented with progressive degeneration and subsequent
loss of !-MNs in the ventral (anterior) horn of the spinal cord (Mercuri, Finkel, et al., 2018;
Finkel et al., 2018).
1.1.1 Pathology and classification
Even though SMA is a monogenic disease caused by the loss of SMN protein, it leads to a
heterogeneous manifestation of neuromuscular features. The pathological spectrum ranges
from severe generalized weakness with respiratory failure in the early period of life to mild
proximal limb weakness in adulthood. The characteristic symptoms are hypotonia, muscular
atrophy, and weakness of proximal muscles, predominantly a!ecting the lower extremities.
Besides the neuropathology in SMA, maturation of acetylcholine receptor subunits is delayed,
and morphological and functional abnormalities at the neuromuscular junction (NMJ) are
observed (Harding et al., 2015). The muscle atrophy a!ects type I and type II muscle fibers
with hypertrophy of the surviving type I fibers (Baloh et al., 2007; Soubrouillard et al., 1995).
In the early days of SMA research, the disease was classified based on the severity, age
of onset, and achieved motor milestones (Munsat & Davies, 1992). In the beginning, only
three types of SMA (Typ I-III) were distinguished (Robak & Marcinkiewicz, 1995). Later, the
classification was extended with an extremely severe type, called Type 0 (Dubowitz, 1999;
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Macleod et al., 1999). Type 0, leading to death within weeks, initiates during prenatal
development, and patients harbor only one copy of SMN2 (Dubowitz, 1999; Macleod et al.,
1999). Furthermore, the classification was extended by a very mild form (Type IV, OMIM #
271150), leading to proximal leg weakness in adulthood but with a normal lifespan (Zerres et
al., 1995). However, only less than 1% of SMA patients are classified as Type IV SMA (Wirth
et al., 2020).
Type I SMA (OMIM #253300), which is also called the Werdnig- Ho!man disease,
is diagnosed in about 35% of SMA cases (Calucho et al., 2018). However, although its
equal distribution at diagnosis compared to other SMA types, Type I has a relatively small
prevalence in the number of all SMA patients living in the population due to the short
survival of ! 7.4 months (range 3-56 months) (Pearn, 1980; Farrar et al., 2013; Lally et
al., 2017). However, due to current therapies, the prevalence of Type I patients among
all SMA patients will change. Diagnosis usually occurs in the first six months of birth
when symptoms start. Those symptoms involve poor control of head movement, muscle
weakness, coughing, and trouble breathing. This type of SMA is very characteristic for
the lack of resistance to passive movement (hypotonia), resulting in a "floppy infant"
appearance.
Type II SMA (OMIM #253550) patients gain the ability to sit unaided but never
achieve the ability to walk (Mercuri, Finkel, et al., 2018). First symptoms appear after 6
months of age, and the life expectancy is between 5 and 25 years. Natural history of
SMA Type II patients reveals a survival rate of 68.5% at 25 years (Zerres et al., 1997).
Similar to Type I SMA, patients with Type II show hypotonia, but they also develop
intercostal weakness, respiratory complications, and scoliosis (Zerres, 1995).
Type III SMA (OMIM #253400) is a mild form of SMA. The age of onset for Type
III SMA is after 18 months with the ability to walk, but in some cases, wheelchair support
is needed later in life (Zerres et al., 1997). Type III can be divided based on the age of
onset into the subclasses Type IIIa (>1.5 years) and Type IIIb (>3 years). Type III is
also called Kugelberg- Welander disease (Kugelberg & Welander, 1956).
However, the development of therapies and the increasing supportive measures, including
respiratory and physical therapy, change the course of the natural history of SMA. Due to the
increasing overlap between SMA types, this old classification is revised (Mercuri, Finkel, et al.,
2018; Finkel et al., 2018; Wirth et al., 2020). Furthermore, the population’s prevalence will
change due to increased survival, especially of type I patients. The new SMA classification is
less based on the age of onset but more on the motor milestones achieved. The recommended
classification divides SMA patients into non-sitters, sitters, and walkers (Mercuri, Finkel, et al.,
2018; Finkel et al., 2018).
1.1.2 SMA as a multisystem disorder
Besides the MN pathology, morphological and functional impairments are observed in other
tissues. Impairments in non-neuronal tissues are mainly observed in SMA mouse models and
severe SMA type I patients with extremely low levels of SMN (Hamilton & Gillingwater, 2013;
Yeo & Darras, 2021). However, the prevalence of non-motor symptoms is low in adult SMA
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patients (Günther et al., 2019). Mostly congenital heart disease is characterized as a feature of
severe SMA type I patients due to SMN deficiency (Rudnik-Schoneborn et al., 2008). Other
impairments are found in blood vessels, liver, bone, intestine, and pancreas (Hamilton &
Gillingwater, 2013; Yeo & Darras, 2021). Defects in other organs correlate with di!erential
cell-type-specific SMN amounts. In contrast, MNs show high susceptibility to low levels of SMN
(Sleigh et al., 2011). However, muscle requires less SMN, and SMN levels produced from two
copies of SMN2 are su"cient for normal muscle function in mice (Iyer et al., 2015). Also, severe
defects in the liver have been shown in SMA mouse models with murine Smn exon 7 deletion
(Vitte et al., 2004). Also, impairments of sensory-motor connectivity have been reported in
SMA mice and patients (Shorrock et al., 2019; Mentis et al., 2011; Rudnik-Schoneborn et al.,
2003). It remains unclear whether low SMN levels cause impairments of proprioceptive sensory
neurons (Mentis et al., 2011) or as a consequence of MN dysfunction (Gogliotti et al., 2012).
Results showing that loss of sensory neurons was prevented upon MN-specific restoration of
SMN supports the hypothesis that sensory-motor defects are a consequence and not a cause of
MN dysfunction (Gogliotti et al., 2012). Further research in a human stem cell model supports
the idea that sensory neurons do not induce MN loss (Schwab & Ebert, 2014). However,
sensory neuron loss was also observed to occur prior to MN loss, suggesting a primary cause of
motor dysfunction (Mentis et al., 2011).
This multisystemic nature of SMA suggests that restoring SMN levels in non-neuronal
tissues is crucial to compensate for internal organ defects other than MN failure. Especially
with newly developed therapies aiming to increase tissue-specific SMN levels in MNs, extremely
low levels of SMN in other tissues can lead to defects in those tissues also in older patients.
1.1.3 Genetics
Thirty years ago, the phenotypically classified SMA types I-II were mapped to the same
chromosomal region 5q11.2-q14 by linkage analysis (Melki et al., 1990; Brzustowicz et al.,
1990; Gilliam et al., 1990). After all, this 500 Kb region is duplicated and highly polymorphic,
resulting in two copies of the SMN gene. Up to four copies per chromosome have been identified
(Schmutz et al., 2004; Mérette et al., 1994; M. Y. Dennis et al., 2017). The disease-determining
gene was conclusively located to chromosome 5q13 and identified as SMN1 in 1995 (Lefebvre et
al., 1995). The centromeric SMN2 is a 99% homologous gene of the disease causing telomeric
SMN1 gene (Lefebvre et al., 1995). Unfortunately, only SMN1 encodes for the full length SMN
protein and SMN2 is resulting in most of the cases in a highly unstable form, that is rapidly
degraded by the proteasome (Figure 1) (Lorson et al., 1998; Chang et al., 2004; Burnett et
al., 2009).
Despite the high heterogeneity of SMA characteristics, homozygous SMN1 deletions or
mutations are found in all 5q SMA patients (Lefebvre et al., 1995; Wirth, 2000). In fact, 96%
of SMA patients show biallelic deletions in SMN1 or gene conversions of SMN1 into SMN2
and 4% have point mutations (Wirth, 2000).
Albeit it has been stated initially that the 29 kb gene SMN1 contains 8 exons (Lefebvre
et al., 1995), exon 2 is composed of two exons, 2a, and 2b, with a stop codon in exon 7,
leaving exon 8 untranslated (Bürglen et al., 1996). Furthermore, an additional exon generated
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by exonization of an intronic Alu-like sequence, called exon 6b was identified to appear in
SMN1 and SMN2 (Seo et al., 2016). Transcripts containing exon 6b appear to be more
stable than transcripts lacking exon 7 transcribed from SMN2 (Seo et al., 2016). However,
SMN1 and SMN2 show high similarity with only five base pair substitutions (Seo et al., 2016).
Nevertheless, three substitutions 27092 G>A (intron 6), 27289 A>G and 27404 A>G (both
intron 7), are intronic, and only the c.840C>T (exon 7) transition and 27869 G>A (exon 8)
are within exons (Figure 1) (Bürglen et al., 1996). However, since exon 8 is not translated,
only the c.840C>T (exon 7) transition is within the coding region (Seo et al., 2016; Burlet
et al., 1996). While SMN1 produces mainly the full-length SMN protein, SMN2 encodes for
alternatively spliced transcripts (Wirth, 2000). Alternatively spliced SMN2 transcripts lack
exon 7 (SMN!7) (Lorson et al., 1999). Nevertheless, the C-to-T transition at codon 280 in
exon 7 is a silent variant, which does not lead to an amino acid exchange (Lefebvre et al., 1995;
Bürglen et al., 1996). However, the c.840C>T transition a!ects correct splicing of exon 7 by
forming an exon splicing silencer (ESS) site from a previous exon splicing enhancer (ESE) site
(Lorson et al., 1999; Kashima & Manley, 2003; Cartegni & Krainer, 2002).
The major modifier of SMA severity is SMN2. Disease severity inversely correlates with
the copy number of SMN2 leading to milder phenotypes with more copies and more severe
phenotypes with fewer SMN2 copies (Feldkötter et al., 2002). Most SMA type I patients carry
only two copies of SMN2, most type II patients have three copies, whereas the majority of type
III patients carries three to four copies, and more than four copies are found in patients with
type IV (Feldkötter et al., 2002; Calucho et al., 2018; Wirth et al., 2006). Complete loss of
SMN protein results in embryonic lethality (Schrank et al., 1997). Due to gene conversion, up
to eight copies on SMN2 are found (Schmutz et al., 2004; Mérette et al., 1994; M. Y. Dennis
et al., 2017). Nevertheless, disease severity and progression can not be fully predicted by
SMN2 alone. Besides the copy number of SMN2, the severity can be influenced by missense
mutations in the SMN1 gene. The point mutations p.Tyr272Cys and p.Thr274Ile are the two
most frequent missense mutations (Lefebvre et al., 1995; Jȩdrzejowska et al., 2014; Wirth,
2000; Hahnen et al., 1997). A more severe phenotype is observed in patients with the point
mutation p.Tyr272Cys, and the mutation p.Thr274Ile was associated with a mild phenotype
(Jȩdrzejowska et al., 2014).
Furthermore, SMN-independent modifiers of SMA phenotype have been identified in
SMA patients (Wirth et al., 2013). Those modifier genes are di!erentially expressed in
asymptomatic SMN1 -deleted individuals. SMN-independent modifiers include F-actin binding
and bundling protein plastin 3 (PLS3), coronin 1C (CORO1C), neurocalcin delta (NCALD)
as well as calcineurin-like EF-hand protein 1 (CHP1) (Oprea et al., 2008; Hosseinibarkooie
et al., 2016; Riessland et al., 2017; Janzen et al., 2018). While overexpression of PLS3 and
CORO1C was found to ameliorate the SMA phenotype (Oprea et al., 2008; Hosseinibarkooie
et al., 2016), reduction of NCALD or CHIP1 was found to be beneficial to SMA pathology
(Riessland et al., 2017; Janzen et al., 2018). While the mechanism of PLS3 up-regulation and
NCALD down-regulation is still under investigation, the protective e!ect is attributed to an
increase of endocytosis, which is impaired in SMA (Riessland et al., 2017; Janzen et al., 2018;
Hosseinibarkooie et al., 2016).
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Figure 1: Illustration of SMN splicing and expression.
The telomeric SMN1 and the centromeric SMN2 are both located on chromosome 5. SMA patients rely
sole on SMN produced from SMN2 as they lack SMN protein from SMN1 due to mutations or deletions
in SMN1. SMN1 and SMN2 di!er only in 5 nucleotide substitutions. Substitutions in the introns
(lines) and exons (bars) are displayed. The only critical substitution is the C-to-T transition in exon 7 of
SMN2. This transition creates an exon splicing silencer, resulting in the exclusion of exon 7 in ! 90%
of the transcripts. Only ! 10% show exon 7 inclusion leading to full-length SMN protein expression.
Transcripts lacking exon 7 result in SMN!7 protein which is rapidly degraded by the proteasome.
Besides those forms of SMA caused by mutations/ deletions in SMN1, there are also other
types of SMA mediated by mutations in other genes. These include spinal muscular atrophy
respiratory distress (SMARD, OMIM #604320), a!ecting primarily distal limb muscles, leading
to severe respiratory distress caused by homozygous or compound heterozygous mutation in
the IGHMBP2 gene (Mellins et al., 1974). Furthermore, Kennedy’s disease is a rare form of
SMA. The X-linked genetic disorder appears between the third and fifth decade of life and
causes muscle weakness and wasting. Di!erent from the 5q-SMA, it primarily a!ects the face
and throat.
1.1.4 Molecular background (SMN protein)
SMN is a 294 amino acid, 38 kDa protein, which is ubiquitously abundant and performs multiple
essential cellular functions, especially in RNA processing. The abundance of SMN protein is
regulated during development, showing decreasing levels after the embryonic stage (Jablonka &
Sendtner, 2017). Mouse models of SMA reveal that SMN abundancy is high in early neonates
and significantly reduced in early postnatal days (Groen et al., 2018). Therefore, it is not
surprising that severe SMA mice are born with a typical number of MNs but lose 35-40% of the
spinal cord and lower brainstem MNs by day 5 (Monani et al., 2000). Consequently, conditional
depletion of SMN in adults shows little e!ect compared to depletion of SMN in neonatal mice
(Kariya et al., 2014). This e!ect was attributed to the temporal requirement for SMN at the
NMJ maturation (Kariya et al., 2014). Consistent with the decreasing levels of SMN after
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embryonic development, the small nuclear ribonucleoprotein (snRNP) assembly activity, being
mediated by SMN, declines in mouse spinal cord in the first postnatal weeks (Sleigh et al.,
2011).
Together with a highly conserved sequence of RNA and other proteins, SMN forms a
ribonucleoprotein (RNP) complex, forming so-called ’gemini of coiled bodies’ or ’gems’. This
SMN RNP complex consists of small- nuclear RNAs (snRNA) and 7 proteins, Gemin2-8 (Figure
2) (Q. Liu & Dreyfuss, 1996; Pellizzoni, 2007; Gubitz, 2004). Furthermore, snRNA levels
resemble the amount of snRNP as snRNAs that are not associated with Sm cores are unstable
(Sauterer et al., 1988).
The SMN complex is localized in the cytoplasm, nucleus, and nuclear gems (Gemini of
Cajal bodies), called Cajal bodies or coiled bodies (Figure 2) (Carvalho et al., 1999). In
neurons, SMN localizes to axons and dendrites (Pagliardini, 2000). Since the cytoplasmic
localization is exon 7 dependent, this might have a pathological e!ect in SMA (H. L. Zhang et
al., 2003). SMN!7, encoded by the SMN2 gene, is highly unstable and rapidly degraded by
the proteasome (Chang et al., 2004). Moreover, full-length SMN itself is also relatively unstable
without its binding partners (Lorson et al., 1998; Otter et al., 2007). Especially reactive oxygen
species (ROS) can inhibit the complex formation by inducing intramolecular disulfide bridging,
even at a subtoxic ROS level (Wan et al., 2008). SMN complex activity and formation are
mainly regulated by phosphorylation, and mostly higher phosphorylation of cytoplasmic SMN
indicates the regulation of snRNP biogenesis via phosphorylation status (Grimmler et al., 2005;
Renvoisé et al., 2012).
1.1.5 Function of SMN
Despite the predominant MN related symptoms of SMA, complete loss of SMN protein is
embryonic lethal, suggesting an essential function for fundamental cellular processes in all cells
(Schrank et al., 1997). It is known that the SMN complex mainly functions as an assemblysome,
regulating snRNP structure, biogenesis, and function (Q. Liu et al., 1997). The assembly of
snRNPs is the best-characterized function of SMN. While the assembly of snRNPs can occur
spontaneously in vitro, it is a highly conserved and tightly regulated process in cells (Pellizzoni,
2002). In the biogenesis of those snRNPs, SMN binds specifically to Sm proteins and snRNAs
and facilitates the assembly of the Sm proteins onto the Sm site of the RNA (Buhler et al.,
1999). The majority of snRNP biogenesis occurs in the cytoplasm after U small nuclear RNAs
are transcribed in the nucleus and exported to the cytoplasm. SMN is only necessary for the
assembly of snRNPs, as it has been shown that injection of snRNPs is su"cient to rescue
the pathologic phenotype in zebrafish (Winkler, 2005). Accordingly, the SMN complex acts
as a molecular chaperone, assembling the snRNP complex without being part of the final
structure (D. K. Li et al., 2014). Correct splicing of pre-messenger RNA (mRNA) is essential
for eukaryotic gene expression, and an incorrect assembly of the spliceosome leads to severe
defects such as seen in SMA. The spliceosome is composed of five uridine-rich snRNPs, namely
U1, U2, U5, and U4/U6 (Will & Lührmann, 2001).
Based on the role of SMN in spliceosome formation and the loss of SMN in SMA, missplicing
of MN-specific pre-mRNAs has been hypothesized. Those pre-mRNA sets might be crucial for
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MN development and survival. Indeed, Agrin is misspliced in MNs of SMA mice and functions
in organizing acetylcholine receptors at the NMJ (J.-K. Kim et al., 2017). Additionally, several
other splicing changes were found after SMN depletion, and those contribute to late pathology
in SMA mice (Custer et al., 2016; Bäumer et al., 2009).
Besides the assembly of snRNPs, which ensures correct pre-messenger RNA splicing, SMN
functions in the metabolism, transport, and assembly of other RNP classes, including telomerase
RNPs or microRNPs (Mourelatos, 2001, 2002; Buhler et al., 1999). Furthermore, after being
assembled into mRNA- binding proteins (mRBPs), SMN fulfills additional steps in mRNA
processing (Figure 2). Those additional functions include but are not limited to intracellular
tra"cking, nuclear export of mRNA, and translation. SMN interacts with mRBPs to assemble
mRNA transport granules directing to axons (Akten et al., 2011; Rossoll et al., 2003). Such
mRBPs include hnRNP, HuD (ELAVL4, ELAV like RNA binding protein 4), KSRP (KH-type
splicing regulatory protein), hnRNPs (heterogeneous nuclear ribonucleoproteins), and IMP1
(also known as IGF2BP1, Insulin like growth factor 2 mRNA binding protein 1) (Akten et al.,
2011; Tadesse et al., 2007; Fallini et al., 2011; Dombert et al., 2014; Fallini et al., 2014). Those
mRNP transport granules are formed by the association of mRBPs with the 3’ untranslated
region (3’ UTR) of the mRNAs (Andreassi & Riccio, 2009). In this context, axonal bidirectional
transport has been shown in axons of primary MNs, and forebrain (H. L. Zhang et al., 2003;
Fallini et al., 2011; Rossoll et al., 2003). After being transported to specific subcellular
compartments, mRNAs and mRPBs form micro-environments for local translation that can
create stimulus-driven responses (Wu et al., 2005; K.-M. Leung et al., 2006). In SMA, reduced
local translation of several mRNAs including "-actin, growth-associated protein 43 (GAP43)
and neuritin/cpg15 have been described upon defective tra"cking (Akten et al., 2011; Rossoll
et al., 2003; Hubers et al., 2011).
As SMN is highly abundant, especially during nervous system development in the axons
of MNs, the MN-specific phenotype in SMA might be related to the function as a molecular
chaperone for "-actin mRNA localization (Giavazzi et al., 2006). Furthermore, mislocalization
and a general reduction of axonal mRNAs have been shown in Smn KD mouse MNs (Fallini et
al., 2011, 2016).
Moreover, SMN can directly bind to ribosomes in a tissue-dependent manner. This
direct association of SMN with ribosomes regulates the translation of SMA-related transcripts,
including mRNAs associated with translation, neurogenesis, ubiquitination, and lipid metabolism.
Furthermore, reduced SMN levels induce ribosome depletion (Lauria et al., 2020).
Reduced and/or mislocalized SMN protein levels lead to several pathomechanisms a!ected in
SMA. Those include defects in endocytosis, RNA processing, protein synthesis and homeostasis,
metabolic dysfunction, defects in the actin cytoskeleton, and Ca2+ homeostasis have been
identified using those mouse models (Bernabò et al., 2017; Hosseinibarkooie et al., 2016; Custer
et al., 2016; Kye et al., 2014; Rossoll et al., 2003; Jablonka et al., 2007). Additionally, defects
in micro RNA (miRNA) metabolism have been associated with reduced SMN levels (Kye et al.,
2014). Especially miR-183 was found to be increased and associated with translation through
mTOR via direct binding to its 3’ UTR (Kye et al., 2014). Other miRNAs are also associated
with SMN deficiency due to altered DROSHA levels in SMA MNs (Kye et al., 2014; Gonçalves
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et al., 2018). Furthermore, the reduction of MN-specific miR-218 has been associated with
systemic neuromuscular failure due to NMJ impairments, hyperexcitability, and MN cell death
(Amin et al., 2015). Additionally, multiple miRNAs have been linked to neurodegenerative
diseases such as Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), or
Huntington’s (HD) (Kye et al., 2014; John et al., 2020). Moreover, mitochondria specific
miRNAs have been shown to play an essential role in aging and neurodegeneration (John et al.,
2020; Catanesi et al., 2020).
Unlike other neurodegenerative diseases, where accumulations of RNA-binding proteins
form pathological aggregates, SMA is characterized as an RNP hypo-assembly disease, deficient
in RNP formation (Shukla & Parker, 2016).
Figure 2: Functions of SMN in MNs.
SMN is localized to the nucleus, the soma, dendrites, and axon. Here, SMN forms the SMN complex
by binding to snRNAs and other proteins. SMN performs multiple functions in MNs. Besides its main
function in snRNP biogenesis and splicing, SMN is important for mRNP assembly, axonal transport of
mRNA, actin dynamics, and local translation. SMN binds to mRNAs and mRBPs. Anterograde, axonal
transport is accomplished by motor proteins such as kinesin. (Thelen & Kye, 2020).
1.1.6 Mouse models
When patient material is inaccessible, it is quite useful to work with an animal model to
study basic pathological mechanisms. In SMA, MNs, the primary a!ected cell type, are only
available for postmortem analyses. Alternatively, MNs can be di!erentiated from induced
pluripotent stem cells (iPSCs) or by direct conversion of fibroblasts (Son et al., 2011). This
limits the use of MNs to validate therapeutic approaches or to identify basic cellular mechanisms
causing SMA. For this reason, many animal models in various organisms have been generated.
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Those organisms include invertebrates such as Caenorhabditis elegans and Drosophila, but also
vertebrates such as zebrafish, mice, and pigs (Edens et al., 2015; Duque et al., 2015). However,
the duplication of the SMN1 gene is unique to the human genome, and therefore none of
the species develop SMA naturally. Over the last years, many di!erent techniques have been
developed to mimic genetic diseases in other organisms.
Here, we want to focus on SMA mouse models. As SMN is crucial for cell survival,
homozygous knockout of Smn is embryonically lethal due to massive cell death during early
blastocyst formation (Schrank et al., 1997). Some techniques used to mimic SMA are conditional
knockout, the introduction of mutations, or the introduction of the human SMN2 gene (Monani
et al., 2000; Hsieh-Li et al., 2000; Le et al., 2005). When human SMN2 or SMN lacking exon
7 (SMN!7) are introduced, the disease severity varies upon the copy number, similar to what
is observed in humans (Monani et al., 2000; Hsieh-Li et al., 2000). This fact has been used to
create various mouse models di!ering in their severity.
The first SMA mouse models, called the "Taiwanese" mouse model and "Line89", were
created in 2000 (Hsieh-Li et al., 2000; Monani et al., 2000). However, being genetically and
phenotypically similar, the Taiwanese mouse model was generated by introduction of the human
SMN2 transgene and knocking out of the murine Smn exon 7 (Hsieh-Li et al., 2000), for the
Line89 model an Smn exon 2 knockout was used (Monani et al., 2000). With an average
lifespan of 5.2 days the Line89 mice, harbouring two human SMN2 copies on a murine Smn null
background, resemble a severe SMA phenotype (Monani et al., 2000). Further addition of an
SMN!7 transgene extends the lifespan from 5.2 to 13.3 days and results in a milder phenotype
(Le et al., 2005). Besides adding human SMN!7 copies on an Smn null background with
two SMN2 copies, the introduction of an SMN1 A2G missense mutation (Smn-/-; SMN2 tg/-;
SMN1A2G, stock #005026) results in a mild type III SMA phenotype. Furthermore, the
introduction of eight SMN2 copies is enough to fully rescue the phenotype, resulting in an
expanded lifespan (Monani et al., 2000).
In this study, the Taiwanese mouse model was used. A phenotypically normal, heterozygous
Smn+/- animal was crossbreed with a homozygous mouse harbouring 4 copies of human
SMN2 on a murine Smn null background, Smn-/-; SMN2 tg/tg (Riessland et al., 2010). The
homozygous animal with 4 human SMN2 transcripts does not show a MN phenotype but
shows necrosis in the tail, toes, and ears. The resulting mouse model has no murine Smn, but
2 copies of human SMN2, Smn-/-; SMN2 tg/-. Finally, these mice show a severe phenotype that
closely resembles the human Type I SMA phenotype, including impaired motor function, loss of
spinal MNs, defects in the NMJ, and survival of 10-15 days (Ackermann et al., 2013; Riessland
et al., 2010). However, the mean survival varies between C57BL/6 background and FVB/N
background with a shorter lifespan of SMA mice on an FVB/N background (Ackermann et al.,
2013; Riessland et al., 2010; Hosseinibarkooie et al., 2016).
Conditional knockout can be used to evaluate tissue-specific disease mechanisms. Whereas
neuronal deletion of Smn exon 7 leads to MN loss and an average lifespan of 25 days (Frugier
et al., 2000), knockout in muscles lead to muscle necrosis, paralysis, and death (Cifuentes-Diaz
et al., 2001). The conditional knockout of Smn in muscle and the resulting phenotype allows
for studies of muscle-specific defects in SMA. Similar to the phenotype observed in humans,
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transgenic mice show loss of spinal MNs, defective NMJs, impaired muscle function, and
reduced survival.
In addition to the genetic variability in those mouse models, the phenotype can be modulated
by up-regulation of SMN levels using antisense oligonucleotides (ASOs). The use of ASOs results
in a milder phenotype that can be used to study the e!ects of reduced SMN in internal organs
later in disease progression. Many SMA pathomechanisms, including defects in endocytosis,
RNA processing, protein synthesis, protein homeostasis, metabolic defects, and defects in
the actin cytoskeleton, and Ca2+ homeostasis have been identified using those mouse models
(Bernabò et al., 2017; Hosseinibarkooie et al., 2016; Custer et al., 2016; Kye et al., 2014; Rossoll
et al., 2003; Jablonka et al., 2007). Severe mouse models of SMA revealed that impairments
of internal organs drive lethality.
1.1.7 Treatment
As a reduction of SMN causes SMA, several therapies have been developed to increase SMN
levels. Further, attempts aim to improve SMA pathology targeting SMN-independent pathways.
The di!erent approaches can be classified as SMN dependent or SMN independent therapies
based on their mode of action. Fortunately, the duplication of the genetic region of SMN1,
creating SMN2 gives a unique opportunity for treatments. As lack of SMN is embryonically
lethal (Schrank et al., 1997), patients with the most severe form of SMA have at least one
copy of SMN2 (Macleod et al., 1999). Therapies aiming to increase SMN levels can therefore
enhance correct splicing of SMN2 to form more of the full-length protein or repair the mutated
SMN1 gene directly (Farrar et al., 2017; Sumner & Crawford, 2018; Wirth, 2021). The first
approved drug is Nusinersen.
Currently, all approved drugs are based on SMN-enhancing approaches. However, multiple
therapies not focusing on SMN enhancement are in the pipeline of clinical trials.
Spinraza (Nusinersen), developed by Ionis Pharmaceuticals and Biogen, was approved in
2016 by the Food and drug administration (FDA) and in 2017 by the European medicines
agency (EMA) to treat all patients with SMA. Multiple intrathecal (IT) injections of Spinraza
maintaining doses are needed with 4 months intervals for a lifetime after loading doses are
completed (Neil & Bisaccia, 2019; Wirth, 2021).
The drug is designed to enhance correct splicing and inclusion of exon 7 from SMN2 by
ASOs. The small single-stranded, synthetic oligonucleotides bind to the SMN2 pre-mRNA
intron downstream of exon 7. By blocking an intron splicing silencer (ISS), it enhances the
inclusion of exon 7, leading to an increase of full-length SMN production (Hua et al., 2008).
The intronic target is identified to be the ISS-N1 gene sequence (Singh et al., 2006). Blocking
the ISS-N1 site with an ASO increases the stability of the U1 snRNP machinery that recognizes
exon 7 (Hua et al., 2008).
Even though the treatment of very severe SMA type 0 patients with Spinraza is reported,
it showed only minimal improvement on mobility, but it was insu"cient to mitigate the mul-
tisystemic involvement and overall severity (Tiberi et al., 2020; Kitaoka et al., 2020). Even
though treatment with Nusinersen prolonged survival and lead to motoric improvements in all
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types of SMA patients, e!ectiveness depends on several factors, including SMN2 copy number,
disease stage, and age (Finkel et al., 2017; Mercuri, Darras, et al., 2018; Wirth, 2021). Here,
the occurrence of non-responders highlights the need for SMN-independent strategies (Hensel
et al., 2020).
Zolgensma (Onasemnogene Abeparvovec), developed by Avexis and Novartis, was approved
by the FDA in 2019 to treat patients younger than 2 years with infantile-onset SMA. The
administration later in life is not possible due to the impenetrable blood-brain barrier for
self-complementary adeno-associated virus 9 (scAAV9). Approval by the EMA was given in
2020 for patients diagnosed with SMA Type I or SMA patients with less than 3 SMN2 copies.
According to the EMA’s approved dosing guidance, approval covers children with SMA up to
21 kg. The administration of Zolgensma is a one-time intravenous (IV) infusion.
The gene replacement therapy with Zolgensma uses a scAAV9 targeting MNs and expressing
SMN1 cDNA under a strong chicken "- actin promotor. It replaces the missing or mutated
SMN1 gene to produce full-length SMN resulting in improved muscle movement and function
and extended lifetime (Mendell et al., 2017).
Evrysdi (Risdiplam), developed by PTC Therapeutics and Roche, was approved by the
FDA in 2020 and Marketing Authorization Application (MAA) for orphan designation by the
EMA in 2020. It is a daily, orally administered small molecule for patients at two months of
age and older.
Like Spinraza, Evrysdi is designed to act as an SMN2 -directed RNA splicing modifier
(Naryshkin et al., 2014). However, as it is intended to be a small molecule, oral administration
is possible (Poirier et al., 2018). Furthermore, while Spinraza is designed to target the central
nervous system (CNS), Evrysdi distributes evenly through the whole body.
In addition, combinatorial therapies are possible. However, treating a Type 0 infant with
Spinraza and Zolgensma lead to the need for tracheostomy with only some motor improvement
with significant medical morbidity (Matesanz et al., 2020). Regardless of the therapy, additional
measures such as pulmonary, gastrointestinal, nutritional, and spinal management are required.
Therefore, specific standard of care considerations have been developed based on the motor
ability of the SMA patients: non-sitter, sitter, and walker (Mercuri, Finkel, et al., 2018; Finkel
et al., 2018). Untreated, most SMA patients develop scoliosis, an abnormally curved spine that
requires surgery (Granata et al., 1989).
In the end, the starting point of treatment is crucial and is dependent on the maturation
status of the NMJ (Kariya et al., 2014). Therefore, it is crucial to start therapy as soon as the
diagnosis is available or even better before symptoms arise. This requires newborn screening as
symptoms in the severe form of SMA can already occur quickly after birth. In fact, up to 90%
of MNs can be lost already six months after birth in severe SMA type I patients (Courtney et al.,
2019). Accordingly, neuronal death can not be reverted. Despite the number of life-prolonging
treatments available for SMA, there is still no cure.
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1.2 Energy homeostasis
Energy homeostasis is the crucial step in keeping the balance between energy consumption
and energy production, mainly in the form of adenosine triphosphate (ATP). Besides using
glucose to generate ATP, cells can also handle amino acids or fatty acids. However, glucose is
the obligatory energy substrate for the brain (Kety & Schmidt, 1948). Neurons are the most
energy-consuming cell type, and as a result, the brain is the most energy-consuming organ
(Vergara et al., 2019; Howarth et al., 2012). Even though the brain makes up only 2% of the
body weight, it consumes 20% of the total energy produced by the body (Mink et al., 1981;
Rolfe & Brown, 1997).
Neuronal energy consumption used for signaling can be divided in 47% to generate action
potentials, 34% for postsynaptic currents, 13% to sustain the resting potential and 3% for
glutamate recycling (Figure 3) (Attwell & Laughlin, 2001). First, ATP-driven Na+/K+-ATPases
along the axon claim energy to generate the action potential and restore the membrane potential
(Harris et al., 2012). Therefore, oxygen consumption, necessary for ATP production, is mainly
controlled by the axonal length, branching complexity, ion channel density, and the action
potential rate (Attwell & Laughlin, 2001). Second, axonal transport of mitochondria, ribosomes,
or RNPs require energy, and their dysfunction is a common pathological mechanism in peripheral
neuropathies (Figure 3) (Prior et al., 2017).
Due to the high energy demand during synaptic transmission, it is not surprising that the
white matter consumes less than 0.5% of the energy compared to the grey matter, as the
white matter contains 80- fold fewer synapses (Harris & Attwell, 2012). Furthermore, inhibitory
neurons require less energy than excitatory, as the reversal potential is closer to the resting
potential (Howarth et al., 2010).
In general, translation is a highly energy-demanding process that consumes up to 20% -
30% of total ATP in mammals (Buttgereit & Brand, 1995). Neurons use most of their so-called
housekeeping energy, which is not used for signaling, for lipid synthesis, and mitochondrial
proton leak (Rolfe & Brown, 1997). Protein synthesis is used for only 1.3% of total energy
consumption in the brain (Attwell & Laughlin, 2001; Rolfe & Brown, 1997). Protein synthesis
requires 4 ATP molecules per peptide bond (Waterlow, 1984). Energy is needed for the
activation of acyl-tRNA, initiation, and termination. The amount of ATP required for initiation
depends on the mRNA species (Jackson, 1991). It is assumed that cap-dependent processes
consume the highest amount of ATP during initiation (Jackson, 1991).
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Figure 3: Energy consumption and neurotransmitter release in neurons.
Neurons consume energy in various processes. Especially, active synaptic transmission is highly energy
demanding. Energy in the form of ATP is necessary for the transport of mitochondria and several mRBPs
by kinesin in the anterograde and dynein in the retrograde direction. Mitochondria are transported
anterogradely to provide ATP at distal ends of the neurons and retrogradely to return defective
mitochondria to the soma for degradation. During an action potential, Na+ accesses the axon via
voltage-gated Na+ channels, causing a depolarization. Further, K+ extrusion via voltage-gated K+
channels, results in a repolarization of the axon. Further, ATP is required by the Na+/K+-ATPase to
restore the membrane potential by exchanging Na+ and K+. As soon as the action potential reaches
the axonal tip, influx of Ca2+ promotes the release of neurotransmitter at the active zone. Here,
ATP is needed to fuel Ca2+-ATPases for Ca2+ export. In addition, vacuolar H+- ATPases energize
vesicle transmitter uptake for neurotransmitter release. Mitochondria are further needed to provide
acetyl coenzyme A (CoA), which is necessary for acetylcholine production by the enzyme choline
acetyltransferase (ChAT).
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1.2.1 Glycolysis
Glucose can be metabolized aerobically in the cytosol into pyruvate that is further used in
mitochondria. When oxygen is limited, glucose can be metabolized into pyruvate and further
reduced to lactate to regenerate NAD+ from NADH. However, full oxidation of glucose leads
to much higher ATP levels as glycolysis only generates 2 mol ATP per mol glucose.
Glucose transporters (GLUT) facilitate glucose import. Among the GLUT superfamily
of 14 isoforms expressed in humans, GLUT1 and GLUT3 are the predominant isoforms in
neurons (Vannucci et al., 1997). GLUT3 is found to be 6-10-fold higher expressed than GLUT1
(Maher & Simpson, 1994). GLUT4 is present at nerve terminals and recruited to the plasma
membrane upon neuronal stimulation (Ashrafi et al., 2017). GLUT4 seems essential for synaptic
transmission, as loss of GLUT4 leads to an arrest of synaptic vesicle endocytosis (Ashrafi et
al., 2017). GLUT3 provides a constant glucose source in physiological and pathophysiological
conditions (Gerhart et al., 1992).
Besides glucose, neurons can use lactate derived from glia. The controversial astrocyte-
neuron lactate shuttle model (ANLS) demonstrates the lactate production in astrocytes upon
glutamate transients and the subsequent shuttle of lactate from astrocytes into neurons
(Brooks, 2002; Mächler et al., 2016; Pellerin & Magistretti, 1994). Moreover, lactate has
been demonstrated to sustain neuronal activity upon glucose deprivation in vitro and in vivo
(Schurr, 2002; Wyss et al., 2011). More recent studies identified that glycolysis is increased
upon neuronal activation, but lactate uptake is unaltered (Díaz-García et al., 2017; Yellen,
2018). In vivo studies even further suggested that neurons rather export than import lactate
upon stimulation (Díaz-García et al., 2017).
Glycolysis is facilitated to produce energy and generate reducing equivalents for subsequent
oxidative phosphorylation (OXPHOS) in neurons. Especially, neuronal activation leads to a
transient increase of cytosolic NADH:NAD+ (Díaz-García et al., 2017). However, lactate import
is not required to generate the transient NADH as glycolysis up-regulation is su"cient to cover
the need for reducing equivalents (Díaz-García et al., 2017).
Even though OXPHOS bears the advantage of producing higher ATP yields, glycolysis can
be facilitated at a much higher rate (Pfei!er et al., 2001). The higher energy production rate can
be beneficial to adapt to recent events and external stimuli (Rangaraju et al., 2014). Therefore,
glycolytic enzymes can be redistributed or locally translated under energy stress to form clusters
termed "glycolytic metabolon" (Jang et al., 2016). The spatial compartmentalization is mainly
required to facilitate the synaptic vesicle cycle and localizes to nerve endings (Jang et al., 2016;
Rangaraju et al., 2014; Knull et al., 1980).
The metabolic compartment harboring glycolytic enzymes was also observed in vivo in
Caenorhabditis elegans (Jang et al., 2016). The glycolytic metabolon formation was suppressed
after phosphofructokinase 1 (PFK-1.1) depletion, a rate-limiting enzyme in glycolysis (Jang et
al., 2016). Impaired glycolysis has been associated with neurodegenerative diseases. Glucose
metabolism is impaired in neurons of an ALS mouse model carrying a mutation in the SOD1
gene (Tefera & Borges, 2019). However, up-regulation of glycolysis by overexpression of human
GLUT3 in Drosophila MNs has been shown to be beneficial (Manzo et al., 2019). Furthermore,
glycolytic impairments with a reduced glycolytic flux were observed in AD patients (An et al.,
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2018).
1.2.2 Mitochondria
Mitochondria are membrane-bound organelles composed of two membranes. The outer mem-
brane enclosing the whole organelle, and the inner membrane is forming the folded structure of
the cristae surrounding the matrix. Proteins of the electron transport chain are localized to the
cristae, the folded inner mitochondrial membrane. The electron transport chain consists of five
complexes, transferring electrons from electron donors to electron acceptors, performing a series
of oxidation-reduction reactions. Therefore, reducing agents generated by the glycolysis or the
tricarboxylic acid (TCA) cycle are oxidized, and protons are exported into the intermembrane
space. The NADH: ubiquinone oxidoreductase (complex I) of the electron transport chains
is the largest complex, the rate-limiting step in respiration, and the primary entry point for
electrons (L. Sharma et al., 2009; Hirst, 2011). The ATPase performs the actual generation of
energy at the end of the electron transport chain. Here, protons generate an electrical potential,
the mitochondrial membrane potential that drives the ATPase upon extrusion.
Mitochondrial proteins are encoded in the nucleus and within their own mitochondrial DNA
(mtDNA). Only 13 protein-coding genes are found in the mitochondrial genome, and most
protein-coding genes are encoded in the nucleus. The largest complex, namely complex I,
consists of 44 proteins, contains 7 proteins encoded in the mtDNA and 38 proteins encoded
in the nucleus (Chinnery & Hudson, 2013; Hirst, 2011). The tasks of mitochondria range
from ATP generation, Ca2+ bu!ering, ROS generation, cell signaling activities, to antioxidant
activity (Adam-Vizi & Starkov, 2010; McBride et al., 2006).
After glycolysis, respiration continues within the mitochondria in the TCA cycle and
OXPHOS. The TCA cycle uses acetyl-CoA derived from proteins, fats, or carbohydrates. The
TCA cycle produces energy in the form of 2 mol ATP per mol glucose and precursors for amino
acids and reducing equivalents for subsequent OXPHOS. The highest amount of energy is
generated by the OXPHOS; in the form of 34 mol ATP per mol glucose.
Mitochondria are not only localized in the soma but also the distal ends of neuronal cells.
The number of mitochondria varies as certain cells such as muscle or liver contain many
mitochondria, but red blood cells have none. The importance of local mitochondria at the
synapse becomes clear considering that ATP synthesized in the soma needs 2 min to di!use
along a 200 µm neurite (Harris et al., 2012). Mitochondria are transported by kinesin and dynein
motor proteins along the microtubule at ! 0.3-1 µm/s to overcome the slow di!usion rate
(MacAskill et al., 2010). The major kinesin motor protein transporting mitochondria away from
the soma is the Kinesin-related protein 5 (KIF5) (Tanaka et al., 1998). Nevertheless, KIF1B
has been identified as a microtubule plus end-directed motor protein transporting mitochondria
(Nangaku et al., 1994). Once mitochondria reach dendritic spines or the synapses, myosins
transport them along actin filaments (Ligon & Steward, 2000). Nevertheless, the majority of
mitochondria (! 80%) are stationary to provide energy. Mitochondrial stalling primarily occurs
at axonal branching points or presynaptic terminals or the axon tip (Sakata & Jones, 2003;
Spillane et al., 2013). Mitochondria cluster in spatially defined compartments to meet local
energy demands and localization to the clusters is regulated by neuronal activity (X. Wang &
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Schwarz, 2009).
Besides the transport of mitochondria along the axon, biogenesis of mitochondrial protein
can occur locally upon stimulation (Kuzniewska et al., 2020). Accordingly, local mitochondria
produce energy to fuel local translation for mitochondrial proteins to assemble the electron
transport chain to provide more energy (Kuzniewska et al., 2020).
1.2.3 Reactive oxygen species (ROS)
ROS are highly reactive molecules generated upon reduction of molecular oxygen. ROS can
emerge as unstable free radicals, carrying an unpaired electron or as more stable non-radical
in the cell (Kohen & Nyska, 2002; Phaniendra et al., 2015). Superoxide (O2•!) is the main
free radical produced in the mitochondrial matrix (Munro & Treberg, 2017; Jensen, 1966).
Besides (O2•!), hydroxyl radicals (•OH) can be found with an even shorter half-life than
O2•! (Phaniendra et al., 2015). However, the copper/zinc superoxide dismutase 1 (SOD1)
in the cytoplasm and the manganese superoxide dismutase 2 (SOD2) in the mitochondrial
intermembrane space convert O2•! rapidly into the non-radical, membrane-permeable hydrogen
peroxide (H2O2) (Chance et al., 1979; Loschen et al., 1974; Forman & Kennedy, 1974; Weisiger
& Fridovich, 1973).
Besides being the primary energy producer, mitochondria also generate the highest amounts
of reactive oxygen species (ROS) in the electron transport chain. The leakage of electrons
leads to a partial reduction of oxygen, resulting in the formation of O2•!. The generation of
free radicals increases exponentially with an increased membrane potential (Korshunov et al.,
1997; S.-s. Liu, 1999). Being the primary entry point for electrons, complex I is also the major
producer of ROS (Y. Liu et al., 2002). ROS levels are exceptionally high when the proton
motive force (mitochondrial membrane potential) and the NADH/NAD+ ratio are high in the
absence of ATP production (Murphy, 2009). ROS needs to be well balanced in a cell to execute
various functions. At non-toxic concentrations, ROS activates di!erent pathways, including
the MAPK, PI3K, Akt, p38 MAPK, mTOR, and Ca2+ signaling (J. Zhang et al., 2016). For
example, low ROS levels can stimulate mTOR activity, but in high doses, it decreases mTOR
activity via the oxidative stress pathway (M. Li et al., 2010).
When ROS levels exceed the antioxidative capacity of a cell, they can lead to oxidative
stress and damage proteins or DNA. Accordingly, ROS can lead to irreversible and unrepairable
carbonylations of proteins (Nyström, 2005; Stadtman, 1990). Furthermore, carbonylations
can lead to conformational changes, proteolysis, or the formation of high-molecular-weight
aggregates that accumulate within the cell (Nyström, 2005). When proteins involved in the
translational machinery are a!ected by carbonylation, global protein synthesis can be attenuated
(Topf et al., 2018).
1.2.4 Mitochondria in neurodegenerative disease
Based on the multiple functions of mitochondria, it is not surprising that defects lead to
pathological features. Accordingly, defective respiration and impairments in the biosynthesis of
amino acids, Ca2+ bu!ering, "-oxidation, and regulation of ROS results in neurodegeneration
(Davis & Williams, 2012). Additionally, mitochondria play a role in regulating apoptosis
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(C. Wang & Youle, 2009). Further, it has been suggested that mitochondrial defects are a
cause rather than a consequence of neurodegeneration (Johri & Beal, 2012).
Sustained imbalance of a cell’s redox state leads to oxidative stress that has been associated
with aging and various diseases, including neurodegenerative diseases (Ashok & Ali, 1999).
The imbalance is a result of increased ROS generation or an impaired antioxidative capacity.
Persistent oxidative stress can alter lipids, proteins, and DNA. Accordingly, an increase of
carbonylated proteins resulting from sustained oxidative stress has been associated with PD,
AD, and HD (Levine, 2002; Dalle-Donne et al., 2003; Schulz & Beal, 1994; Browne et al., 1997).
In PD, oxidative stress further results in DNA damage, leading to 8-hydroxy-2’-deoxyguanosine
formation (Alam et al., 2002). Furthermore, damage on nuclear and mitochondrial DNA upon
increased oxidative stress has been shown in AD (J. Wang et al., 2005; Mecocci et al., 1994).
Moreover, oxidative stress leads to damage of proteins, lipids, and DNA in the neuromuscular
diseases ALS, where SOD1 is mutated (Ferrante et al., 2002; Rosen et al., 1993). Here, the
loss of antioxidative capacity is detrimental to the cell and the formation of toxic aggregates
within the mitochondria, resulting in impaired respiration and mitochondrial function (Boillée
et al., 2006; Vijayvergiya, 2005; Ferri et al., 2006).
Over the last years, various impairments in energy homeostasis, including defective mi-
tochondria and increased oxidative stress, have been found in SMA (Acsadi et al., 2009;
Hayashi et al., 2002; C. C. Xu et al., 2016; Miller et al., 2016). Moreover, the hypothesis
that mitochondrial defects are instead a cause than a secondary e!ect is strengthened by
the fact that mitochondrial defects occurred before the onset of disease symptoms in SMA
(Miller et al., 2016). Transcriptome analyses showed a reduction in vacuolar H+-ATPase at a
pre-symptomatic stage in a Caenorhabditis elegans SMA model (X. Gao et al., 2019). Early
studies on SMA energy homeostasis revealed reduced ATP levels upon SMN reduction in
NSC-34 cells (Acsadi et al., 2009). Moreover, a decrease of SMN leads to increased oxidative
stress in those cells (Acsadi et al., 2009). Later, spinal MNs generated from SMA type 1
patient-specific iPSCs display a reduced mitochondrial number, area, transport, and membrane
potential (C. C. Xu et al., 2016). This circumstance was further shown to be MN-specific, as
the impairments observed in iPSCs were not observed in SMA forebrain neurons (C. C. Xu et
al., 2016). Moreover, the impairments in mobility, shape, and membrane potential could be
rescued upon the addition of N-acetylcysteine (NAC) (C. C. Xu et al., 2016). Additionally, a
transcriptome analysis of spinal MNs in an SMA mouse model revealed changes in mitochondrial
genes (Miller et al., 2016). Further functional analyses in this study confirmed the impairments
of reduced respiration, mitochondrial mobility, and increased oxidative stress seen in iPSCs
(Miller et al., 2016). Recent studies confirmed the ATP reduction in an in vivo SMA zebrafish
model (Boyd et al., 2017).
However, contradictory findings about the increase of oxidative stress in SMA iPSC- derived
astrocytes and MNs has emerged (Patitucci & Ebert, 2016). This finding implicated that
oxidative stress caused by SMN deficiency is cell-type specific.
Furthermore, impaired mitochondrial biogenesis and depletion of mtDNA have been found to
be impaired in quadriceps muscles of SMA type I-III patients (Ripolone et al., 2015). Moreover,
it has been shown that the bioenergetic status of MNs innervating di!erent muscles contributes
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to their vulnerability in mice (Boyd et al., 2017). On a molecular basis, oxidative stress can
impair SMN function by inactivating the SMN complex formation (Wan et al., 2008).
Additionally, miRNA biogenesis defects have been suggested to contribute to neurodegener-
ative and neuromuscular diseases, including AD, HD, ALS, and SMA (Gonçalves et al., 2018;
Kye & Gonçalves, 2014). Further, many miRNAs are associated with mitochondria (Duarte et
al., 2014).
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1.3 Translation
The translation is part of the gene expression and is performed by ribosomes in the cytoplasm
or on the endoplasmic reticulum (ER). Briefly, long chains of amino acids are formed by the
binding of amino groups and carboxyl groups of amino acids. In general, translation is a process,
which is performed through the decoding of mRNA by ribosomes, supported by other proteins,
called translation factors (Nürenberg-Goloub & Tampé, 2019; Nakamoto, 2011).
The traditional translation of ribosomes is divided into three phases: Initiation, elongation,
and termination. The starting point of the translation is the attachment of the mRNA to the
small 40S ribosomal subunit of the ribosome. With this, the mRNA is attached to the ribosome
and a transfer RNA (tRNA) conjugated with a methionine (Met) residue that can bind to the
peptidyl (P) site of the small ribosomal subunit, specifically at the start codon AUG. Binding of
the 40S subunit with GTP- bound eukaryotic initiation factor (eIF)2 and the Met-tRNA forms
a ternary complex required for translation initiation (Figure 4). Together with other proteins
including eIF1, eIF1A, eIF5, and eIF3 the 43S preinitiation complex (PIC) is formed (Figure 4).
Attachment of the 43S PIC to the 5’ 7-methylguanosine (m7G) cap of the mRNA is facilitated by
the heterotrimeric eIF4F complex (Figure 4). The eIF4F complex contains the DEAD-box RNA
helicase eIF4A, the cap-binding protein eIF4E, and the large "sca!old" protein eIF4G and forms
the 48S PIC together with the 43S PIC. Upon phosphorylation, eIF4B associates with eIF4A and
enhances its helicase activity (Andreou et al., 2017). Interaction of eIF4G with eIF4E increases
the a"nity of eIF4E to the 5’ cap structure (Gross et al., 2003). The cap-binding protein
eIF4E is phosphorylated via the protein kinases MAP kinase-interacting serine/threonine-protein
kinase 1 (MKNK1) and MKNK2, downstream of the activated extracellular signal-regulated
kinase (ERK) and p38. Circularization of the mRNA is enabled after binding of the poly(A)
binding protein (PABP) to the poly-A tail, and eIF4G (Kahvejian et al., 2005). Using ATP,
eIF4A unwinds the 5’ UTR, and the 48S PIC can scan the mRNA for the start codon, AUG.
After scanning was successful, several initiation factors are released, and the large 60S ribosomal
subunit attaches to the complex, forming the 80S ribosome (Jackson et al., 2010; Sonenberg
& Hinnebusch, 2009; Hinnebusch, 2014).
The eIF4F complex can regulate not only global protein synthesis but also favor specific
mRNAs. Some mRNAs with highly structured 5’ UTRs can be more dependent on eIF4F
interaction than others (Sonenberg & Hinnebusch, 2009). Here, the helicase eIF4A unwinds
secondary structures that would interfere with the recruitment of the 43S PIC. Proteins with
this eIF4E-sensitivity are important for cellular growth, angiogenesis, and survival, such as
cyclin D1, c-myc, vascular endothelial growth factor (De Benedetti & Gra!, 2004).
After the PIC is assembled on the mRNA, elongation occurs at the ribosome’s acceptor
(A) side. The correct sequence is mediated through the binding of tRNAs specific to the
next mRNA codons (Figure 4). Elongation is terminated when a peptidyl tRNA binds to a
stop codon on the mRNA. Non-AUG translation, called Internal Ribosome Entry Site (IRES)-
mediated translation can happen independently of the start codon (Lacerda et al., 2017). Even
though the mechanism of pathogenesis is unclear, it has been shown that Tau protein, which
contributes to AD pathology, is synthesized via IRES-mediated translation (Veo & Krushel,
2009).
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As protein synthesis is a high energy-consuming process, protein synthesis is tightly regulated
by the process of translational control (Buttgereit & Brand, 1995; Gebauer & Hentze, 2004).
This regulation can a!ect global translation or specific mRNAs. Translation of specific mRNAs
can be regulated by miRNAs in a sequence-specific manner (Sonenberg & Hinnebusch, 2009).
In neurons, protein synthesis and its regulation is particularly important as it supplies proteins
in the cell body and also distal parts of axons or dendrites (Holt et al., 2019). Therefore, it is
not surprising that mutations in genes involved in RNA metabolism can cause various diseases,
especially neurodegenerative, neurodevelopmental, and neuromuscular diseases (Thelen & Kye,
2020). Various dysregulations in translation, including tRNA synthesis, ribosome biogenesis,
sequestration of mRNA, or mislocalization of mRNA, can lead to multiple pathologies with a
heterogeneity of disease phenotypes (Nussbacher et al., 2019). Furthermore, proper control of
protein synthesis is crucial for learning, and memory formation and defects are associated with
multiple cognitive diseases (Bu"ngton et al., 2014; Richter & Coller, 2015).
Figure 4: Eukaryotic cap-dependent translation initiation and its regulation by mTOR.
Binding of eIF1, eIF1A and eIF3 to the 40S subunit promotes dissociation of the 40S subunit from
the 80S ribosome. Further, the 43S preinitiation complex (PIC) is formed after binding of the ternary
complex (eIF2-GTP-Met-tRNA) to the free 40S subunit and eIF5. Formation of the cap-binding
complex is promoted via mTOR by the release of 4E-BP from eIF4E. Afterwards, the eIF4F complex
(eIF4A-eIF4E-eIF4G) binds to the 5’ capped mRNA. Binding of the poly-A tail to PABP results in
circularization of the mRNA. The 48S PIC complex is formed upon binding of the 43S PIC to the 5’
capped mRNA. After successful scanning for the start codon on the mRNA, the large 60S ribosomal
subunit attaches, forming the 80S ribosome (adapted from (Kapur et al., 2017)).
1.3.1 Cap dependent translation
Initially, genes are transcribed as precursor mRNAs (pre-mRNAs) that undergo maturation.
Maturation of pre-mRNA is achieved by adding a 5’ cap to the 5’ end of the primary transcript,
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a poly-adenosine tail to the 3’ end, and splicing out introns. The term 5’ cap refers to a
specifically modified nucleotide at the 5’ end of pre-mRNAs. In contrast, mitochondrial mRNAs
do not possess the 5’ cap structure (Temperley et al., 2010). The 5’ cap structure facilitates
multiple functions. Besides regulating nuclear export (Visa et al., 1996; Lewis & Izaurflde,
1997) or protection against degradation by 5’ exonucleases (Burkard & Butler, 2000; M. Gao
et al., 2000), it regulates splicing (M. Gao et al., 2000) and also promotes translation (Shatkin,
1976; Banerjee, 1980; Sonenberg & Gingras, 1998). The 5’ cap contains a 7-methylguanosine
(m7G) connected by a triphosphate bridge to the first nucleotide of the mRNA (Banerjee, 1980).
This form of a 5’ cap is su"cient to increase resistance to exonuclease mediated degradation
and promotes recruiting translation initiation factors. Additional methylations at the first
nucleosides can occur and regulate gene expression in vivo (Elliott et al., 2019). Furthermore,
the methylation of the 2’ hydroxy-groups of the first two ribose sugars of the 5’ end controls
recognition of the mRNA by the innate immune system and promotes innate immune tolerance
(Schuberth-Wagner et al., 2015; D. W. Leung & Amarasinghe, 2016; Da"s et al., 2010).
In addition to mRNAs, non-coding RNAs, such as snRNAs and snoRNAs, contain 5’ cap
structures (Ro-Choi, 1999). However, di!erent from the m7G cap on most mRNAs, ncRNAs,
and several selenoprotein mRNAs contain 5’-trimethylguanosine (TMG) caps (Matera et al.,
2007; Wurth et al., 2014). Catalysis of the m7G cap into a TMG cap is facilitated in two serial
methylation steps by the trimethylguanosine synthase (TGS1) (Mouaikel et al., 2002; Girard
et al., 2008). The cytoplasmic modification of the TMG cap on snRNAs and the cytoplasmic
assembly of the Sm-core complex is required for nuclear re-entry of snRNAs (Hamm et al.,
1990). Interestingly, TGS1 directly interacts with SMN, providing an additional function to the
Sm-core complex assembly by SMN in recruiting TGS1 (Mouaikel et al., 2003; Maccallini et
al., 2020).
Most often, the regulation of global translation takes place at the initiation step. Therefore,
phosphorylation or availability of initiation factors a!ects the e"ciency of global translation.
Accordingly, the availability of the eIF4E is crucial for the initiation of cap-dependent translation.
The interaction of the cap-binding protein eIF4E and the ribosomal-subunit-associated eIF4G
plays an essential role at this step, as eIF4G links the small ribosomal subunit to the 5’ cap.
Several eIF4E inhibitory proteins modulate this interaction. However, phosphorylation of eIF4G
does increase cap-dependent translation and IRES-dependent translation (León et al., 2014).
The availability of eIF4E is regulated by the phosphorylation of 4E-binding proteins (4E-BPs).
Translation initiation is repressed by binding of 4E-BP1 to eIF4E (Haghighat et al., 1995).
mTOR can regulate the release of 4E-BP1 by phosphorylation (K. Hara et al., 1997). Protein
synthesis should be well regulated as it is vital for cell growth, development, and synaptic
plasticity (Bu"ngton et al., 2014; Costa-Mattioli et al., 2009; Shanbhogue et al., 1992).
In addition to translational control by 4E-BP, other proteins can regulate cap-dependent
translation initiation (Sonenberg & Hinnebusch, 2009). Those eIF4E inhibitory proteins modify
the interaction of eIF4E with eIF4G (Sonenberg & Hinnebusch, 2009). Moreover, those eIF4E
inhibitory proteins can interact with eIF4E on specific mRNAs via RBPs or interaction with
certain RNA elements (Richter & Sonenberg, 2005). In Xenopus, Maskin and the cytoplasmic
polyadenylation element-binding protein CPEB bind to RNAs that contain a CPE and in
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Drosophila Cup has been identified to interact together with Bruno on Bruno response element
(BRE) containing RNAs (Richter & Sonenberg, 2005). Mammalian eIF4E inhibitors include
the homeodomain transcription factor EMX2 and the proline-rich homeodomain protein PRH
(Nedelec et al., 2004; Topisirovic et al., 2003). However, regulation of cap-dependent translation
initiation in the nervous system heavily relies on the control of 4E-BP (Richter & Sonenberg,
2005).
1.3.2 Local translation
Especially in neurons, it is necessary to respond to extracellular stimuli distal from the cell body.
However, establishing a local proteome in dendritic spines, along axons, and at the growth cone
can be challenging due to the high polarization and extreme length of the axons. Local protein
synthesis in dendrites supports neurons during development, in synapse formation and function,
axonal branching, and growth and steering at the growth cones (J.-M. M. Cioni et al., 2018).
It is believed that activity-dependent synaptic plasticity occurs, especially during learning and
memory formation processes (Bu"ngton et al., 2014).
The ability to establish a specific axonal proteome is based on the tra"cking of proteins and
mRNAs or local protein synthesis. It has been suggested that mRNA localization is the major
contributor to maintain this local proteome (Zappulo et al., 2017). In fact, mRNA localization
contributes to half of the proteome localized to neurites (Zappulo et al., 2017). Localization
of mRNAs is facilitated by transport via RBPs to the axons and dendrites. After maturation,
nuclear-exported mRNAs bind to proteins that remain attached to the mRNA in the cytoplasm
(Moore, 2005; Cole & Scarcelli, 2006). Those mRNA bound RBPs, also called ribonucleotide
particles (RNPs), are further transported to their subcellular destination (Andreassi & Riccio,
2009). Furthermore, RNPs can be associated with motile late endosomes that act as a site for
translation (J.-M. Cioni et al., 2019).
While the 5’ UTR of mRNAs is predominantly involved in the regulation of translation
(Pickering & Willis, 2005), several steps of mRNA metabolism are regulated by the 3’ UTR
(Moore, 2005). Those functions of RNA metabolism include translation e"ciency and mRNA
stability and nuclear export and localization to the cytoplasm (Moore, 2005). Furthermore,
the localization sequence to neuronal projections is often located in the 3’-UTR of the mRNA
(Andreassi & Riccio, 2009). Explicitly, subcellular localization is determined by cis-acting
sequences, called "localizer" or "zip-codes" (Kislauskis & Singer, 1992). Interestingly, in some
cases, the localization sequence can appear in multiple copies or can be formed by di!erent
elements and therefore range from a few nucleotides to over 1 kb (Jambhekar & DeRisi, 2007).
Many factors are present at the synaptic site that enable or regulate local translation.
These factors include mRNAs, tRNAs, ribosomes, translation initiation, elongation factors,
RNA-induced silencing complex (RISC), and miRNAs. Alterations in the supply of those
molecules can lead to disturbed cellular function and neurodegenerative diseases (Kapur et al.,
2017; S. Sharma & Lu, 2018; Fernandopulle et al., 2021).
Additionally, local translation in neurons can be mediated by the formation of RNA granules.
Those macromolecular structures repress translation of mRNA until the final destination is
reached (Kiebler & Bassell, 2006). Upon depolarization, RNA granules can be disassembled
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and shift to polysomes in an activity-dependent manner (Krichevsky & Kosik, 2001). Prion-
like domains mediate the assembly and the disassembly of such mRNP granules with low
amino acid complexity (LC domain) on RNA-binding proteins (Malinovska et al., 2013).
Mutations in the domains that mediate assembly and disassembly of mRNP granules can lead
to neurodegenerative diseases, such as ALS through the biophysical properties of stress granule
formation (H. J. Kim et al., 2013).
In general, axonal local translation appears to happen predominantly during development
(Fallini et al., 2016; Jung & Holt, 2011). With the spatial and temporal abundance of SMN,
an important neuron-specific role in axonogenesis and axonal sprouting has been suggested
(Giavazzi et al., 2006). Components of the mTOR cascade have been found at the synapse,
and given its role as an essential regulator of mRNA translation, it influences synaptic plasticity
locally (Huber et al., 2015).
1.3.3 mTOR
Precise regulation of cell growth is essential during all phases of a eukaryotic cell. One important
regulator is the serine/ threonine kinase, the mammalian target of rapamycin (mTOR). mTOR
responds to nutrients and growth factors balancing anabolic and catabolic pathways (Figure
5) (Laplante & Sabatini, 2012). The mTOR pathway is activated by the phosphoinositide
3-kinase (PI3K) and ERK pathways (Costa-Mattioli et al., 2009). mTOR was first discovered
after isolation of rapamycin, a cytostatic compound produced by Streptomyces hygroscopicus.
It was identified to target the TOR kinases in yeast (Brown et al., 1994; Ca!erkey et al., 1993;
Kunz et al., 1993). In mammals, mTOR can form two signaling complexes based on its binding
partners: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Figure 5). Since
mTORC1 binds to the regulatory-associated protein of TOR (Raptor), mTORC2 binds to the
rapamycin-insensitive companion of TOR (Rictor). As the name of the mTORC2 binding
partner Rictor already suggests, mTORC2 is less sensitive to rapamycin. Nevertheless, chronic
treatment of rapamycin has been shown to impair also mTORC2 (Sarbassov et al., 2006).
Furthermore, mTOR binds in both complexes to the GTPase "-subunit like protein (G"L or
mLST8) (Jacinto et al., 2004; D.-H. Kim et al., 2003), the DEP domain-containing mTOR-
interacting protein (DEPTOR) (Peterson et al., 2009), and the Tti1/Tel2 complex (Kaizuka
et al., 2010). Even though mTORC2 has been shown to interact with ribosomes, translation
regulation is mainly mediated by mTORC1 (Oh et al., 2010; Zinzalla et al., 2011). Furthermore,
in contrast to mTOR1, mTORC2 is insensitive to nutrient signaling but is regulated by growth
factors (Laplante & Sabatini, 2012). In addition to regulating apoptosis or the cell cycle,
mTORC2 regulates cytoskeletal organization via the protein kinase C alpha (PKC!) Figure 5)
(Angliker & Rüegg, 2013; X. Li & Gao, 2014).
mTOR complex 1 (mTORC1) is a positive regulator of cell growth and proliferation and
acts as an integral node between cellular energy production and consumption. It promotes
anabolic processes such as protein synthesis, lipogenesis and restricts catabolic processes such as
autophagy (T. Hara & Mizushima, 2009; Noda & Ohsumi, 1998; Scott et al., 2004). mTORC1
can be activated through the PI3K pathway and several other stimuli, including nutrients,
energy levels, oxygen, amino acids, and stress signals. One of the anabolic processes promoted
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by mTORC1 is the transcription of mitochondrial biogenesis and metabolism by controlling
the transcriptional activity of PPAR!-coactivator-1 (PGC1!) (Figure 5) (Cunningham et al.,
2007). Furthermore, mTORC1 leads to an up-regulation of transcription factor hypoxia-inducible
factor 1 (HIF1!), resulting in increased glucose uptake and glycolysis (Yecies & Manning,
2011; Dodd et al., 2015). Another anabolic process controlled by mTOR is the translation of
mRNA into proteins. mTOR positively regulates translation initiation by phosphorylation of
the initiation factors eIF4B and eIF4G. Furthermore, it promotes the release of eIF4A from
the programmed cell death 4 (PDCD4) protein after phosphorylation of PDCD4 (Dorrello et
al., 2006; M. D. Dennis et al., 2012). Additionally, cap-dependent translation initiation is
promoted by mTORC1. The rate-limiting step in translation initiation is the association of the
cap-binding protein, eukaryotic translation initiation factor 4E (eIF4E) into the eIF4F complex,
that recruits the small ribosomal unit to mRNAs (Yanagiya et al., 2012; K. Hara et al., 1997)
(Figure 4). mTORC1 phosphorylates 4E-BP and promotes the dissociation of 4E-BP from
eIF4E to increase cap-dependent translation (Gingras et al., 1999). Furthermore, translation
initiation is promoted by phosphorylation of S6 kinase (S6K), phosphorylating eIF4B. Besides
translational initiation, mTOR promotes ribosomal biogenesis through phosphorylation of the
ribosomal protein S6, downstream of the S6K, and further control of the ribosome biogenesis
transcriptional program (Kapahi et al., 2010; Laplante & Sabatini, 2012; Chauvin et al., 2014).
Besides mediating global translation, mTOR has been shown to increase the translation
of 5’ terminal oligopyrimidine (5’ TOP) mRNAs, which encode proteins mainly involved in
translation (Thoreen, 2017). It is assumed that around 100 mRNAs display this motif (Meyuhas
& Kahan, 2015). However, based on bioinformatic analyses, it is speculated that up to 10%
of the transcriptome shows this motif (Yamashita et al., 2008). Nevertheless, all ribosomal
proteins, elongation factors, and PABPs are shown to bear the 5’ TOP motif (Yamashita et al.,
2008). The expression of TOP mRNAs can be repressed by di!erent stresses such as ribosomal
stress, mechanical stress, deprivation of oxygen, and amino acids (Meyuhas & Kahan, 2015).
Previous research has indicated that phosphorylation of 4E-BP1, 4E-BP2, and the ribosomal
protein S6 is abolished by mTOR inhibition (Morita et al., 2013). It is also known that mTOR
regulates the translation of a subset of mitochondria-related mRNAs (Morita et al., 2013).
It has been demonstrated that mTOR controls mitochondrial function and ATP production
through 4EBP inhibition in vivo (Morita et al., 2013).
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Figure 5: The mTOR signaling pathways.
mTOR forms the two distinct complexes, mTORC1 and mTORC2, based on its binding partners.
Growth factors activate both complexes. Additionally, mTORC1 is activated by amino acids, the
energy status of the cell, or oxygen. Rapamycin primarily inhibits the activity of mTORC1. mTORC2
promotes cytoskeletal organization, cell survival, and metabolism. Active mTORC1 inhibits autophagy
and promotes lipogenesis and the pentose phosphate pathway. In addition, mTORC1 regulates energy
metabolism via the transcriptional activity of PGC1! and HIF1!. Protein synthesis is regulated at the
translation initiation step.
1.3.4 mRNA translation in neurodegenerative disease
The impaired or altered mRNA translation is a typical phenotype in neurodegenerative disorders.
Such neurodegenerative diseases include ALS/FTD, Fragile X syndrome (FXS), AD, and SMA
(Thelen & Kye, 2020). mRNA translation can be dysregulated by sequestration of mRNAs
or initiation factors, failed localization of mRNAs, an altered tRNA synthesis, altered miRNA
processing, or defects in ribosome biogenesis (Lehmkuhl & Zarnescu, 2018).
In ALS/FTD, defects in the mRNA translation are linked to impaired RNA processing
due to mutations in the TAR DNA-binding protein 43 (TARDBP) gene, encoding TDP-43.
Physiologically TDP-43 is predominantly nuclear and functions in various mechanisms of RNA
regulation, including RNA stability, mRNA transport, splicing, and miRNA processing (Ratti &
Buratti, 2016). However, mutations in TARDBP can result in cytoplasmic aggregations linked
to ALS/ FTD neuropathology (Lee et al., 2011). Furthermore, FXS and autism spectrum
disorder (ASD) are examples of defective protein synthesis in dendrites based on defective RBPs
(Belmonte et al., 2004).
In SMA, a reduction of global translation has been associated with reduced mTOR activity
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(Kye et al., 2014). This can be attributed to the interaction of SMN with many proteins along
the axon, including ribosomes (Lauria et al., 2020). Further, reduced SMN levels are associated
with reduced local translation as SMN is involved in tra"cking of mRNAs along the axon
(Béchade et al., 1999; Pagliardini, 2000). In fact, SMN can localize to the nucleus and the
cytoplasm. However, for cytoplasmic localization and bidirectional transport along the axon,
exon 7 is required (H. L. Zhang et al., 2003). Consequently, correct localization of mRNA,
which is essential for local translation as seen by the localization defects of "-actin mRNA
in SMA, is caused by SMN (Giavazzi et al., 2006). Besides, the zipcode binding protein 1
(ZBP1) binds the 3’UTR of "-actin and prevents translation initiation unless "-actin mRNA is
not localized to its destination (Hüttelmaier et al., 2005). Previous studies have shown that
reduced SMN levels impair mRNA localization and result in a reduced local translation (Fallini
et al., 2016).
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2 AIMS AND OBJECTIVES OF THE STUDY
Loss of SMN1 results in insu"cient SMN levels, causing degeneration of alpha MNs and muscle
wasting. Multiple studies aimed to increase SMN production in MNs. Recently developed
therapies focused on MNs lead to significant improvement in clinical phenotypes of SMA patients.
However, there is still no ideal cure, and especially multisystemic e!ects in SMA patients
are barely investigated. Especially, the increased life expectancy might reveal unexpected
pathological defects in other tissues than MNs.
Previous studies implicated energy deprivation and contribution of oxidative stress to SMA
pathology (Acsadi et al., 2009; Miller et al., 2016; C. C. Xu et al., 2016). However, the role of
both impairments in SMA pathology remains mostly unknown. Furthermore, while reduced
protein synthesis is documented in SMA, the possible molecular connections among energy
homeostasis, oxidative stress, and protein synthesis are not well understood.
Based on previous findings, we hypothesize that energy deprivation is a major driver of SMA
pathology. As energy homeostasis is crucial for cell survival and growth, it might contribute to
impaired protein synthesis in SMA. Therefore, it can be beneficial to restore impaired energy
homeostasis in SMA MNs. Furthermore, systemically improving energy homeostasis might have
global e!ects also on other tissues.
This study aimed to clarify several aspects of energy homeostasis and protein synthesis,
contributing to SMA pathology. In detail, this study aimed to address the following topics:
(1) Identify the major contributors of impaired energy homeostasis in SMA MNs by
whole proteome analysis.
(a) Restore energy homeostasis via improving glycolysis and mitochondrial function
by supplementation of energy substrates.
(b) Reduce oxidative stress in SMA MNs with anti-oxidative supplements.
(2) Identify the mechanism of impaired translation in SMA MNs.
(a) Rescue defective protein synthesis by supplementation of substrates. Protein
synthesis e"ciency can be improved by an enhanced energy production due to pyruvate
or lactate supplementation or oxidative stress reduction by anti-oxidative agents such as
N-acetylcysteine (NAC).
The following experimental objectives are set to resolve those aims.
(1) This research examines the emerging role of energy homeostasis in the context of
SMA pathology. Comparing primary WT and SMA MNs by whole proteome analysis
will highlight key pathways contributing to SMA pathology. Focusing the proteomics
approach on energy-producing pathways will guide further research to molecular defects
involved in energy homeostasis. Possible defects involve respiration by mitochondria or
glycolysis. Whole proteome analysis will reveal alterations in mitochondrial respiratory
complexes. Biochemical quantification of the ATP levels and glucose uptake ability will
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verify and further characterize energy homeostasis in SMA.
(a) Since previous studies suggested defects in energy homeostasis in SMA, improving
ATP production is supposed to mitigate SMA pathology. The external supply of lactate
or pyruvate will be used as energy substrates.
(b) As the implications of oxidative stress in SMA are not fully resolved, this study
aims to elaborate the influence of oxidative stress on SMA pathology. Therefore, biochem-
ical detection of ROS might verify oxidative stress in primary SMA MNs. Additionally,
reducing ROS by the antioxidant NAC or pyruvate supplementation might reduce oxida-
tive stress in SMA MNs.
(2) Oxidative stress can alter protein synthesis. This mechanism needs further in-
vestigation. Protein carbonylation will be quantified to understand the molecular link
between oxidative stress and impaired protein synthesis. Additionally, SUnSET and Sun-
RiSE assays will be used to distinguish the e!ect of translation initiation and elongation,
respectively.
(a) Impaired protein synthesis can be ameliorated by ROS reduction and improv-
ing energy homeostasis. Therefore, pyruvate and NAC supplementation can counteract
oxidative stress, and pyruvate or lactate supplementation can be used to increase ATP
levels in MNs.
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3 RESULTS
3.1 Quantitative screening of primary MN proteins
Previous studies have shown that translation in SMA is impaired, and therefore a di!erential
expression of proteins might contribute to SMA pathology in MNs (Sanchez et al., 2013;
Kye et al., 2014). Recent evidence suggests that SMN binds to ribosomes and regulates a
subset of proteins translationally (Lauria et al., 2020). As the clinical manifestation of SMA is
first observed in MNs, investigating the proteome of primary MNs might reveal dysfunctional
pathways, leading to the progression of SMA. Changes in the proteome of primary MNs isolated
from an SMA mouse model (Hsieh-Li et al., 2000) and wild-type (WT) mice were compared
using quantitative mass spectrometry analysis in a 2 h data-independent acquisition. Four
independent biological samples of WT MNs were used to compare the proteome with three
independent biological samples of SMA MNs. Raw data of the whole proteome analysis has
been deposited at the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019)
partner repository with the dataset identifier PXD020403. The mass spectrometry dataset
results, supporting the conclusions of this thesis, are included within the research article (Thelen
et al., 2020) as "Additional file 2: Mass Spectrometry source data". Furthermore, significantly
changed proteins are listed within the results section and the Appendix of this thesis.
3.1.1 Mitochondrial proteins are dysregulated in SMA MNs
Whole proteome analysis was performed on primary MNs isolated from E13.5 WT and SMA
mice after 10 days in vitro (DIV). Based on the literature, around 8101 proteins are expressed in
MNs from E12.5 mouse embryos (Hornburg et al., 2014). In total, 5165 proteins were identified
in our whole proteome analysis in WT and SMA primary MNs (Figure 6A). The data shows that
the majority of significantly changed proteins are down-regulated in SMA MNs compared to WT
ones (Figure 6B and Table S1). The dataset was annotated with the MitoCarta2.0 database,
which includes 1158 proteins with strong support for mitochondrial localization, to compare
the proteins detected in this whole proteome analysis with mitochondrial proteins. Compared
to the MitoCarta2.0 database (Calvo et al., 2016), 681 (~13 %) proteins are associated with
mitochondrial function and localization (Figure 6A and Figure 8).
29
3 RESULTS Maximilian Paul Thelen
A



































-6 -5 -4 -3 -2 -1 0 1 2 43 5 6
Kif1bp
Figure 6: Quantitative proteomics of WT and SMA MNs.
A) Pie chart of proteins identified by whole proteome analysis between WT and SMA MNs (10DIV).
Mitochondria associated proteins (681) are highlighted in purple. B) Volcano plot of whole proteome
analysis comparing WT and SMA MNs; plotted p-values (-log10) against fold changes (log2, SMA/
WT). Four independent samples of WT MNs and three independent samples of SMA MNs were used
for analysis. P- values were determined using unpaired two-sided t-test. Proteins with p < 0.05 are
highlighted in blue (313 down-regulated) and red (120 up-regulated), and proteins with localization
in mitochondria are marked in purple (32 down-regulated and 29 up-regulated). Annotations show
corresponding gene names.
Among 5165 identified proteins, 494 proteins were significantly changed in SMA compared
to WT, and 61 (~12 %) are localized to mitochondria based on the MitoCarta2.0 database
(Calvo et al., 2016) (Figure 7 and Table S1). Significantly changed mitochondrial proteins
divide into equal parts of up-and down-regulated proteins. In contrast, the majority of all
significantly changed proteins was lower expressed in SMA MNs compared to WT MNs. Overall
345 (~70 %) proteins were down-regulated and 149 proteins (~30 %) were increased in their











494 proteins signicantly changed  in SMA MNs
Figure 7: Significantly changed proteins in SMA MNs.
Pie chart of whole proteome analysis comparing WT and SMA MNs. Four independent samples of WT
MNs and three independent samples of SMA MNs were used for analysis. Proteins with p < 0.05 are
highlighted in blue (313 down-regulated) and red (120 up-regulated), and proteins with localization to
mitochondria are marked in purple (32 down-regulated and 29 up-regulated).
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A focused view on the mitochondrial proteins found in our whole proteome analysis identified
35 proteins of the respiratory complex I. Thereby, we detected about 92% of nuclear-encoded
proteins of this complex (Figure 8). In total, one quarter (9 proteins) of the detected complex
I proteins were significantly changed in SMA MNs (see Box Figure 8). In addition to complex
I proteins, mitochondrial motor proteins KIF1B and KIF1BP are down-regulated in SMA MNs
(Figure 6B, Figure 8, and Table S1). In summary, these results strengthen the hypothesis







































Figure 8: Quantitative proteomics of mitochondrial proteins of SMA and WT MNs.
Volcano plot of proteins identified in whole proteome analysis that overlap with the MitoCarta 2.0
database; plotted p-values (-log10) against fold changes (log2, SMA/ WT). Four independent samples of
WT MNs and three independent samples of SMA MNs were used for analysis. P-values were determined
using unpaired two-sided t-test. Proteins with p < 0.05 are highlighted in blue (32 down-regulated) or
red (29 up-regulated). Annotations show corresponding gene names.
3.1.2 Pathway analysis in WT vs SMA
To understand the biological meaning of dysregulated proteins in SMA MNs, we analyzed gene
ontology (GO) terms using the online database DAVID 6.7. 345 significantly down-regulated and
149 significantly up-regulated proteins were analyzed separately (Figure 9). Enriched GO terms
were clustered in biological process, cellular compartment, and molecular function. Among the
down-regulated proteins in SMA MNs, we identified previously documented pathways in SMA
pathology such as RNA binding, protein transport, ribonucleoprotein complexes, and protein
synthesis, confirming the reliability of the data set (Figure 9A) (Akten et al., 2011; Fallini et
al., 2011; Kye et al., 2014; Pellizzoni, 2002; Rossoll et al., 2003). Especially ribosomes and
their function in translation were a!ected in all three categories. Among the 149 up-regulated
proteins, especially mitochondrial dysfunction and ATP production was annotated (Figure 9B).
Also, the cellular compartment annotation of up-regulated proteins showed strong support for
mitochondrial dysfunction in SMA MNs.
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Figure 9: Pathway analysis of SMA MNs.
Gene ontology (GO) analysis of 345 down-regulated (A) and 149 up-regulated proteins (B) in SMA
MNs. Enriched annotations are divided into biological process, cellular compartment and molecular
function. The 5 most significant terms in each category are shown.
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3.2 Characterization of mitochondria in MNs
A variety of defective cellular pathways are described in SMA. Malfunctional mitochondria
and impaired OXPHOS have been associated with a wide range of neurological disorders and
are shown to play an important role in neurodegenerative diseases such as PD, AD, HD, and
ALS (Hauser & Hastings, 2013; Fukui & Moraes, 2008; Carmo et al., 2018). Also, in SMA,
metabolic defects and defective mitochondrial biogenesis have been shown (Bowerman et al.,
2014; Ripolone et al., 2015). Furthermore, functional mitochondrial defects are associated with
SMA pathology (Acsadi et al., 2009; Miller et al., 2016; C. C. Xu et al., 2016). A reduced
oxygen consumption rate and increased oxidative stress, and a dysregulated mitochondrial
membrane potential were found (Miller et al., 2016; C. C. Xu et al., 2016).
Due to our findings, a significant number of mitochondrial proteins are dysregulated in
SMA MNs (Figure 8). Therefore, the impact of those dysregulated proteins on mitochondrial
function and the associated pathological outcome in SMA needs to be investigated.
Furthermore, dysfunctional mitochondria can be characterized by a fragmented shape.
Consequently, the shape of mitochondria might indicate mitochondrial defects in SMA MNs.
Due to the compartmentalization of MNs and the high energy demand in the cell body and the
distal parts of the axons, mitochondria need to be available throughout the whole cell. Therefore,
we focused not only on the cell body but also investigated the availability of mitochondria
along the axons.
3.2.1 Axonal mitochondria are reduced
To investigate the localization and function of mitochondria in motor axons, labeling of
mitochondria using the fluorescent dye MitoTracker and specific antibody staining against
TOM20 was performed (Figure 10A). Two di!erent methods were applied to distinguish
between the total number of mitochondria and the number of functional mitochondria. By
labeling the mitochondrial protein TOM20, the entirety of neuronal mitochondria is tagged,
and by use of the membrane intercalating dye MitoTracker, only mitochondria with a functional
membrane potential are stained. At least 100 µm of the axon from 10DIV MNs was measured,
and mitochondrial signals were quantified automatically using a modified version of the ImageJ
Mitophagy Macro (Dagda et al., 2008). In brief, axons were followed by the segmented line tool
based on the channel representing the Tau-antibody staining. Subsequently, the outside of the
selection was cleared to remove signals from other cells. Individual mitochondria were labeled
with a threshold on the channel representing either the MitoTracker staining or immunostaining
with TOM20 specific antibodies. Mitochondrial number and shape were quantified automatically
by ImageJ based on the given threshold. Both numbers of total and functional mitochondria
are reduced in SMA axons (Figure 10B). On average, the number of mitochondria labeled
with TOM20 antibody (~8.7 mitochondria/ 100 µm neurite) was decreased by half (reduction
by ~51 %) in SMA axons compared to WT ones (~17.8 mitochondria/ 100 µm neurite) (Figure
10B). The number of functional mitochondria based on MitoTracker staining was even more
reduced (reduction by ~64 %) in SMA axons (~4.7 mitochondria/ 100 µm neurite) compared
to WT ones (~12.9 mitochondria/ 100 µm neurite). Interestingly, not only SMA axons showed
reduced numbers of mitochondria compared to WT ones but also the number of functional
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mitochondria within each group was lower than the number of total mitochondria labeled
with TOM20 antibody staining (Figure 10B). The finding of mitochondrial mislocalization is
further strengthened by down-regulated mitochondrial motor proteins KIF1B and KIF1BP in
SMA MNs in our whole proteome analysis (Figure 6B, Figure 8, and Table S1). However,












































Figure 10: Immunofluorescence of mitochondria.
A) Representative images of mitochondria in 100 µm long primary axons of WT and SMA MNs (10DIV)
labelled with anti-Tau antibody (green), DAPI (blue) and anti-TOM20 antibody or MitoTracker® (white).
Scale bars: 20 µm. B) Quantification of mitochondria in neurites. Each dot represents the average
number of mitochondria in each neuron (n=30; biological replicates N=3). Two-way ANOVA with
Tukey HSD post hoc analysis was used on independent biological replicates to determine statistical
significance. Bar graphs depict the mean ± SD. ***p <0.001.
In addition to the mitochondrial number, the appearance was investigated. For this analysis,
the ImageJ Mitophagy Macro, which was used to quantify mitochondria, was used. As a
result, mitochondria are smaller and more fragmented in SMA MNs compared to WT ones
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(Figure 11). Mitochondria were labeled by antibody staining or MitoTracker. No di!erences
between the two groups were observed when comparing the two staining methods. However,
mitochondria of SMA MNs showed a reduction in their average size (~0.67 µm2) compared
with ones (~1.03 µm2) in WT MNs using TOM20 staining. Furthermore, also MitoTracker
staining revealed a reduction of mitochondrial size in SMA MNs (~0.72 µm2) compared with
mitochondria of WT MNs (~0.97 µm2) (Figure 11B). Interestingly, there were also di!erences
in the ratio of mitochondrial circularity. Based on TOM20 staining, WT MNs have more
elongated mitochondria in their axons, and SMA MNs display more round mitochondria than
WT ones. The analysis shows that the average circularity of all mitochondria in WT axons
(~0.65 a.u.) is significantly higher compared to mitochondria in SMA MNs (~0.75 a.u.). In
addition, functional mitochondria are also fragmented in SMA MNs (~ 0.7 a.u.) compared to
















































Figure 11: Immunofluorescence of mitochondrial appearance.
A) Representative images of mitochondrial size and circularity of WT and SMA MNs (10DIV) labelled
with anti-TOM20 antibody or MitoTracker®. Enlarged areas are highlighted with yellow boxes in the
corresponding image of the whole neuron. Scale bar in enlarged images: 10 µm; Scale bar in whole
neuron images: 20 µm. B) Quantification of mitochondrial size and circularity of WT and SMA MNs
(10DIV). Each dot represents the quantification of individual neurons (n=30). To compare WT (blue
circles) and SMA (red squares), two-way ANOVA with Tukey HSD post hoc analysis was used on
independent biological replicates (N=3) to determine statistical significance. Bar graphs depict the
mean ± SD. *p <0.05, **p <0.01.
3.2.2 Total amount of mitochondria is increased
Most surprisingly, even though the number of axonal mitochondria is reduced, elevated TOM20
protein levels were observed in the quantitative proteomics (Figure 8), as well as after western
blot analysis of 10DIV primary MNs (Figure 12). These results suggest an accumulation of
mitochondria in the soma.
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Figure 12: TOM20 protein levels are increased in SMA MNs.
Western blot analysis and quantification of TOM20 protein in 10DIV MNs. Each dot represents data
from biological replicates (N=4). Two-tailed unpaired t-test was used to determine statistical significance.
Bar graph depict the mean ± SD. *p <0.05. Blue circles represent WT MNs and red squares represent
SMA MNs.
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3.3 Defective complex I causes higher ROS levels and hypercarbonylation of
proteins in SMA MNs
Based on our whole proteome analysis, a great amount of mitochondrial proteins is dysregulated
in SMA. Moreover, fewer mitochondria with a di!erent shape were observed in axons of SMA
MNs compared to WT axons. However, recent evidence suggests that also the functionality of
mitochondria is impaired in SMA MNs. This includes the energy metabolism, Ca2+ bu!ering,
and reactive oxygen species (ROS) regulation (Acsadi et al., 2009; Boyd et al., 2017; Miller
et al., 2016; McGivern et al., 2013). In particular, complex I, the rate-limiting enzyme in
respiration and the primary producer of ROS (L. Sharma et al., 2009; Y. Liu et al., 2002) seems
to be a!ected in SMA due to our data. Consequently, mitochondrial energy production might
be impaired, and ROS production might be increased in SMA MNs. Increased ROS levels could
lead to excessive protein carbonylation resulting in impaired protein synthesis (Stadtman, 1990;
Topf et al., 2018).
3.3.1 Complex I activity is reduced
Among the 61 proteins dysregulated in SMA and located to mitochondria, 11 proteins are
localized to the OXPHOS machinery (Figure 13, Table 1). Complex I of the OXPHOS is a
large multi-subunit protein complex comprised of 45 subunits. The vast majority of (38) proteins
are encoded in the nucleus, whether only 7 proteins are encoded by mtDNA. Interestingly, 35
of the 38 nuclear-encoded proteins of complex I were detected in our whole proteome analysis,
and 9 of them were significantly altered in SMA MNs (Figure 13).
Table 1: Di!erentially expressed proteins in the OXPHOS of SMA MNs.
List of significantly changed proteins in the respiratory chain complexes of SMA compared to WT MNs
(p < 0.05). For all proteins, gene names, protein description, p-value and fold change (FC) are listed.
Proteins associated with complex I of the respiratory chain are marked with bold letters. Proteins above
the red line are down-regulated and below the red line are up-regulated.
Gene
name
Protein description p-value Fold change
SMA/ WT
Cox7c Cytochrome c oxidase subunit 7C, mitochondrial 0.006 0.39
Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 8, mitochondrial
0.038 0.75
Ndufv2 NADH dehydrogenase [ubiquinone] flavoprotein 2,
mitochondrial
0.028 0.78
Ppa2 Inorganic pyrophosphatase 2, mitochondrial 0.008 0.83
Ndufa5 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 5
0.002 0.86
Ndufb5 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 5, mitochondrial
0.032 0.88
Ndufa6 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 6
0.008 1.55
Ndufc2 NADH dehydrogenase [ubiquinone] 1 subunit C2 0.001 1.52
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Protein description p-value Fold change
SMA/ WT
Ndufab1 Acyl carrier protein. mitochondrial 0.017 1.47
Ndufb4 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 4
0.002 1.40
Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 10, mitochondrial
0.019 1,16
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Figure 13: Representation of oxidative phosphorylation KEGG Pathway (mmu00190).
Green boxes highlight organism-specific complexes (Mus musculus). Stars mark significantly up- regulated
(red) and down-regulated (blue) proteins in SMA MNs (10DIV). Copyright permission obtained from
KEGG (Kanehisa, 2000).
39
3 RESULTS Maximilian Paul Thelen
Based on our MS results indicating defects in complex I of the electron transport chain, we
measured the activity of complex I in WT and SMA MNs biochemically. In brief, mitochondria
were isolated from 10DIV MNs and subsequently lysed. After isolation of individual respiratory
complexes, complex I was bound to a 96-well plate with specific antibodies attached to the
plate. After unbound proteins were removed, the oxidation of NADH to NAD+ is visualized by
simultaneous reduction of a dye, resulting in an increased absorbance at OD = 450 nm.
Di!erent amounts of mitochondrial extracts from WT MNs were tested to evaluate the
sensitivity of the assay (Figure 14). The assay showed high sensitivity in a range between




























Figure 14: Optimization of complex I assay in primary WT MNs.
Optimization of Complex I activity for 1 h using di!erent amounts of mitochondria extract isolated from
WT MNs (10DIV).
As the complex I assay showed high sensitivity with 15 µg of isolated mitochondria, but we
hypothesized a lower enzyme activity in SMA, 20 µg extract was used when comparing WT
and SMA MNs. Indeed, complex I activity is significantly reduced in SMA MNs compared to
WT MNs by comparing the two slopes (Figure 15A). By comparing the ratio of mean OD450
per h, complex I activity is reduced by half in SMA MNs (Figure 15B).
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Figure 15: Complex I activity is reduced in SMA MNs.
A) Complex I activity using 20 µg mitochondria extract isolated from WT and SMA MNs (10DIV).
Quantification represents the increase of OD450 nm during 1 h. B) Complex I activity rate using 20 µg
mitochondria extract isolated from WT and SMA MNs (10DIV) (N=4). Quantification represents the
increase of mean OD450 nm/ h. Bar graph depict the mean ± SD. Two-tailed unpaired t-test was used
on independent biological replicates to determine statistical significance **p <0.01.
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Furthermore, we measured the complex I activity in two other tissues. One was the
metabolically active heart tissue, and the other one was the spinal cord (Figure 16). Neither


























Figure 16: Complex I activity is not changed in heart or spinal cord.
Complex I activity using 300 µg protein extracts of heart and spinal cord from P7 WT and SMA mice
(N=4). Quantification represents the increase of mean OD450 nm/ h ± SD. To compare WT (blue
circles) and SMA (red squares), two-way ANOVA with Tukey HSD post hoc analysis was used on
independent biological replicates (N=4) to determine statistical significance. ns p >0.05.
3.3.2 ROS levels are increased in SMA MNs
As our MS results indicated defects in complex I and activity measurements confirmed the
dysfunction biochemically, we measured intracellular ROS levels using CellROX® (Figure 17A
and Figure 17B). In brief, CellROXTM Green is a cell-permeant nonfluorescent probe, which
exhibits fluorescence upon oxidation by the sample. The oxidized probe remains localized within
the cell due to binding to DNA.
As mitochondria are accumulated in the soma, di!erences in ROS between WT and SMA
MNs can be measured most precisely in the soma. Indeed, our data showed that ROS levels
were higher in SMA compared to WT (Figure 17A and Figure 17B). Two independent
detection methods confirmed this finding. First, fluorescence signals of individual neurons
were observed and quantified by imaging. This technique showed an ~25% increase of ROS
in SMA somata compared to WT ones (Figure 17A). In addition to individual quantification
of cell bodies, ROS levels in whole cells were quantified. Measurements using a microplate
reader, resulted in an ~40% increase of ROS in SMA MNs compared to WT ones (Figure
17B). In healthy condition, ROS can be eliminated by oxidative stress defense proteins such as
superoxide dismutase (SOD1), which clears ROS from the mitochondrial intermembrane space
(Klöppel et al., 2010). Interestingly, SOD1 protein levels are down-regulated in SMA MNs due
to our proteomics analysis, indicating defective oxidative stress defense mechanism in SMA
(Figure 8).
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Figure 17: ROS levels are increased in SMA MNs.
A) Representative images of WT and SMA MNs labelled with CellROX® (green and rainbow color) for
reactive oxygen species (ROS) detection, DAPI (blue) and Phalloidin (red). Rainbow color indicates the
intensity of CellROX® signal. Scale bar of enlarged CellROX® images: 10 µm; Scale bar of neuron: 20
µm. Quantification of mean fluorescence intensity of the CellROX® signal in WT and SMA MN (red
squares) (n=40, N=4). B) Quantification of CellROX® signal of WT and SMA MNs measured with
microplate reader (N=5). Bar graphs depict the mean ± SD. Two-tailed unpaired t-test was used on
independent biological replicates to determine statistical significance *p <0.05, **p <0.01.
3.3.3 Proteins are hypercarbonylated in SMA MNs
One direct e!ect of oxidative stress on proteins is carbonylation (Suzuki et al., 2010). Thus,
carbonylation is a well-used indicator for oxidative stress. The oxidation of proteins occurs
when excessive ROS form reactive ketones or aldehydes at the amino acid side chains. We
made use of the hydrazone formation by reaction of the ketone or aldehyde side chains with
2,4-dinitrophenylhydrazine (DNPH). Subsequently, DNP moieties were detected using an anti-
DNP antibody and quantified the signals by western blotting. As higher levels of ROS were
detected in SMA MNs, we measured levels of carbonylated proteins in SMA MNs (Figure 18).
Indeed, nearly double the amount (~89%) of protein carbonylation was detected in SMA MNs
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compared to WT ones (Figure 18). This data confirmed our finding that SMA MNs are under










































Figure 18: Proteins are hypercarbonylated in SMA MNs.
Western blot analysis and quantification of carbonylated proteins (DNP = 2,4-dinitrophenyl) in 10DIV
WT and SMA MNs (N=4). Quantification of DNP signal was normalized to ACTB. Bar graphs depict
the mean ± SD. Two-tailed unpaired t-test was used on independent biological replicates to determine
statistical significance *p <0.05.
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3.4 Energy homeostasis in MNs
During development, neurons switch their way of producing energy from aerobic glycolysis
towards oxidative phosphorylation (Zheng et al., 2016). In this study, primary MNs were used
after 10DIV as it is assumed that, after 7 to 14 days in culture, embryonic and postnatal
neurons show similar properties in their energy homeostasis and response to oxidative stress
(Surin et al., 2013).
3.4.1 Glucose uptake is reduced in SMA MNs
Mature neurons are considered to produce their energy mainly through OXPHOS (Zheng et al.,
2016), but neurons can produce energy from glycolysis to compensate for their high energy
demand (Díaz-García et al., 2017). Especially, neurons are shown to up-regulate glycolysis at
nerve terminals upon high energy demand in firing neurons (Ashrafi et al., 2017). Therefore,
glucose uptake was monitored. In brief, 10DIV MNs were lysed, and intracellular glucose is
detected by a coupled enzyme reaction of glucose oxidation, leading to NADH production with
a bioluminescent NADH detection system. Interestingly, glucose uptake is impaired in SMA




















Figure 19: Glucose uptake is reduced in primary SMA MNs.
Each dot represents data from biological replicates (N=7). Two-tailed unpaired t-test was used to
determine statistical significance. Graphs depict the mean ± SD. **p <0.01. Blue circles represent WT
MNs and red squares represent SMA MNs. 10DIV MNs were used.
3.4.2 ATP levels are lower in SMA MNs
As both energy-producing pathways, glycolysis, and OXPHOS are impaired in SMA MNs, we
next measured the intracellular ATP concentrations. Intracellular ATP concentrations can be
measured in di!erent ways. Here, we used a fluorimetric but also a luminescence approach. The
fluorimetric detection is achieved by phosphorylation of glycerol, consuming the intracellular
ATP, subsequently resulting in a proportional fluorimetric signal (# ex = 535/#em = 587 nm).
The luminescence approach uses a recombinant firefly luciferase, generating a light signal
by consuming intracellular ATP together with the substrate D-luciferin (emission maximum
~560 nm at pH 7.8). Indeed, ATP concentration is between 3-fold and 4-fold lower in SMA
compared to WT MNs (Figure 20). Together, these results suggest that energy homeostasis
is impaired in SMA MNs due to defective mitochondria, and glycolysis cannot compensate for
this defect.
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Figure 20: ATP levels are reduced in primary SMA MNs.
Intracellular ATP levels of primary MNs normalized to solubilized protein detected by luminescence
(A) and fluorescence (B). Each dot represents data from biological replicates of WT MNs (N=7) and
SMA MNs (N=8) (A) and (N=3) (B). Two-tailed unpaired t-test was used to determine statistical
significance. Graphs depict the mean ± SD. **p <0.01. Blue circles represent WT MNs and red squares
represent SMA MNs. 10DIV MNs were used.
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3.5 Oxidative stress impairs global translation in SMA MNs
Mitochondria are considered the major producer of intracellular ROS. An imbalance of ROS can
occur due to increased electron leakage of dysfunctional respiratory chain complexes. Mostly,
complex I of the electron transport chain is known to be the major source of ROS in mitochondria
(Y. Liu et al., 2002). Increased levels of ROS can lead to intracellular oxidative stress and
amplify mitochondrial defects by damaging mitochondrial DNA. However, mitochondrial DNA
damage is not the only impairment resulting from increased ROS levels. Also, increased ROS
can result in reversible and irreversible changes in the translation machinery (Topf et al., 2018).
3.5.1 Global translation is impaired in SMA MNs
Furthermore, irreversible carbonylation of proteins can alter their conformation and lead to
protein degradation by the proteasome (Nyström, 2005). In case ribosomal proteins are a!ected
by carbonylation, this can alter subsequent protein synthesis (Nyström, 2005; Scott et al.,
2004). Due to our quantitative proteomics approach, proteins associated with ribosomes and
translation-related proteins are dysregulated in SMA. Therefore, we measured protein synthesis
e"ciency with Surface sensing of translation (SUnSET) (Schmidt et al., 2009) and AHA-Click-iT
assay in WT and SMA MNs (Figure 21A and Figure 22A). Both methods are used to label
newly synthesized proteins by either low concentrations (1 µM) of the tyrosyl-aminoacyl-tRNA
analog puromycin (Figure 21A) or the methionine analog L-azidohomoalanine (L-AHA). Due
to the lack of a hydrolyzable amide bond, the incorporation of puromycin leads to translation
elongation termination. However, even though puromycin can be used as a protein synthesis
inhibitor, at low dosage, it does not interfere with the overall rate of protein synthesis (Schmidt
et al., 2009).
10DIV primary WT and SMA MNs were incubated with 1 µM puromycin for 30 min. Subse-
quently, puromycin labeled proteins were detected by western blotting and normalized to ACTB
levels. Indeed, we show that SMA MNs have a reduced protein synthesis e"ciency (~42%)





































Figure 21: Translation is reduced in SMA MNs (SUnSET).
A) Schematic drawing of SUnSET method. Puromycin labels newly synthesized proteins. Puromycin is
detected by an anti-puromycin antibody. B) SUnSET assay in WT and SMA MNs (N=5). ACTB was
used as loading control. Blue circles represent data from WT, and red squares represent SMA MNs. Bar
graph depict the mean ± SD. Two-tailed unpaired t-test was used on independent biological replicates
to determine statistical significance ***p <0.001.
To rule out any inhibitory e!ects of the increased ROS levels on the SUnSET assay, the
results were confirmed by an alternative method, the AHA-Click-iT assay. In brief, 500 µM
of the methionine analog L-azidohomoalanine (L-AHA) were added to 10DIV MNs for 1 h
after endogenous methionine reserves were depleted by incubation for 30 min in HBSS. After
incorporation of AHA during protein synthesis, the azide residue is covalently bound with biotin
alkyne by click chemistry. Further, biotin is detected with specific antibodies during western
blot analysis. As a result, a reduction of one third was observed in SMA MNs compared to WT
ones (Figure 22B). Taken together, these results suggest a negative relationship between ROS








































Figure 22: Translation is reduced in SMA MNs (AHA).
A) Schematic drawing of the AHA method. L-azidohomoalanine (L-AHA) is incorporated into newly
synthesized proteins, followed by click chemistry reaction with biotin alkyne. Biotin labelled proteins can
be detected by western blot analysis. B) AHA assay in WT and SMA MNs (N=4). ACTB was used as
loading control. Blue circles represent data from WT, and red squares represent SMA MNs. Bar graph
depicts the mean ± SD. Two-tailed unpaired t-test was used on independent biological replicates to
determine statistical significance **p <0.01.
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3.6 Pyruvate restores ATP levels and reduces ROS levels in SMA MNs
Based on the imbalanced energy homeostasis in SMA MNs, we aimed to restore intracellular
ATP levels by supplementing appropriate substrates used for energy production. By now, lactate
is not only seen as a by-product of glycolysis but rather an important energy substrate for
neurons. Prior studies that have noted the importance of lactate in neurons revealed a shuttle of
astrocyte-derived lactate towards neurons in vivo (Mächler et al., 2016). In addition, pyruvate
can be used by neurons directly for energy production via OXPHOS in mitochondria. Also, we
pursued to counteract oxidative stress, the consequence of defective mitochondria in SMA. As
pyruvate is known to reduce ROS in a non-enzymatic way and is a known substrate of the TCA
cycle (Desagher et al., 1997), we supplemented NSC-34 cells as well as WT and SMA MNs
with 10 mM or 50 mM sodium lactate or sodium pyruvate.
3.6.1 Lactate does not increase intracellular ATP
To optimize lactate concentrations as a substrate for energy production, NSC-34 cells were used.
Those cells have well-working mitochondria, and therefore supplementing lactate is supposed to
be beneficial. Over a time period of 1 h, two concentrations, 10 mM and 50 mM lactate were
added into the culture medium (Figure 23A and Figure 23B). None of the concentrations
increased the intracellular ATP levels significantly over 1 h supplementation (Figure 23).
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Figure 23: Lactate does not increase ATP in NSC-34 cells.
Optimization of treatment with 10 mM lactate (A) and 50 mM lactate (B) for 1 h. 10 mM lactate and
50 mM lactate supplement do not increase ATP levels in NSC-34 cells (N=5). Bar graph depicts the
mean ± SD. One-way ANOVA with Dunnett post hoc analysis was used to compare each timepoint
with the control.
3.6.2 Pyruvate increases intracellular ATP
Since lactate was unable to increase intracellular ATP levels, pyruvate was used as a supplement.
Pyruvate is proposed to increase ATP levels in postnatal neurons upon glucose deprivation
(Surin et al., 2013). Again, NSC-34 cells were used to optimize the concentration over 1 h.
No significant increase of intracellular ATP was observed after 1 h supplementation of 10 mM
pyruvate (Figure 24A). However, supplementation of 50 mM pyruvate increased ATP levels
significantly in NSC-34 cells within 1 h (Figure 24B). Already 10 min of supplementation with
50 mM pyruvate were su"cient to double the concentration of intracellular ATP (Figure 24B).
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Figure 24: Pyruvate 50 mM increases ATP in NSC-34 cells.
Optimization of treatment with 10 mM pyruvate (A) and 50 mM pyruvate (B) for 1 h. 10 mM pyruvate
supplement does not increase ATP levels in NSC-34 cells (N=5). 50 mM pyruvate increases ATP levels
after 10 min in NSC-34 cells (N=5). Bar graph depicts the mean ± SD. One-way ANOVA with Dunnett
post hoc analysis was used on independent biological replicates to compare each timepoint with the
control. **p <0.01, ***p <0.001.
Pyruvate needs to be taken up by the cell to reach the mitochondria for energy production.
Therefore 50 mM pyruvate was added into the culture medium for 10 min, 20 min, and
60 min. Afterward, cells were lysed and intracellular pyruvate concentration was measured
by a coupled enzyme assay, which results in a fluorometric (#ex = 535/ #em = 587 nm)
product, proportional to the pyruvate in the sample. Interestingly, the intracellular pyruvate
concentration was significantly increased already after 10 min (Figure 25). The intracellular
pyruvate concentration was stable over 1 h, meaning the amount of pyruvate supplied to MNs
is su"cient for this period of time.



























Figure 25: Pyruvate uptake in MNs.
Supplementation of WT MNs (blue circles) and SMA MNs (red squares) with 50 mM pyruvate shows a
significant increase of intracellular pyruvate uptake (N=3). Bar graph depicts the mean ± SD. One-way
ANOVA with Dunnett post hoc analysis was used to compare each timepoint with the control. **p
<0.01, ***p <0.001.
Surprisingly, lactate did not only fail to increase ATP levels in NSC-34 cells but also showed
no e!ect in WT MNs or SMA MNs (Figure 26).
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Figure 26: Pyruvate increases ATP in MNs.
Supplementation of WT MNs (blue circles) and SMA MNs (red squares) with 10 mM/ 50 mM lactate or
10 mM/ 50 mM pyruvate for 1 h. 50 mM pyruvate treatment shows a significant increase of ATP levels
in SMA MNs (N=6). Graph depicts the mean ± SD. Two-tailed unpaired t-test was used on independent
biological replicates to determine statistical significance. Means of two groups were compared, *p <0.05,
**p <0.01.
The single most striking observation to emerge from supplementing lactate and pyruvate as
substrates was the increase of ATP in SMA MNs after 50 mM pyurvate supplementation for
1 h (Figure 26 & Figure 27). However pyruvate did not significantly increase ATP levels in






















Figure 27: Pyruvate increases ATP in SMA MNs.
ATP levels in WT and SMA MNs normalized to solubilized protein after 50 mM pyruvate supplementation
for 1 h. 50 mM pyruvate increased ATP in SMA MNs with no e!ect in WT MNs. Two-tailed unpaired
t-test was used on independent biological replicates to determine statistical significance *p <0.05.
Blue circles represent data from WT and red squares represent SMA MNs. Each dot represents the
quantification of individual biological replicates (N=6). Bar graphs depict the mean ± SD.
Overall, lactate, which can be converted to pyruvate by lactate dehydrogenase in the
cytoplasm (Adams et al., 1973), neither improved ATP levels in NSC-34 cell (Figure 23) nor
in primary MNs (Figure 26). However, direct supplementation of pyruvate was su"cient to
increase ATP levels in SMA MNs (Figure 27).
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3.6.3 Pyruvate reduces ROS
In addition, as pyruvate has been suggested to act as a ROS scavenger (K#adna et al., 2015),
we treated SMA MNs with 50 mM pyruvate for 1 h and measured ROS levels via fluorescence
CellROX® dye. Detection of the fluorescence signal was achieved by a microplate reader. As a
positive control, 10 µM of the antioxidant NAC was supplied for 1 h to NSC-34 cells. Since
NSC-34 cells do not have elevated ROS levels, supplementation of pyruvate or NAC showed
no e!ect (Figure 28). Nevertheless, menadione, which increases intracellular ROS levels via
futile redox cycling (Loor et al., 2010), increased ROS levels in NSC-34 cells drastically up to
four times (Figure 28). Instead, 50 mM pyruvate or 10 µM NAC simultaneously applied with
100 µM menadione for 1 h could reduce menadione-induced ROS levels by ~25% (Figure 28).
Overall, these results indicate a possible benefit of antioxidants for cells with elevated ROS














































Figure 28: Pyruvate reduces ROS after pharmacologically induced oxidative stress.
Quantification of mean fluorescence intensity of CellROX® signal in NSC-34 cells. Menadione increases
ROS levels, whereas 10 µM NAC or 50 mM pyruvate reduces ROS induced by 100 µM menadione for
1 h (N=6). One-way ANOVA with Tukey HSD post hoc analysis was used on independent biological
replicates (N=3) to determine statistical significance. *p <0.05, ***p <0.001. Each dot represents the
quantification of individual biological replicates. Bar graphs depict the mean ± SD.
Since pyruvate and NAC were able to reduce pharmacologically induced ROS, the e!ect
of pyruvate or NAC on ROS levels in SMA MNs needs to be investigated. Indeed, pyruvate
successfully reduces ROS levels in SMA MNs. However, menadione further increased ROS
levels in SMA MNs as it was observed in NSC-34 cells (Figure 29). These results suggest
that pyruvate is a valuable supplement to restore ATP levels and simultaneously balance
intracellular ROS levels in SMA MNs. Our results are in line with previous experiments, stating
the ant-oxidative e!ect of pyruvate (K#adna et al., 2015).
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Figure 29: Pyruvate reduces ROS in SMA MNs.
ROS levels of SMA MNs after 50 mM pyruvate and 100 µM menadione supplementation for 1 h.
While pyruvate reduces ROS, menadione increases ROS in SMA MNs. Two-tailed unpaired t-tests with
Holm-Bonferroni correction for multiple comparisons were used to determine statistical significance. *p
<0.05, **p <0.01. Each dot represents the quantification of individual biological replicates (N=6). Bar
graphs depict the mean ± SD.
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3.7 E!ect of ROS on global protein synthesis in neurons
Based on our data, we hypothesized that the elevated ROS levels and the associated hyper-
carbonylation hinder protein synthesis. Thus, the reduction of ROS might restore impaired
protein synthesis in SMA MNs. To further understand the e!ect of ROS on protein synthesis,
we modified cellular ROS levels in MNs and measured protein synthesis e"ciency. To measure
the protein synthesis rate, again, the nonradioactive SUnSET assay was used. The relationship
between ROS and protein synthesis was examined in NSC-34 cells, WT MNs, and SMA MNs.
NSC-34 cells were di!erentiated for three days using retinoic acid. Primary MNs were harvested
10 days after isolation from E13.5 embryonic spinal cords. All cells were supplied with 10 µM
NAC or 50 mM pyruvate for 1 h. To evaluate the e!ect of induced ROS, 100 µM menadione
was used. As a negative control, 50 µM of the protein synthesis inhibitor anisomycin was added
for 1 h. Labeling with 1 µM puromycin was carried out 30 min before cells were harvested. Our












Figure 30: Experimental set up of SUnSET assay in NSC-34 cells, WT & SMA MNs.
NSC-34 cells are di!erentiated for 3 days before treatment with 50 mM pyruvate, 10 µM NAC or 100 µM
menadione for 1 h. WT & SMA MNs were additionally treated with 50 µM anisomycin for 1 h. 1 µM
puromycin was added after 30 min of treatment for an additional 30 min.
3.7.1 Regulating ROS has no e!ect on global translation in NSC-34 cells or WT
MNs
As we already found out, pyruvate or NAC had no anti-oxidative e!ect on NSC-34 cells, whose
ROS levels are in a normal range. Therefore, it is not surprising that protein synthesis e"ciency
is also unaltered by pyruvate or NAC in NSC-34 cells (Figure 31). However, 100 µM menadione
induced ROS clearly and, therefore, also reduced protein synthesis drastically (Figure 31).
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Figure 31: Regulating ROS has no e!ect on NSC-34 cells.
Representative western blot and quantification of SUnSET assay in NSC-34 cells. Neither 50 mM
pyruvate nor 10 µM NAC changed protein synthesis significantly. Each dot represents the quantification
of individual biological replicates (N=5). Bar graphs depict the mean ± SD. Two- tailed unpaired t-test
with Holm-Bonferroni correction for multiple comparisons was used to determine statistical significance.
ns p >0.05.
Similar to NSC-34 cells, WT MNs are capable of regulating intracellular ROS levels.
Therefore, it is not particularly surprising that 50 mM pyruvate and 10 µM NAC does not
increase protein synthesis e"ciency in WT MNs (Figure 32). Nevertheless, inducing ROS by
100 µM menadione results in a reduction of protein synthesis e"ciency (Figure 32), which
means that inducing ROS, in general, does reduce global protein synthesis. As a negative
control, 50 µM anisomycin was used.
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Figure 32: Regulating ROS has no e!ect on protein synthesis in WT MNs.
Representative western blot and quantification of SUnSET assay after ROS modification in WT MNs
(N=5). Neither 10 µM NAC nor 50 mM pyruvate supplementation for 1 h changed protein synthesis
significantly in WT MNs. Bar graphs depict the mean ± SD. Two-tailed unpaired t-tests with Holm-
Bonferroni correction for multiple comparisons were used to determine statistical significance. ns p
>0.05.
3.7.2 Regulating ROS modulates global protein synthesis in SMA MNs
Interestingly, for SMA MNs, where cellular ROS levels are higher, a reduction of ROS by adding
10 µM NAC could increase protein synthesis (Figure 33). However, no consistent increase
in protein synthesis was observed in pyruvate supplemented SMA MNs. The use of 100 µM
menadione further increased ROS in SMA MNs (Figure 29) and therefore reduced protein
synthesis even further (Figure 33).
Taken together, our data strongly suggests that intracellular ROS influences protein synthesis
in MNs. Modulating ROS can inversely regulate global protein synthesis.
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Figure 33: Regulating ROS with NAC increases protein synthesis in SMA MNs.
Representative western blot and quantification of SUnSET assay after ROS modification in SMA MNs
(N=5). Supplementation of 10 µM NAC increased protein synthesis in SMA MNs. However, 50 mM
pyruvate supplementation for 1 h did not change protein synthesis in SMA MNs. Bar graphs depict the
mean ± SD. Two-tailed unpaired t-tests with Holm-Bonferroni correction for multiple comparisons were
used to determine statistical significance. ns p >0.05, *p <0.05.
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3.8 E!ect of ROS on local protein synthesis in neurons
One important aspect of investigating neurons is the subcellular compartmentalization. More
frequently, defective local translation is observed in neurodegenerative disorders (Thelen & Kye,
2020). In order to investigate local protein synthesis in primary MNs, we performed the SUnSET
experiment. However, instead of evaluating global translation by western blotting, we analyzed
the neuronal compartments individually by imaging analysis. Furthermore, we investigated
whether ROS regulates axonal local protein synthesis in MNs. Same with previous experiments,
10DIV MNs were used and supplied with 1 µM puromycin to mark newly synthesized proteins.
However, puromycin labeled proteins were detected with a fluorescently conjugated secondary
antibody. To track the axon, MNs were simultaneously labeled with anti-Tau specific antibodies.
For the quantification of the protein synthesis along the axon, 100 µm fractions were analyzed
separately. To compare WT and SMA MNs with and without ROS modification, five biological
replicates were analyzed.
3.8.1 Local protein synthesis is reduced in SMA MNs
As we used 10DIV MNs, protein synthesis is expected to be lower compared to actively growing
neurons. Therefore, we analyzed newly synthesized proteins in di!erent axonal compartments.
First, we measured the mean fluorescence signals of newly synthesized proteins labeled with
puromycin in the soma of WT and SMA MNs. Our data reveals a reduction of ~50% in SMA
MNs compared to WT ones (Figure 34B). The axonal compartment was divided into 20 µm
bins, and the mean values of each 100 µm fraction were compared between WT and SMA
MNs. As expected, proximal fractions have higher anti-puromycin signals compared to distal
parts. However, a significant reduction of protein synthesis in SMA MNs compared to WT
MNs was observed in the first three, most proximal fractions (Figure 34C).
Overall, protein synthesis is globally impaired in SMA MNs, but also individual compartments
such as soma and axon show reduced protein synthesis in SMA MNs.
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Figure 34: Axonal local translation is reduced in SMA MNs.
Quantification of mean puromycin intensity profiles confirms that protein synthesis is reduced in soma
and axonal compartment of SMA MNs. A) Representative images of 10DIV WT and SMA MNs labelled
with anti-puromycin antibody (rainbow color). Neurites were selected with a segmented line, straightened
and divided into 20 µm bins using the concentric circles plugin. B) Quantification of mean puromycin
intensity of soma. C) Quantification of mean puromycin intensity profiles in axonal compartment. Scale
bar: 20 µm. Each dot represents the average quantification of 10 neurons of 5 individual biological
replicates (N=5). Bar graphs depict the mean ± SD. Two-tailed unpaired t-test with Holm-Bonferroni
correction for multiple comparisons was used to determine statistical significance. ns p >0.05, *p <0.05,
**p <0.01.
3.8.2 Regulating ROS does not improve local protein synthesis in WT MNs
We were able to modulate ROS levels in primary MNs by supplementation of NAC or pyruvate.
Furthermore, global protein synthesis was modulated by ROS regulation presented in section
3.7. However, NAC and pyruvate did not change global translation in NSC-34 cells or WT
MNs, whose ROS levels are in an optimal range. Nevertheless, a closer look comparing the
soma of WT MNs treated with 10 µM NAC, 50 mM pyruvate, 100 µM menadione, or 50 µM
anisomycin for 1 h confirmed our previous results of global protein synthesis. Neither NAC, nor
pyruvate changed protein synthesis in the soma of WT MNs (Figure 35). However, induction
of ROS by menadione or inhibition of translation by anisomycin showed a clear reduction of
protein synthesis in the soma of WT MNs (Figure 35B).
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Figure 35: Modification of ROS does not increase protein synthesis in WT MN soma.
A) Representative images of WT MNs labelled with anti-puromycin antibody (rainbow color) and anti-
Tau antibody (white). MNs were treated with 10 µM NAC or 50 mM pyruvate or 100 µM menadione or
50 µM anisomycin for 1 h. Images confirm that protein synthesis is blocked by anisomycin or menadione
in WT MNs. Scale bar: 20 µm. B) Quantification of mean puromycin intensity in soma of WT MNs,
corresponding to protein levels. Each dot represents the average quantification of 10 neurons of 5
individual biological replicates (N=5). Bar graph depict the mean ± SD. Two-tailed unpaired t-test
with Holm-Bonferroni correction for multiple comparisons was used to determine statistical significance.
ns p >0.05, **p <0.01.
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Additionally, we analyzed the axonal compartment after ROS modulation. Consistent with
previous results of global protein synthesis and protein synthesis in the soma of WT MN, no
e!ect was observed in the axonal compartment after ROS reduction by NAC or pyruvate (Figure
36). Again anisomycin and menadione reduced protein synthesis in WT MNs drastically even
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Figure 36: Modification of ROS does not alter protein synthesis in WT MN axons.
A) Representative images of WT MNs labelled with anti-puromycin antibody (rainbow color). Neurites
were selected with a segmented line, straightened and divided into 20 qµm bins using the concentric
circles plugin. MNs were treated with 10 µM NAC or 50 mM pyruvate or 100 µM menadione or 50 µM
anisomycin for 1 h. Images confirm that protein synthesis is blocked by anisomycin or menadione. Scale
bar: 20 µm. B) Quantification of mean puromycin intensity profiles, corresponding to protein levels,
against distance in discrete categories. Each dot represents the average quantification of 10 neurons of
5 individual biological replicates (N=5). Bar graph depict the mean ± SD. Two-tailed unpaired t-test
with Holm-Bonferroni correction for multiple comparisons was used to determine statistical significance.
ns p >0.05, **p <0.01.
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3.8.3 Regulating ROS modulates axonal protein synthesis in SMA MNs
More importantly, we wanted to see the e!ect on local protein synthesis after reducing ROS
in SMA MNs. Supplementation of 10 µM NAC for 1 h was already su"cient to reduce
ROS and increased global translation. Of note, supplementation of 50 mM pyruvate did not
increase global protein synthesis consistently (Figure 33). In agreement with the change in
global translation, protein synthesis was also increased in the somatic compartment after NAC
supplementation and not changed after the addition of pyruvate (Figure 37). However, 100 µM
menadione and 50 µM anisomycin blocked protein synthesis (Figure 37B).
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Figure 37: Reducing ROS increases protein synthesis in SMA MN soma.
A) Representative images of neurons after SUnSET assay after ROS modification in SMA MNs. Tau
staining (white) shows whole neuronal morphology and puromycin signal represents newly synthesized
proteins in given time. Rainbow color scale shows the intensity of puromycin signal. Scale bar: 20 µm.
B) Quantification of mean puromycin intensity profiles, corresponding to protein levels in SMA soma.
10 µM NAC enhanced and 100 µM menadione or 50 µM anisomycin inhibited protein synthesis in SMA
MNs. Supplementation of 50 mM pyruvate for 1 h showed no e!ect on protein synthesis in SMA MN
soma. Each dot represents the average intensity of 15 neurons (N=5). One-way ANOVA with Tukey
HSD post hoc analysis was used to determine statistical significance for multiple comparisons. Bar
graphs depict the mean ± SD. ns p >0.05, ***p <0.001.
In SMA MNs, the antioxidant NAC increased protein synthesis in the first three most
proximal fractions of the axon (Figure 38). These results confirmed that NAC could restore
impaired protein synthesis e"ciently in SMA MNs. Overall, reducing ROS in SMA MNs shows
benefit in all compartments of the neurons. However, supplementation of 50 mM pyruvate for
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Figure 38: Reducing ROS increases local protein synthesis in SMA MN axons.
A) Representative images of SMA MN axons labelled with anti-puromycin antibody (rainbow color)
and anti-Tau antibody (white). Neurites were selected with a segmented line, straightened and divided
into 20 µm bins using the concentric circles plugin. MNs were treated with 10 µM NAC or 50 mM
pyruvate or 100 µM menadione or 50 µM anisomycin for 1 h. Images confirm that protein synthesis is
blocked by anisomycin or menadione and increased by 10 µM NAC in SMA MNs. Scale bar: 20 µm. B)
Quantification of mean puromycin intensity profiles, corresponding to protein levels, against distance in
discrete categories. Each dot represents the average quantification of 10 neurons of 5 individual biological
replicates (N=5). Bar graph depicts the mean ± SD. Two-tailed unpaired t-test with Holm-Bonferroni
correction for multiple comparisons was used to determine statistical significance. ns p >0.05, *p <0.05.
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3.9 Whole proteome analysis of MNs with ROS manipulation
As our results suggested a relationship between ATP increase, ROS reduction, and increased
protein synthesis by pyruvate and NAC, we aimed to identify systemic changes in the proteome
of WT and SMA MNs after ATP and/or ROS modifications. Quantitative MS analysis in a 2 h
data-independent acquisition was performed after primary WT and SMA MNs were treated
with 50 mM pyruvate, 10 µM NAC, or 100 µM menadione 1 h. Whole proteome analysis was
performed on four independent biological replicates of 10DIV WT MNs from E13.5 mice and
three biological replicates of SMA MNs after 10DIV.
3.9.1 Pyruvate
First, cells were incubated with 50 mM pyruvate for 1 h, and the whole proteome was analyzed
by MS. We found that the levels of 144 proteins were altered in WT MNs (Figure 39A and
Table S2) and 122 proteins were altered in SMA MNs (Figure 39B and Table S3). Among
those 144 proteins, 115 proteins were significantly up-regulated after pyruvate treatment in WT
MNs. However, the amount of up-or down-regulated proteins after pyruvate treatment in SMA
MNs was rather balanced: 59 proteins were up-regulated, and 63 proteins were down-regulated.
Comparing WT and SMA MNs treated with pyruvate, only two proteins, namely DLG-associated
protein 1 (DLGAP1) and Islet cell autoantigen 1 (ICA1), were commonly changed. However,
DLGAP1 was down-regulated in WT MNs and up-regulated in SMA MNs upon pyruvate
treatment (Figure 39). The opposite was observed for ICA1. In pyruvate-treated WT MNs,
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Figure 39: Pyruvate modifies the proteome of MNs.
Volcano plot of whole proteome analysis in WT (A) and SMA MNs (B) after 50 mM pyruvate treatment
for 1 h; plotted p-value (-log10) against fold change (log2) (N=3). P-values were determined by unpaired
two-sided t-test. Significantly changed proteins with p < 0.05 are highlighted in blue (down-regulated)
or in red (up-regulated). Annotations show corresponding gene names.
To understand the biological meaning of pyruvate treatment on the proteome of SMA
MNs, we performed pathway analyses on the significantly changed proteins. Gene ontology
(GO) analyses are grouped in biological process, cellular compartment, and molecular function.
The 5 most significantly changed pathways in each category are listed. All of those categories
suggest a strong involvement of mitochondria (Table 2). The biological process of oxidative
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phosphorylation was enriched, and the cellular compartment of mitochondria was a!ected by
pyruvate supplementation (Table 2). Also, ribonucleotide binding, spliceosome, RNA splicing,
and mRNA processing were a!ected by pyruvate. Interestingly, these terms have been reported
as altered pathways in SMA (Pellizzoni, 2002; Fallini et al., 2011; Custer et al., 2016).
Table 2: GO analysis: Pathways regulated by pyruvate in SMA MNs.
Biological processes, cellular compartments and molecular functions a!ected by significantly changed
proteins after 50 mM pyruvate treatment for 1h in SMA MNs.
Term P-Value Gene name
Biological Process
Mitochondrion organization 2,79E-04 Fxn, Mrpl17, Spg7, Timm13, Tmem70
RNA splicing 1,26E-03 Ddx39a, Pabpc1, Ppil1, Scaf1, Snrpb, Srek1,
Syncrip
Oxidative phosphorylation 4,51E-03 Atp6v0a1, Atp6v1h, Fxn, Ndufb8
mRNA processing 4,71E-03 Ddx39a, Pabpc1, Ppil1, Scaf1, Snrpb, Srek1,
Syncrip
mRNA metabolic process 9,24E-03 Ddx39a, Pabpc1, Ppil1, Scaf1, Snrpb, Srek1,
Syncrip
Cellular compartment
Extrinsic to membrane 1,76E-06 Becn1, Cdc42ep1, Dlgap1, Dnm1l, Gng4,
Gphn, Ica1, Jup, Map3k12, Pitpnm2, Plcd4,
Plekha2, Sh2d3c, Stambp, Strn3
Internal side of plasma mem-
brane
5,27E-04 Adi1, Fnbp1, Gng4, Gphn, Gpsm1, Jup,
Rab39b, Rhog, Snap91
Mitochondrion 4,22E-03 Akap1, Amacr, Clpp, Comt, Fxn, Lypla1,
Micu1, Mmaa, Mrpl17, Mrpl50, Ndufb8,
Rpl35a, Spg7, Timm13, Tmem11, Tmem70,
Tst
Spliceosome 8,52E-03 Pabpc1, Ppil1, Snrpb, Srek1, Syncrip
Ribonucleoprotein complex 9,94E-03 Commd1, Mrpl17, Mrpl50, Pabpc1, Ppil1,
Rpl35a, Snrpb, Srek1, Syncrip
Molecular function
Nucleotide binding 1,77E-05 Cdk1, Clpp, Cpeb3, Dclk1, Ddx39a, Dhfr,
Dnm1l, Dock7, Gnl1, Gphn, Grk2, Hcn3,
Kif5c, Map3k12, Map4k3, Mmaa, Myo5b,
Pabpc1, Rab39b, Rbm26, Recql, Rhog,
Rimklb, Septin7, Smc2, Spg7, Srek1, Stk24,
Stk38, Syncrip, Ube2f, Xrcc5
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Table 2: (continued)
Term P-Value Gene name
Ribonucleotide binding 5,59E-04 Cdk1, Clpp, Dclk1, Ddx39a, Dnm1l, Dock7,
Gnl1, Grk2, Hcn3, Kif5c, Map3k12, Map4k3,
Mmaa, Myo5b, Rab39b, Recql, Rhog,
Rimklb, Septin7, Smc2, Spg7, Stk24, Stk38,
Ube2f, Xrcc5
Purine ribonucleotide binding 5,59E-04 Cdk1, Clpp, Dclk1, Ddx39a, Dnm1l, Dock7,
Gnl1, Grk2, Hcn3, Kif5c, Map3k12, Map4k3,
Mmaa, Myo5b, Rab39b, Recql, Rhog,
Rimklb, Septin7, Smc2, Spg7, Stk24, Stk38,
Ube2f, Xrcc5
Purine nucleotide binding 1,01E-03 Cdk1, Clpp, Dclk1, Ddx39a, Dnm1l, Dock7,
Gnl1, Grk2, Hcn3, Kif5c, Map3k12, Map4k3,
Mmaa, Myo5b, Rab39b, Recql, Rhog,
Rimklb, Septin7, Smc2, Spg7, Stk24, Stk38,
Ube2f, Xrcc5
Adenyl ribonucleotide binding 7,42E-03 Cdk1, Clpp, Dclk1, Ddx39a, Grk2, Hcn3,
Kif5c, Map3k12, Map4k3, Mmaa, Myo5b,
Recql, Rimklb, Smc2, Spg7, Stk24, Stk38,
Ube2f, Xrcc5
Next, we pursued identifying common proteins whose levels are altered by SMA and changed
by pyruvate treatment in MNs. Among the 494 proteins changed in SMA MNs compared to
WT MNs, 22 were also altered by pyruvate in WT MNs, and 28 were altered by pyruvate in
















Figure 40: Pyruvate regulates a similar number of proteins in WT and SMA MNs.
Venn diagram showing overlap of ’altered proteins in SMA compared to WT’ and ‘changed proteins by
pyruvate’ in WT (A) or in SMA MNs (B).
Focusing on the fold change of those 22 proteins changed in WT MNs (Table 3), and
28 proteins changed in SMA MNs (Table 4), which overlap with proteins changed in SMA
MNs without treatment, we found that the e!ect of pyruvate was more apparent in SMA MNs
(Figure 41). Proteins that were down-regulated in SMA MNs were still down-regulated after
pyruvate treatment and also up-regulated proteins were not a!ected by pyruvate treatment
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(Figure 41A). However, among the 28 proteins changed in SMA MNs and after pyruvate
treatment in SMA MNs, 21 proteins were down-regulated in SMA compared to WT and



























Figure 41: Pyruvate changes proteins in SMA more than in WT MNs.
Scatterplot showing the fold change (log2) of SMA MNs compared to WT MNs against significantly
changed proteins in pyruvate treated WT (A) or SMA MNs (B).
Table 3: Di!erentially expressed proteins in SMA compared to WT MNs and in WT MNs
after pyruvate treatment.
List of 22 changed proteins in SMA compared to WT MNs (p < 0.05), which are also changed in WT
MNs after pyruvate treatment. Gene names, protein names, and fold changes (FC) are listed.
Gene
name





Cptp Ceramide-1-phosphate transfer protein -2.18 -1.59
Fam126b Protein FAM126B -2.17 -2.30
Sec11c Signal peptidase complex catalytic subunit
SEC11C
-1.55 -1.55
Toe1 Target of EGR1 protein 1 -1.26 -0.60
Mrpl37 39S ribosomal protein L37, mitochondrial -0.60 -0.45
Kif1bp KIF1-binding protein -0.39 -0.21
Rpl9 60S ribosomal protein L9 -0.38 0.20
Srp68 Signal recognition particle subunit SRP68 -0.37 0.21
Cstf1 Cleavage stimulation factor subunit 1 -0.36 0.24
Rwdd1 RWD domain-containing protein 1 -0.34 0.35
Ppia Peptidyl-prolyl cis-trans isomerase A -0.29 0.22
Mrps17 28S ribosomal protein S17, mitochondrial 0.21 0.22
Arxes1 Adipocyte-related X-chromosome expressed
sequence 1
0.35 0.37
Gpr107 Protein GPR107 0.42 0.35
Afg3l1 AFG3-like protein 1 0.61 0.49
GOLGA7B Golgin subfamily A member 7B 0.61 0.35
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Gene
name





Prpf38b Pre-mRNA-splicing factor 38B 0.61 0.71
Rad23a UV excision repair protein RAD23 homolog A 0.73 0.76
Gnpda1 Glucosamine-6-phosphate isomerase 1 1.18 1.57
Cdkn1a Cyclin-dependent kinase inhibitor 1 1.92 0.95
Jakmip1 Janus kinase and microtubule-interacting pro-
tein 1
1.92 1.44
Mcm2 DNA replication licensing factor MCM2 5.54 4.48
Table 4: Di!erentially expressed proteins in SMA compared to WT MNs and in SMA MNs
after pyruvate treatment.
List of 28 changed proteins in SMA compared to WT MNs (p < 0.05), which are also changed in SMA
MNs after pyruvate treatment. Gene names, protein names, and fold changes (FC) are listed. Gene
names in red mark 21 proteins which were down-regulated in SMA compared to WT and up-regulated
by pyruvate in SMA MNs.
Gene
name





Xrcc5 X-ray repair cross-complementing protein 5 -2.41 2.21
Commd1 COMM domain-containing protein 1 -2.23 1.79
Psmg3 Proteasome assembly chaperone 3 -2.14 1.67
Brix1 Ribosome biogenesis protein BRX1 homolog -2.07 1.35
Recql ATP-dependent DNA helicase Q1 -1.83 1.91
Srek1 Splicing regulatory glutamine/lysine-rich protein
1
-1.60 1.83
Scaf1 Splicing factor, arginine/serine-rich 19 -1.51 2.16
Lbr Delta(14)-sterol reductase LBR -1.48 1.39
Mmaa Methylmalonic aciduria type A homolog, mito-
chondrial
-1.39 0.58
Ppfibp1 Liprin-beta-1 -1.39 1.04
Tmem175 Endosomal/lysosomal potassium channel
TMEM175
-1.24 1.37
Tmem70 Transmembrane protein 70, mitochondrial -1.19 1.23
Nelfcd Negative elongation factor D -1.16 1.26
Map3k12 Mitogen-activated protein kinase kinase kinase
12
-1.04 0.80
Slc8a2 Sodium/calcium exchanger 2 -0.58 0.27
Otud6b Deubiquitinase OTUD6B -0.53 0.46
Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta sub-
complex subunit 8, mitochondrial
-0.42 0.31
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Gene
name





Cul1 Cullin-1 -0.40 0.16
Fam20b Glycosaminoglycan xylosylkinase -0.40 0.29
Mrpl50 39S ribosomal protein L50, mitochondrial -0.32 0.31
Dtd1 D-aminoacyl-tRNA deacylase 1 -0.24 -0.33
Clpp ATP-dependent Clp protease proteolytic subunit,
mitochondrial
-0.24 0.23
Ddx39a ATP-dependent RNA helicase DDX39A 0.24 -0.22
Syncrip Heterogeneous nuclear ribonucleoprotein Q 0.40 -0.19
Jup Junction plakoglobin 0.42 0.22
Grk2 Beta-adrenergic receptor kinase 1 0.52 -0.45
Akap1 A-kinase anchor protein 1, mitochondrial 0.54 -0.33




Next, to obtain an overview of the antioxidant e!ect on the MN proteome, WT and SMA
MNs were treated with 10 µM NAC for 1 h. Whole proteome analysis identified that 105
proteins were changed by NAC treatment in WT MNs (Figure 42A and Table S4) and 143
proteins were changed in SMA MNs (Figure 42B and Table S5). Here, no clear di!erence
in the number of up- (54) or down-regulated (51) proteins was observed in WT MNs after
NAC treatment. However, the majority (91 proteins) of proteins was down-regulated after NAC
treatment in SMA MNs. Interestingly, NAC changed only one protein commonly in WT and
SMA MNs. The deubiquitinase OTUD6B was down-regulated after NAC treatment in WT and
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Figure 42: NAC modifies the proteome of MNs.
Volcano plot of whole proteome analysis in WT (A) and SMA MNs (B) after 10 µM NAC treatment for
1 h; plotted p-value (-log10) against fold change (log2) (N=3). P-values were determined by unpaired
two-sided t-test. Significantly changed proteins with p < 0.05 are highlighted in blue (down-regulated)
or in red (up-regulated). Annotations show corresponding gene names.
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Next, GO analysis was performed on the significantly changed proteins. The data suggested a
variety of functions including nucleotide-binding and RNA processing (Table 5). The biological
processes category suggested strong involvement of RNA metabolism, including RNA splicing,
RNA processing, or mRNA processing.
Table 5: GO analysis: Pathways regulated by NAC in SMA MNs.
Biological processes, cellular compartments and molecular functions a!ected by significantly changed
proteins after 10 µM NAC treatment for 1 h in SMA MNs.
Term P-Value Gene name
Biological Process
RNA splicing 2,81E-07 Ddx39a, Ddx5, Lsm6, Nono, Pabpc1, Prpf3, Sart1,
Scaf1, Snrpb, Snrpg, Usp39, Ybx1
RNA processing 7,57E-07 Ddx39a, Ddx5, Exosc7, Gar1, Lsm6, Nono, Nop2,
Pabpc1, Prpf3, Sart1, Scaf1, Snrpb, Snrpg,
Trmt10c, Usp39, Ybx1
mRNA processing 3,81E-06 Ddx39a, Ddx5, Lsm6, Nono, Pabpc1, Prpf3, Sart1,
Scaf1, Snrpb, Snrpg, Usp39, Ybx1
mRNA metabolic process 1,46E-05 Ddx39a, Ddx5, Lsm6, Nono, Pabpc1, Prpf3, Sart1,




1,22E-04 Gspt1, Nedd4, Rnf2, Sumo3, Trim32, Ube3a,
Uchl1
Cellular compartment
Ribonucleoprotein complex 2,09E-04 Ddx5, Gar1, Hnrnpul1, Lsm6, Mrpl14, Mrps21,
Mrps5, Pabpc1, Prpf3, Rpl32, Sart1, Snrpb, Snrpg
Mitochondrion 2,21E-03 Adck1, Armc10, Bcs1l, Gatd3a, Idh3a, Mmaa,
Mrpl14, Mrps21, Mrps5, Mtg1, Ndufa5, Ndufaf4,
Pacs2, Pde12, Rab1b, Rexo2, Slc25a25, Timm8b,
Tmem65, Trmt10c, Tst
Spliceosome 2,63E-03 Ddx5, Pabpc1, Prpf3, Sart1, Snrpb, Snrpg
Axon 9,22E-03 Dock7, L1cam, Scn2a, Tac1, Uchl1
Organelle inner membrane 1,01E-02 Bcs1l, Lbr, Lemd3, Mrps21, Ndufa5, Slc25a25,
Timm8b, Tst
Molecular function
Nucleotide binding 2,72E-05 Adck1, Arf2, Arl5a, Atl1, Atrx, Bcs1l, Clcn6,
Cpne1, Csnk1a1, Dclk1, Ddx39a, Ddx5, Dhfr,
Dock7, Fyn, G3bp2, Gphn, Grk2, Gspt1, Hcn3,
Idh3a, Lemd3, Mink1, Mmaa, Mtg1, Nono,
Pabpc1, Ppip5k2, Rab10, Rab1b, Rab39b, Rab6a,
Tnrc6c, Ube2r2
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Table 5: (continued)
Term P-Value Gene name
RNA binding 3,42E-05 Cpne1, Ddx5, Exosc7, G3bp2, Gar1, Hnrnpul1,
Lsm6, Mrps5, Nono, Nop2, Pabpc1, Scaf1, Snrpb,
Snrpg, Thumpd3, Tnrc6c, Ybx1




1,53E-03 Arf2, Arl5a, Atl1, Dock7, Gspt1, Mtg1, Rab10,
Rab1b, Rab39b, Rab6a
Guanyl nucleotide binding 1,53E-03 Arf2, Arl5a, Atl1, Dock7, Gspt1, Mtg1, Rab10,
Rab1b, Rab39b, Rab6a
Compared with di!erentially expressed proteins between WT and SMA MNs, 40 proteins
were common with NAC treatment in WT MNs (Figure 43A and Table 6) and 31 proteins















Figure 43: NAC regulates the same number of proteins in WT and SMA MNs.
Venn diagram showing overlap of ‘altered proteins in SMA compared to WT’ and ‘changed proteins by
NAC’ in WT (A) or SMA MNs (B).
Again, NAC treatment showed only little e!ect on WT MNs (Figure 44A and Table 6),
whereas 17 proteins were down-regulated in SMA compared to WT, and up-regulated by NAC
treatment in SMA (Figure 44B and Table 7).
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p= 1.2e-12
Figure 44: NAC changes proteins in SMA more than in WT MNs.
Scatterplot showing the fold change (log2) of SMA MNs compared to WT MNs against significantly
changed proteins in NAC treated WT (A) or SMA MNs (B).
Table 6: Di!erentially expressed proteins in SMA compared to WT MNs and in WT MNs
after NAC treatment.
List of 40 changed proteins in SMA compared to WT MNs (p < 0.05), which are also changed in WT
MNs after NAC treatment. Gene names, protein names, and fold changes (FC) are listed.
Gene
name




Slc25a16 Graves disease carrier protein homolog -1.59 -1.20
Fcho2 F-BAR domain only protein 2 -1.49 -1.50
Bbc3 Bcl-2-binding component 3 -1.30 1.19
Stat3 Signal transducer and activator of transcription
3
-1.30 -0.81
Cyp46a1 Cholesterol 24-hydroxylase -1.23 -0.98
Kctd16 BTB/POZ domain-containing protein KCTD16 -0.87 -0.60
Smyd3 Histone-lysine N-methyltransferase SMYD3 -0.79 -0.71
Washc4 WASH complex subunit 4 -0.71 -0.83
Ap1s1 AP-1 complex subunit sigma-1A -0.65 -0.56
Dusp12 Dual specificity protein phosphatase 12 -0.62 -1.20
Cyp51a1 Lanosterol 14-alpha demethylase -0.58 -0.43
Otud6b Deubiquitinase OTUD6B -0.53 -0.58
Sar1b GTP-binding protein SAR1b -0.52 -0.34
Kif1b Kinesin-like protein KIF1B -0.49 -0.34
Rpl27a 60S ribosomal protein L27a -0.48 -0.26
Sec24a Protein transport protein Sec24A -0.48 -0.32
Pid1 PTB-containing, cubilin and LRP1-interacting
protein
-0.47 -0.40
Epb41l3 Band 4.1-like protein 3 -0.44 -0.34
Kif1bp KIF1-binding protein -0.39 -0.29
Rpl7a 60S ribosomal protein L7a -0.39 -0.21
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Gene
name




Mrpl45 39S ribosomal protein L45, mitochondrial -0.36 -0.29
Elp2 Elongator complex protein 2 -0.33 -0.26
Rab9a Ras-related protein Rab-9A -0.28 -0.37
Rack1 Receptor of activated protein C kinase 1 -0.25 -0.18
Lrrc47 Leucine-rich repeat-containing protein 47 -0.25 -0.22
Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 10, mitochondrial
0.21 0.18
Ppm1l Protein phosphatase 1L 0.23 0.25
Ergic3 Endoplasmic reticulum-Golgi intermediate com-
partment protein 3
0.27 0.18
Gnai2 Guanine nucleotide-binding protein G(i) subunit
alpha-2
0.32 0.29
Cuedc1 CUE domain-containing protein 1 0.33 0.51
Arxes1 Adipocyte-related X-chromosome expressed
sequence 1
0.35 0.27
Ano10 Anoctamin-10 0.39 0.29
Mrto4 mRNA turnover protein 4 homolog 0.47 0.44
Bcap29 B-cell receptor-associated protein 29 0.49 0.37
Ndufab1 Acyl carrier protein, mitochondrial 0.56 0.25
Afg3l1 AFG3-like protein 1 0.61 0.49
Hdac4 Histone deacetylase 4 0.61 0.66
Rad23a UV excision repair protein RAD23 homolog A 0.73 0.80
Asic1 Acid-sensing ion channel 1 0.84 0.76
Tomm20 Mitochondrial import receptor subunit TOM20
homolog
1.28 1.30
Table 7: Di!erentially expressed proteins in SMA compared to WT MNs and in SMA MNs
after NAC treatment.
List of 31 changed proteins in SMA compared to WT MNs (p < 0.05), which are also changed in SMA
MNs after NAC treatment. Gene names, protein names, and fold changes (FC) are listed. Gene names








Mturn Maturin -2.47 2.11
Psmg3 Proteasome assembly chaperone 3 -2.14 0.94
Brix1 Ribosome biogenesis protein BRX1 homolog -2.07 1.17
Scaf1 Splicing factor, arginine/serine-rich 19 -1.51 2.02
Lbr Delta(14)-sterol reductase LBR -1.48 1.64
Ppfibp1 Liprin-beta-1 -1.39 0.93
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Gene
name




Mmaa Methylmalonic aciduria type A homolog, mito-
chondrial
-1.39 0.63
Prpf3 U4/U6 small nuclear ribonucleoprotein Prp3 -0.79 0.36
Slc8a2 Sodium/calcium exchanger 2 -0.58 0.33
Atrx Transcriptional regulator ATRX -0.57 0.46
Otud6b Deubiquitinase OTUD6B -0.53 0.27
Scrib Protein scribble homolog -0.47 0.55
Timm8b Mitochondrial import inner membrane translo-
case subunit Tim8 B
-0.40 -0.38
Ube3a Ubiquitin-protein ligase E3A -0.39 0.17
Ciapin1 Anamorsin -0.39 0.39
Hnrnpul1 Heterogeneous nuclear ribonucleoprotein U-like
protein 1
-0.35 0.23
Ybx1 Nuclease-sensitive element-binding protein 1 -0.34 -0.25
Rpl32 60S ribosomal protein L32 -0.27 0.13
Ndufa5 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 5
-0.21 0.12
Ttc9c Tetratricopeptide repeat protein 9C 0.15 -0.18
Ddx39a ATP-dependent RNA helicase DDX39A 0.24 -0.32
Bcs1l Mitochondrial chaperone BCS1 0.33 0.23
Nptx1 Neuronal pentraxin-1 0.33 -0.31
Snrpg Small nuclear ribonucleoprotein G 0.33 -0.53
Ppip5k2 Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 2
0.50 -0.36
Grk2 Beta-adrenergic receptor kinase 1 0.52 -0.56
Arid1a AT-rich interactive domain-containing protein
1A
0.58 -0.25
Thumpd3 THUMP domain-containing protein 3 0.70 -0.55
Ints14 Integrator complex subunit 14 0.98 -0.40
Foxk2 Forkhead box protein K2 1.11 -1.17
Dmxl1 DmX-like protein 1 1.80 -2.27
3.9.3 Menadione
ROS induction in WT MNs had the most prominent e!ects on the proteome. Supplementation
of 100 µM menadione for 1 h altered expression of 344 proteins (Figure 45 and Table S6).
However, the majority of proteins were down-regulated. Only 119 proteins were up-regulated,
but 225 proteins were down-regulated after menadione treatment in WT MNs.
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Figure 45: Menadione modifies the proteome of MNs.
Volcano plot of whole proteome analysis in WT MNs after 100 µM menadione treatment for 1 h; plotted
p-value (-log10) against fold change (log2) (N=3). P-values were determined by unpaired two-sided
t-test. Significantly changed proteins with p < 0.05 are highlighted in blue (down-regulated) or in red
(up-regulated). Annotations show corresponding gene names.
In addition, menadione also showed the biggest overlap of altered proteins with SMA







Figure 46: Menadione changes proteins in WT MNs, that are also altered in SMA MNs.
Venn diagram showing overlap of ‘altered proteins in SMA compared to WT’ and ‘changed proteins by
menadione’ in WT MNs.
Menadione treated WT MNs showed great overlap with altered proteins in SMA. As
visualized by the scatter plot in Figure 47, proteins with a negative fold change (down-
regulated) in SMA compared to WT MNs also show a lower expression in WT MNs after
menadione treatment. Similar, proteins with a positive fold change in SMA MNs compared to
WT MNs were also up-regulated in WT MNs after ROS induction by menadione. Those results
show that increasing ROS in WT MNs a!ects similar proteins that are a!ected by SMA.
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Figure 47: Menadione reduces protein levels in WT MNs.
Scatterplot showing the fold change (log2) of protein levels in SMA MNs compared to WT MNs against
significantly changed proteins in menadione treated WT MNs.
Table 8: Di!erentially expressed proteins in SMA compared to WT MNs and in WT MNs
after menadione treatment.
List of 56 changed proteins in SMA compared to WT MNs (p < 0.05), which are also changed in WT
MNs after menadione treatment. Gene names, protein names, and fold changes (FC) are listed.
Gene
name




Fgf13 Fibroblast growth factor 13 -2.26 -2.58
Fam126b Protein FAM126B -2.17 -2.12
Ehmt1 Histone-lysine N-methyltransferase EHMT1 -1.64 -1.57
Ntrk3 NT-3 growth factor receptor -1.55 -1.59
Mmaa Methylmalonic aciduria type A homolog, mito-
chondrial
-1.39 -0.92
Ddx20 Probable ATP-dependent RNA helicase DDX20 -1.37 -1.35
Stat3 Signal transducer and activator of transcription
3
-1.30 -1.19
Toe1 Target of EGR1 protein 1 -1.26 -0.90
Cyp46a1 Cholesterol 24-hydroxylase -1.23 -0.56
Map3k12 Mitogen-activated protein kinase kinase kinase
12
-1.04 -1.50
Cnot2 CCR4-NOT transcription complex subunit 2 -1.00 -0.32
Usp22 Ubiquitin carboxyl-terminal hydrolase 22 -0.91 -1.17
Son Protein SON -0.52 -1.30
Eml1 Echinoderm microtubule-associated protein-like
1
-0.48 -0.77
Scrib Protein scribble homolog -0.47 -0.95
Mlf2 Myeloid leukemia factor 2 -0.47 -0.64
Dtx3 Probable E3 ubiquitin-protein ligase DTX3 -0.44 -0.53
Nup43 Nucleoporin Nup43 -0.43 -0.35
Fads1 Acyl-CoA (8-3)-desaturase -0.43 -0.75
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Gene
name




Srrm2 Serine/arginine repetitive matrix protein 2 -0.42 -1.07
Fndc3a Fibronectin type-III domain-containing protein
3A
-0.38 -0.31
Cep170b Centrosomal protein of 170 kDa protein B -0.37 -0.65
Srpk1 SRSF protein kinase 1 -0.35 -0.22




Rpl12 60S ribosomal protein L12 -0.30 0.18
Hnrnpa0 Heterogeneous nuclear ribonucleoprotein A0 -0.29 -0.51
Bclaf1 Bcl-2-associated transcription factor 1 -0.28 0.25
Rack1 Receptor of activated protein C kinase 1 -0.25 0.15
Impa1 Inositol monophosphatase 1 -0.24 0.20
Poldip3 Polymerase delta-interacting protein 3 -0.21 -0.39
Eif2s1 Eukaryotic translation initiation factor 2 subunit
1
-0.20 0.17
Fip1l1 Pre-mRNA 3’-end-processing factor FIP1 -0.19 -0.29
Ndufb5 NADH dehydrogenase [ubiquinone] 1 beta sub-
complex subunit 5, mitochondrial
-0.19 0.31
Zdhhc17 Palmitoyltransferase ZDHHC17 -0.16 -0.18
Ppp6c Serine/threonine-protein phosphatase 6 catalytic
subunit
-0.14 -0.27
Prkaa2 5’-AMP-activated protein kinase catalytic sub-
unit alpha-2
0.16 -0.13
Dhodh Dihydroorotate dehydrogenase (quinone), mito-
chondrial
0.19 0.21
Dmac2l ATP synthase subunit s, mitochondrial 0.21 -0.25
Mrpl15 39S ribosomal protein L15, mitochondrial 0.21 0.27
Raf1 RAF proto-oncogene serine/threonine-protein
kinase
0.22 -0.33
Ppm1l Protein phosphatase 1L 0.23 0.27
Dnajc11 DnaJ homolog subfamily C member 11 0.23 0.28
Ergic3 Endoplasmic reticulum-Golgi intermediate com-
partment protein 3
0.27 0.25
Pelp1 Proline-, glutamic acid- and leucine-rich protein
1
0.27 -0.32
Actr1b Beta-centractin 0.28 0.46
Cuedc1 CUE domain-containing protein 1 0.33 0.24
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Gene
name




Arxes1 Adipocyte-related X-chromosome expressed
sequence 1
0.35 0.44
Ano10 Anoctamin-10 0.39 0.27
Vdac1 Voltage-dependent anion-selective channel pro-
tein 1
0.41 0.18




Ndufc2 NADH dehydrogenase [ubiquinone] 1 subunit C2 0.60 0.23
Afg3l1 AFG3-like protein 1 0.61 0.33
Cdkn1a Cyclin-dependent kinase inhibitor 1 1.92 0.91
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3.10 ROS regulates mRNA translation
Protein synthesis is tightly regulated in eukaryotic cells by two major processes; initiation and
elongation. Due to our data and previous studies, protein synthesis is impaired in SMA MNs
(Akten et al., 2011; Kye et al., 2014). However, it is still unclear at which step of protein
synthesis is impaired. It has not yet been established whether translation initiation or elongation
is a!ected by the loss of SMN. Therefore, we measured both processes in WT and SMA MNs.
As our pathway analysis of the whole proteomics approach suggested, that mRNA translation
might be dysregulated in SMA MNs (Figure 9A). Based on these findings, we filtered the whole
proteomics data by proteins related to mRNA translation. For this, we used the MGI database
with 616 annotated proteins. From the database, we detected 360 proteins in our whole
proteome data (Figure 48). Among them, 47 proteins were significantly changed between WT
and SMA MNs. Interestingly, 40 out of those 47 significantly changed proteins were down-
regulated in SMA MNs compared to WT ones, and only 7 proteins were up-regulated (Figure
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Figure 48: Quantitative proteomics of translation related proteins of SMA and WT MNs.
Volcano plot of translation related proteins comparing WT and SMA MNs; plotted p-value (-log10) against
fold change (log2, SMA/ WT). Four independent samples of WT MNs and three independent samples
for SMA MNs were used for analysis. P-values were determined using an unpaired two-sided t-test.
Proteins with p < 0.05 are highlighted in blue (down-regulated) and red (up-regulated). Annotations
show corresponding gene names.
3.10.1 Translation elongation in primary MNs
In order to assess the rate of protein elongation, we used the SunRiSE assay. This assay is a
modified version of the SUnSET assay (Argüello et al., 2018). In brief, translation initiation was
blocked by 2 µg/ml harringtonine at di!erent time intervals. Subsequently, newly synthesized
peptides were labeled with 10 µg/ml puromycin for 10 min and detected by western blot analysis
using an anti-puromycin specific antibody (Figure 49). All signals were normalized to ACTB
after puromycin signals were eradicated.
Blocking translation initiation at the same time and adding puromycin at di!erent timepoints
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after ribosomes run o! the mRNA or blocking translation at di!erent time points before labeling
with puromycin at the same time gives similar results (Argüello et al., 2018). To ensure that the
concentration of puromycin was homogenous, we choose to block translation first at di!erent
time points and added puromycin to all cells simultaneously. Again, WT and SMA MNs
were used after 10DIV. Furthermore, we aimed to measure translation elongation speed by
supplementation of 10 µM NAC or 50 mM pyruvate for 1 h.
We separated the analysis into three categories to see if only specific proteins with di!erent
molecular weights are a!ected - first, proteins with high molecular weight over 100 kDa. Second,
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Figure 49: Scheme of SunRiSE assay.
Translation initiation of 10DIV WT or SMA MNs was blocked with 2 µg/ml harringtonine at di!erent
timepoints before adding 10 µg/ml puromycin for 10 min and subsequent western blot analysis.
3.10.1.1 Translation elongation is not changed in SMA MNs
To identify the mechanism that contributes to the impaired protein synthesis in SMA, we
compared elongation speeds between WT and SMA MNs. As mentioned above, we detected
newly synthesized proteins by western blot analysis after translation initiation was blocked. For
this, we analyzed four individual biological replicates and compared the puromycin signal slopes
between di!erent conditions and genotypes. However, no di!erences in the elongation speed of
WT and SMA MNs was observed comparing the least squared means of the regression analysis
(Figure 50).
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Figure 50: SunRiSE assay of WT and SMA MNs.
Elongation speed is not altered in SMA MN compared to WT MNs. Each dot and line represent the
average of four independent biological replicates (N=4). Regression analysis comparing the least square
means does not show any significant di!erence between WT MNs (blue circles) and SMA MNs (red
squares).
3.10.1.2 ROS modulation does not change translation elongation in WT MNs
To test whether NAC or pyruvate can improve the elongation speed and exclude any adverse
e!ects on elongation, we first used WT MNs. Before performing the SunRiSE assay, MNs were
treated with 10 µM NAC or 50 mM pyruvate for 1 h. Not surprisingly, elongation speed was
not altered by either NAC or pyruvate treatment in WT MNs. This was expected as global and
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Figure 51: SunRiSE assay in WT MNs.
NAC or pyruvate does not change elongation speed in WT MNs. Each dot and line represent the average
of four independent biological replicates (N=4). Regression analysis comparing the least square means
does not show any significant di!erence between di!erent treatments.
3.10.1.3 ROS modulation does not change translation elongation in SMA MNs
As we already showed the positive e!ect of NAC on reducing ROS, improving global and
local translation, it is essential to evaluate if translation elongation is a!ected by this. Same
as with WT MNs, we treated 10 µM NAC and 50 mM pyruvate 1 h before performing the
SunRiSE assay. However, using four independent biological replicates, regression analysis did
not reveal any significant di!erence after treatment in any of the three MW categories.
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Figure 52: SunRiSE assay in SMA MNs.
NAC or pyruvate does not change elongation speed in SMA MNs. Each dot and line represent the
average of four independent biological replicates (N=4). Regression analysis comparing the least square
means does not show any significant di!erence between di!erent treatments.
3.10.2 Translation initiation is reduced in SMA MNs
As translational elongation is unaltered in SMA or by ROS modification, next, we tested
translational initiation. One of the well-described translational initiation mechanisms is cap-
dependent translation initiation by 4E-BP1 (eukaryotic translation initiation factor 4E-binding
protein 1). The rate-limiting step in translation initiation is the association of the cap-binding
protein, eukaryotic translation initiation factor 4E (eIF4E) into the eIF4F complex that recruits
the small ribosomal unit to mRNAs (Yanagiya et al., 2012). Translation initiation is repressed
by 4E-BP1 (Pause et al., 1994). In the first phosphorylation step, 4E-BP1 is phosphorylated at
Threonine residue 37 and Threonine 46. Subsequent phosphorylation at Threonine residue 70
and Serine 65 enables the release of 4E-BP from eIF4E.
Figure 53: Cap-dependent translation initiation.
mTORC1 increases phosphorylation of the translation-initiation repressor 4E-BP. After additional
phosphorylation, 4E-BP dissociates from eIF4E. Unbound eIF4E can bind the 5! cap of mRNA and
assembles the eIF4F pre-initiation complex required for cap-dependent translation.
In order to test translation initiation in SMA, we measured the phosphorylation of 4E-BP1
in WT and SMA MNs at residue Thr37/46. A reduced phosphorylation status of 4E-BP1
indicates that initiation of mRNA translation is impaired in SMA MNs (Figure 54).
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Figure 54: Phosphorylation status of 4E-BP in WT and SMA MNs.
Western blot analysis measuring p4E-BP1 and total 4E-BP1 levels in WT (blue circles) and SMA MNs
(red squares) (N=5). ATCB was used as loading control. Each dot represents the data from individual
biological replicates. Bar graphs depict the mean ± SD. Two-tailed unpaired t-test was used to determine
statistical significance *p <0.05, **p <0.01, ***p <0.001.
3.10.2.1 ROS inhibits translation initiation in WT MNs
Next, we evaluated the e!ect of ROS modulation on 4E-BP mediated translation initiation.
Again, we supplied WT MNs with the ROS modulating supplements NAC, pyruvate, or
menadione for 1 h and measured the phosphorylation status of the translation repressor 4E-BP1.
No significant di!erence was observed after pyruvate or NAC supplementation in WT cells
(Figure 55). While induction of ROS by 100 µM menadione resulted in a reduction of 4E-BP1
phosphorylation. This result suggests that excessive ROS can inhibit mRNA translation at the













































































Figure 55: Translation initiation in WT MNs.
Western blot analysis shows that pharmacologically modifying ROS levels changes p4E-BP1 levels in WT
MNs (N=6). Each dot represents the data from individual biological replicates. One-way ANOVA with
Tukey HSD post hoc analysis was used to determine statistical significance for multiple comparisons.
Bar graphs depict the mean ± SD. ns p >0.05, *p <0.05, ***p <0.001.
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3.10.2.2 Reducing ROS increases translation initiation in SMA MNs
As we are particularly interested in the e!ect of reducing ROS on translation initiation
in SMA, we performed the same experiments with SMA MNs. Indeed, pyruvate and NAC
increased the phosphorylation of 4E- BP1 in SMA MNs (Figure 55). Moreover, further increase
of ROS by 100 µM menadione did not reduce phosphorylation as observed in WT MNs.
Taken together, this unprecedented data reveals that mRNA translation is impaired at the
initiation step in SMA MNs, while elongation is unaltered. Moreover, the initiation of mRNA














































































Figure 56: 4E-BP mediated translation initiation in SMA MNs.
Western blot analysis shows that pharmacologically modifying ROS levels changes p4E-BP1 levels in
SMA MNs (N=6). Each dot represents the data from individual biological replicates. One-way ANOVA
with Tukey HSD post hoc analysis was used to determine statistical significance for multiple comparisons.
Bar graphs depict the mean ± SD. ns p >0.05, *p <0.05, **p <0.01.
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3.11 SMN protein levels are regulated by pyruvate and ROS via mTOR
Since we aim to ameliorate the phenotypes of SMA, it is crucial to investigate the e!ect of ROS
on the disease-causing protein SMN. As pyruvate increased ATP levels and reduced ROS, we
further investigated the e!ect of pyruvate on SMN protein levels. Additionally, it is interesting
to identify by which pathway the translational regulation is mediated. Here, the mTOR pathway
is one candidate as it regulates protein synthesis post-transcriptionally.
3.11.1 Pyruvate increases SMN in NSC-34 cells, WT MNs and SMA MNs
As our previous results suggested, pyruvate had no beneficial e!ect in NSC-34 cells or WT MNs
on protein synthesis or ROS regulation when those levels were in a normal range. However, we
were able to increase ATP levels in those cells. Therefore, to exclude any negative e!ects of
pyruvate on the SMN levels, we added 50 mM pyruvate over 1 h to those cells. Surprisingly,
pyruvate increased SMN protein levels in NSC-34 cells and also in WT MNs (Figure 57A
& Figure 57B). Even though SMN levels doubled in NSC-34 after 10 min, treatment for
40 min or 60 min did not show any significant benefit (Figure 57A). Additionally and most
importantly, pyruvate increased SMN protein levels over 1 h in SMA MNs (Figure 57C).
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Figure 57: Pyruvate increases SMN protein levels.
Representative western blot and quantification show an increase of SMN protein level after 50 mM
pyruvate supplementation for 1 h in NSC-34 cells (N=5) (A), WT MNs (N=7) (B) and SMA MNs
(N=7) (C). Bar graphs depict the mean ± SD. One-way ANOVA with Dunnett post hoc analysis was
used to compare each timepoint with the control. ns p>0.05, *p <0.05, **p <0.01.
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3.11.2 Increase of SMN is post-transcriptionally regulated
As our results showed that pyruvate could increase SMN protein levels, it is important to test
whether this increase is mediated transcriptionally or post-transcriptionally. To understand
the molecular mechanism underlying increased SMN levels, we performed qRT-PCR with
Smn specific primers to measure Smn mRNA levels in WT MNs and NSC-34 cells after
pyruvate treatment. No significant increase of Smn mRNA levels was observed after pyruvate
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Figure 58: Pyruvate does not change Smn mRNA expression.
Quantitative real-time PCR using gene specific Smn primers confirms that pyruvate supplementation
does not change Smn transcript levels in NSC-34 cells and WT MNs (N=4). Actb was used as loading
control. Bar graphs depict the mean ± SD.
To strengthen our results that pyruvate regulates SMN post-transcriptionally, we blocked
translation with 50 µM anisomycin and measured SMN after 50 mM pyruvate supplementation
for 10 min and 20 min. In line with our hypothesis, the increase of SMN was abolished entirely
when anisomycin was present (Figure 59). However, as a control, SMN levels were measured
without protein synthesis inhibition, and an increase was detected after 10 min and 20 min
of pyruvate (Figure 59). This data confirms that protein synthesis of SMN is regulated by
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Figure 59: Increase of SMN by pyruvate is abolished by anisomycin.
50 µM anisomycin prevents increase of SMN protein levels induced by pyruvate (N=6). 50 mM pyruvate
was treated for 10 min or 20 min. Bar graphs depict the mean ± SD. One-way ANOVA with Tukey
HSD post hoc analysis was used to determine statistical significance. *p <0.05, **p <0.01.
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3.11.3 Modulation of ROS regulates SMN
Also, we wanted to see the e!ect of ROS on SMN protein levels. As we already saw the
connection between ROS and global or local translation, it is most interesting if SMN is also
increased by reducing ROS. Indeed, 10 µM NAC increased SMN levels in WT MNs (Figure
60A). Furthermore, SMN was also a!ected by increasing ROS with menadione in WT MNs. In
both WT and SMA MNs, SMN was almost completely depleted after 1 h menadione treatment.
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Figure 60: SMN levels after 1h NAC and menadione treatment.
Representative western blot images and quantification of SMN levels treated with 10 µM NAC or 100 µM
menadione for 1 h in WT MNs (A) and SMA MNs (B). One-way ANOVA with Tukey HSD post hoc
analysis was used to determine statistical significance for multiple comparisons. Each dot represents the
quantification of individual biological replicates. Bar graphs depict the mean ± SD. ns p >0.05, *p
<0.05, ***p <0.001.
3.11.4 Increase of SMN is mTOR-dependent
Translation can be regulated by the mTOR pathway. Especially mTORC1 is a central regulator
of protein synthesis (Sarbassov & Sabatini, 2005). Therefore, we tested whether the increase
in SMN protein levels is mTOR dependent. We treated MNs with 100 nM of the water-soluble
mTOR inhibitor, WYE-687 dihydrochloride, and supplied 50 mM pyruvate. As our previous
results already showed, pyruvate increased SMN levels in WT MNs after 10 min or 20 min.
However, blocking the mTOR pathway by WYE-687 dihydrochloride abolished this e!ect
completely (Figure 61).
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Figure 61: Increase of SMN by pyruvate is blocked by mTOR inhibition.
100 nM WYE-687 dihydrochloride treatment blocks mTOR dependent increase of SMN levels after
pyruvate treatment in WT MNs. One-way ANOVA with Tukey HSD post hoc analysis was used to
determine statistical significance for multiple comparisons. Each dot represents the quantification of
individual biological replicates. Bar graphs depict the mean ± SD. ns p >0.05, *p <0.05, **p <0.01.
To further investigate the e!ect of pyruvate on the mTOR pathway, we treated WT and
SMA MNs with 50 mM pyruvate for 10 min and 20 min and measured phosphorylation of
the S6 Kinase as well as phosphorylation of the downstream target ribosomal protein S6 (S6).
Supplementation of WT MNs resulted in higher phosphorylation of both, S6K and S6 proteins
(Figure 62A & Figure 62B). Especially the S6 protein was three-fold higher phosphorylated
after 10 min and 20 min pyruvate supplementation in WT MNs. In addition, pyruvate increased
the phosphorylation status of S6 in SMA MNs (Figure 62C). This data conclusively shows
that the activity of the mTOR pathway is increased after pyruvate treatment.
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Figure 62: Pyruvate increases mTOR in WT and SMA MNs.
(A) Representative western blot and quantification show that pyruvate treatment increases phosphory-
lation status of p70S6 kinase. (B) Representative western blot and quantification of phosphorylated
S6 and total S6 protein levels after pyruvate treatment in WT MNs (N=7) and in SMA MNs (N=7)
(C). One-way ANOVA with Tukey HSD post hoc analysis was used to determine statistical significance
for multiple comparisons. Each dot represents the quantification of individual biological replicates. Bar
graphs depict the mean ± SD. ns p >0.05, *p <0.05, ***p <0.001.
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Further, reduction of ROS by NAC treatment in SMA MNs also increased mTORC1 activity
(Figure 63).
Taken together, our data showed that cellular ROS and ATP levels regulate SMN protein
synthesis via regulating mTORC1. Furthermore, re-balancing ROS levels with an antioxidant in
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Figure 63: Reducing ROS increases mTOR in SMA MNs.
Representative western blot and quantification of phosphorylated S6 and total S6 protein levels after
10 µM NAC treatment and 100 µM menadione in SMA MNs (N=7). One-way ANOVA with Tukey
HSD post hoc analysis was used to determine statistical significance for multiple comparisons. Each dot
represents the quantification of individual biological replicates. Bar graphs depict the mean ± SD. ns p
>0.05, *p <0.05.
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Previous studies revealed several molecular impairments leading to SMA. Early studies noted
indications of disturbed energy homeostasis (Acsadi et al., 2009). Additionally, several studies
revealed impairments of mitochondria in SMA (Miller et al., 2016; C. C. Xu et al., 2016;
Z.-B. Wang et al., 2013). Moreover, emerging research on ribosome biology revealed a reduced
number of ribosomes and impaired translation e"ciency in SMA (Bernabò et al., 2017; Lauria
et al., 2020). However, the interactions of those impairments remain still elusive. Our study
clarified the interplay of energy homeostasis, oxidative stress, and protein synthesis in SMA.
Additionally, we add new insights into tissue-specific impairments of SMA based on our
findings of MN specific mitochondrial complex I defects. However, the pathology of SMA
exceeds MNs as their primary a!ected tissue (Hamilton & Gillingwater, 2013). Therefore,
determination of tissue-specific impairments is essential, but for future therapies, other tissues
a!ected in SMA must also be taken into consideration.
Some of the molecular impairments, including decreased ATP levels, have been shown to
occur at early symptomatic stages (Boyd et al., 2017). However, it was not of aim to answer the
question if deprived energy homeostasis or increased oxidative stress is a cause or consequence
of SMA. Further studies investigating presymptomatic and symptomatic tissues might answer
this question. Regardless of its role in SMA, our study shows that alleviating oxidative stress
and improving energy homeostasis is beneficial for SMA MNs. With this study, we attempt to
clarify the role of defective energy homeostasis, including the formation of oxidative stress.
By performing a quantitative proteome analysis, we could verify previously known processes
that are dysregulated in SMA. Those processes include RNA binding, protein transport, the
formation of ribonucleoprotein complexes, and protein synthesis (Akten et al., 2011; Bernabò
et al., 2017; Fallini et al., 2011; Kye et al., 2014; Pellizzoni, 2002; Rossoll et al., 2003). The
major findings of this study are:
(I) Mitochondrial defects in SMA MNs result in reduced ATP levels that could not be
compensated by glycolysis.
(II) We identified a defective complex I in the respiratory chain as causative for increased
ROS formation.
(III) Oxidative stress in SMA MNs results in increased protein carbonylation and reduced
translation.
Impaired protein synthesis has also been reported earlier in SMA (Kye et al., 2014;
Bernabò et al., 2017). However, the molecular link between oxidative stress and impaired
protein synthesis was not reported.
(IV) We found out that especially translation initiation is a!ected by increased oxidative
stress.
(V) Counteracting oxidative stress and energy homeostasis results in an improved initia-
tion of mRNA translation. The mTOR pathway mediates this process.
In summary, we revealed a previously unknown relationship between oxidative stress generated
by defective mitochondrial complex I and mRNA translation initiation in SMA MNs. Also, this
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study conclusively connects oxidative stress to impaired mRNA translation. Furthermore, we
showed that targeting mitochondrial defects ameliorates the defective protein synthesis. In
addition, ROS reduction results in an increase of SMN, possibly mitigating SMA pathology. The
newly found insights will be discussed hereafter in detail under consideration of methodological
limitations of this investigation and the perspective of current knowledge.
Primary MNs from SMA mice and control mice were used for in vitro experiments to
evaluate pathological changes in SMA. Spinal cords of E13.5 embryos were isolated, and
primary MNs were cultured for 10 days. Of note, only 3%-5% of all neurons in the spinal
cord of E12-E14 embryos are MNs (Arce et al., 1999; Wiese et al., 2010). However, during
in vitro culture, MNs are enriched. After 2DIV, a 10-fold enrichment of MNs by the culture
conditions is already observed, even without enrichment by p75NTR-antibody panning (Wiese et
al., 2010). Therefore, primary MN cultures are highly enriched after 10DIV. With enrichment by
p75NTR-antibody panning, MNs can be enriched to about 90% after 7DIV (Wiese et al., 1999,
2010). Furthermore, successful enrichment of MNs, using the same protocol has been shown in
previous studies by ChAT stainings (Kye et al., 2014; Gonçalves et al., 2018; Rehorst et al.,
2019). Moreover, MNs are morphologically easily distinguishable from other non-neuronal cells.
4.1 The mitochondrial proteome is significantly altered in SMA MNs
The initial objective of this study was to identify altered pathways in SMA MNs. Therefore,
quantitative proteome analysis was conducted. As previous studies implicated metabolic
defects in SMA and especially an impaired energy homeostasis, we focused on proteins
associated with mitochondrial localization or function. Surprisingly no di!erence in the
amount of significantly altered mitochondrial proteins and the overall number of detected
mitochondrial proteins was found. Our dataset was compared to the MitoCarta2.0 dataset,
including 1158 mitochondrial proteins. Based on literature, it is assumed that ! 14% -
! 16% of the neuronal proteome is associated with mitochondria (Hornburg et al., 2014; Calvo
et al., 2016; Bogetofte et al., 2019). However, we detected ! 13% of proteins associated
with mitochondria in our proteome analysis. Furthermore, ! 12% of all significantly changed
proteins were also found in the MitoCarta2.0 database. Of note, it is essential to keep the time
of di!erentiation in consideration as neurons shift their metabolism from aerobic glycolysis to
OXPHOS during di!erentiation (Zheng et al., 2016). After 1 or 2 weeks in culture, embryonic
and postnatal neurons show similar properties with regard to metabolic properties, energy
homeostasis, and stress resistance (Surin et al., 2013). Therefore, neurons in our experiments,
which are cultured for 10 days, can be compared to postnatal neurons in terms of energy
homeostasis.
4.2 The number of mitochondria is reduced in SMA MN axons
Mitochondria generate ATP and regulate Ca2+ homeostasis and apoptosis. Moreover, mitochon-
dria are transported along the axon to support local energy demands or bu!er Ca2+ necessary
for neurotransmitter release and neuronal signaling. Mitochondria are transported anterogradely
by kinesin motor proteins of the KIF5 family and retrogradely by dyneins (Sheng & Cai, 2012).
In addition, KIF1B and KIF1BP regulate mitochondria localization in the anterograde direction
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(Nangaku et al., 1994; Pilling et al., 2006; Wozniak et al., 2005). An axonal Ca2+ increase
and Na+/K+-ATPase activity upon action potentials, results in mitochondrial immobilization
(C. L. Zhang et al., 2010). Even though the mechanism remains unclear, it is hypothesized that
mitochondria are stalled upon ATP depletion to generate local energy supplies (C. L. Zhang
et al., 2010). Impairments in mitochondrial transport are associated with neurodegeneration
caused by an impaired synaptic homeostasis (Sheng & Cai, 2012).
Previous studies in SMA MNs focusing on mitochondrial mobility along the axon showed
concordantly a reduced retrograde transport (C. C. Xu et al., 2016; Miller et al., 2016). However,
there is little agreement on mitochondrial size and occupancy along the axon. While Xu et
al. reported a reduced mitochondrial size and number, they noticed no di!erence in the
mitochondrial length (C. C. Xu et al., 2016). In contrast, Miller et al. detected a reduced
mitochondrial length, but the same density of mitochondria in SMA MNs and control MNs
(Miller et al., 2016). Our initial hypothesis suggesting a link between oxidative stress and SMA
pathology is further supported by the increased mitochondrial motility upon NAC treatment
(C. C. Xu et al., 2016).
In accordance with the results of Xu et al., our investigations demonstrate that the
number and size of mitochondria are reduced in the axonal compartment of SMA MNs. In
addition, our whole proteome analysis suggested altered levels of mitochondrial proteins in
SMA MNs. Increased TOM20 levels found in the MS data were further confirmed by WB
analysis. Nonetheless, an increase of TOM20 is contradictory to the quantification of TOM20
within the axon. A reasonable explanation for these results may be that defective mitochondria
accumulate in the soma. Therefore, total TOM20 amounts appear to be increased despite the
reduction in the axon.
Nevertheless, the diverse results, including ours, might be explained by methodological
di!erences in the studies. While Miller and colleagues visualized mitochondria by aberrantly
expressed mitochondrial proteins, Xu et al. and we used the mitochondria membrane interca-
lating dye MitoTracker. In addition, we labeled endogenous TOM20 immunofluorescently to
visualize functional and non-functional mitochondria. In SMA and WT MNs, we observed fewer
mitochondria by MitoTracker staining than by TOM20 labeling. This finding confirms that
MitoTracker labeling visualizes only functional mitochondria, and the actual number, including
defective mitochondria, is higher than the ones visualized by MitoTracker staining.
Although our studies did not focus on mitochondrial motility, we found reduced KIF1B and
KIF1BP levels in our whole proteome analysis. Reduced motor proteins can explain the reduced
motility of mitochondria in the axons and the reduced ATP availability. Further, increased
action potentials resulting from hyperexcitability might contribute to the immobilization of
mitochondria.
In addition, the increased circularity of mitochondria suggests an impairment and fragmen-
tation of mitochondria in SMA MNs.
4.3 Complex I activity is impaired in SMA MNs
ROS generation arises from proton leakage in the respiratory chain and subsequent partial
reduction of oxygen. Although complex I-III can generate ROS, the overall amount generated by
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the complexes varies among cell types and their mitochondrial activities (Barja, 1999; Turrens,
2003). However, complex I is the major ROS producer in neurons (Barja & Herrero, 1998).
Most interestingly, proteins of complex I were most prominent among the significantly
changed proteins in SMA MNs. Quantitative proteome analysis revealed alterations in one-
quarter of the detected proteins in complex I. It is somewhat surprising that no respiratory chain
proteins encoded in the mitochondrial DNA were significantly altered in SMA. This finding is
unexpected as oxidative stress can damage mtDNA in defective mitochondria, and therefore, an
altered expression of those proteins would be not surprising. Furthermore, several translation
factors and components of the mitochondrial small and large ribosome subunits encoded in the
nucleus were altered in SMA.
Functional analyses of the complex I confirmed an impairment of the respiratory chain
activity caused by defective complex I in SMA MNs. Additionally, complex I activity was
measured in di!erent tissues of SMA to test a neuron-specific alteration. Interestingly, complex
I activity was unchanged in the heart and spinal cord of SMA. While the proper function of
complex I implicates a cell type-specific e!ect, the unaltered activity in SC neurons raises new
questions. However, only a small proportion of 3% - 5% of cells in the spinal cord are MNs
(Arce et al., 1999; Wiese et al., 2010). Therefore, a MN specific e!ect of complex I deficiency
can not be detected in the whole spinal cord. In addition, tissue samples of heart and SC were
taken from P5 mice, while MNs were taken from E13.5 mice and cultured for 10 days. SMA
mice of this model show a mean survival of 10 days (Riessland et al., 2010). Moreover, P5
SMA mice are early symptomatic. Therefore it can not be excluded that any e!ect can be
observed when more severe symptoms occur.
4.4 Oxidative stress is increased in SMA MNs
The issue of oxidative stress in SMA has been a controversial and much-disputed subject in
the field. Early studies suggested increased oxidative stress with an increased mitochondrial
membrane potential upon SMN depletion in NSC-34 cells (Acsadi et al., 2009). In contrast,
more recent studies found increased oxidative stress in the soma and axon but a decreased
mitochondrial membrane potential (Miller et al., 2016). Additional studies in MNs generated
from SMA type 1 patient-specific iPSCs confirmed a reduced membrane potential with an
increase of oxidative stress (C. C. Xu et al., 2016; Z.-B. Wang et al., 2013). Nevertheless,
the assumption of increased oxidative stress in SMA has recently been challenged by studies
in SMA iPSC- derived MNs demonstrating that SMN deficiency does not induce oxidative
stress (Patitucci & Ebert, 2016). This controversy highlights the importance of gaining deeper
insights into the mechanisms regulating oxidative stress in SMA MNs.
Based on fluorescence labeling, we concluded that SMA MNs su!er from increased ROS
levels. We showed elevated ROS by fluorescence labeling in a microplate reader and by
microscopy. Here, we did not distinguish between the soma and axonal compartment. As we
speculate that ROS a!ecting SMA MNs is produced in mitochondria, it is not surprising that
fluorescence signals appear very faint in the axonal compartment. However, previous studies
using transfection of a redox-sensitive green fluorescent protein to visualize ROS distinguished
between individual compartments and found increased ROS in both soma and axon (Miller et
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al., 2016).
Important enzymatic scavengers of antioxidant defense are superoxide dismutases, catalases,
glutathione S-transferases (GSTs), or glutathione peroxidases (GTPx) (Birben et al., 2012).
Moreover, the study of Patitucci et al. revealed an increase of endogenous catalase expression,
suggesting a successful compensatory mechanism of the cellular antioxidant defense (Patitucci
& Ebert, 2016). Even though Patitucci and colleagues’ study did not observe an increase of
oxidative stress in SMA MNs, the upregulation of antioxidative catalases suggests a compensatory
mechanism towards oxidative stress. Reducing oxidative stress in SMA MNs with NAC has
been proven to mitigate pathology, including defective mitochondrial transport (Z.-B. Wang et
al., 2013; C. C. Xu et al., 2016). Nevertheless, those studies did not elaborate further on the
mechanism of amelioration.
Several proteins, including SOD1 or GSTP1, were found in our MS data significantly
reduced in SMA MNs. It is possible, therefore, that SMA MNs fail to mitigate oxidative
stress e"ciently. Nonetheless, several other proteins involved in oxidative stress defense, albeit
less, were significantly increased in SMA MNs. However, a compensatory mechanism of
up-regulated ROS scavengers can not be excluded, based solely on the quantitative proteomics
approach. Further functional studies with more focus on oxidative stress defense mechanisms
are therefore required. Taken together, it appears that oxidative stress occurs in SMA MNs, but
the mechanism of oxidative stress defense is very fragile and might fail to reduce intracellular
ROS levels.
Increased ROS levels can result in various pathological changes in a cell. Molecular targets
of ROS include DNA, lipids, and proteins (Auten & Davis, 2009). Further, protein oxidation
caused by ROS can result in impaired global protein synthesis (Topf et al., 2018). Indeed
we detected increased protein carbonylation and reduced protein synthesis in SMA MNs. A
reduced protein synthesis in SMA MNs was also observed in previous studies (Kye et al., 2014;
Bernabò et al., 2017; Lauria et al., 2020)
As the decrease of protein synthesis in SMA MNs is a substantial impairment, we confirmed
the results with two independent methods. The first method uses puromycin labeling; the
SUnSET assay. Puromycin labels newly synthesized proteins and causes a termination of
protein synthesis. Furthermore, we used a second method to eradicate any possible e!ect on
puromycin due to increased ROS in SMA. The second method uses the stable incorporation of a
methionine analog without termination of protein synthesis. Both methods showed conclusively
a massive decrease in protein synthesis in SMA MNs.
It has been shown that hypoxia induces ROS production in the brain (Lewén et al., 2000;
Maiti et al., 2006). In severe SMA forms of SMA mouse models and patients, vascular defects
resulting in hypoxia of MNs have been noticed (Somers et al., 2016). Further, widespread tissue
hypoxia, including muscle, was observed in SMA mice, with MNs being especially susceptible
to hypoxia (Hernandez-Gerez et al., 2020). As a result of hypoxia, the hypoxia-inducible factor
3 alpha (Hif3!) is increased in symptomatic SMN!7 SMA mice. Moreover, hypoxia reduced
SMN levels by increased SMN2 exon 7 skipping (Bebee et al., 2012).
In all our experiments, isolated MNs were cultured under normoxic conditions. Further,
our whole proteome analysis did not reveal any increase in hypoxia-inducible factors. However,
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considering the vascular defects and the interplay in the organism, the e!ect of hypoxia and
subsequent induction of oxidative stress on other tissues needs to be considered.
4.5 Glycolysis does not compensate for mitochondrial defects
It is widely accepted that mitochondrial OXPHOS is the primary energy-producing process in
neurons. However, the preference of energy production in neurons switches during di!erentiation
from glycolysis to OXPHOS (Zheng et al., 2016). Additionally, neurons are capable of adapting
to external stimuli and fluctuating energy requests.
In terms of glycolysis, GLUT3 provides a basal supply of glucose to neurons (Gerhart et
al., 1992; Ashrafi et al., 2017). Further, it has been shown that energetic demands in neurons
can promote the mobilization of GLUT4 to active synapses (Ashrafi et al., 2017). In an ALS
Drosophila model, glycolysis has been found to be up-regulated as a compensatory mechanism,
and supply of glucose was neuroprotective (Manzo et al., 2019). Also, prior studies in SMA
suggested metabolic impairments contributing to SMA pathology, including defective glucose
metabolism (Bowerman et al., 2014). Moreover, while basal glycolysis has been shown to be
unaltered in patient myoblasts, compensatory glycolysis was lower in SMA than healthy control
myoblasts (Hellbach et al., 2018). Surprisingly, we found that glucose uptake is reduced in
SMA MNs and does not compensate for mitochondrial impairments.
Nevertheless, it remains unclear why SMA MNs fail to adapt to fluctuating energy demands.
Direct quantification of glucose transporter at the synapse could reveal if SMA MNs are
incapable of glucose transporter exocytosis. Further, the e"ciency of glucose utilization remains
unclear in SMA.
4.6 Rescuing energy homeostasis fails to rescue SMA pathology fully
As mentioned in the literature review, neuronal signal transmission is metabolically expensive.
In fact, action potentials can consume up to 47% of the energy used for synaptic transmission
(Attwell & Laughlin, 2001). Furthermore, previous studies revealed that SMA MNs are
hyperexcitable due to increased Na+ channel activity (H. Liu et al., 2015). In addition, focusing
on energy used in non-signaling processes, global translation is a very energy-demanding process.
Up to 20-30% of the whole energy consumption is attributed to protein synthesis (Buttgereit
& Brand, 1995). However, energy consumption is very diverse in di!erent tissues. Even though
protein synthesis uses a tremendous amount of the total energy, it is assumed that protein
synthesis in neurons only accounts for ! 1.3% of energy that is not used for signaling (Rolfe &
Brown, 1997; Attwell & Laughlin, 2001; Engl & Attwell, 2015). Still, the impact of protein
synthesis can be higher than in other tissues as the overall energy consumption is very high in
neurons.
Considering the high energy demands in neurons and the hyperexcitability in SMA MNs,
we hypothesized that SMA MNs require significant amounts of ATP. Nevertheless, decreased
ATP levels in MNs of di!erent SMA models were observed in previous studies (Acsadi et al.,
2009; Boyd et al., 2017). Additionally, Boyd and colleagues’ previous study revealed that
ATP concentrations were reduced early and late symptomatically in the spinal cord (Boyd
et al., 2017). The findings of the current study are consistent with the previous studies and
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provide evidence for reduced ATP levels in SMA MNs. Additionally, we provide data from
bioluminescence and fluorescence signals showing a consistent decrease of ATP in SMA MNs.
Both methods show individual advantages in terms of signal intensity, background signal, and
signal stability. However, luminescence has been proven to be more sensitive than fluorescence
signals due to a reduced background signal (Fan & Wood, 2007). Still, our results showed a
higher reduction of ATP in SMA samples measured by fluorescence. A possible explanation for
these outcomes may be the quenching e!ect of ROS on the fluorescence signal. Therefore,
luminescence was used to detect ATP in all further experiments.
4.6.1 The astrocyte-neuron lactate shuttle hypothesis and why lactate fails to in-
crease ATP in neurons
Previous research, including our results, showed an impairment of the energy homeostasis in
SMA MNs. Therefore, we hypothesize that rescuing energy homeostasis might ameliorate the
SMA phenotype. Therefore, this study set out with the aim to restore energy homeostasis
in SMA MNs. However, there are multiple ways to support the energy homeostasis in a cell.
One e"cient way is to supply the cells with the necessary substrates. As our results suggested
that glucose uptake is impaired in SMA MNs, we aimed to bypass glycolysis and supply either
lactate or pyruvate.
In 1994, the controversial astrocyte-neuron lactate shuttle hypothesis (ANLS) was estab-
lished by Pellerin and Magistretti (Pellerin & Magistretti, 1994). Based on the ANLS, it was
assumed that neuronal activity could trigger glucose uptake in astrocytes (Pellerin & Magistretti,
1994). The initial ANLS hypothesis focused on the quantitative coupling of synaptically released
glutamate with glucose utilization in astrocytes to produce lactate. Also, the shuttle of lactate
from astrocytes to neurons has been shown in vivo (Mächler et al., 2016).
One major issue in the ANLS hypothesis was raised by more recent research. It was demon-
strated that glycolysis and lactate export is instead down-regulated in neurons under neuronal
activity (Díaz-García et al., 2017; Díaz-García & Yellen, 2019). These results are in agreement
with the increased GLUT4 localization at the plasma membrane under neuronal stimulation
(Ashrafi et al., 2017). Therefore, it is more likely that the metabolic response to neuronal
activation is determined by the kinetics of neuronal glycolysis rather than increased lactate
shuttle. While lactate is undoubtedly a valuable oxidative substrate to neurons. Nevertheless,
the importance during neuronal activity is questionable.
As the ANLS still holds true in many aspects, it was reshaped into the concept of astrocyte-
neuron communication (ANC) (Roosterman & S. Cottrell, 2020). The ANC concept focuses
primarily on the proton-driven transfer of lactate and pyruvate linked to glucose provision.
Therefore, a variety of monocarboxylate transporter (MCT) in complexes with proton donors
stabilizes the import of lactate to neurons in the presence of glucose, generating an energy flow.
In general, MCT are used to facilitate the transport of molecules containing one carboxylate
group such as lactate or pyruvate (Halestrap & Meredith, 2004). Monocarboxylates can
be exported unidirectionally from highly glycolytic cells by MCT4 (Dimmer et al., 2000).
While MCT4 shows a higher a"nity towards lactate, the export of lactate is more likely
(Halestrap, 2013; Contreras-Baeza et al., 2019). Additionally, MCT1 unidirectionally imports
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monocarboxylates (Debernardi et al., 2003). Here, MCT1 shows a higher a"nity towards
pyruvate (Halestrap, 2013). However, also lactate shuttle from neurons to astrocytes has
been shown in vivo (Mangia et al., 2009). Therefore, it is assumed that monocarboxylates
can be simultaneously imported and exported in astrocytes (Lynch et al., 2015; Roosterman
& S. Cottrell, 2020). In neurons, MCT2 is a major transporter for monocarboxylates and is
capable of importing lactate (Pierre et al., 2002). Moreover, the direction of MCT2 transfer
can change from import to export based on the MCT2-proton donor complex (Halestrap &
Meredith, 2004).
Unquestionably, lactate can be used as an energy substrate regardless of neuronal stimulation.
Inside of the neuron, lactate can be converted into pyruvate for subsequent OXPHOS via the
lactate dehydrogenase. However, supplementation of lactate failed to increase ATP levels in
MNs. The reason for this is not apparent, but it may have something to do with the ability to
export lactate from neurons as supposed in the neuron to astrocyte lactate shuttle. Especially,
highly active SMA MNs, might tend to export lactate rather than import it as this was also
seen in vivo in previous studies (Díaz-García et al., 2017). Another possible explanation for
this is that we only used two di!erent lactate concentrations, which might not be optimal.
4.6.2 Pyruvate improves energy homeostasis and reduces ROS
Following our aim to restore defective energy homeostasis, we supplied MNs with pyruvate.
As described in the previous chapter, pyruvate is imported into neurons via MCT2 and can
serve as a substrate during OXPHOS. There are multiple advantages of supplying pyruvate
over lactate to neurons.
One disadvantage of lactate is that it can be exported from neurons and shuttle to astrocytes.
Further, protonated MCT2 shows a ten-times higher a"nity towards pyruvate over lactate
(Lin et al., 1998; Halestrap, 2013). Therefore, another advantage of pyruvate is the preferred
substrate for import into neurons. Indeed, our results showed stable pyruvate uptake in SMA
and control MNs. Even though we did provide evidence for intercellular pyruvate uptake, we
did not show pyruvate uptake into mitochondria. Nevertheless, the stable increase of ATP after
pyruvate supplementation suggests a successful import into mitochondria.
Additionally, pyruvate can act as a ROS scavenger and reduce oxidative stress (K#adna et
al., 2015). The beneficial e!ect of ROS reduction was not observed in WT MNs or NSC-34
cells. However, these results are not surprising, as oxidative stress does not occur in those cells.
Therefore, oxidative stress was induced pharmacologically in those cells by menadione. Those
experiments support our hypothesis that ROS reduction is possible by pyruvate supplementation.
Additionally, pyruvate supplementation reduced ROS in SMA MNs su!ering from oxidative
stress.
In contrast, previous studies showed that lactate and pyruvate could also induce ROS
(Tau!enberger et al., 2019). Nevertheless, this study suggested a protective e!ect of lactate
and pyruvate. It was suggested that ROS induction results in a transcriptional upregulation
of oxidative stress defense genes (Tau!enberger et al., 2019). Accordingly, in this study,
neuroprotection is preferably achieved by increased antioxidative proteins than a direct ROS
reduction. Nevertheless, the capability of SMA MNs to cope with oxidative stress might be
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impaired already, as suggested by our MS data and discussed in section 4.4. Due to defective
defense machinery, pyruvate might not result in protective through transcriptional upregulation.
Moreover, the e!ect of ROS reduction and induction might be concentration-dependent.
4.7 Reducing ROS, not increasing ATP improves global translation
The two most striking e!ects of defective mitochondria we found in SMA MNs are increased
ROS and reduced ATP production. One pathological e!ect linked to excessive ROS is a
decreased protein synthesis. Therefore, reducing ROS is hypothesized to restore impaired
protein synthesis in SMA MNs.
Indeed, pyruvate increased ATP in NSC-34 cells and SMA MNs but showed no e!ect on
global protein synthesis. Accordingly, it can be assumed that ATP plays only a minor role in
regulating global protein synthesis. However, this result is expected as only ! 1.3% of the
energy consumption that is not used for signaling in neurons accounts for protein synthesis
(Rolfe & Brown, 1997; Attwell & Laughlin, 2001; Engl & Attwell, 2015). Moreover, NAC
treatment increased protein synthesis in SMA MNs without an e!ect in WT MNs or NSC-34
cells, as only SMA MNs showed increased ROS levels. One unanticipated finding was that
pyruvate did not increase global protein synthesis despite its ROS reducing properties. This
somewhat contradictory result may be due to a superior antioxidative e!ect of NAC compared
to pyruvate.
These results collectively outline a critical role for ROS on protein synthesis with only a
small impact of ATP availability.
4.8 Local translation in SMA MNs
It is essential for neurons to synthesize proteins at the distal ends of the neurites to adapt
to local changes during development and activity. Based on immunofluorescence stainings
of the SUnSET assay, we can conclude that protein synthesis is decreased in the soma and
the axonal compartment. However, even though we measure the pathological outcome of
decreased protein synthesis, we can not conclude the cause of this e!ect. These data must
be interpreted with caution because puromycin labeling is carried out for one hour, and the
transport of newly synthesized proteins might be decreased in SMA MNs. Therefore, we can
not exclude the possible scenario, based only on this experiment, that the impaired protein
synthesis appears mainly in the soma and a reduced transport results in a decreased signal in
distal parts of the neurites. A further study with more focus on axonal protein transport is
therefore suggested. Blocking protein transport in SMA and WT MNs before facilitating the
SUnSET assay might solve this issue. Nevertheless, an impaired local protein synthesis shown
in this study corroborates earlier findings showing a reduced number of axonal ribosomes in an
SMA in vivo model (Bernabò et al., 2017).
Treating MNs with pyruvate and NAC resembled the same results observed in the whole-cell
experiments also in the axonal compartment. Here, only NAC increased local translation in
SMA MNs. In fact, impaired protein synthesis is regulated by ROS, and newly synthesized
proteins are less abundant in the axon.
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Moreover, our experimental setup did not allow us to investigate local translation at the
growth cone. We used 10DIV MNs in all experiments to keep consistency. However, axons of
cultured primary MNs can already exceed 500 µm after 7DIV (Bömmel et al., 2002; Wiese et
al., 2010). Additionally, MN axons and dendrites reach their maximum length after 7DIV and
do not increase significantly afterward (Wiese et al., 2010). Therefore, it is impossible to trace
an entire axon in our cultures.
It has been shown that mitochondria serve as hubs for local translation in dendrites, along
the axon, and at the growth cone (Rossoll & Bassell, 2019; Rangaraju et al., 2019; J.-M. Cioni
et al., 2019). As our results showed a reduced number of mitochondria along the axon in SMA
MNs, this might also a!ect local translation. Furthermore, RNPs, containing mRNAs important
for mitochondrial maintenance, are found to associate with Ras-related protein Rab-7a (Rab7a)
endosomes attached to mitochondria (J.-M. Cioni et al., 2019). The interaction of Rab7
and mitochondria, necessary for local translation, opens new avenues for future studies. Co-
stainings of those components together with puromycin labeling for newly synthesized proteins
can lead to deeper insights into this field.
4.9 Whole proteome analysis after pyruvate treatment
We aimed to determine pathways changed by pyruvate treatment using whole proteome analysis.
As we already detected an increase of ATP after pyruvate treatment, alterations in OXPHOS
are expected. Moreover, multiple alterations occurred in proteins related to nucleotide and
ribonucleotide binding. Biological processes a!ected by these proteins include RNA splicing and
mRNA processing. Furthermore, proteins in the cellular compartments of the spliceosome or
RNP complexes are a!ected by pyruvate treatment. It is essential to keep in mind that those
results solely rely on proteome changes observed in MS analysis. Therefore, any conclusions
must be interpreted with caution. Furthermore, we observed a translational upregulation of
SMN after pyruvate treatment. Therefore, it seems possible that an increase of SMN stabilizes
other RNPs, causing increased nucleotide-binding and mRNA processing.
Interestingly, pyruvate did change the proteome of SMA MNs more than WT MNs. The
mode of action of pyruvate may explain this result. In WT MNs, ATP and ROS levels are
equilibrated, and additional pyruvate does not a!ect the cells much. Additionally, only two
proteins, namely DLGAP1 and ICA1, were changed by pyruvate simultaneously. However, no
further conclusions can be drawn from those proteins.
4.10 Whole proteome analysis after NAC treatment
As our results demonstrated, NAC works e"ciently as an antioxidant in SMA MNs. Further,
whole proteome analysis was facilitated to identify possible pathways altered by NAC treatment.
Similar to pyruvate treatment, NAC treatment led to alterations in RNA splicing and mRNA
processing. Again, those results need to be evaluated carefully but might be explained by an
increase of SMN after NAC treatment.
A more interesting finding was the identification of OTUD6B. While this protein was
down-regulated in SMA, it was up-regulated in SMA MNs after NAC treatment. However, it
was rather down-regulated in WT MNs after NAC treatment. OTUD6B is a deubiquitinase
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involved in ubiquitin-dependent regulation of protein synthesis, downstream of mTORC1 (Sobol
et al., 2017). In detail, OTUD6B regulates translation initiation by modifying the 48S PIC
(Sobol et al., 2017). Interestingly, there are two splicing isoforms of OTUD6B acting in the
opposite direction. While isoform 1 represses protein synthesis (Z. Xu et al., 2011), isoform 2
enhances it (Sobol et al., 2017). Unfortunately, those isoforms can not be distinguished by MS
because of the nearly identical sequences. Nevertheless, this is an important protein for future
research.
4.11 Whole proteome analysis after menadione treatment
Interestingly, menadione treatment reduced most of the proteins in WT MNs and showed
the biggest overlap with proteins altered in SMA. Menadione is used to induce oxidative
stress by increasing ROS through futile redox cycling (Loor et al., 2010). Therefore, these
findings further support the idea of pathological changes due to increased ROS in SMA MNs.
However, the e!ects of menadione can not solely be restricted to increased proteolysis upon
carbonylation due to increased ROS. Additionally, increased ROS by menadione can trigger cell
death independent of apoptosis via poly (ADP-ribose) polymerase (PARP) activation (Loor et
al., 2010). Nevertheless, increased cell death upon menadione treatment was not observed in
our cultures.
4.12 Cap-dependent translation initiation is inhibited in SMA MNs
Recent studies in SMA showed defects in mRNA translation in vivo based on impairments of
ribosome biogenesis (Bernabò et al., 2017). This study revealed a decreased ribosome number
in SMA, and consequently, impairments in the translatome (Bernabò et al., 2017). Moreover,
reduced translation e"ciency was specifically observed in transcripts, including translation
initiation and elongation factors but also ribosome biogenesis.
Focusing on translation-related proteins in our whole proteome approach suggested an
impairment of protein synthesis due to several down-regulated proteins in SMA. However,
proteins involved in translation elongation were barely changed in our MS data. Further
functional experiments in terms of the SunRiSE assay supported the idea of unaltered translation
elongation in SMA. eEF1A2 is a translation elongation factor associated with SMA. Our whole
proteome approach did not reveal any changes in the expression of eEF1A. However, eEF1A2
is not directly associated with SMA, but by complex formation of eEF1A with SMN (Murray et
al., 2008). Loss of eEF1A2 results in disruption of protein synthesis and also to dying-back
neuropathies (Murray et al., 2008). However, due to technical limitations, the e!ect of impaired
translation elongation could not be related to the dying back of neurons in vivo (Murray et
al., 2008). Therefore, no functional evidence in the current literature can be found that shows
altered translation elongation in SMA.
Since no di!erence in translation elongation was detected in SMA MNs, it is not surprising
that NAC or pyruvate treatment do not change the elongation speed. Besides translation
elongation, translation initiation can limit protein synthesis. Therefore, a major objective of
this study was to investigate the role of translation initiation in SMA. Indeed, our data provides
sustained evidence of reduced cap-dependent translation initiation. WB analysis revealed
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reduced phosphorylation of 4EBP in SMA. Accordingly, 4EBP blocks the formation of the
cap-binding complex eIF4F (Pause et al., 1994; Haghighat et al., 1995). Additionally, mTORC1
regulates the phosphorylation of 4EBP and therefore regulating global translation (Gingras et
al., 1999).
Previous studies revealed a reduced protein synthesis together with a reduced mTOR activity
in SMA (Kye et al., 2014). However, this study did not link the decreased protein synthesis
to an impaired translation initiation via 4EBP. Moreover, another study demonstrates the
benefits of mTORC1 activation and subsequent phosphorylation of 4EBP by muscle secreted
C1q/TNF-related protein 3 (CTRP3) in SMA MNs (Rehorst et al., 2019).
Recently, literature has emerged that o!ers controversial findings of mTORC1 activity in
SMA. In this study, no di!erence in 4E-BP phosphorylation was observed at P5, and an increase
of phosphorylation was noted at P8 in SMA. However, this increase of 4E-BP phosphorylation
was observed in SMA brain tissue (Lauria et al., 2020). Moreover, our data suggested a MN
specific implication of complex I defects in SMA, resulting in elevated ROS levels in MNs and
subsequent inhibition of cap-dependent translation via 4E-BP.
Previous studies also assumed a negative feedback loop of SMN, repressing cap-dependent
translation initiation (Sanchez et al., 2013). Indeed, they showed an upregulation of the arginine
methyltransferase CARM1 upon SMN depletion in vitro (Sanchez et al., 2013). However,
based on their own critical discussion, implications of miRNA in this process could not be
fully excluded (Sanchez et al., 2013). Since more recent studies demonstrated the influence
of reduced mature miRNAs upon DROSHA reduction in SMA, this controversy is not to
be neglected (Gonçalves et al., 2018). Moreover, several other studies, including in vivo
experiments, suggested translational repression upon SMN loss (Fallini et al., 2016; Bernabò et
al., 2017; Lauria et al., 2020).
4.13 The mTOR pathways regulates translation in SMA MNs
This study provides sustained evidence of mTOR regulation by pyruvate and NAC. Downstream
targets of mTOR, including 4E-BP, S6K, and S6, showed increased phosphorylation upon NAC
and pyruvate treatment. Interestingly, the induction of ROS by menadione supplementation did
not further reduce mTOR activity in SMA MNs. However, previous studies revealed a reduced
mTOR activity in SMA (Kye et al., 2014). Therefore, an additional reduction of mTOR activity
by increased ROS might not be detectable as it is already extremely low.
Additionally, mTORC1 controls mitochondrial activity by regulating the synthesis of mito-
chondrial proteins via 4E-BP (Morita et al., 2013). Furthermore, this study showed that mTOR
inhibition impairs energy metabolism and respiration in vivo (Morita et al., 2013). This data is
in line with our study showing mTORC1 involvement in mitochondrial regulation via 4E-BP.
We provide not only data on mitochondrial protein synthesis by whole proteome analysis but
also included functional studies on mitochondrial activity.
Besides the regulation of cap-dependent translation, mTORC1 regulates the translation of
mRNAs containing a TOP motif. Primarily proteins in the translational machinery, including
all ribosomal proteins and all translation elongation factors, contain the TOP motif on their
mRNA (Iadevaia et al., 2008; Meyuhas & Kahan, 2015). The whole proteome analysis in
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the current study detected several proteins encoded by TOP mRNAs. Furthermore, TOP
mRNAs can be translationally repressed upon various stresses, including oxygen or amino acid
deprivation independent of 4E-BP activity (Meyuhas & Kahan, 2015; B. B. Li et al., 2018).
Based on our experiments, we can not resolve if the regulation of TOP mRNA encoded proteins
is based on a cap-dependent or cap-independent manner. Therefore, individual targets need to
be tested after mTOR inhibition, similar to the experiments performed in this study on SMN
expression. Alternatively, a whole proteome analysis can be performed after inhibition of mTOR
or components of the cap-dependent translation machinery.
4.14 Increase of SMN by pyruvate and NAC supplementation is mTOR-
dependent
The most striking result for the field of SMA is that NAC and pyruvate increased SMN levels
mTOR-dependently. While NAC increased not only SMN but also global translation, pyruvate
supplementation led to a specific increase of SMN. The e!ect was clearly translationally
regulated as pyruvate supplementation did not increase SMN transcript levels. Furthermore,
inhibition of mTOR abolished the e!ect of pyruvate. Nevertheless, it can not be excluded that
NAC increases mTORC1 activity resulting in increased ribosomal biogenesis and accordingly,
an increased global translation. However, SMN mRNA does not contain a TOP motif, and
therefore direct regulation via mTOR is not possible.
Menadione supplementation of WT and SMA MNs showed even lower SMN levels than
untreated cells, implicating that not only translation is inhibited, but SMN protein is additionally
degraded. Oxidative stress induction can inhibit SMN complex formation, leading to rapid
degradation (Wan et al., 2008).
Recent studies showed the direct association of SMN with ribosomes, which are reduced
in SMA (Lauria et al., 2020). Consequently, a subset of SMA specific transcripts have been
found di!erentially translated (Lauria et al., 2020). While our results are in full agreement
with this study, we add an additional mechanism contributing to SMA pathology. However,
the study of Lauria and colleagues is specific to SMA pathology. Our study describes a more
general problem involving oxidative stress and translation initiation in MNs. Therefore, other
diseases might also benefit from the regulation of mitochondrial function and oxidative stress.
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In recent years, there has been an increasing interest in SMN-independent therapies of SMA.
With Spinraza and Evrysdi, two very promising drugs have been approved in the last years,
focusing on enhancing SMN full-length production from SMN2. Additionally, Zolgensma is
the first approved gene therapy in SMA that is also SMN dependent. Moreover, Evrysdi is the
only drug potentially elevating SMN levels in other tissues than MNs and therefore mitigating
multisystemic e!ects of SMA (Wirth, 2021).
This study set out to determine the e!ect of deprived energy homeostasis in SMA. Further-
more, the present study was designed to decipher the e!ect of increased oxidative stress on
neuronal protein synthesis in SMA. The four major findings in this study are:
(I) SMA MNs su!er from an impaired energy homeostasis, including defective mitochon-
dria and no compensation by glycolysis.
(II) Oxidative stress in SMA MNs is caused by an impaired mitochondrial respiratory
complex I.
(III) Increased oxidative stress leads to reduced translation initiation in SMA MNs.
(IV) Counteracting mitochondrial defects by NAC or pyruvate enhances translation,
including mTOR-dependent translation of SMN.
This work contributes to existing knowledge in SMA research by clarifying the role of
oxidative stress resulting in impaired translation initiation. Furthermore, this study suggests an
additional therapeutic target, enhancing translation by decreasing oxidative stress (Figure 64).
Still, several questions remain unanswered at present, and further studies on the current topic
are therefore recommended:
(1) The present study confirms previous findings of impaired energy homeostasis in SMA
and contributes additional evidence that locates mitochondrial defects to complex I.
Additionally, it was suggested that glycolysis is not able to compensate for the impaired
energy homeostasis. While this study reveals a reduced glucose uptake in SMA MNs,
glycolysis e"ciency remains largely unknown. However, since upregulation has been
shown to be beneficial in ALS (Manzo et al., 2019), it is worth investigating this approach
in SMA.
(2) It has conclusively been shown that NAC or pyruvate treatment can be used to
increase SMN levels in a short time. It would be interesting to assess the e!ects of NAC
or pyruvate treatment over a longer period in vitro and in vivo.
(3) Additionally, pyruvate treatment has been shown to increase SMN in WT MNs that are
not a!ected by mitochondrial defects without altering the whole proteome. Considering
the multisystemic e!ects observed in SMA, it would be interesting to evaluate the e!ect
of pyruvate treatment in other cells di!erent from MNs.
(4) This research has shown that pyruvate e!ectively increases ATP and NAC reduces
ROS. As decreased energy and increased ROS are two major events contributing to SMA
pathology, a combinatorial treatment is of interest.
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(5) Since pyruvate treatment lead to specific upregulation of SMN without altering global
protein synthesis, further investigations into the specificity are recommended. Considering
new insights by Lauria et al., suggesting SMN primed ribosomes translating SMA specific
transcripts might help solve SMN and SMA specificity.
(6) While the whole proteome analysis revealed new insights of SMA a!ected pathways
and NAC or pyruvate treated MNs; it opens new possibilities for further investigation.
Here, the role of OTUD6B deserves further examination. Especially due to its involvement
in protein synthesis regulation by mTOR.
(7) Several studies, including this one, investigated the role of energy deprivation or
impaired protein synthesis in SMA. However, there is still a lack of information on whether
those impairments are causative for SMA or result as a consequence of other e!ects.
(8) Since NAC e"ciently reduced ROS in SMA MNs and pyruvate increased ATP levels,
it is worth investigating the e!ects of a combinatorial treatment. Additionally, both
supplements lead to an increase of SMN in SMA MNs. Therefore, NAC and pyruvate
can be applied simultaneously to primary MN cultures or iPSC derived MNs.
(9) Certainly, the field would highly benefit from confirming the results in vivo.
Figure 64: Representation of impairments, targeted by NAC and pyruvate in SMA.
Energy homeostasis is disturbed in SMA MNs due to defective mitochondria and reduced glucose
uptake. Additionally, complex I defects result in increased ROS levels. Increased ROS leads to decreased
translation initiation. NAC reduces ROS and increases global protein synthesis in SMA MNs via mTOR
and translation initiation. Pyruvate reduces ROS and increases ATP. Furthermore, pyruvate increases
translation initiation of a subset of proteins in SMA MNs, including SMN via mTOR.
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Heating block HTMR132 HLC Bio Tech






Luminometer GloMax 96 Promega
Magnetic stirrer MR 3001 Heidolph






Neubauer chamber 1100000 LO Laboroptik Ltd
pH meter inoLab pH Level WTW
Photometer NanoDrop 1000 Peqlab
Pipettes
0.1 µl – 5000 µl







Power Supplies PowerPac™ Basic/HC Bio-Rad





















SDS-PAGE + Western blot
Blotting paper 550 g/m2 Hartenstein






Spectrophotometer BioPhotometer 6131 Eppendorf








Vacuum pump Vacusip Integra Biosciences
Vortex mixer 444-1372 VWR
Water bath 1083 GFL
6.1.2 Chemicals
Chemical Manufacturer
2-Propanol (" 99.5%) Applichem
Agarose Sigma-Aldrich
"-Mercaptoethanol (99%, p.a.) AppliChem
Bovine serum albumin (BSA) Sigma-Aldrich
Bradford - Solution for protein determination AppliChem
Bromphenol blue Sigma-Aldrich
Dimethyl sulfoxide (DMSO) Sigma-Aldrich
Ethanol (" 99.5%, p.a.) Sigma-Aldrich
Ethidium bromide (1% in H2O) AppliChem
Ethylenediaminetetratic acid solution 0.5 M (EDTA) Thermo Fisher Scientific
Formaldehyde (37%) AppliChem
GelRed® Nucleic Acid Gel Stain Biotium
Glycerol (86%, p.a.) AppliChem
Glycine AppliChem
Hydrochloric acid (37%) Sigma-Aldrich
Hydroxymethylaminoethane AppliChem
Methanol (" 99.9%, p.a.) AppliChem
Milk powder (low fat) AppliChem
Mowiol AppliChem
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Chemical Manufacturer
Phenol Red Sigma-Aldrich
Phosphate bu!ered saline (PBS) Thermo Fisher Scientific
Ponceau S Sigma-Aldrich












Water (HPLC grade) AppliChem
6.1.3 Reagents
6.1.3.1 Reagents for molecular biology
Reagent Manufacturer
Commonly used




6 x DNA loading dye Thermo Fisher Scientific
DNA ladder (100 bp/ 1 kb) Thermo Fisher Scientific
Protein work
Acetonitrile Biosolve
Acrylamide-bisacrylamide Mix (40%) (39:1) AppliChem
Ammonium persulfate (APS) (AquaPlus Mix) AppliChem
Azidohomoalanine (AHA) Thermo Fisher Scientific
Bradford- solution for protein determination AppliChem
Complete mini protease inhibitors Roche
Formic acid Biosolve
Page RulerTM Plus Prestained Protein Ladder Thermo Fisher Scientific
PierceTM Protease and phosphatase inhibitor mini tablets Thermo Fisher Scientific
Ponceau S Sigma-Aldrich
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Reagent Manufacturer
Restore Western Blot Stripping Bu!er Sigma-Aldrich
RIPA bu!er Sigma-Aldrich
Super Signal West Pico ECL Substrate Thermo Fisher Scientific
6.1.3.2 Cell culture reagents and media
All cell culture media were stored at 4 °C. All cell culture reagents were stored in aliquots
at -20 °C until use. Reagents in use were stored at 4 °C.
Reagent Manufacturer
Amphothericin B Thermo Fisher Scientific
B-27 Supplement (#17540) Thermo Fisher Scientific
Brain derived neurotrophic factor (BDNF) Peprotech
Cilliary neurotrophic factor (CNTF) Peprotech
Cytosine arabinoside (AraC) Sigma-Aldrich
DMEM (+ 4.5 g/L D-Glucose, + L-Glutamine, + Pyruvate) Thermo Fisher Scientific
DMSO (#D12345) Thermo Fisher Scientific
DNase I (2000 U/ml) New England Biolabs
DPBS (#14190) Thermo Fisher Scientic
Fetal calf serum (FCS) Biochrom AG
Glial cell-line derived neurotrophic factor (GDNF) Peprotech
Laminin, mouse EHS sarcoma Sigma-Aldrich
L-Glutamine Thermo Fisher Scientific
NeuroBasalTM Medium (#21103) Thermo Fisher Scientific
Penicillin/Streptomycin (Pen/Strep) Thermo Fisher Scientific
Poly-D-Lysine Sigma-Aldrich













Trypsin(TRL3) (for MN Isolation) Worthington
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Enzyme Manufacturer
Trypsin (for proteomics) Promega
Trypsin-EDTA Thermo Fisher Scientific
6.1.5 Drugs
All drugs supplied to motor neuron cultures or NSC-34 cells were diluted in growth medium.
Exact concentrations are given in each figure legend.
Drug Working concentration Solvent Manufacturer/
#catalog
Anisomycin 40 µM/ 50 µM Water Sigma; A9789
Harringtonine 2 mg/ml DMSO Abcam; ab141941
Menadione 0.1 µM-100 µM DMSO Sigma; M5625
N-Acetyl-L-cysteine
(NAC)
1 µM-1000 µM Water Sigma; A9165
Puromycin dihy-
drochloride
1 µM/ 10 µg/ml Water Gibco; A1113803
Sodium pyruvate 1 mM – 50 mM Water Sigma; P5280
Sodium lactate 1 mM – 50 mM Water Sigma; L7022
WYE-687 dihy-
drochloride
100 nM Water Tocris; #4282
6.1.6 Primary antibodies and staining reagents
All primary and secondary antibodies used for immunofluorescence were incubated in a humidi-
fied chamber at 4 °C overnight (ON) or at room temperature (RT) for 3 h.





anti-4E-BP1 rabbit; WB 1:1000 Cell Signaling; #9644 AB_2097841
anti-p4E-BP1
(Thr37/46)
rabbit; WB 1:1000 Cell Signaling; #2855 AB_560835
anti-ACTB, HRP-
conjugated
mouse; WB 1:10000 Santa Cruz; sc-47778
HRP
AB_2714189
anti-ChAT rabbit; IF 1:100 Thermo Scientific; PA5-
26597
AB_2544097
anti-Puromycin mouse; WB 1:1500
IF 1:150
Merck; MABE343 AB_2566826
anti-S6 mouse; WB 1:1000 Cell Signaling; #2317 AB_2238583
anti-pS6 rabbit; WB 1:1000 Cell Signaling; #2211 AB_331679
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anti-S6K rabbit; WB 1:2000 Cell Signaling; #2708 AB_390722
anti-pS6K rabbit; WB 1:750 Cell Signaling; #9234 AB_2269803
anti-SMN mouse; WB 1:3000 BD Biosciences; 610646 AB_397973
anti-Tau mouse; IF 1:800 Santa Cruz; sc-390476
anti-Tau chicken; IF 1:100 Abcam; ab75714 AB_1310734
anti-Tom20 rabbit; IF 1:500 Santa Cruz; sc-11415 AB_2207533
6.1.7 Secondary antibodies
Dilutions are indicated for Western blot (WB) or immunofluorescence (IF) application.
All secondary antibodies used for WB or IF were incubated at 4 °C ON or at RT for 3 h,










goat; WB 1:3000 Dianova; 115-035-146 AB_2307392
anti-rabbit IgG, HRP-
conjugated


























Primers used for genotyping and qRT-PCR were purchased from Metabion. Lyophilized primers
were diluted in nuclease-free water to obtain a 100 pmol/µl stock solution and a 10 pmol/µl
working solution.
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mSmn KO fw1 ATA ACA CCA CCA CTC TTA CTC 950 59
mSmn KO fw2 GTA GCC GTG ATG CCA TTG TCA 1050 59
mSmn KO rev AGC CTG AAG AAC GAG ATC AGC 59
qRT-PCR
Actb fw AGC CAT GTA CGT AGC CAT CC 201 60
Actb rev CTC TCA GCT GTG GTG GTG AA 60
Smn fw ACT CCT CCA GAT CGC TCA GA 227 58
Smn rev AGG GGG TGG CGG GAT TAT TG 58
SMN fw ACT CCT CCA GAT CGC TCA GA 227 58
SMN rev AGG GGG TGG AGG AAT TAT G 58
fw = forward primer; rev = reverse primer.
6.1.9 Mouse & cell lines
• Control mice: Inbreed WT FVBN mice were obtained from the CMMC mouse facility
(University of Cologne).
• SMA mice: SMA mice are generated based on the Taiwanese SMA mouse model
(FVB.Cg-Smn1tm1HungTg(SMN2)2Hung/J, reference number 005058).
The breeding scheme is described in 6.2.2.
• NSC-34 cell line: The immortalized hybrid cell line NSC-34 was produced by fusion
of mouse neuroblastoma cells with motor neuron enriched, embryonic cells from mouse
spinal cords (Cashman et al., 1992). Therefore, NSC-34 cells display characteristics of
motor neurons, including generation of action potentials, acetylcholine synthesis, storage
and release (Cashman et al., 1992).
In this study, NSC-34 cells were used to optimize experimental setups. Conclusions were
drawn from experiments with primary motor neurons derived from WT or SMA mice.
6.1.10 Solutions and media
6.1.10.1 Routinely used solutions
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Name Composition
Lysis bu!er (500 ml) 50 ml Tris/HCl (1 M, pH 8.5); 5 ml EDTA (0.5 M);
5 ml SDS (20%); 5 ml NaCl (5 M); ddH2O to 500 ml;
add 7 µl proteinase K per 493 µl bu!er before use
Resuspension bu!er (50 ml) 0.5 ml Tris (1 M, pH 7.4); 0.01 ml EDTA (0.5 M);
ddH2O to 50 ml; 0.06 µl RNase per 50 µl bu!er be-
fore use
IF
Blocking solution (BSA) 3% (w/v) BSA in 1x PBS-T
Mowiol Mix 6 g glycerin with 2.4 g mowiol 4-88 for 1 h at
RT; add 6 ml ddH2O and stir for 1 h; add 12 ml
Tris/HCl (0.2 M, pH 8.5) and stir for 2 h at 50 °C
Paraformaldehyde 4% (w/v) paraformaldehyde dissolved in 1x PBS (pH
7.4) at 60 °C; raise pH with 1 M NaOH until solution
clears; cool the solution and filter
Protein work
Ammonium persulfate 1% (w/v) in ddH2O, aliquot and stored at -20 °C
Blocking solution (BSA) 5% (w/v) BSA in TBS-T, store at 4 °C
Blocking solution (milk) 5% (w/v) non-fat milk powder in TBS-T, store at
4 °C
Laemmli bu!er (3x) 2.4 ml Tris (1 M, pH 6.8); 3 ml SDS (20%); 3 ml
glycerol; 1.6 ml "-mercaptoethanol; 6 mg bromophe-
nol blue, store at 4 °C
Ponceau staining solution 1% (w/v) Ponceau S; 2% (v/v) ml acetic acid in
ddH2O
Protease and phosphatase inhibitors 1 tablet in 1 ml ddH2O (10x)
Resolving gel (12%, 10 ml) 4.2 ml ddH2O; 3 ml 40% (39:1) Acrylamide/ bisacry-
lamide mix; 2.6 ml Tris (1.5 M, pH 8.8); 0.1 ml SDS
(10%); 0.1 ml APS (10%); 40 µl TEMED
SDS Electrophoresis bu!er (10x, 1
L)
30.29 g Tris (Base); 144,13 g Glycin; 10 g SDS;
ddH2O to 1 L
Stacking gel (5%, 2 ml) 1.45 ml ddH2O; 0.25 ml 40% (39:1) Acrylamide/
bisacrylamide mix; 0.26 ml Tris (1 M, pH 6.8); 20 µl
SDS (10%); 20 µl APS (10%); 2 µl TEMED
TBS-T (1 L) 2.42 g Tris (20 mM); 8 g NaCl (137 mM); 5 ml
Tween 20 (0.5%); H2O; pH 7.56 (HCl)
Transfer bu!er (2 L) 4.84 g Tris (Base); 22.52 g Glycin; 400 ml methanol;
ddH2O to 2 L
Tris-HCl (1 M, pH 6.8, 200 ml) 12.22 g Tris-HCl; ddH2O to 200 ml; adjust pH to 6.8
(HCl)
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Name Composition
Tris-HCl (1.5 M, pH 8.8, 200 ml) 36.34 g Tris-HCl; ddH2O to 200 ml; adjust pH to 8.8
(HCl)
6.1.10.2 Cell culture media
All cell culture media were prepared under sterile conditions and stored at 4 °C. Growth
factors and antibiotics were stored at -20 °C.
Name Composition
MN growth medium (500 ml) 500 ml NeurobasalTM medium; 10 ml B-27 sup-
plement (50x); 5 ml L-Glutamine; 1% (v/v) ml
Pen/Strep (10 U/ml); 250 µg/ml Amphotericin B;
sterile filtered before use, 10 ng/ml BDNF; 10 ng/ml
CNTF; 10 ng/ml GDNF added after filtration
MN plating medium (50 ml) 45 ml DMEM; 2.5 ml FCS; 1.5 ml Glucose (20%)
(w/v); 1% (v/v) Pen/Strep; 250 µg/ml Amphotericin
B; sterile filtered before use
NSC-34 freezing medium 60% NSC-34 growth medium; 20% FCS; 10% DMSO
NSC-34 growth medium (500 ml) 500 ml DMEM; 50 ml FCS; 1% (v/v) Pen/Strep
(10 U/ml); 250 µg/ml Amphotericin B
6.1.11 Kits
All kits were stored and used according to manufacturer’s instructions. Adjustments in volume
or incubation times can be found in the appropriate section in 6.2.
Name Manufacturer
Amicon® Ultra-0.5 Centrifugal Filter (#UFC5010) Merck Millipore
ATP Assay Kit (#MAK190) Sigma-Aldrich
ATP Determination Kit (#A22066) Thermo Fischer Scientific
Complex I Enzyme Activity Microplate Assay Kit (#ab109721) Abcam
Glucose Uptake-GloTM Assay (#J1341) Promega
High Capacity cDNA Reverse Transcription Kit (#4368814) Thermo Fisher Scientific
KAPA Mouse Genotyping Kit (#KK7301) Kapa Biosystems
mirVanaTM miRNA Isolation Kit (#AM1560) Thermo Fisher Scientific
Mitochondria Isolation Kit for Cultured Cells (#ab11070) Abcam
Pierce BCA Protein Assay (#23225) Thermo Fisher Scientific
Protein Carbonylation Assay Kit (#ab178020) Abcam
Pyruvate Assay Kit (#MAK071) Sigma-Aldrich
qPCRBIO SyGreen Mix Lo-ROX (#PB20.11) PCR Biosystems
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6.1.12 Software packages
Software Application Distributor
Andromeda Proteomics analysis (CECAD) MaxQuant
Findings 2 Electronic lab notebook Findings Software SAS
Fiji/ImageJ Image analysis NIH, Open Source
ImageLab 6.0 WB analysis BioRad
Mendeley Reference manager Mendeley Ltd.
Perseus Proteomics analysis (CECAD) MaxQuant
PyRAT Laboratory animal management (CMMC) Scionics
Quantity One Image acquisition and analysis Bio-Rad
RStudio Statistics IDE for R RStudio, Inc.
Spectronaut 13 Proteomics analysis (CECAD) Biognosys
TeXShop Text processing IDE for TeX Open Source GPLv2
Vectornator Vector graphics software Linearity GmbH
ZEN Image acquisition and analysis Zeiss
6.1.13 Internet databases
Software Website
Database for Annotation, Visualization and Inte-








PRIDE PRoteomics IDEntification Database https://www.ebi.ac.uk/pride
UniProt http://www.uniprot.org
6.2 Methods
6.2.1 Working with laboratory mice
All experimental animals were bred and housed in accordance with the institutional animal
care guidelines and the German animal welfare laws in the mouse facility of the Center for
Molecular Medicine Cologne (CMMC, University of Cologne). Experimental animal protocols
were approved by the "Landesamt für Natur, Umwelt und Verbraucherschutz” of North Rhine-
Westfalia” (LANUV, NRW). Breedings of the mouse lines are approved under the reference
number 84-02.04.2015.A378, and experimental use of animals was approved under the reference
numbers UniKoeln_Anziege§4.16.020 and UniKoeln_Anziege§4.17.025. For all experiments,
FVB/N wild type mice (Jackson) were used as controls.
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6.2.2 SMA mouse model
Numerous mouse models have been developed to mimic the SMA phenotype in mice and
understand the basic SMA pathology. Since mice do not have a second Smn gene in their
genome, homozygous ubiquitous knockout of the murine Smn is embryonically lethal (Schrank
et al., 1997). Among the numerous SMA mouse models, we used the ’Taiwanese’ SMA mouse
model on an FVB background. This model is homozygous for the Tg(SMN2)2Hung human
SMN2 transgene on a homozygous murine Smn1tm1Hung knock-out background (Hsieh-Li
et al., 2000). The knock-out of endogenous Smn was accomplished by introduction of an
hypoxanthine phosphoribosyltransferase (HPRT) cassette. The SMA model was established by
a breeding scheme previously described (Riessland et al., 2010). Here, homozygous Taiwanese
Smnko/ko; SMN2 tg/tg mice carrying 4 copies of the transgene with heterozygous Smnko/wt
mice, resulting in 50% SMA mice, which display a Type I SMA-like phenotype and die at
~10 days of age (Smnko/ko; SMN2 tg/0) and 50% phenotypically normal littermates (Smnko/wt;
SMN2 tg/0) (Riessland et al., 2010). The initial "Hung” or "Taiwanese” Smnko/ko; SMN2 tg/tg
mice were purchased from Jackson Laboratory (FVB.Cg-Smn1tm1Hung Tg(SMN2)2Hung/J,
reference number 005058).
6.2.3 Cell culture work
Handling of primary cells and cell lines was done under sterile conditions. The equipment was
sterilized with ethanol, and cells were handled in a laminar flow hood to avoid contamination.
All cells were cultured in sterile incubators at 37 °C and with 5% CO2. Time outside of the
incubator was kept to a minimum to reduce stress on the cells. All cell media were filtered
before use and supplied with antibiotics and anti-fungal agents if not otherwise stated. Cell
culture plates and coverslips were coated with poly-D-lysine (PDL) to increase the attachment
of primary motor neurons or NSC-34 cells. Briefly, the surface of the plates and coverslips were
covered with 20 µg/ml PDL in DPBS and incubated for 1 h at RT. Afterward, plates were
thoroughly rinsed with DPBS three times to remove residual PDL.
6.2.4 Counting cells
Cells were counted with a Neubauer counting chamber. Primary motor neurons were counted
after trituration, and NSC-34 cells were counted after being detached using Trypsin/ EDTA
and resuspended in medium. After that, a 1:10 dilution of the cell suspension was applied to
the counting chamber. Cells in all four quadrants of the counting chamber were assessed to
increase the precision of the counting. In attempt to visualize individual motor neurons during
imaging analyses, 15,000 cells/cm2 were plated on glass coverslips, and for all other analyses,
120,000 cells/cm2 were plated in 12- well plates or 6-well plates containing 1 ml and 2 ml
plating medium, respectively. NSC-34 cells were seeded at a density of 20,000 cells/cm2 in
normal growth medium, described in 6.2.5.
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6.2.5 Cultivation of NSC-34 cells
For optimizing experimental setups, including time and dose optimization, motor neuron-like
NSC-34 cells (Eggett et al., 2008) were used. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 10% fetal calf serum, 1% penicillin/streptomycin, and amphotericin
B in cell culture flasks. At 80% confluency, cultures were rinsed with DPBS, detached with
Trypsin/EDTA for 3 min at 37 °C, and diluted into new flasks. For biochemical assays,
20,000 cells/cm2 were plated in PDL coated 12-well plates. Cells were di!erentiated for 3 days
by adding 50 µM retinoic acid into the medium the day after plating.
6.2.5.1 Cryopreservation of NSC-34 cells
For long-term storage of NSC-34 cells, 80% confluent flasks were enzymatically dissociated
with trypsin as noted in 6.2.5 and isolated by centrifugation at 200 x g for 10 min. The pellet
was resuspended in freezing medium containing 60% growth medium, 30% FCS and 10%
DMSO. A cryo-container was used to slow the freezing of the cells to -80 °C.
6.2.5.2 Isolation of murine spinal cords
Primary motor neurons were isolated from Smnko/ko; SMN2tg/0 and WT embryos. Pregnant
mice were euthanized by CO2 at 13.5 days post-fertilization. The day of fertilization was noted
by plug check. The embryos were released from the uterus and placed immediately in ice-cold
PBS. Tail snips from SMA embryos were used for genotyping described in 6.2.10.1 using the
KAPA mouse genotyping kit before further processing. Embryos were fixed in prone position
with minutien pins on a Sylgard-coated petri dish filled with DPBS. Under the dissection
microscope, the skin was removed, and the spinal meninges were opened inferior from the
prebrachial region to the caudal region of the spinal cord using fine forceps. The spinal cord
was separated from the spinal meninges prebrachial to extract the pure spinal cord by pulling
it out using forceps. Any remaining pieces of meninges or dorsal root ganglion were carefully
removed after isolation. Isolated spinal cords were transferred immediately into a reaction tube
containing 500 µl DPBS and stored on ice. All subsequent steps of primary motor neuron
isolation were performed under sterile conditions under a laminar flow hood.
6.2.6 Culture of primary motor neurons
All reagents and media were filtered with a 0.2 µm filter before use. Isolated spinal cords were
dissociated (described in 6.2.5.2) with 1% trypsin in DPBS for 2 min. Afterward, spinal cords
were triturated in plating medium (noted in 6.1.10) with DNase I (100U/ml). The single-cell
suspension was collected after bigger pieces of debris have settled. Motor neurons of the same
litter were merged and considered as one biological replicate to reduce technical variability.
For imaging analyses, 15,000 cells/cm2 were plated on glass coverslips coated with 20 µg/ml
poly-D-lysine (PDL, Sigma) and for protein analyses or RNA extraction, 120,000 cells/cm2
were plated on PDL coated cell culture plates with neuronal plating medium. Neuronal plating
medium was replaced the following day by motor neuron maintenance medium (noted in 6.1.10)
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with additional growth factors: brain-derived neurotrophic factor (BDNF, 10 ng/ml), ciliary
neurotrophic factor (CNTF, 10 ng/ml), and glia cell line-derived neurotrophic factor (GDNF,
10 ng/ml). Every third day half of the medium was exchanged, and cytosine arabinoside (AraC)
was added after 3 days in culture to a final concentration of 1 µM to inhibit glia cell growth.
Cells were cultured for 10DIV at 37 °C in a humidified incubator with 5% CO2.
6.2.7 Surface SEnsing of Translation assay (SUnSET)
Protein synthesis e"ciency was measured by SUnSET assay (Schmidt et al., 2009). Briefly,
the Tyrosyl-tRNA analog puromycin is incorporated during protein elongation and labels newly
synthesized proteins. Detection of puromycin labeled proteins was achieved by western blotting or
immunostaining using an anti-puromycin antibody. For immunofluorescence assay, neurites were
selected with a segmented line, straightened, and divided into 20 µm bins using the concentric
circles plugin. Mean puromycin intensities were quantified using plot profiles. SUnSET assay
was performed on primary motor neurons at 10DIV and on three days di!erentiated NSC-34
cells. Cells were cultured at a density of 120,000 cells/cm2 on PDL coated cell culture plates.
ROS modifying drugs were treated for 30 min before 30 min puromycin labeling (1 µM). As
a negative control, protein synthesis was inhibited by 50 µM anisomycin for 30 min before
puromycin labeling (1 µM).
6.2.8 SUnSET-based Ribosome Speed of Elongation assay (SunRiSE)
To measure protein elongation speed, SunRiSE assay was used (Argüello et al., 2018). In
contrast to SUnSET assay, initiation of mRNA translation was blocked by 2 µg/ml harringtonine
at di!erent time points, prior incubation with 10 µg/ml (16.7 µM) puromycin for 10 min.
Puromycin labeled peptides were detected by western blotting using an anti-puromycin specific
antibody.
6.2.9 Drug treatment
For drug treatment, half of the medium was removed, and drugs were diluted to twice the
working concentration in freshly prepared maintenance medium. After the medium was supplied
with the drug, the conditioned medium was added to the old maintenance medium on the
cells in a 1:1 ratio. Cells were incubated after drug treatment for given times in a humidified
chamber with 5% CO2 at 37 °C. The supplied substances to motor neurons and NSC-34 cells
are as follows and listed in 6.1.5 with given concentration in each figure legend: The cell culture
supplements sodium pyruvate and sodium lactate, the antioxidant NAC, the ROS inducer
menadione, the protein synthesis inhibitor anisomycin and the water-soluble mTOR inhibitor
WYE-687 dihydrochloride.
6.2.10 Nucleic acid methods
6.2.10.1 Isolation of DNA
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Mouse lines were routinely genotyped to ensure the correctness of stock animals for further
breeding. Tail tips or ear biopsies after tagging of 10 to 14 days old stock animals were provided
by the animal facility. Samples were lysed in 500 µl tissue lysis bu!er, containing fresh 200 µg/ml
proteinase K at 55 °C ON or at least for 4 h shaking at 1500 rpm. Samples were centrifuged
at maximum speed (16,000 x g) for 5 min to remove insoluble tissue. Without disturbing
the settled debris, the supernatant was transferred into new reaction tubes containing 500 µl
isopropanol. By shortly mixing the samples, DNA is precipitated and isolated by centrifugation
for 5 min at maximum speed. To remove salts in the samples, 300 µl of 70% ethanol was
added, and samples were centrifuged at maximum speed for 5 min. As remaining ethanol could
inhibit the subsequent PCR, samples were dried by centrifugation in a vacuum concentrator for
10 min. Further on, genomic DNA was dissolved by 40 µl resuspension bu!er supplied with
RNase.
In addition to routinely genotyped stock animals, embryos used for cell culture experiments
were genotyped due to the breeding scheme of SMA, described in 6.2.2. After retrieving the
embryos from the pregnant female mouse described in 6.2.5.2, ~1 mm of the tail was collected
from each embryo. In order to mix primary motor neurons with the same genotype before
plating, each embryo was genotyped with the KAPA Mouse Genotyping Kit. This allows for
rapid lysis of the tissue and fast processing of DNA isolation. We followed the manufacturer’s
protocol. In brief, tail tips were lysed in a heating block at 75 °C for 10 min with subsequent
inactivation of the enzyme at 95 °C for 5 min. Before use in PCR analysis, the DNA was
diluted 1:10.
6.2.10.2 Isolation of RNA
To prevent degradation of RNA, all procedures were performed on ice and under RNase-free
conditions. Total RNA was extracted from cells using the mirVana™ miRNA Isolation Kit,
according to the manufacturer’s instructions to measure mRNA expression levels. In brief, the
cell culture medium was removed, and cells were rinsed with DPBS. Lysis of the cells was
carried out by adding Lysis/Binding bu!er of the mirVanaTM miRNA Isolation Kit directly
on the cells and thoroughly pipetting up and down. Samples were either frozen at -20 °C or
directly used for further processing. Cellular components and most of the DNA was removed
by acid-phenol: chloroform. In the final purification step, total RNA was isolated on glass-fiber
filters and eluted in RNase-free water. For long-term storage, samples were stored at -80 °C.
6.2.10.3 Quantification of RNA
The concentration and purity of RNA were determined with the NanoDrop ND-1000
spectrometer. The absorbance at 260nm was used to quantify the RNA, and the ratio of
A260/A280 was used to determine the purity. For high purity and the absence of contaminants,
a value close to 2 was aimed.
6.2.10.4 Polymerase chain reaction (PCR)
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The polymerase chain reaction (PCR) technique was used to identify genotypes of mice
by amplifying genomic DNA isolated from mouse tails. The PCR technique enables the
amplification of a distinct DNA sequence using gene-specific primers flanking the region of
interest (Mullis, 1990). The temperature for the primer annealing step is experimentally
optimized for each primer pair used, and a temperature of 60 °C was used for genotyping and
qRT-PCR. Lyophilized primers used in the PCR were diluted in nuclease-free water to obtain a
stock solution of 100 pmol/µl and a final working solution of 10 pmol/µl. In the last step, the
elongation, a thermostable DNA-polymerase, synthesizes the new DNA strand. All three steps
are repeated 35 times for genotyping and 40 times during qRT-PCR. For routine genotyping,
the standard composition of PCR reagents listed in Table 9 were used. To speed up genotyping
during MN culture preparation, the rapid PCR mix components listed in Table 9 were used. To
test the primers’ specificity during qRT-PCR, amplification products of the qRT-PCR were also
used in PCR with the standard reagent composition.
Table 9: Components and volumes for genotyping PCR reactions.
Rapid genotyping PCR Standard genotyping
PCR













mSmn KO rv 1.5 3
mSmn KO fw-1 1.25 2
mSmn KO fw-2 1.25 2
Additional MgCl2 0.5 -
Template DNA 0.5 1
Table 10: Thermocycler Smn PCR program.
Step Duration Temperature [°C]
1. Initial denaturation 5 min 95
2. Denaturation 30 sec 95
3. Primer annealing 30 sec 60
4. Elongation 1 min per 1 kb 72
Repeat steps 2-4 for 35x
5. Final elongation 10 min 72
Cooling # 4
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6.2.10.5 cDNA synthesis
To compare expression levels of specific mRNAs by qRT-PCR analysis, RNA templates
were reversely transcribed into complementary DNA (cDNA) using the High-Capacity cDNA
Reverse Transcription Kit. RNA was isolated from motor neuron cell cultures as described
in 6.2.10.2. In each reaction, 100 ng RNA was transcribed using random primers, and the
manufacturer’s protocol was followed. The full composition of the reaction is listed in Table 11
and the conditions of the PCR in the thermocycler are noted in Table 12.
Table 11: Components for cDNA synthesis
Reagent Amount
10x RT Bu!er 2 µl
25x dNTP Mix (100mM) 0.8 µl
10x RT Random Primers 2 µl
MultiScribeTM Reverse Transcriptase (50 U/µl) 1µl
RNase Inhibitor 0.2 µl
Total RNA 100 ng
Nuclease-free H2O to a final volume of 20 µl
Table 12: Conditions for cDNA synthesis PCR
Step 1 Step 2 Step 3 Step 4
Temperature [°C] 25 37 85 4
Time [min] 10 120 5 #
6.2.10.6 Quantitative real time PCR
To measure the number of transcripts produced by a given gene, mRNA levels were
quantified by qRT-PCR using gene-specific primers. Similar to the PCR reaction described
in 6.2.10.4, gene-specific primers are annealed to the template DNA and multiplied by a
thermostable DNA polymerase. In this case, cDNA produced from total RNA serves as a
template for the reaction after 1:2 dilution. The formation of dsDNA allows the intercalating
dye SYBR® green to bind nonspecifically into dsDNA products. SYBR® green binds with lower
a"nity and a lower fluorescence signal to ssDNA or RNA than to dsDNA and is, therefore, a
suitable reporter dye in qRT-PCR. The increase of amplified products can be monitored in
real-time due to a fluorescent dye’s intercalation. Here, PowerSYBR® Green PCR Master Mix
and 1 µM of gene-specific forward and reverse primers were used (Table 6.1.8). The reaction’s
full composition can be found in Table 13. The exponential increase of fluorescence signal was
measured using the 7500 Real-Time PCR System. The threshold of the cycle (Ct) value, which
displays the cycle number at which the fluorescence signal exceeds the background signal by
exponential amplification, was used to compare di!erent samples. Samples were normalized to
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a housekeeping gene product. Relative quantification levels were obtained using an internal
control, and relative changes were analyzed using the 2(-Delta Delta C(T)) method (Livak &
Schmittgen, 2001). The primers’ specificity was confirmed by a single peak of a dissociation
curve, agarose gel electrophoresis (6.2.10.7) and Sanger sequencing.
Table 13: Components for qRT-PCR
Reagent Amount
2x qPCRBIO SyGreen Mix 10 µl
1 µM forward primer 2 µl
1 µM reverse primer 2 µl
cDNA 2 µl
Nuclease-free H2O to a final volume of 20 µl
Table 14: Conditions for qRT-PCR
Step Duration Temperature [°C]
1. Hold 2 min 50
2. Initial denaturation 10 min 95
3. Denaturation 15 sec 95
4. Primer annealing 30 sec 60
5. Elongation 40 sec 72
Repeat steps 3-5 for 40x
6. Cooling # 4
6.2.10.7 Agarose gel electrophoresis
Agarose gel electrophoresis was used to confirm the primers’ specificity used in qRT-PCR
described in 6.2.10.6, but also to verify the genotype after DNA isolation from mouse tails
described in 6.2.10.1. Based on sizes separation in an 1.5% agarose gel in 1x TBE bu!er due
to the electric force between DNA and an electric field, a single band with the correct size
of the qRT-PCR product was determined. Di!erences in genotypes were determined using
sequence-specific primers, leading to either a single band or two bands. Single band represents
the homozygously interrupted murine Smn by the HPRT cassette while two bands represent
the heterozygous genotype containing one interrupted murine Smn allele and one intact Smn
allele. PCR products were separated for 30-40 min at 100 V and visualized using the ChemiDoc
XRS Imaging System.
6.2.11 Proteinbiochemistry methods
To avoid degradation or aggregation of isolated proteins, all subsequent steps were handled on
ice or at 4 °C. For long term storage, proteins were kept at -20 °C, and repetitive freezing and
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thawing of samples was avoided when possible.
6.2.11.1 Isolation of proteins from cells
Primary motor neurons and NSC-34 cells were carefully rinsed with DPBS twice before
proteins were isolated. To lyse cells, the surface of each well was covered with RIPA bu!er
(Sigma) supplemented with phosphatase and protease inhibitors. After 10 min incubation on
ice, samples were collected using a cell scraper and rinsing with RIPA bu!er. Lysates were
centrifuged at 8000 x g for 10 min in a pre-cooled centrifuge to seperate insoluble cellular
compartments. Supernatants containing the soluble proteins were transferred into a new tube
and stored at -20 °C until further use. Proteins used to detect phosphorylated proteins were
stored in aliquots to minimize freeze and thaw cycles.
6.2.11.2 Isolation of mitochondria
To investigate the functionality of the respiratory chain in SMA motor neurons, mitochondria
were isolated from primary motor neurons using the ’Mitochondria Isolation Kit’ noted in 6.1.11.
In brief, 3 x 107 cells were cultivated for 10DIV and mitochondria were collected. After cells
were rinsed carefully, a cell scraper was used to collect the cells. To weaken the cell membrane,
collected cells were frozen for 10 min and subsequently thawed. Cells were disrupted after
10 min incubation on ice by a pre-cooled Dounce homogenizer. The complete rupture was
performed on the cell pellet after centrifugation. After an additional centrifugation step at
1000 x g, supernatants were combined and centrifuged at 12000 x g. The cell pellet was
resuspended in a bu!er included in the kit after addition of protease inhibitor (6.1.3). Isolated
mitochondria were stored at -80 °C until further use.
6.2.11.3 Determining protein concentrations
Proteins lysed in RIPA bu!er are quantified by BCA assay, but proteins used in the
carbonylation assay described in 6.2.19 were quantified by Bradford due to the inhibitory e!ect
of dithiothreitol (DTT).
BCA assay Proteins were quantified using the colorimetric detection assay PierceTM BCA
protein assay kit. This assay is based on the biuret reaction reducing Cu2+ to Cu+ by protein in
an alkaline medium, combined with the chelation of bicinchoninic acid (BCA) by Cu+ (Smith
et al., 1985). The resulting color change is quantified in a microplate reader by measurement
of the absorbance at 562 nm after 30 min incubation at 37 °C. Samples are compared to an
internal BSA standard in the range of 20-2000 µg/ml.
Bradford To quantify proteins used in the carbonylation assay described in 6.2.19, the
Bradford assay was used. In brief, the colorimetric shift in absorbance of Coomassie Brilliant
Blue G-250 upon protein binding is detected by a spectrophotometer at 595nm. Concentrations
were calculated using an internal standard curve with known BSA concentrations (0.5 µg -
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5 µg). To minimize the amount of protein used, 2 µl of each sample was diluted in 500 µl
Bradford reagent in duplicate. Samples were incubated 5 min at RT before detection.
6.2.11.4 Sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) In order
to measure protein expression, the widely used western blotting technique, composed of sodium
dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunodetection was
applied. All reagents and solutions used to perform western blot analysis in the Mini-Protean
3 cell system are listed in 6.1.3.1 and 6.1.10.1. After protein concentration was determined
by BCA assay or Bradford, equal amounts between 10 µg and 20 µg of soluble protein were
mixed with SDS containing Laemmli bu!er (Laemmli, 1970). Negatively charged SDS binds to
proteins and enables migration through a polyacrylamide gel in an electric field towards the
anode. Here, proteins are primarily separated by their molecular weight (MW). Proteins were
denatured by boiling at 95 °C for 5 min, and disulfide bonds are reduced by "-Mercaptoethanol.
Samples were loaded into the pockets of a discontinuous SDS gel consisting of a 5% stacking
gel and a separating gel. Due to a lower pH and bigger pore size in the stacking gel (pH 6.8),
proteins can concentrate without separation. The actual separation of proteins by MW happens
in the separating gel, which has a pH of 8.8 and smaller pore sizes. Depended on the size of
the protein of interest, separating gels between 10% and 15% polyacrylamide were used. To
estimate protein size, one pocket of the gel was loaded with PageRulerTM Prestained Protein
Ladder. Electrophoresis was initially performed at 90 V to concentrate the samples in the
stacking gel and voltage was subsequently increased up to 120 V to separate proteins in the
resolving gel.
6.2.11.5 Western blotting
After separation in SDS-PAGE, proteins were transferred from the gel to nitrocellulose or
polyvinylidene fluoride (PVDF) membranes. Nitrocellulose membranes have the advantage of
lower background signals, but PVDF membranes are capable of binding more protein. Due to
PVDF membranes’ hydrophobicity, incubation in methanol for 1 min before is required. All
other components were first equilibrated in the transfer bu!er. The appropriate membrane
to use was determined for each protein empirically. For the complete transfer of proteins of
all sizes, a wet transfer was performed. A transfer stack of the SDS gel and the membrane,
surrounded by Whatman paper and two sponges were assembled. To ensure the negatively
charged proteins migrate into the membrane, the gel was placed inside the transfer stack facing
towards the cathode, and the membrane was facing towards the anode. Further on, the transfer
stack was locked in a cassette and placed into the transfer chamber filled with transfer bu!er.
To reduce heat during transfer, a cooling pad was added, and the transfer tank was placed in
the cold room at 4 °C. After 1 h of transfer at 110 V, the transfer stack was disassembled, and
the transfer was confirmed by short incubation of the membrane in Ponceau S.
6.2.11.6 Detection of proteins by Western blot analysis
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Once proteins are transferred to a membrane, proteins of interest were detected by antigen-
specific antibodies. The information about antibodies is listed in 6.1.6 and 6.1.7. To avoid
non-specific binding of antibodies, the membrane was first incubated in 5% BSA solution or
5% milk for 1 h at RT. Next, the membrane was incubated with primary antibodies diluted in
blocking bu!er at 4 °C ON. To remove excessive antibodies, the membrane was washed three
times with PBS-T for 10 min each wash. Membranes were incubated at RT for 3 h in secondary
antibodies conjugated with horseradish peroxidase (HRP). Secondary antibodies are directed
against the host species of the primary antibody and diluted in a blocking solution. After
membranes were washed three times, membranes were incubated for 5 min in Super Signal®
West Pico Chemiluminescent Substrate. The enhanced chemiluminescent substrate is converted
by the HRP conjugated to the secondary antibody. The resulting light signal is detected by the
ChemiDoc XRS+ System. Signal intensities were quantified using the ImageLab 6.0 software.
In order to detect multiple proteins on the same membrane, Restore Western Blot Stripping
Bu!er was used. Membranes were incubated for 15 - 30 min in stripping bu!er and subsequently
washed 3 times with PBS-T. Afterward, membranes were blocked for 30 min in a blocking
bu!er.
6.2.12 Proteomics
Primary MNs were treated with 50 mM pyruvate, 10 µM NAC and 100 µM menadione for 1 h,
lysed in RIPA bu!er with protease and phosphatase inhibitors and further processed for mass
spectrometry (MS) analysis. To avoid contaminations of the samples, all subsequent steps
were carried out particularly clean. MS sample preparation and analysis were accomplished in
cooperation with the proteomics facility (CECAD, University of Cologne).
6.2.12.1 Sample lysis and acetone precipitation
Cells were collected and lysed in RIPA bu!er with protease and phosphatase inhibitor as
previously described in 6.2.11.1. To use the same amount of protein in every sample, proteins
were quantified by BCA assay as described in 6.2.11.3. In total, 50 µg protein was used for
acetone precipitation and subsequent MS processing. In order to precipitate samples, 4 times
the volume of ice-cold acetone was added to the samples and incubated for 15 min at -80 °C,
following 120 min incubation at -20 °C. After centrifugation for 5 min at 16000 x g, the
supernatant was carefully discarded. Again, 500 µl of ice-cold acetone was added to the protein
pellet and centrifuged for 5 min at 1600 x g. The supernatant was discarded, and the process
was repeated once more. The resulting pellets were air-dried and resuspended in 50 µl of 8
M urea in 50 mM Triethylammoniumbicarbonate (TEAB) bu!er supplemented with protease
inhibitor.
6.2.12.2 In solution reduction, alkylation and digestion of proteins
After precipitation and resuspension in urea bu!er, disulfide bonds in the samples were
reduced, alkylated, and digested. Reduction of the samples was achieved using 5 mM dithio-
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threitol (DTT) at RT for 1 h. Immediately after reduction, samples were alkylated using
40 mM chloroacetamide (CAA) in the dark for 30 min. The final digestion was carried out
using endoproteinase Lys-C in an enzyme: substrate ratio of 1:75 for 4 h at RT and trypsin
in an enzyme: substrate ratio of 1:75 ON at RT. Before digestion with trypsin, samples were
diluted with 50 mM TEAB bu!er to a final concentration of Urea $ 2 M. To stop enzymatic
digestion, samples were acidified with 2% formic acid.
6.2.12.3 Stage Tip sample purification
Acidified samples were purified with C-18 styrenedivinylbenzene-reverse phase sulfonate
(SDB-RPS) Stage Tips. Before samples were loaded, Stage Tips were activated with methanol
and equilibrated using bu!ers containing 0.1% formic acid in water or 80% acetonitrile,
respectively.
6.2.12.4 Liquid chromatography-mass spectrometry and data analysis
All samples were analyzed on a Q Exactive Plus Orbitrap mass spectrometer that was
coupled to an EASY nLC at the CECAD proteomics facility (University of Cologne). Peptides
were loaded with solvent A (0.1% formic acid in water) onto an in-house packed analytical
column (50 cm - 75 µm I.D., filled with 2.7 µm Poroshell EC120 C18). Peptides were
chromatographically separated at a constant flow rate of 250 nL/min and the following gradient:
3-5% solvent B (0.1% formic acid in 80% acetonitrile) within 1.0 min, 5-30% solvent B within
91.0 min, 30-50% solvent B within 17.0 min, 50-95% solvent B within 1.0 min, followed by
washing and column equilibration. DDA library runs were acquired from distinct pools of the
sample groups. The MS1 survey scan was acquired from 300-1750 m/z at a resolution of 70,000.
The top 10 most abundant peptides were isolated within a 2.0 Th window and subjected to
HCD fragmentation with a normalized collision energy of 27%. The AGC target was set to
5e5 charges, allowing a maximum injection time of 55 ms. Product ions were detected in the
Orbitrap at a resolution of 17,500. Precursors were dynamically excluded for 20.0 s. For the
acquisition of the samples, the mass spectrometer was operated in data-independent mode.
For MS1 and MS/MS scans the maximum IT was restricted to 60 ms and the AGC target
was set to 1e6 charges. The MS1 scan was acquired from 400-1220 m/z at a resolution of
35,000. MSMS scans were acquired in in DIA mode using 25 x 24 m/z windows covering
the mass range from m/z 400 to m/z1000 at a resolution of 17,500. The default charge
state for the MS2 was set to 3. Stepped normalized collision energy was set to 27%. The
MS/MS spectra were acquired in centroid mode. DIA data were analyzed with assay-specific
hybrid library using default settings in Spectronaut 13 (Bruderer et al., 2015). The library
was generated by searching a mus musculus fasta library (UP000000589, 50331 entries from
Swiss-Prot and TrEMBL) with DDA library runs plus all DIA sample runs using PulsarX and
direct DIA. Normalized log2 intensities were exported for protein identifications with q-values
below 0.01. Perseus was used for subsequent statistical analysis (Tyanova et al., 2016). The
MS proteomics raw data has been deposited to the ProteomeXchange Consortium via the
PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD020403.
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6.2.12.5 Gene ontology
Further gene ontology (GO) analysis was conducted by using the Database for Annotation,
Visualization and Integrated Discovery 6.7 (DAVID). Statistical analysis and data visualization
were performed using RStudio. The mouse MitoCarta 2.0 dataset was used to identify
mitochondrial proteins (Calvo et al., 2016).
6.2.13 Immunofluorescence methods
6.2.13.1 Immunofluorescence staining of cells
Immunofluorescence is an ideal method to visualize the localization and distribution of
specific proteins inside a cell. Antibodies against specific epitopes tag the desired proteins, and
secondary antibodies targeted against the primary antibody are conjugated to a fluorophore,
which can be visualized in a fluorescence microscope. We used the advantage of low-density
neuronal cultures to determine the subcellular localization of proteins at a single-cell level. For
this experiment, motor neurons were cultured on PDL coated coverslips as described in 6.2.6.
After the desired days in vitro cultivation, the maintenance medium was removed, and cells
were carefully rinsed with DPBS 3 times. Fixation of cells was accomplished using 4% PFA
for 20 min at RT and subsequent washing with DPBS. To visualize intracellular proteins, cells
were permeabilized using PBS containing 0.3% Tween20 for 10 min at RT and three wash
steps with PBS were followed. In order to avoid unspecific binding of the antibody, coverslips
were incubated for 1 h in PBS containing 0.2% Tween-20 and 3% BSA. After blocking, cells
were incubated with primary antibody diluted in blocking bu!er ON at 4 °C. For optimal
distribution of the antibody on the coverslip surface and to reduce the amount used, coverslips
were incubated inverted with the cell side down facing one drop of the antibody dilution.
After coverslips were washed three times with PBS, secondary antibody conjugated with the
fluorophore was applied the same way as the primary antibody. Dilution factors of primary
antibodies used are listed in 6.1.6, and secondary antibodies are noted in 6.1.7. To visualize
the nuclei, DNA was stained by 4’,6-diamidino-2-phenylindole (DAPI) staining solution after
coverslips were washed three times with PBS. Coverslips were mounted on microscope slides
using mowiol with the cells facing down and stored in the dark at 4 °C until analysis.
6.2.13.2 MitoTracker® staining
The use of the mitochondria membrane intercalating dye MitoTracker® Red CMXRos gives
the advantage to label mitochondria before fixation and permeabilization. Using MitoTracker,
functional mitochondria can be detected based on their membrane potential, and labeling is
retained in the mitochondria after fixation. Staining was accomplished by 100nM MitoTracker®
Red CMXRos added directly in serum-free medium on the cells. Further on, fixation and
antibody staining were performed as described in 6.2.13.
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6.2.13.3 Microscopic analysis
All fluorescence images were acquired blinded with an Axio Imager.M2 fluorescence mi-
croscope equipped with an AxioCam MRm camera and an ApoTome.2 system. Images were
analyzed blindly with FIJI. To quantify the number and appearance of mitochondria along
neurites, a modified version of the ImageJ Mitophagy Macro by Ruben K. Dagda was used
(Dagda et al., 2008).
6.2.14 Complex I activity assay
In order to test the functionality of mitochondrial respiratory chain complexes, the Complex
I enzyme activity assay kit was used (noted in 6.1.11). After mitochondria were isolated
(6.2.11.2), proteins were isolated by detergent extraction and loaded onto a microwell plate.
To enable attachment of complex I proteins to the microplate via antibody coupling, plates
were incubated for 3 h at RT. Di!erences of complex I activity in SMA and WT motor neurons
were assessed by measuring the optical density (OD450 nm) after adding the assay solution on
the plate. The enzyme kinetic was followed for 1 h. For tissue samples from the heart and
spinal cord (SC) 300 µg of cell extracts were used, and 20 µg of mitochondrial extracts were
used from motor neuron samples.
6.2.15 ATP assay
To increase the accuracy of the measures, two independent methods were used to determine the
intracellular ATP concentration. One was by phosphorylating glycerol, resulting in a fluorometric
(#ex = 535/#ex = 587 nm) product using the ATP Assay Kit. The other approach was the ATP
Determination Kit using a recombinant firefly luciferase and a bioluminescence signal produced
by the substrate D-luciferin. Both methods result in a signal proportional to the amount of
ATP present in the sample and were normalized to soluble protein concentrations. Results
of fluorescence signal were quantified using the Safire 2 microplate reader and luminescence
signals were detected by GloMax® luminescence reader.
6.2.16 Glucose uptake assay
In order to compare glucose uptake e"ciency between WT and SMA MNs the Glucose
Uptake-Glo kit was used. In this assay, NADH is produced via glucose oxidation by glucose
dehydrogenase. The production of NADH is coupled to a reduction of pro-luciferin into luciferin,
which is subsequently used by luciferase to produce a light signal. Primary MNs were cultured
at a density of 120,000 cells/cm2 and manufacturer’s instructions were followed. The emitted
light signal was measured by the GloMax luminescence reader and normalized to protein
concentration measured by BCA assay.
6.2.17 Pyruvate uptake assay
Pyruvate uptake was measured with the Pyruvate assay kit. MNs were supplied with pyruvate
over 1 h and cells were lysed using assay bu!er and mechanical disruption by pipetting. To reduce
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the conversion of pyruvate to lactate by lactate dehydrogenase, samples were deproteinized
using 10 kDa spin columns. Further on, samples were compared to standards ranging between
0 and 200 µm pyruvate. Fluorescence signal was measured at #ex = 535/ #em = 587 nm with
the Safire 2 microplate reader and normalized to soluble protein amount.
6.2.18 Detection of oxidative stress
To measure ROS in MNs and NSC-34 cells, CellROXTM Green was used. CellROXTM Green is
a cell-permeant nonfluorescent probe, which exhibits fluorescence upon oxidation. The oxidized
probe remains localized within the cell due to binding to DNA. In our analysis, WT and SMA
MNs were incubated with 5 µM CellROXTM Green reagent for 30 min. After fixation with 3.7%
formaldehyde, nuclei and F-actin of the cells were co-stained with DAPI and Alexa FluorTM 568
Phalloidin respectively. To increase the reliability of measures, CellROXTM signal was measured
with two independent methods. CellROXTM signal on coverslip images were acquired with
a fluorescence microscope equipped with an ApoTome.2 system. In addition, the signal was
also quantified with a Safire 2 microplate reader. Data acquired by microplate reader were
normalized to soluble protein concentration after lysis with RIPA bu!er. To monitor oxidative
stress after manipulation of ROS levels in cells, 50 mM pyruvate, 10 µm NAC, and 100 µm
Menadione were added 45 min before measurement. Those signals were quantified with the
Safire 2 microplate reader.
6.2.19 Protein carbonylation assay
The amount of protein carbonyl groups was measured with the Protein carbonyl assay kit
according to the manufacturer’s instructions. In brief, carbonyl groups are derivatized to
DNP-hydrazone by reaction with 2,4-Dinitrophenylhydrazine (DNPH). To prevent oxidation
of proteins after cell lysis, 50 mM DTT was added. Protein concentration was measured by
Bradford, described in 6.2.11.3. The amount of carbonylated protein was quantified by use of
an anti-DNP specific antibody in western blot analysis.
6.2.20 AHA-click iT assay
L-azidohomoalanine (AHA) is incorporated into proteins during active protein synthesis and later
on detected by click chemistry reaction with biotin alkyne. To deplete endogenous methionine
reserves of primary motor neurons, the culture medium was exchanged for 30 min with HBSS.
For AHA labeling, 500 µM L-AHA, 500 µM L-AHA in addition with 40 µM anisomycin, and
L-AHA in addition with ROS modulating drugs were added for 1 h. After incubation at 37 °C,
cells were washed with PBS and lysed for 20 min on ice with RIPA bu!er supplemented with
protease and phosphatase inhibitors. Click chemistry reaction was achieved by adding 40 µM
biotin alkyne and following the manufacturer’s protocol of the Click-iT® protein reaction bu!er
kit. Further, L-AHA labeled proteins were detected by western blotting.
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6.2.21 Statistical analyses
All statistical analyses were conducted in R version 3.6.2 using RStudio (RStudio Team, 2019).
Quantities of peptides in proteomics data were determined at the proteomics facility (CECAD)
using Perseus. Statistical significances of quantified peptides were determined by a two-sided
unpaired t-test. All graphs of experiment quantification represent the average by mean, including
error bars depicting the standard deviation (± SD). Also, individual data points from either
independent biological replicates (N) or technical replicates (n) are presented. Statistical tests
were applied only to biological replicates. For experiments with small sample sizes, normality
tests have little power to reject the null-hypothesis and result in the assumption of normal
distribution (Le Boedec, 2016). Therefore, the distribution of samples in all experiments was
observed post hoc visually and by Shapiro-Wilk normality test, as it provides the highest power at
small sample sizes among normality tests (Ghasemi & Zahediasl, 2012). Statistically significant
di!erences of normally distributed means of two groups were determined by t-test (two-tailed).
Multiple group comparisons where t-tests were applied were corrected with the Holm-Bonferroni
method (Holm, 1979). Di!erences among multiple group means are determined with Tukey’s
honestly significant di!erence (HSD) test after the rejection of the null hypothesis by one-way
analysis of variance (ANOVA). Normally distributed experimental results including two factors
were analyzed by two-way ANOVA with Tukey HSD post-hoc analysis. In time-course and
dose-response experiments, comparing multiple mean values to a single control mean, Dunnett’s
post hoc test was used after one-way ANOVA. Significance is indicated by asterisks as follows:
n.s. = not significant, *p <0.05; **p <0.01; *** <0.001.
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Appendix A Thelen et al., (2020) Acta Neuropathologica Com-
munications
Results embedded in this doctoral thesis were published in the research article "Mitochondrial
defects in respiratory complex I contribute to impaired translational initiation via ROS
and energy homeostasis in SMA motor neurons" in the journal Acta Neuropathologica
Communications in December 2020. The authors’ contributions are listed in the article.
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Mitochondrial defects in!the!respiratory 
complex I contribute to!impaired translational 
initiation via!ROS and!energy homeostasis 
in!SMA motor neurons
Maximilian Paul Thelen1,2 , Brunhilde Wirth1,2,3  and Min Jeong Kye1,2* 
Abstract 
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by loss of lower motor neurons, which leads 
to proximal muscle weakness and atrophy. SMA is caused by reduced survival motor neuron (SMN) protein levels due 
to biallelic deletions or mutations in the SMN1 gene. When SMN levels fall under a certain threshold, a plethora of 
cellular pathways are disturbed, including RNA processing, protein synthesis, metabolic defects, and mitochondrial 
function. Dysfunctional mitochondria can harm cells by decreased ATP production and increased oxidative stress due 
to elevated cellular levels of reactive oxygen species (ROS). Since neurons mainly produce energy via mitochondrial 
oxidative phosphorylation, restoring metabolic/oxidative homeostasis might rescue SMA pathology. Here, we report, 
based on proteome analysis, that SMA motor neurons show disturbed energy homeostasis due to dysfunction of 
mitochondrial complex I. This results in a lower basal ATP concentration and higher ROS production that causes an 
increase of protein carbonylation and impaired protein synthesis in SMA motor neurons. Counteracting these cellular 
impairments with pyruvate reduces elevated ROS levels, increases ATP and SMN protein levels in SMA motor neurons. 
Furthermore, we found that pyruvate-mediated SMN protein synthesis is mTOR-dependent. Most importantly, we 
showed that ROS regulates protein synthesis at the translational initiation step, which is impaired in SMA. As many 
neuropathies share pathological phenotypes such as dysfunctional mitochondria, excessive ROS, and impaired 
protein synthesis, our findings suggest new molecular interactions among these pathways. Additionally, counteract-
ing these impairments by reducing ROS and increasing ATP might be beneficial for motor neuron survival in SMA 
patients.
Keywords: Spinal muscular atrophy, SMN, SMN1, SMN2, Mitochondria, Reactive oxygen species, Translation initiation
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Background
Spinal muscular atrophy (SMA) is an inherited neuro-
muscular disease that is characterized by loss of lower 
motor neurons (MNs) due to reduced levels of the ubiq-
uitously expressed survival motor neuron (SMN) protein 
[1]. !e incidence of SMA varies between 1 per 6000–
10,000 newborns in the human population [2]. In 96% 
of SMA patients, homozygous deletions, or mutations 
in SMN1, the gene encoding for full-length SMN, have 
been described [2]. Interestingly, the human genome 
contains an almost identical gene"-"SMN2 -, that mainly 
produces a transcript lacking exon 7 due to a single silent 
mutation [3]. Hence, SMN2 produces approximately 
10% of the full-length SMN protein compared to SMN1. 
As the amount of SMN protein inversely correlates with 
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disease severity [4], the copy number of SMN2 is often 
used as a good predictor of SMA severity. SMN forms 
a stable complex with other proteins such as Gemin2-8 
[5]. Additionally, SMN is an RNA binding protein that is 
involved in multiple essential cellular functions, includ-
ing biogenesis of spliceosomal small nuclear ribonucleo-
proteins (snRNPs) [6] and tra#cking of mRNAs to axon 
terminals [7–10]. Furthermore, SMN deficient cells show 
dysregulated splicing and miRNA processing [11, 12], 
hyperexcitability and impaired  Ca2+ homeostasis [13–
15], decreased translation [8, 16, 17], and also results in 
impaired axon growth [9]. !ese findings suggest SMN as 
a multifunctional protein.
Recent evidence suggests that energy metabolism is 
impaired in SMA, including mitochondria and glucose 
metabolism [18–20]. In the mitochondrial oxidative 
phosphorylation (OXPHOS), the NADH:ubiquinone 
oxidoreductase (complex I) of the electron transport 
chain is the rate-limiting enzyme in respiration and the 
major producer of reactive oxygen species (ROS) [21, 22]. 
!erefore, a dysfunctional complex I could impair energy 
production as well as ROS homeostasis. ROS can func-
tion as signaling molecules by activating various path-
ways, including MAPK, PI3K, and  Ca2+ signaling [21], 
and harm cells by irreversible protein modifications such 
as carbonylation [23, 24]. For example, oxidative stress 
can hinder the SMN complex formation [25].
Various cellular mechanisms regulate neuronal pro-
tein synthesis, including tra#cking of molecules, axonal 
local translation, and local protein degradation. Notably, 
impaired protein synthesis has been reported in various 
neurodegenerative disorders, including Alzheimer’s dis-
ease (AD) and SMA. !e mammalian target of rapamy-
cin (mTOR) is the master regulator of protein synthesis 
in neurons. Lost balance in the mTOR pathway causes 
neuronal dysfunction from Tuberous sclerosis com-
plex (TSC) to Rett syndrome [26]. mTOR can form two 
complexes based on its binding partners, mTORC1 and 
mTORC2. mTORC1 acts as an integral node between cel-
lular energy production and consumption. It promotes 
anabolic processes but also restricts catabolic processes 
such as autophagy [27–29]. Anabolic processes promoted 
by active mTORC1 include mitochondrial biogenesis [30] 
and protein synthesis [31]. Cap-dependent translation 
initiation is promoted by mTORC1 via phosphorylation 
of 4E-BP1 or S6 kinase (S6K) [32–34].
Here, we first report the molecular mechanism explain-
ing how mitochondria regulate protein synthesis via ATP 
and ROS production in spinal MNs. Furthermore, when 
this pathway is disturbed, it contributes to the MN dis-
ease, SMA. Particularly, cellular ATP and ROS signaling 
regulate protein synthesis at the translational initiation 
step, which is impaired in SMA MNs. Our findings imply 
that mitochondria control neuronal energy and ROS 




An SMA mouse model carrying two SMN2 copies on 
one allele and a murine Smn null, FVB/N background 
was used" [35]. It was established by breeding SmnKO/
KO; SMN2tg/tg mice with SmnKO/WT mice resulting in 
50% SMA mice (SmnKO/KO; SMN2tg/0) and 50% pheno-
typically normal heterozygous littermates (SmnKO/WT; 
SMN2tg/0) [36]. FVB/N wild type mice were used as con-
trols (Charles River).
Primary MN culture
E13.5 embryos were used for primary MN culture. SMA 
embryos were genotyped (KAPA mouse genotyping 
kit, Sigma) and cultured as previously described [36]. 
Briefly, spinal cords were isolated and dissociated with 
1% trypsin (Worthington) in PBS. Single cell suspension 
was achieved by trituration with DNase I (Applichem) in 
plating medium (Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 5% fetal calf serum (Biochrom), 0.6% glu-
cose, penicillin/streptomycin (!ermo Fisher Scientific), 
and amphotericin B (Promocell)). For imaging analyses, 
15,000" cells/cm2 were plated on poly-$-lysine (PDL, 
10"µg/ml, Sigma) coated coverslips, and for biochemical 
analyses, 120,000" cells/cm2 were plated on PDL coated 
plates with plating media. Plating media was replaced 
by MN maintenance medium (Neurobasal medium with 
B27 supplement (!ermo Fisher Scientific), 2"mM"%-glu-
tamine, 1% penicillin/streptomycin and 0.25% ampho-
tericin B with additional growth factors: brain derived 
neurotrophic factor (BDNF, 10" ng/ml), ciliary neuro-
trophic factor (CNTF, 10"ng/ml), and glia cell line derived 
neurotrophic factor (GDNF, 10"ng/ml, all purchased from 
PeproTech)). Half of the medium was exchanged every 
third day, and cytosine arabinoside (AraC) was added 
continuously after 3" days to a final concentration of 
1"&M. Cells were cultured at 37"°C in a humidified incu-
bator with 5%  CO2.
Culture of!cell lines
MN-like NSC-34 [37] cells were cultured in DMEM with 
10% fetal calf serum, 1% penicillin/streptomycin, and 
amphotericin B. 20,000"cells/cm2 were plated onto PDL 
coated 12- well plates. Di'erentiation was induced by 
50"µM retinoic acid (Sigma) for 3"days. Cells were main-
tained at 37"°C in a humidified incubator with 5%  CO2.
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RNA isolation, cDNA synthesis and!real-time PCR
Total RNA was extracted from cells using the mirVana   
miRNA Isolation Kit (!ermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. cDNA was pro-
duced from total RNA using the High-Capacity cDNA 
Reverse Transcription Kit (!ermo Fisher Scientific) 
with random primers. mRNA expression levels were 
quantified with  PowerSYBR   Green PCR Master Mix 
(!ermo Fisher Scientific) and 1" &M of gene-specific 
primers using real-time PCR (7500 Real-Time PCR Sys-
tem, !ermo Fisher Scientific). Specificity of the prim-
ers was confirmed by Sanger’s sequencing. Sequences 
of primers are listed in Additional file"1: Supplementary 
Table"1.
Protein isolation and!Western blot analysis
Proteins were extracted with RIPA bu'er (Sigma) with 
protease and phosphatase inhibitors (!ermo Fisher 
Scientific), and protein concentration was determined 
by Pierce   BCA protein assay kit (!ermo Fisher Scien-
tific). Western blot analysis was performed with a stand-
ard protocol. !e information about antibodies is listed 
in Additional file"1: Supplementary Table"2. Signals were 
detected with ChemiDoc XRS + System (BioRad) using 
ECL chemiluminescence (!ermo Scientific) and quanti-
fied using the ImageLab 6.0 software (BioRad).
MitoTracker   and!immunostaining of!MNs
Cells were incubated with MitoTracker Red CMXRos 
(!ermo Fisher Scientific) at a final concentration of 
100"nM for 15"min and fixed with 4% paraformaldehyde 
(PFA). !e information about dyes can be found in 
Additional file"1: Supplementary Table"3. Images were 
acquired with a fluorescence microscope (Zeiss Axio 
Imager.M2) equipped with an AxioCam MR camera 
and an ApoTome.2 system and analyzed with FIJI. All 
image analyses were performed blindly.
Drug treatment
Primary MNs and NSC34 cells were supplemented 
in culture with the following substances at given 
concentrations in each figure legend and Additional 
file"1: Supplementary Table"4: !e supplements sodium 
pyruvate and sodium lactate, the antioxidant N-acetyl-
cysteine (NAC), the ROS inducer menadione, the pro-
tein synthesis inhibitor anisomycin (all purchased from 
Sigma) and the water-soluble mTOR inhibitor WYE-
687 dihydrochloride (Tocris).
Proteomics of!primary MNs
Primary MNs were treated with 50" mM pyruvate, 
10"µM NAC, and 100"µM menadione for 1"h, lysed in 
RIPA bu'er with protease and phosphatase inhibitors, 
and further processed for mass spectrometry (MS) 
analysis. Proteins were precipitated using ice-cold ace-
tone at !80"°C for 15"min and at ! 20"°C for 2"h. Next, 
proteins were resuspended in 8" M urea bu'er with 
protease inhibitor, reduced in-solution using 5" mM 
dithiothreitol (DTT) at room temperature (RT) for 
1"h, alkylated with 40"mM chloroacetamide (CAA) in 
the dark for 30"min, and digested with endo-proteinase 
Lys-C at RT for 4"h. Samples were diluted with 50"mM 
triethylammoniumbicarbonate (TEAB) to a final con-
centration of urea " 2"M and digested with trypsin at 
RT for 8" h. After digestion was completed, samples 
were acidified with 1% formic acid and purified with 
styrenedivinylbenzene-reverse phase sulfonate (SDB-
RPS) Stage Tips. Proteomic analysis was performed 
with ultra-high-performance liquid chromatography 
(UHPLC) coupled to a Quadrupole-Orbitrap mass 
spectrometer (CECAD/CMMC Proteomics core facil-
ity, University of Cologne). Raw data were analyzed by 
MaxQuant. As a reference, a canonical mouse database 
from Uniprot (22.08.19) was used. For gene ontology 
(GO) analysis, the Database for Annotation, Visualiza-
tion and Integrated Discovery 6.7 (DAVID) was used. 
Statistical analysis and data visualization were per-
formed using RStudio and R version 3.6.2. We used the 
mouse MitoCarta2.0 dataset to identify mitochondrial 
proteins [38]. Additional data about identified pro-
teins and GO analysis are listed in Additional file"2: MS 
Source data.
Fig. 1 Mitochondria are defective in SMA MNs. a, b Volcano plot (a) and pie chart (b) of whole proteome analysis comparing WT and SMA 
MNs; plotted p values (!log10) against fold changes  (log2, SMA/WT). Four independent samples of WT MNs and three independent samples of 
SMA MNs were used for analysis. p values were determined using unpaired two-sided t-test. Proteins with p < 0.05 are highlighted in blue (313 
down-regulated) and red (120 up-regulated), and proteins with localization in mitochondria are marked in purple (32 down-regulated and 29 
up-regulated). c, d Gene ontology (GO) analysis of 345 down-regulated (c) and 149 up-regulated proteins (d) in SMA MNs. The 5 most significant 
terms of each category are shown. e Representative images and quantification of mitochondria in 100 !m long primary axons of WT and SMA MNs 
labeled with anti-Tau antibody (green), DAPI (blue), and anti-TOM20 antibody or MitoTracker (white). Scale bars: 20 µm. Each dot represents the 
average number of mitochondria in each neuron (n = 30; biological replicates N = 3). Two-way ANOVA with Tukey HSD post hoc analysis was used 
to determine statistical significance for multiple comparisons. Bar graphs depict the mean ± S.D. ***p < 0.001
(See figure on next page.)
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Isolation of!mitochondria and!complex I activity assay
Mitochondria were isolated from cultured primary 
MNs using the Mitochondria Isolation Kit (Abcam) 
according to the manufacturer’s instructions. In brief, 
3 # 107 10" days in" vitro (DIV) cultured MNs were 
collected, frozen for 10"min, and subsequently thawed. 
Cells were disrupted by a pre-cooled Dounce homog-
enizer after 10"min incubation on ice. After additional 
centrifugation at 1000" x" g, the supernatant was col-
lected and centrifuged again at 12,000" x" g. Finally, 
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isolated mitochondria were resuspended in a storage 
buffer and kept at !80"°C until further use. To test the 
functionality of mitochondrial respiratory chain com-
plexes, complex I enzyme activity assay kit (Abcam) 
was used. In brief, proteins extracted from the isolated 
mitochondria were loaded onto a microwell plate and 
complex I proteins were attached to the microplate via 
antibody coupling. Complex I activity was measured 
by the optical density  (OD450 nm) after adding sub-
strates. The enzyme kinetic was followed for 1"h. We 
used 300" µg of cell extracts for tissue samples from 
heart and 20" µg of mitochondrial extracts for MN 
samples.
SUnSET assay (surface sensing of!translation)
Protein synthesis was measured by SUnSET assay [39]. 
Cells were treated with ROS modifying drugs or 50"µM 
anisomycin as negative control. Afterward, the cells were 
incubated with 1" µM puromycin for 30" min. Finally, 
puromycin labeled peptides were detected by western 
blotting or immunostaining using an anti-puromycin 
antibody. Axons were selected with a segmented line, 
straightened, and divided into 20"µm bins using the con-
centric circles plugin. Mean puromycin intensities were 
quantified using plot profiles.
SunRiSE (SUnSET-based Ribosome Speed of!Elongation)
SunRiSE assay was used to monitor protein elongation 
speed [40]. Initiation of mRNA translation was blocked 
by 2" µg/ml harringtonine (Abcam) at di'erent time 
points, and all samples were incubated with 10" µg/ml 
(16.7"µM) puromycin for 10"min. Puromycin labeled pep-
tides were detected by western blotting.
ATP assay
Intracellular ATP concentrations were measured with the 
ATP determination kit (!ermo Fisher Scientific) based 
on bioluminescence signal detection by the  GloMax   
luminescence reader (Promega). ATP levels were normal-
ized to the amounts of soluble proteins determined by 
BCA assay.
Glucose uptake assay
Glucose Uptake-Glo kit (Promega) was used to meas-
ure glucose uptake e#ciency using 120,000" cells/cm2. 
We mainly followed the manufacturer’s instruction and 
luminescence was detected by the GloMax luminescence 
reader. Signal was normalized to protein concentration 
measured by BCA assay.
Pyruvate uptake assay
Pyruvate uptake was measured with the Pyruvate assay 
kit (Sigma). Fluorescence signal was measured with a 
Safire 2 microplate reader (Tecan) and normalized to sol-
uble protein amount.
Detection of!oxidative stress
CellROX   Green reagent (!ermo Fisher Scientific) was 
used to measure oxidative stress. Cells were incubated 
with 5"µM CellROX Green reagent for 30"min, fixed with 
3.7% formaldehyde, nuclei, and F-actin were labeled with 
DAPI and Alexa Fluor 568 Phalloidin (!ermo Fisher 
Scientific), respectively. Images were acquired with a 
fluorescence microscope equipped with an ApoTome.2 
system. CellROX signal was quantified with a Safire 2 
microplate reader (Tecan). Signals of the microplate 
reader were normalized to soluble protein concentration 
after lysis with RIPA bu'er.
Protein carbonylation assay
!e amount of protein carbonyl groups was measured 
with the Protein carbonyl assay kit (Abcam). Proteins 
were quantified by Bradford.
(See figure on next page.)
Fig. 2 Defective mitochondrial complex I causes cellular dysfunction in SMA MNs. a Complex I activity using 20 µg mitochondria extract isolated 
from WT and SMA MNs (10DIV) (N = 4). Quantification represents the increase in mean  OD450 nm/h. b Representative images and quantification 
of WT and SMA MNs labeled with CellROX (green and rainbow color) for ROS detection, DAPI (blue), and Phalloidin (red). Rainbow color indicates 
the intensity of CellROX signal. Quantification of mean fluorescence intensity of the CellROX signal in WT and SMA MN (red squares) (n = 40, 
N = 4). Scale bars are written on individual images. c Quantification of CellROX signal of WT and SMA MNs measured with a microplate reader 
(N = 5). d Western blot analysis and quantification of carbonylated proteins (DNP = 2,4-dinitrophenyl) in 10DIV WT and SMA MNs (N = 4). Bar graph 
represents the quantification of the DNP signal. ACTB was used as a loading control. e ATP levels in WT (N = 7) and SMA MNs (N = 8). Data are 
normalized to solubilized protein amounts. f ATP levels in WT and SMA MNs (N = 6) after 50 mM pyruvate treatment for 1 h. Data are normalized 
to solubilized protein amounts. Individual data (circle or square) represent biological replicates. g ROS levels of SMA MNs after 50 mM pyruvate 
or 100 µM menadione treatment for 1 h. Two-tailed unpaired t-tests with Holm-Bonferroni correction for multiple comparisons were used on 
independent biological replicates (N = 6) to determine statistical significance. *p < 0.05, **p < 0.01. a–f Blue circles represent data from WT and red 
squares represent SMA MNs. 10DIV MNs were used. Each dot represents the quantification of individual biological replicates. A two-tailed unpaired 
t-test was used on independent biological replicates to determine statistical significance. Bar graphs depict the mean ± S.D., n.s. p > 0.05, *p < 0.05, 
**p < 0.01
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Click-iT   AHA assay
To deplete endogenous methionine reserves, cells were 
incubated with HBSS for 30"min. 500"µM L-azidohomo-
alanine (AHA, !ermo Fisher Scientific) was treated to 
cells at 37" °C for 1"h. Cells were washed and lysed with 
RIPA bu'er supplemented with protease and phosphatase 
inhibitors on ice. Click chemistry reaction was performed 
with Click-iT protein reaction bu'er kit (!ermo Fisher 
Scientific), using manufacturer’s protocol.
Statistical analysis
Statistical analysis was conducted in R version 3.6.2 using 
RStudio [41]. All graphs for cell biological experiments 
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variables, statistical significance was analyzed with an 
unpaired, two-tailed Student’s t-test. Multiple compari-
sons are corrected with the Holm-Bonferroni method. 
Di'erences among group means are determined with 
Tukey’s honestly significant di'erence (HSD) test after 
rejection of the null hypothesis by one-way analysis of 
variance (ANOVA). Normally distributed experimen-
tal results with two factors are analyzed by two-way 
ANOVA with Tukey HSD post hoc analysis. To compare 
multiple mean values to the mean from a single control, 
especially for time-course and dose–response experi-
ments, Dunnett’s post hoc test was used after one-way 
ANOVA. Statistical tests were applied only to biologi-
cal replicates, even when data is presented as individual 
measurement counts. Statistical methods are listed in 
the figure legends of individual experiments. Signifi-
cance is indicated by stars (*p < 0.05; **p < 0.01; *** < 0.001, 
n.s. = not significant).
Results
Mitochondria are defective in!SMA MNs
To discover dysregulated pathways in SMA, we investi-
gated di'erentially expressed proteins in primary MNs 
isolated from an SMA mouse model compared to wild-
type mice [35]. It has been shown that around 8101 pro-
teins are expressed in MNs from E12.5 mouse embryos 
[42]. We detected 5165 proteins using whole proteome 
analysis of 10DIV-cultured MNs, isolated from E13.5 
embryos (Fig."1a). 494 proteins are significantly changed 
in SMA MNs compared to WT MNs, and 61 proteins 
are localized to mitochondria based on the MitoCarta2.0 
database containing 1158 proteins (Fig." 1b and Addi-
tional file"3: Figure S1a). From 44 known proteins of the 
respiratory complex I, we identified 35 proteins in our 
dataset, and 9 of them were significantly altered in SMA 
MNs (Additional file"3: Figure S1a, S2a). To understand 
the biological meaning of SMA a'ected proteins, we per-
formed gene ontology (GO) analysis of 345 significantly 
down-regulated and 149 significantly up-regulated pro-
teins in SMA (Fig."1c and d). Among the down-regulated 
proteins, we identified previously reported dysfunctional 
processes in SMA such as mRNA processing, protein 
transport, and protein synthesis, confirming the reliabil-
ity of the data set (Fig."1c) [6–9, 16]. Data from the 149 
up-regulated proteins strongly suggested mitochondrial 
dysfunction (Fig."1d). !erefore, we further investigated 
the function and localization of mitochondria in MNs 
by staining with MitoTracker (functional mitochondria) 
and TOM20 (total mitochondria). Indeed, numbers of 
total and functional mitochondria are reduced in SMA 
axons (Fig."1e). !e finding of mitochondrial mislocali-
zation is strengthened by reduced levels of mitochon-
drial motor proteins KIF1B and KIF1BP in SMA MNs 
in our whole proteome analysis (Additional file"3: Figure 
S1a and Additional file"2: MS source data). In addition, 
we found that mitochondria are smaller and fragmented 
in SMA MNs (Additional file" 3: Figure S1b). Together, 
these results suggest that mitochondria are defective in 
SMA MNs.
Defective complex I can induce higher ROS levels 
and!lower ATP levels in!SMA MNs
As our proteomics results indicated defects in complex I 
of the electron transport chain, we biochemically meas-
ured the activity of complex I in WT and SMA MNs 
(Additional file"3: Figure S2a and S2b). Indeed, complex 
I activity was 50% lower in SMA MNs (Fig."2a and Addi-
tional file"3: Figure S2c). Additionally, we measured com-
plex I activity in the heart, another metabolically active 
tissue, and found no di'erence between WT and SMA 
MNs (Additional file"3: Figure S2d). !is data suggested 
that complex I dysfunction in SMA is MN specific. Next, 
as complex I is a known source of reactive oxygen species 
(ROS) in mitochondria [22], we measured intracellular 
ROS levels using CellROX. As expected, ROS levels were 
increased in SMA MNs compared to WT ones (Fig."2b 
and Fig." 2c). Furthermore, as excessive ROS can cause 
carbonylation of proteins [43], we measured the levels 
of carbonylated proteins in SMA MNs. Indeed, higher 
amounts of proteins were carbonylated in SMA (Fig."2d). 
!ese data confirmed our finding that SMA MNs are 
under oxidative stress.
Since mitochondrial OXPHOS besides the tri-
carboxylic acid (TCA) cycle is the main source of 
energy in neurons, we measured the intracellular ATP 
Fig. 3 E"ect of ROS on protein synthesis in neurons. a Schematic drawing of the SUnSET method. Puromycin labels newly synthesized proteins. 
Puromycin is detected by anti-puromycin antibody. b SUnSET assay in WT and SMA MNs (N = 5). ACTB was used as loading control. c Schematic 
drawing of the Click-iT AHA method. L-azidohomoalanine (L-AHA) is incorporated into newly synthesized proteins, followed by click chemistry 
reaction with biotin alkyne. Biotin-labeled proteins can be detected by western blot analysis. d Click-iT AHA assay in WT and SMA MNs (N = 4). ACTB 
was used as loading control. e Scheme of experimental design. 10DIV MNs were treated with 10 µM NAC or 50 mM pyruvate for 1 h. Cells were 
incubated with 1 !M puromycin for 30 min before analysis. f, g SUnSET assay after ROS modification in (f) WT MNs (N = 5) and (g) SMA MNs (N = 5). 
Blue circles represent data from WT and red squares represent SMA MNs. Two-tailed unpaired t-tests with Holm-Bonferroni correction for multiple 
comparisons were used to determine statistical significance. All bar graphs depict the mean ± S.D., n.s. p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001
(See figure on next page.)
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concentrations in WT and SMA MNs. ATP concen-
tration is up to threefold lower in SMA compared to 
WT MNs (Fig."2e). Furthermore, as ATP can also be 
produced by glycolysis to compensate for high energy 
demand in neurons [44], glucose uptake was moni-
tored. Interestingly, glucose uptake is also impaired in 
SMA MNs (Additional file"3: Figure S2e). These data 
indicate that SMA MNs are in an energy-deprived sta-
tus. Next, we pursued to restore the effects of defec-
tive mitochondria in SMA. Since pyruvate is known 
to reduce ROS in a non-enzymatic way and is also a 
known substrate of the TCA cycle [45], we supple-
mented MNs with sodium pyruvate. First, we con-
firmed that MNs can take up pyruvate within 5"min 
after treatment (Additional file" 3: Figure S2f ). While 
10"mM pyruvate showed no clear effect, 50"mM pyru-
vate treatment for 1"h could increase ATP concentra-
tion significantly in SMA MNs (Fig."2f and Additional 
file" 3: Figure S2" g). However, lactate, which can be 
converted to pyruvate by lactate dehydrogenase in the 
cytoplasm [46], did not alter ATP levels in primary 
MNs (Additional file" 3: Figure S2g). In addition, as 
pyruvate has been suggested to be a ROS scavenger 
[47], we treated SMA MNs with pyruvate and subse-
quently measured ROS levels. Indeed, pyruvate could 
successfully reduce ROS levels in SMA MNs (Fig."2g). 
Further, we confirmed ROS reduction by treatment 
with 50" mM pyruvate or 10" µM of the antioxidant 
NAC in menadione mediated ROS induced NSC-34 
cells (Additional file"3: Figure S2h). These results sug-
gest that pyruvate is a valuable supplement to restore 
ATP levels and simultaneously balance intracellular 
ROS levels in MNs.
E"ect of!ROS on!protein synthesis in!neurons
Carbonylation of proteins can alter their conformation 
and hinder protein synthesis [23, 48]. Furthermore, as 
levels of ribosomes and proteins associated with trans-
lation are also changed in SMA according to our MS 
data, we measured protein synthesis e#ciency with 
Surface sensing of translation (SUnSET) and Click-iT 
AHA assay in WT and SMA MNs. Indeed, we con-
firmed that SMA MNs show a reduced protein synthe-
sis e#ciency compared to WT ones (Fig."3a-d). Based 
on these data, we hypothesized that the elevated ROS 
levels hinder protein synthesis, therefore, reducing 
elevated ROS might restore impaired protein synthesis 
in SMA MNs. To further understand the e'ect of ROS 
on protein synthesis, we modified cellular ROS levels 
and measured protein synthesis e#ciency. We treated 
MNs with 10" µM NAC, 50" mM pyruvate or 100" µM 
menadione and performed SUnSET analysis (Scheme 
in Fig."3e). While protein synthesis e#ciency was unal-
tered by pyruvate or NAC, menadione-induced ROS 
clearly inhibited protein synthesis in NSC-34 cells and 
WT MNs. As a negative control, 50"µM of the transla-
tion inhibitor anisomycin was used (Fig." 3f and Addi-
tional file"3: Figure S3a, b). Interestingly, NAC treatment 
could increase protein synthesis in SMA MNs, where 
cellular ROS levels are higher (Fig."3g). However, pyru-
vate treatment failed to increase protein synthesis in 
SMA MNs (Fig."3g). Taken together, our data strongly 
suggests that intracellular ROS levels influence protein 
synthesis in MNs.
ROS regulates axonal local translation in!MNs
Next, we investigated whether ROS regulates axonal 
local protein synthesis in MNs. We performed a 
SUnSET assay, but MNs were analyzed individually 
through imaging analysis. We are aware that local 
protein synthesis is lower in 10DIV-cultured MNs 
than in actively growing neurons [49, 50]. Therefore, 
we examined newly synthesized proteins in differ-
ent axonal compartments. First, we measured anti-
puromycin signals in 20" µm fractions and analyzed 
100" µm fractions starting from the soma, comparing 
WT and SMA MNs. As expected, proximal fractions 
have higher anti-puromycin signals compared to distal 
parts. Importantly, the anti-puromycin signal in both 
soma and axonal part is lower in SMA MNs compared 
(See figure on next page.)
Fig. 4 ROS regulates axonal local translation in MNs. a SUnSET assay. Representative images of WT and SMA MNs. Neurites were selected with a 
segmented line, straightened, and divided into 20 µm bins using the concentric circles plugin. Quantification of mean puromycin intensity profiles 
confirms that protein synthesis is reduced in the soma and axonal compartment of SMA MNs. b SUnSET assay. Representative images of SMA MNs 
after ROS modification. Tau staining shows whole neuronal morphology and puromycin signal represents newly synthesized proteins after 1 h 
treatment. 10 µM NAC, 100 µM menadione or 50 µM anisomycin were treated. Each dot represents the average intensity of 15 neurons (N = 5). 
One-way ANOVA with Tukey HSD post hoc analysis was used to determine statistical significance for multiple comparisons. Bar graphs depict the 
mean ± S.D. n.s. p > 0.05, ***p < 0.001. c SUnSET assay. Representative images of SMA axons. MNs were treated with 10 µM NAC, 50 mM pyruvate, 
100 µM menadione, or 50 µM anisomycin for 1 h. a–c Intensity of incorporated puromycin signal is represented in rainbow scale. Scale bar: 20 µm. 
a, c Each dot represents the average quantification of 10 neurons of 5 individual biological replicates (N = 5). Bar graphs depict the mean ± S.D. 
Two-tailed unpaired t-test with Holm-Bonferroni correction for multiple comparisons was used to determine statistical significance. n.s. p > 0.05, 
*p < 0.05, **p < 0.01
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to WT ones (Fig."4a). Next, we treated SMA MNs with 
NAC, pyruvate, menadione, and anisomycin and per-
formed the same experiment. As expected, while NAC 
treatment increased protein synthesis, menadione or 
anisomycin inhibited protein synthesis in the soma 
as well as in the axonal compartment of SMA MNs 
(Fig."4b, c and Additional file"3: Figure S4a). Consist-
ent with the results in Fig."3f, WT MNs did not show 
clear differences following NAC treatment (Additional 
file"3: Figure S4a and b).
Whole proteome analysis of!MNs with!ROS manipulation
Next, we tried to obtain a systemic view of the whole 
proteome regulated by ROS in MNs. First, cells were 
incubated with 50" mM pyruvate for 1" h and the 
whole proteome was analyzed by MS. We found that 
the levels of 122 proteins were altered in SMA MNs 
(Fig." 5a). GO analysis of altered proteins suggests 
that pyruvate regulates proteins related to mito-
chondria (Fig." 5b). The biological process of oxida-
tive phosphorylation was enriched, and the cellular 
compartment of mitochondria was affected by pyru-
vate supplementation (Fig."5b). In addition, molecu-
lar functions involved in ribonucleotide binding, 
cellular compartments of the spliceosome, or bio-
logical processes such as RNA splicing and mRNA 
processing were also affected by pyruvate. Interest-
ingly, these terms have previously been reported as 
altered pathways in SMA. Among the 494 proteins 
significantly changed in SMA MNs compared to WT 
MNs, 22 were also significantly changed by pyru-
vate in WT MNs, and 28 were significantly altered 
in pyruvate-treated SMA MNs (Fig."5c). Intriguingly, 
when we compare proteins altered in SMA to pyru-
vate-affected proteins in WT or SMA MNs, we found 
that the effect of pyruvate was more apparent in 
SMA MNs (Fig."5d and Additional file"3: Figure S5a). 
Among these 28 proteins, 21 proteins were down-
regulated in SMA compared to WT and up-regulated 
by pyruvate in SMA (Fig." 5d). In contrast, pyruvate 
changed levels of 144 proteins in WT MNs, and 
among those, 22 proteins were also altered in SMA 
compared to WT (Fig."5c and Additional file"3: Fig-
ure S5a, b). However, these 22 proteins showed far 
fewer changes after pyruvate treatment (Additional 
file" 3: Figure S5a). Only two proteins, DLG-associ-
ated protein 1 (DLGAP1) and Islet cell autoantigen 1 
(ICA1), were commonly changed by pyruvate treat-
ment between WT and SMA MNs (Fig."5a and Addi-
tional file"3: Figure S5b, c).
Subsequently, to obtain an overview of the antioxidant 
e'ect on the MN proteome, SMA MNs were treated 
with 10"µM NAC for 1"h. Whole proteome analysis iden-
tified that 143 proteins were significantly changed by 
NAC treatment (Fig." 5e). GO analysis suggested these 
proteins have multiple functions, including nucleotide-
binding and RNA processing (Fig." 5f ). Compared with 
di'erentially expressed proteins between WT and SMA 
MNs, 31 proteins were common with NAC treatment 
in SMA MNs (Fig."5g). Among them, 17 proteins were 
down-regulated in SMA compared to WT, and up-reg-
ulated by NAC treatment in SMA (Fig."5h). Again, NAC 
treatment showed little e'ect on WT MNs (Additional 
file" 3: Figure S5d, e). NAC treatment altered only one 
protein, namely the deubiquitinase OTUD6B, in both 
WT and SMA MNs (Fig."5e and Additional file"3: Fig-
ure S5e, f ). ROS induction by 100" µM menadione for 
1"h in WT MNs had the biggest e'ect on the proteome 
with 344 significantly altered proteins (Additional file"3: 
Figure S5g). In addition, menadione showed with 56 
proteins the biggest overlap of altered proteins with pro-
teins changed in SMA (Additional file"3: Figure S5h, i). 
It is worth mentioning that pyruvate and NAC had only 
a small e'ect on WT MNs, whereas they can induce a 
considerable up-regulation of proteins in SMA MNs. A 
possible explanation could be that the basal amounts of 
these proteins are lower in SMA MNs compared to WT 
MNs.
ROS regulates initiation of!mRNA translation
Whole proteome analysis suggested that mRNA transla-
tion is dysregulated in SMA MNs (Fig."1c). !e volcano 
plot illustrates 360 proteins identified in our whole-pro-
teome analysis related to mRNA translation based on 
the Mouse Genome Informatics (MGI) database (Addi-
tional file"3: Figure S6a). Among them, 40 out of 47 are 
significantly down-regulated in SMA MNs compared 
to WT (Additional file" 3: Figure S6a). mRNA transla-
tion is tightly regulated in eukaryotic cells by two major 
processes: initiation and elongation. As it has already 
Fig. 5 NAC and pyruvate modify the proteome of SMA MNs. a, e Volcano plot of whole proteome analysis in SMA MNs after (a) pyruvate or (e) 
NAC treatment; plotted p value (-log10) against fold change  (log2) (N = 3). p values were determined by unpaired two-sided t-test. Significantly 
changed proteins with p < 0.05 are highlighted in blue (down-regulated) or red (up-regulated). b, f GO analysis of significantly changed proteins 
by (b) pyruvate or (f) NAC-treated SMA MNs. c, g Venn diagram showing the overlap of ‘significantly altered proteins in SMA compared to WT’ and 
‘significantly changed proteins by (c) pyruvate or (g) NAC’ treatment in WT MNs or SMA MNs. d Levels of proteins altered in SMA compared to WT 
and by (d) pyruvate or (h) NAC treatment in SMA; plotted fold change  (log2) comparing with and without pyruvate treatment
(See figure on next page.)
XXVI
Maximilian Paul Thelen THELEN et al., 2020
Page 12 of 19Thelen!et!al. acta neuropathol commun           (2020) 8:223 




































































































protein modification by small
protein conjunction or removal
0 2 4 6



































































































































THELEN et al., 2020 Maximilian Paul Thelen
Page 13 of 19Thelen!et!al. acta neuropathol commun           (2020) 8:223  
been reported that protein synthesis is impaired in SMA 
MNs [7, 8, 16],"we aimed to seek further which step is 
disrupted by SMN loss. To distinguish the initiation and 
elongation of translation, we measured both processes 
in MNs. First, to assess the rate of protein elongation, 
we used the SunRiSE assay. In brief, translation initia-
tion was blocked by 2"µg/ml harringtonine at di'erent 
time intervals, then newly synthesized peptides were 
labeled with 10"µg/ml puromycin and detected by anti-
puromycin antibody (Fig."6a). !e elongation speed was 
not altered by either NAC or pyruvate treatment in WT 
and SMA MNs (Fig."6b, c). Furthermore, the elongation 
speed between WT and SMA MNs did not show any sig-
nificant di'erence (Additional file"3: Figure S6b).
As translational elongation is unaltered in SMA or by 
ROS modification, we focused on translational initiation 
next. As one of the well-described translational initia-
tion mechanisms is the cap-dependent translation initia-
tion by 4E-BP1 (eukaryotic translation initiation factor 
4E-binding protein 1), we measured the phosphoryla-
tion status of 4E-BP1 in WT and SMA MNs. A reduced 
phosphorylation status of 4E-BP1 indicates that initiation 
of mRNA translation is impaired in SMA MNs (Fig."6d). 
Next, we measured the phosphorylation status in MNs 
after pharmacological modulation of ROS levels. While 
a significant di'erence was not observed by pyruvate or 
NAC treatment in WT cells, menadione impaired phos-
phorylation of 4E-BP1. !is data suggests that exces-
sive ROS can inhibit mRNA translation at the initiation 
step (Fig." 6e). Notably, pyruvate and NAC treatment 
increased the phosphorylation of 4E-BP1 in SMA MNs 
(Fig."6f). Taken together, this unprecedented data reveals 
that mRNA translation is impaired at the initiation step 
in SMA MNs, while elongation is unaltered. Moreover, 
the initiation of mRNA translation can be regulated by 
ROS via 4E-BP1.
SMN protein levels are regulated by!pyruvate and!ROS 
via!mTOR
Most interestingly, pyruvate increased SMN levels in 
WT and SMA MNs as well as NSC-34 cells (Fig." 7a, 
b, and Additional file" 3: Figure S7a). To identify the 
molecular mechanism underlying increased SMN lev-
els, we measured Smn mRNA levels in WT MNs and 
NSC-34 cells after pyruvate treatment and found no 
significant increase of Smn mRNA levels (Additional 
file"3: Figure S7b). !is data suggests a post-transcrip-
tional regulation of SMN levels. Next, we found that 
the protein synthesis inhibitor anisomycin could pre-
vent pyruvate-induced elevation of SMN levels (Addi-
tional file"3: Figure S7c). !is data confirms that protein 
synthesis of SMN is regulated by pyruvate post-tran-
scriptionally. In addition, NAC increased SMN levels 
in MNs (Fig."7c, d). As mTOR, especially mTORC1, is 
a central regulator of protein synthesis [51], we tested 
whether the increase of SMN levels is mTOR-depend-
ent. We treated MNs with the water-soluble mTOR 
inhibitor WYE-687 dihydrochloride and subsequently 
with pyruvate. Indeed, pyruvate failed to increase SMN 
levels when mTOR activity was inhibited (Fig." 7e). In 
addition, pyruvate increased mTORC1 activity in WT 
MNs (Fig."7f, g and Additional file"3: Figure S7d). Fur-
thermore, a reduction of ROS by NAC treatment in 
SMA MNs increased the mTORC1 activity (Fig." 7h). 
Taken together, our data showed that cellular ROS and 
ATP levels regulate SMN protein synthesis via regulat-
ing mTORC1. Furthermore, re-balancing ROS levels 
with an antioxidant in SMA MNs can increase SMN 
protein synthesis.
Discussion
!rough whole proteome analysis, we identified that 
SMA MNs exhibit mitochondrial dysfunction. Prior 
studies have noted mitochondrial defects in SMA, 
including decreased respiration, increased oxidative 
stress, and impaired mitochondrial mobility [18, 20]. 
Here, we further investigated the molecular mecha-
nisms underlying mitochondrial defects and reported 
that the function of complex I of the electron transport 
chain in mitochondria is impaired in SMA MNs. Fur-
thermore, due to the dysfunctional complex I, intra-
cellular ATP concentration is lower, and ROS levels 
(See figure on next page.)
Fig. 6 ROS regulates initiation of protein translation without altering elongation speed. a Scheme of SunRiSE assay. Translation initiation of 10DIV 
WT or SMA MNs was blocked with 2 µg/ml harringtonine at di"erent time points before adding 10 !g/ml puromycin treatment for 10 min. b, 
c Neither NAC nor pyruvate changes elongation speed in (b) WT or (c) SMA MNs. Each dot and line represent the average of four independent 
biological replicates (N = 4). Regression analysis comparing the least square means does not show any significant di"erence between treatments. 
d Western blot analysis of p-4EBP1 and 4EBP1 levels in WT (blue circles) and SMA MNs (red squares) (N = 5). ATCB was used as loading control. Each 
dot represents the data from biological replicates. Two-tailed unpaired t-test was used to determine statistical significance *p < 0.05, **p < 0.01, 
***p < 0.001. e, f Western blot analysis of p-4EBP1 and 4EBP1 levels after pharmacological modifications of ROS levels in (e) WT MNs (N = 6) and (f) 
SMA MNs (N = 6). Each dot represents the data from biological replicates. One-way ANOVA with Tukey HSD post hoc analysis was used to determine 
statistical significance for multiple comparisons. Bar graphs depict the mean ± S.D. n.s. p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001
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are higher in SMA MNs. Regarding ROS generation, 
complex I and complex III are the known critical com-
ponents. However, as the physiological or pathologi-
cal relevance of complex III in ROS generation seems 
controversial, we focused on complex I function [22]. 
Moreover, complex I activity was not altered in the 
heart, another energy-demanding tissue. !is finding 
indicates that complex I dysfunction can be a neuron-
specific phenotype in SMA.
While a previous report did not show changes in the 
number of axonal mitochondria [20], we found that the 
number of axonal mitochondria is reduced. !is con-
troversy might be explained by methodological di'er-
ences. In the previous study, mitochondria were labeled 
by aberrantly expressed mitochondrial proteins, while 
we used MitoTracker, a membrane potential dependent 
dye, which does not stain non-functional mitochondria 
or antibodies against the mitochondrial protein TOM20. 
!is implicates that the proportion of dysfunctional 
mitochondria in SMA axons is higher compared to WT 
ones.
It has widely been accepted that neurons use mito-
chondria as their primary source of energy. However, a 
recent study suggested that neurons can obtain energy 
from glycolysis in energy-demanding conditions and 
locations [52]. Based on our results, glucose uptake is 
impaired in SMA MNs. !erefore, reduced energy pro-
duction due to defective mitochondria might not be 
compensated by glycolysis. Taken together, we could 
conclude that SMA MNs are in a status of energy dep-
rivation caused by mitochondrial defects as well as 
impaired glucose uptake. Glycolysis is also impaired in 
other neurodegenerative diseases such as AD and amyo-
trophic lateral sclerosis (ALS) [53, 54]. Furthermore, it 
has been proposed that enhancing glycolysis is neuro-
protective in ALS [55]. However, it is unclear whether 
glycolysis is also impaired in SMA MNs. !is needs to 
be investigated further.
As excessive cellular ROS are harmful to the cellular 
system, production and scavenging mechanisms are 
tightly regulated in all living organisms. Imbalanced 
ROS has been reported in numerous pathological con-
ditions [56, 57]. ROS can be produced by mitochondria 
and cleared up by enzymes and chelating agents [58]. 
With our current data, we can speculate that ROS pro-
duction can be increased by defective mitochondrial 
complex I, yet it is not clear whether ROS scavenging 
mechanisms are also altered in SMA MNs. Importantly, 
we revealed that ROS regulates mRNA translation at 
the initiation step and this mechanism is dysregulated 
in SMA. Counteracting this molecular pathway by sup-
plementing pyruvate or the antioxidant NAC restores 
impaired translational initiation in SMA MNs. Never-
theless, in WT MNs, reducing ROS did not a'ect pro-
tein synthesis as WT MNs do not su'er from oxidative 
stress. !is data intensifies our conclusion that healthy 
cells tightly regulate the balance of ROS levels, but SMA 
cells lost their ability to regulate ROS homeostasis due 
to defective mitochondrial complex I. Furthermore, 
our data revealed that ROS regulates mRNA transla-
tion at the initiation step, contributing to impaired 
protein synthesis, a known SMA pathology [16, 17]. 
Additionally, we found that the number and functional-
ity of axonal mitochondria are reduced in SMA MNs. 
!erefore, to test whether impaired axonal mitochon-
dria also influence protein synthesis in axons, we meas-
ured mRNA translation in the axonal compartment of 
the neurons. In a compartment-specific analysis, we 
revealed reduced protein synthesis in SMA MNs within 
the soma and along the axon. In 10"days cultured MNs, 
active protein synthesis was not observed at the distal 
part of the axons, while active protein synthesis could 
be observed and quantified in the proximal part of the 
axons.
Interestingly, reduction of ROS via pyruvate or 
NAC led to an increase of SMN protein levels in an 
mTOR-dependent manner. An increase of SMN lev-
els by pyruvate or NAC was also observed in WT 
MNs, even though it did not change the overall pro-
tein synthesis rate. While the underlying molecular 
mechanism is unclear, our data suggests that pyru-
vate and NAC specifically increase SMN protein lev-
els via the mTOR pathway without altering the whole 
proteome, independent of oxidative stress. It has pre-
viously been reported that SMN is involved in ribo-
some biology, and mTOR activity is reduced in SMA 
neurons [16, 17]. These findings suggest an SMN-
specific feedback mechanism of gene expression. 
Fig. 7 SMN levels are regulated by pyruvate and ROS modifying drugs. a–d Representative western blot images and quantification of SMN levels 
after pyruvate treatment for 1 h in (a) WT MNs and (b) SMA MNs or after ROS modification in (c) WT MNs and (d) SMA MNs. e 100 nM WYE-687 
dihydrochloride blocks elevation of SMN levels after pyruvate treatment in WT MNs. f–h Representative western blot images and quantification 
of phosphorylated S6 and total S6 protein levels after pyruvate treatment in (f) WT MNs (N = 7) and (g) SMA MNs (N = 7) or after (h) NAC and 
menadione treatment in SMA MNs (N = 4). One-way ANOVA with Dunnett post hoc analysis was used to compare each time point with the control 
(a, b). One-way ANOVA with Tukey HSD post hoc analysis was used to determine statistical significance for multiple comparisons (c-h). Each dot 
represents the quantification of individual biological replicates. Bar graphs depict the mean ± S.D., n.s. p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001
(See figure on next page.)
XXX
Maximilian Paul Thelen THELEN et al., 2020






THELEN et al., 2020 Maximilian Paul Thelen
Page 17 of 19Thelen!et!al. acta neuropathol commun           (2020) 8:223  
However, the mechanism underlying mTOR-depend-
ent SMN protein synthesis needs to be investigated.
Overall, we unraveled the previously unknown molecu-
lar connections between mitochondria and protein syn-
thesis by impairing translation initiation in neurons. !is 
dysfunction contributes to the pathology of SMA via 
decreased ATP and increased ROS levels.
Conclusion
!is study describes the previously unknown mechanism 
that defective mitochondria influence SMA pathology, 
especially impaired protein synthesis. With a proteom-
ics approach using an SMA mouse model, we identified 
that mitochondrial respiratory complex I is dysfunctional 
in SMA MNs. Due to this, ATP levels are decreased and 
ROS levels are increased in SMA MNs. Furthermore, we 
could restore the homeostasis of cellular energy and the 
redox system in SMA MNs by supplementation of pyru-
vate. Modifying ROS levels influences protein synthesis 
at the translation initiation step, which is impaired in 
SMA MNs. In addition, pyruvate enhances SMN protein 
synthesis in an mTOR-dependent manner. As mitochon-
drial defects have been reported in other neurological 
disorders, our study reveals the basic cellular mechanism 
of how mitochondria can influence protein synthesis in 
MNs. !is study will lead to new insights into pharmaco-
logically targetable pathways for neurological disorders, 
including SMA.
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Supplementary Table 1: Primer sequences 
Applications Name Sequence Expected 
size 
qRT-PCR Actb-fw AGCCATGTACGTAGCCATCC 201 
Actb-rev CTCTCAGCTGTGGTGGTGAA 




Supplementary Table 2: Antibodies and conditions for Western blot (WB) and 








anti-4E-BP1 rabbit; WB 1:1000 Cell Signaling; #9644 AB_2097841 
anti-p4E-BP1 
(Thr37/46) 





Santa Cruz; sc-47778 
HRP 
AB_2714189 
anti-ChAT  rabbit; IF 1:100 Thermo Scientific; PA5-26597 
AB_2544097 
anti-Puromycin mouse; WB 1:1500 
IF 1:150 
Merck; MABE343 AB_2566826 
anti-S6 mouse; WB 1:1000 Cell Signaling; #2317 AB_2238583 
anti-pS6 rabbit; WB 1:1000 Cell Signaling; #2211 AB_331679 
anti-S6K rabbit; WB 1:2000 Cell Signaling; #2708 AB_390722 
anti-pS6K rabbit; WB 1:750 Cell Signaling; #9234 AB_2269803 
anti-SMN mouse; WB 1:3000 BD Biosciences; 
610646 
AB_397973 
anti-Tau mouse; IF 1:800 Santa Cruz; sc-
390476 
 
anti-Tau chicken; IF 1:100 Abcam; ab75714 AB_1310734 











goat; WB 1:3000 Dianova; 115-035-146 AB_2307392 
anti-rabbit IgG, 
HRP-conjugated 





























Supplementary Table 3: Fluorescence dyes 
Fluorescence dye Manufacturer/ #catalog  
Alexa FluorTM 568 Phalloidin Thermo Scientific; A12380 
CellROXTM Green reagent Thermo Scientific; C10444 
DAPI Thermo Scientific; R37606 
MitoTracker® Red CMXRos Thermo Scientific; M7512 
 
 
Supplementary Table 4: Drugs and supplements for in vitro assays 
Drugs/ supplements Concentration Solvent Manufacturer/ 
#catalog  
Anisomycin 40 µM/ 50 µM Water Sigma; A9789 
Harringtonine 2 mg/ml DMSO Abcam; ab141941 
Menadione 0.1 µM-100 µM DMSO Sigma; M5625 
N-Acetyl-L-cysteine (NAC) 1 µM-1000 µM Water Sigma; A9165 
Puromycin Dihydrochloride 1 µM/ 10 µg/ml Water Gibco; A1113803 
Sodium pyruvate 1 mM – 50 mM Water Sigma; P5280 
Sodium lactate 1 mM – 50 mM Water Sigma; L7022 
WYE-687 dihydrochloride 100 nM Water Tocris; #4282 
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Fig.S1 Complex I deciency leads to dysfunctional and fragmented mitochondria. 
a Volcano plot of proteins identied in whole proteome analysis and reported in the MitoCarta2.0 database; 
plotted p-values (-log10) against fold changes (log2, SMA/ WT). Four independent samples of WT MNs and 
three independent samples of SMA MNs were used for analysis. P-values were determined using unpaired 
two-sided t-test. Proteins with p < 0.05 are highlighted in blue (32 down-regulated) or red (29 up-regulated).
b Representative images and quantication of mitochondrial size and circularity of 10DIV WT and SMA MNs 
labelled with anti-TOM20 antibody or MitoTracker®. Enlarged areas are highlighted with yellow boxes in the 
corresponding image of the whole neuron. Scale bar in enlarged images: 10µm; Scale bar in whole neuron 
images: 20µm. Each dot represents the quantication of individual neurons (n=30). To compare WT (blue 
circles) and SMA (red squares), two-way ANOVA with Tukey HSD post hoc analysis was used on 
independent biological replicates (N=3) to determine statistical signicance. Bar graphs depict the mean ± 
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Fig.S2 Mitochondrial complex I is impaired in SMA MNs. 
 
a Representation of oxidative phosphorylation KEGG Pathway (mmu00190) [1]. Green boxes 
highlight organism-specific complexes (Mus musculus). Stars mark significantly up-regulated 
(red) and down-regulated (blue) proteins in SMA MNs (10DIV).  
b Optimization of Complex I activity using different amounts of mitochondria extract isolated 
from 10DIV WT MNs. Linear regression shows that complex I activity and reaction time is 
proportional over 1 h.    
c Complex I activity using 20 µg mitochondria extract isolated from 10DIV WT and SMA MNs. 
Linear regression shows that complex I activitiy from WT and SMA MNs is proportional over 
1 h, with a reduced slope for SMA MNs.   
d Complex I activity rate using 300 µg protein extracts of heart from P7 WT and SMA mice 
(N=4). Quantification represents the increase of mean OD450 nm/ h. Two-way ANOVA with 
Tukey HSD post hoc analysis was used on independent biological replicates (N=4) to 
determine statistical significance. n.s. p >0.05. 
e Glucose uptake in 10DIV WT and SMA MNs. Each dot represents data from biological 
replicates (N=7). Two-tailed unpaired t-test was used to determine statistical significance. **p 
<0.01. 
f Pyruvate uptake is increased in WT MNs and SMA after 1 h supplementation (N=3). One-
way ANOVA with Dunnett post hoc analysis was used to compare each timepoint with the 
control. **p <0.01, ***p<0.001. 
g Supplementation of WT MNs and SMA MNs with 10 mM/ 50 mM lactate or 10mM/ 50 mM 
pyruvate for 1 h. 50 mM pyruvate treatment shows a significant increase of ATP levels in SMA 
MNs (N=6). Two-tailed unpaired t-test was used on independent biological replicates to 
determine statistical significance. Means of two groups were compared, *p <0.05, **p <0.01. 
h Quantification of mean fluorescence intensity of CellROX signal in NSC-34 cells. One hour 
treatment of 100 µM menadione increases ROS levels, whereas co-treatment of 10 µM NAC 
or 50 mM reduces menadione-induced ROS (N=6). One-way ANOVA with Tukey HSD post 
hoc analysis was used on independent biological replicates (N=3) to determine statistical 
significance. n.s. p >0.05, *p <0.05, ***p <0.001. 
Bar graphs scatterplots depict the mean ± s.d. 
 
1.         Kanehisa M (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids 



















Fig.S3 Optimization of SUnSET assay 
a Schematic representation of SUnSET assay in NSC-34 cells, WT MNs and SMA MNs. NSC-34 cells are 
differentiated for 3 days and MNs are cultured for 10 days before treatment with 50 mM pyruvate, 10 µM 
NAC or 100 µM menadione for 1 h. Puromycin was added in addition after 30 min of treatment.
b Representative western blot images and quantication of SUnSET assay in NSC-34 cells. Neither 50 mM 
pyruvate nor 10 µM NAC increased protein synthesis signicantly. Each dot represents the quantication of 
individual biological replicates (N=5). Bar graphs depict the mean ± s.d. Two-tailed unpaired t-test with 
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Fig.S4 Reduction of ROS improves protein synthesis in SMA MNs, but not in WT MNs.
a Representative images of WT and SMA MNs after SUnSET assay. Anti-puromycin (rainbow color) and anti-Tau 
(white) antibodies are used. Tau positive neurites (axons) were selected with a segmented line, straightened and 
divided into 20 µm bins using the concentric circles plugin. MNs were treated with 10 µM NAC or 50 mM pyruvate 
or 100 µM menadione or 50 µM anisomycin for 1 h. Images conrm that protein synthesis is blocked by 
anisomycin or menadione and increased in SMA MNs by 10 µM NAC. Scale bar: 20 µm.
b Quantication of mean puromycin intensity proles, corresponding to protein levels, against distance in discrete 
categories. Each dot represents the average quantication of 10 neurons. Data are obtained from 5 individual 
biological replicates (N=5). Bar graph depict the mean ± s.d. Two-tailed unpaired t-test with Holm-Bonferroni 
correction for multiple comparisons was used to determine statistical signicance. n.s. p >0.05, *p <0.05.
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Fig.S5 Whole cell proteome after modifying ROS levels. 
 
a Graph representing 22 proteins changed in SMA MNs compared to WT MNs, and pyruvate 
treated WT MNs compared to non-treated WT MNs; plotted fold change (log2) comparing with 
and without pyruvate treatment. 
b Volcano plot of whole proteome analysis after 50 mM pyruvate treatment to WT MNs for 1 
h; plotted p-value (-log10) against fold change (log2). Four independent samples were used for 
analysis. P-values were determined using an unpaired two-sided t-test. Proteins with p < 0.05 
are highlighted in blue (down-regulated) and red (up-regulated).  
c Venn diagram showing quantity of proteins in WT MNs compared to SMA MNs treated with 
50 mM pyruvate for 1 h. 
d Graph representing 40 proteins changed in SMA MNs compared to WT MNs, and NAC 
treated WT MNs compared to non-treated WT MNs; plotted fold change (log2) comparing with 
and without NAC treatment. 
e Volcano plot of whole proteome analysis after 10 µM NAC treatment to WT MNs for 1 h; 
plotted p-value (-log10) against fold change (log2). Four independent samples were used for 
analysis. P-values were determined using an unpaired two-sided t-test. Proteins with p < 0.05 
are highlighted in blue (down-regulated) and red (up-regulated).  
f Venn diagram showing quantity of proteins in WT MNs compared to SMA MNs treated with 
10 µM NAC for 1 h. 
g Volcano plot of whole proteome analysis after 100 µM menadione to WT MNs for 1 h; plotted 
p-value (-log10) against fold change (log2). Four independent samples were used for analysis. 
P-values were determined using an unpaired two-sided t-test. Proteins with p < 0.05 are 
highlighted in blue (down-regulated) and red (up-regulated).  
h Upper Venn diagram showing quantity of proteins in WT MNs compared to SMA MNs treated 
with 100 µM menadione for 1 h. Lower Venn diagram representing 56 proteins commonly 
altered in SMA and after menadione treatment.  
i Scatterplot showing the fold changes (log2) of significantly changed proteins in SMA against 
WT MNs after menadione treatment.  
  
XLIII
SUPPLEMENTARY: THELEN et al., 2020 Maximilian Paul Thelen
Fig.S6 Proteins related to translation are signicantly changed in SMA MNs without affecting 
elongation speed. 
a Volcano plot of translation related proteins comparing WT and SMA MNs; plotted p-value (-log10) 
against fold change (log2, SMA/ WT). Four independent samples of WT MNs and three independent 
samples for SMA MNs were used for analysis. P-values were determined using an unpaired two-
sided t-test. Proteins with p < 0.05 are highlighted in blue (down-regulated) and red (up-regulated).
b Elongation speed is not altered in SMA MN compared to WT MNs. Each dot and each line 
represent the average of four independent biological replicates (N=4). Regression analysis 
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Fig.S7 Pyruvate regulates SMN levels. 
a Representative western blot and quantication shows that 50 mM pyruvate increases SMN protein levels in 
NSC-34 cells after 1 h treatment (N=5). One-way ANOVA with Dunnett post hoc analysis was used to compare 
each timepoint with the control. n.s. p>0.05, *p <0.05, **p <0.01.
b Quantitative real-time PCR using gene specic Smn primers conrms that pyruvate supplementation did not 
change Smn transcript levels in NSC-34 cells and WT MNs (N=4). Actb was used as a loading control.
c 50 µM anisomycin prevents pyruvate-induced elevation of SMN protein levels (N=6). 50 mM pyruvate was 
treated for 10 or 20 min. One-way ANOVA with Tukey HSD post hoc analysis was used to determine statistical 
signicance. *p <0.05, **p <0.01.
d Representative western blot and quantication show that pyruvate treatment increases phosphorylation status 
of p70S6 kinase. One-way ANOVA with Tukey HSD post hoc analysis was used to determine statistical 
signicance. *p <0.05.
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Table S1: Di!erentially expressed proteins in SMA compared to WT MNs.
List of significantly changed proteins in SMA compared to WT MNs (p < 0.05). Gene names, protein
names, p-values, and fold change (FC) are listed. Proteins above the red line are down-regulated and
below the red line are up-regulated in SMA compared to WT MNs. Gene names in red mark proteins
found in the MitoCarta2.0 database. Gene names in blue are related to translation and gene names in







Cuedc2 CUE domain-containing protein 2 4,17 -1,75
Srek1 Splicing regulatory glutamine/lysine-rich protein 1 4,11 -1,6
Cnot2 CCR4-NOT transcription complex subunit 2 4,1 -1
Ankrd17 Ankyrin repeat domain-containing protein 17 3,87 -0,59
Cops7a COP9 signalosome complex subunit 7a 3,79 -0,52
Nipbl Nipped-B-like protein 3,71 -4,78
Ctsc Dipeptidyl peptidase 1 3,67 -2,74
Rpl28 60S ribosomal protein L28 3,52 -0,45
Ppm1g Protein phosphatase 1G 3,4 -0,31
Brix1 Ribosome biogenesis protein BRX1 homolog 3,33 -2,07
Slc8a2 Sodium/calcium exchanger 2 3,17 -0,58
Ntrk3 NT-3 growth factor receptor 3,14 -1,55
Ssr3 Translocon-associated protein subunit gamma 3,07 -3,27
Sec13 Protein SEC13 homolog 3,06 -0,54
Fbxo22 F-box only protein 22 3,04 -0,42
Ampd3 AMP deaminase 3 3,02 -1,98
Nasp Nuclear autoantigenic sperm protein 3,01 -0,42
Son Protein SON 3 -0,52
Rpl26 60S ribosomal protein L26 2,89 -0,54
Kif1bp KIF1-binding protein 2,88 -0,39
Ppfibp1 Liprin-beta-1 2,87 -1,39
Rps27 40S ribosomal protein S27 2,87 -0,37
Lbr Delta(14)-sterol reductase LBR 2,86 -1,48
Slc25a16 Graves disease carrier protein homolog 2,83 -1,59
Fabp5 Fatty acid-binding protein 5 2,81 -0,39
Senp7 Sentrin-specific protease 7 2,8 -0,84
Ndufa5 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 5
2,79 -0,21
Nup43 Nucleoporin Nup43 2,78 -0,43
Cntnap4 Contactin-associated protein-like 4 2,76 -2,01
Sec61a1 Protein transport protein Sec61 subunit alpha iso-
form 1
2,74 -0,95
Rps14 40S ribosomal protein S14 2,74 -0,22
XLVI







Snrpf Small nuclear ribonucleoprotein F 2,72 -0,83
Tmem70 Transmembrane protein 70, mitochondrial 2,71 -1,19
Rnf11 RING finger protein 11 2,7 -0,77
Eftud2 116 kDa U5 small nuclear ribonucleoprotein compo-
nent
2,7 -0,61
Vta1 Vacuolar protein sorting-associated protein VTA1
homolog
2,7 -0,43
Btf3l4 Transcription factor BTF3 homolog 4 2,67 -0,38
Edf1 Endothelial di!erentiation-related factor 1 2,66 -0,51
Phpt1 14 kDa phosphohistidine phosphatase 2,66 -0,31
Cstf1 Cleavage stimulation factor subunit 1 2,64 -0,36
Mrpl50 39S ribosomal protein L50, mitochondrial 2,63 -0,32
Srp68 Signal recognition particle subunit SRP68 2,62 -0,37






Otud6b Deubiquitinase OTUD6B 2,53 -0,53
Rpl27a 60S ribosomal protein L27a 2,51 -0,48
Sh3bgrl3 SH3 domain-binding glutamic acid-rich-like protein
3
2,51 -0,45
Fam126b Protein FAM126B 2,48 -2,17
Recql ATP-dependent DNA helicase Q1 2,47 -1,83
Poldip3 Polymerase delta-interacting protein 3 2,47 -0,21
Maea E3 ubiquitin-protein transferase MAEA 2,46 -0,44
Rab5c Ras-related protein Rab-5C 2,45 -0,4
Ptms Parathymosin 2,42 -0,56
Rpl13 60S ribosomal protein L13 2,41 -0,37
Dnaja2 DnaJ homolog subfamily A member 2 2,41 -0,24
Cyp46a1 Cholesterol 24-hydroxylase 2,4 -1,23
Psmc1 26S proteasome regulatory subunit 4 2,38 -0,31
Mmaa Methylmalonic aciduria type A homolog, mitochon-
drial
2,37 -1,39
Ahcyl1 S-adenosylhomocysteine hydrolase-like protein 1 2,37 -0,41
Rwdd1 RWD domain-containing protein 1 2,35 -0,34
Rps3 40S ribosomal protein S3 2,35 -0,28
Slc35b1 Solute carrier family 35 member B1 2,34 -1,51
Tcea1 Transcription elongation factor A protein 1 2,33 -0,42
Fkbp3 Peptidyl-prolyl cis-trans isomerase FKBP3 2,32 -0,38
Xrcc5 X-ray repair cross-complementing protein 5 2,31 -2,41
XLVII







Mien1 Migration and invasion enhancer 1 2,28 -0,34
Trappc12 Tra"cking protein particle complex subunit 12 2,28 -0,34
Rbm15 RNA-binding protein 15 2,28 -0,29
Cggbp1 CGG triplet repeat-binding protein 1 2,27 -3,42
Prpf3 U4/U6 small nuclear ribonucleoprotein Prp3 2,27 -0,79
Rack1 Receptor of activated protein C kinase 1 2,27 -0,25
Dtx3 Probable E3 ubiquitin-protein ligase DTX3 2,26 -0,44
Rbm3 RNA-binding protein 3 2,25 -0,53
Nudt10 Diphosphoinositol polyphosphate phosphohydrolase
3-alpha
2,24 -0,56
Washc4 WASH complex subunit 4 2,23 -0,71
Rpl8 60S ribosomal protein L8 2,22 -0,42
Bub3 Mitotic checkpoint protein BUB3 2,21 -0,42
Iqcb1 IQ calmodulin-binding motif-containing protein 1 2,2 -0,75
Sec61a2 Protein transport protein Sec61 subunit alpha iso-
form 2
2,2 -0,75
Fam20b Glycosaminoglycan xylosylkinase 2,2 -0,4
Cox7c Cytochrome c oxidase subunit 7C, mitochondrial 2,19 -1,36
Tmem175 Endosomal/lysosomal potassium channel TMEM175 2,19 -1,24
Seh1l Nucleoporin SEH1 2,19 -0,16
Fundc1 FUN14 domain-containing protein 1 2,16 -0,36
Hnrnpul1 Heterogeneous nuclear ribonucleoprotein U-like
protein 1
2,16 -0,35
Syvn1 E3 ubiquitin-protein ligase synoviolin 2,15 -0,92
Rplp2 60S acidic ribosomal protein P2 2,14 -0,33
Cc2d1a Coiled-coil and C2 domain-containing protein 1A 2,14 -0,29
Hddc2 HD domain-containing protein 2 2,13 -0,44
Srpk1 SRSF protein kinase 1 2,12 -0,35
Fcho2 F-BAR domain only protein 2 2,1 -1,49
Apeh Acylamino-acid-releasing enzyme 2,1 -0,3
Nelfcd Negative elongation factor D 2,09 -1,16




Ppa2 Inorganic pyrophosphatase 2, mitochondrial 2,08 -0,27
Uba3 NEDD8-activating enzyme E1 catalytic subunit 2,06 -0,96
Tbc1d5 TBC1 domain family member 5 2,06 -0,94
Ints9 Integrator complex subunit 9 2,06 -0,64
Cyp51a1 Lanosterol 14-alpha demethylase 2,05 -0,58
Fads1 Acyl-CoA (8-3)-desaturase 2,05 -0,43
XLVIII







Rpl9 60S ribosomal protein L9 2,05 -0,38
Eif3i Eukaryotic translation initiation factor 3 subunit I 2,05 -0,13
Ehmt1 Histone-lysine N-methyltransferase EHMT1 2,04 -1,64
Elovl5 Elongation of very long chain fatty acids protein 5 2,03 -0,62
Mrpl37 39S ribosomal protein L37, mitochondrial 2,02 -0,6
Srp54 Signal recognition particle 54 kDa protein 2,01 -0,43
Psmb6 Proteasome subunit beta type-6 2,01 -0,35
Arfgap2 ADP-ribosylation factor GTPase-activating protein
2
2 -0,44
Psmd4 26S proteasome non-ATPase regulatory subunit 4 2 -0,43
Eif3g Eukaryotic translation initiation factor 3 subunit G 1,99 -0,44
Ddx6 Probable ATP-dependent RNA helicase DDX6 1,99 -0,24
Sar1b GTP-binding protein SAR1b 1,98 -0,52
Eef1b Elongation factor 1-beta 1,97 -0,34
Sptbn1 Spectrin beta chain, non-erythrocytic 1 1,97 -0,08
Pih1d1 PIH1 domain-containing protein 1 1,95 -0,93
Dync1li2 Cytoplasmic dynein 1 light intermediate chain 2 1,95 -0,54
Sfpq Splicing factor, proline- and glutamine-rich 1,94 -0,29
Noc2l Nucleolar complex protein 2 homolog 1,93 -0,95
Dusp12 Dual specificity protein phosphatase 12 1,93 -0,62
Znf326 DBIRD complex subunit ZNF326 1,93 -0,36
Map3k12 Mitogen-activated protein kinase kinase kinase 12 1,92 -1,04
Scaf1 Splicing factor, arginine/serine-rich 19 1,91 -1,51
Cfdp1 Craniofacial development protein 1 1,91 -0,48
Me1 NADP-dependent malic enzyme 1,91 -0,42
Tram1 Translocating chain-associated membrane protein 1 1,9 -1,66
Smyd3 Histone-lysine N-methyltransferase SMYD3 1,9 -0,79
Slc39a7 Zinc transporter SLC39A7 1,88 -1,22
Itpk1 Inositol-tetrakisphosphate 1-kinase 1,88 -0,78
Sec24a Protein transport protein Sec24A 1,88 -0,48
Huwe1 E3 ubiquitin-protein ligase HUWE1 1,88 -0,39
Tapt1 Transmembrane anterior posterior transformation
protein 1
1,87 -0,55
Urm1 Ubiquitin-related modifier 1 1,87 -0,49
Pde6d Retinal rod rhodopsin-sensitive cGMP 3’,5’-cyclic
phosphodiesterase subunit delta
1,87 -0,45
Cul1 Cullin-1 1,87 -0,4
Nsfl1c NSFL1 cofactor p47 1,87 -0,18
Sptlc1 Serine palmitoyltransferase 1 1,86 -0,49
Ap1s1 AP-1 complex subunit sigma-1A 1,85 -0,65
XLIX







Rab5b Ras-related protein Rab-5B 1,83 -0,27
Impa1 Inositol monophosphatase 1 1,83 -0,24
Ddx17 Probable ATP-dependent RNA helicase DDX17 1,83 -0,24
Scly Selenocysteine lyase 1,82 -1,23
Arf4 ADP-ribosylation factor 4 1,81 -0,88
Rpl7 60S ribosomal protein L7 1,81 -0,35
Smap1 Stromal membrane-associated protein 1 1,8 -0,56
Kif1b Kinesin-like protein KIF1B 1,8 -0,49
Fn3krp Ketosamine-3-kinase 1,8 -0,36
Hspa2 Heat shock-related 70 kDa protein 2 1,8 -0,29
Capn1 Calpain-1 catalytic subunit 1,79 -1,04
Pcnp PEST proteolytic signal-containing nuclear protein 1,78 -0,45
Gps1 COP9 signalosome complex subunit 1 1,78 -0,44
Rps11 40S ribosomal protein S11 1,78 -0,31
Ythdc1 YTH domain-containing protein 1 1,77 -0,83
Zranb2 Zinc finger Ran-binding domain-containing protein
2
1,76 -0,43
Lrsam1 E3 ubiquitin-protein ligase LRSAM1 1,75 -0,91
Ube3a Ubiquitin-protein ligase E3A 1,75 -0,39
Rnf114 E3 ubiquitin-protein ligase RNF114 1,74 -0,37
Fgf13 Fibroblast growth factor 13 1,73 -2,26
Vps25 Vacuolar protein-sorting-associated protein 25 1,73 -0,5
Sf1 Splicing factor 1 1,73 -0,18
Scrib Protein scribble homolog 1,72 -0,47
Ldha L-lactate dehydrogenase A chain 1,72 -0,46
Puf60 Poly(U)-binding-splicing factor PUF60 1,72 -0,39
Rpl32 60S ribosomal protein L32 1,72 -0,27
Mrpl43 39S ribosomal protein L43, mitochondrial 1,71 -0,3
Ndufaf2 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex assembly factor 2
1,71 -0,29
Mrps11 28S ribosomal protein S11, mitochondrial 1,7 -0,44
Cpsf7 Cleavage and polyadenylation specificity factor sub-
unit 7
1,7 -0,39
Supt16h FACT complex subunit SPT16 1,7 -0,34
Mturn Maturin 1,69 -2,47
Nup188 Nucleoporin NUP188 homolog 1,69 -0,85
Rab27b Ras-related protein Rab-27B 1,69 -0,64
Gria1 Glutamate receptor 1 1,69 -0,27
Itpa Inosine triphosphate pyrophosphatase 1,69 -0,21
Eprs Bifunctional glutamate/proline–tRNA ligase 1,69 -0,2
L







Eif2s1 Eukaryotic translation initiation factor 2 subunit 1 1,69 -0,2
Sod1 Superoxide dismutase [Cu-Zn] 1,68 -0,27
Tomm5 Mitochondrial import receptor subunit TOM5 ho-
molog
1,67 -1,42
Pcyt1a Choline-phosphate cytidylyltransferase A 1,67 -0,39
Ppp6c Serine/threonine-protein phosphatase 6 catalytic
subunit
1,67 -0,14
Psmg3 Proteasome assembly chaperone 3 1,66 -2,14
Tbcc Tubulin-specific chaperone C 1,66 -0,6
Pid1 PTB-containing, cubilin and LRP1-interacting pro-
tein
1,66 -0,47
Ubfd1 Ubiquitin domain-containing protein UBFD1 1,65 -0,54
Eml1 Echinoderm microtubule-associated protein-like 1 1,65 -0,48
Cdc37 Hsp90 co-chaperone Cdc37 1,65 -0,22
Fip1l1 Pre-mRNA 3’-end-processing factor FIP1 1,65 -0,19
Mlec Malectin 1,64 -0,39
Dbnl Drebrin-like protein 1,63 -0,21
Aup1 Ancient ubiquitous protein 1 1,62 -2
Fkbp1a Peptidyl-prolyl cis-trans isomerase FKBP1A 1,62 -0,45
Pfdn2 Prefoldin subunit 2 1,62 -0,24
Coro1a Coronin-1A 1,61 -0,76
Als2 Alsin 1,61 -0,47
Sec61b Protein transport protein Sec61 subunit beta 1,6 -0,98
Kdm1a Lysine-specific histone demethylase 1A 1,6 -0,74
Wbp2 WW domain-binding protein 2 1,6 -0,47
Hdac6 Histone deacetylase 6 1,59 -0,46
Plrg1 Pleiotropic regulator 1 1,59 -0,33
Rpl14 60S ribosomal protein L14 1,59 -0,3
Swi5 DNA repair protein SWI5 homolog 1,58 -0,54
Wdr5 WD repeat-containing protein 5 1,58 -0,42
Elp2 Elongator complex protein 2 1,58 -0,33
Toe1 Target of EGR1 protein 1 1,57 -1,26
Commd2 COMM domain-containing protein 2 1,57 -1,07
Cep170b Centrosomal protein of 170 kDa protein B 1,57 -0,37
Mlf2 Myeloid leukemia factor 2 1,56 -0,47
Erh Enhancer of rudimentary homolog 1,55 -0,59
Rad23b UV excision repair protein RAD23 homolog B 1,55 -0,53
Dnal1 Dynein light chain 1, axonemal 1,55 -0,5











Lancl1 Glutathione S-transferase LANCL1 1,55 -0,31
Cnpy2 Protein canopy homolog 2 1,55 -0,29
Commd1 COMM domain-containing protein 1 1,54 -2,23
Slc6a11 Sodium- and chloride-dependent GABA transporter
3
1,54 -0,87
Rufy2 RUN and FYVE domain-containing protein 2 1,54 -0,54
Pfn2 Profilin-2 1,54 -0,3
Hdgfl2 Hepatoma-derived growth factor-related protein 2 1,53 -2,03
Dnajc8 DnaJ homolog subfamily C member 8 1,53 -0,33
Pik3r4 Phosphoinositide 3-kinase regulatory subunit 4 1,53 -0,24
Mrps33 28S ribosomal protein S33, mitochondrial 1,52 -3,44
Rrp12 RRP12-like protein 1,52 -0,74
Ccdc91 Coiled-coil domain-containing protein 91 1,52 -0,53
Gatd1 Glutamine amidotransferase-like class 1 domain-
containing protein 1
1,52 -0,48
Srrm2 Serine/arginine repetitive matrix protein 2 1,52 -0,42
Bbc3 Bcl-2-binding component 3 1,51 -1,3
Dhcr7 7-dehydrocholesterol reductase 1,51 -0,4
Ybx1 Nuclease-sensitive element-binding protein 1 1,51 -0,34
Pum1 Pumilio homolog 1 1,51 -0,17
Cptp Ceramide-1-phosphate transfer protein 1,5 -2,18
Srp19 Signal recognition particle 19 kDa protein 1,5 -0,79
Rpl7a 60S ribosomal protein L7a 1,5 -0,39
Elp3 Elongator complex protein 3 1,5 -0,34
Ndufb5 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 5, mitochondrial
1,5 -0,19
Sec11c Signal peptidase complex catalytic subunit SEC11C 1,49 -1,55
Gla Alpha-galactosidase A 1,49 -0,54
Ythdf2 YTH domain-containing family protein 2 1,49 -0,31
Gtf2e1 General transcription factor IIE subunit 1 1,48 -1,13
Mdp1 Magnesium-dependent phosphatase 1 1,48 -0,51
Sacm1l Phosphatidylinositide phosphatase SAC1 1,47 -0,28
Med1 Mediator of RNA polymerase II transcription sub-
unit 1
1,46 -2,53
Mrpl23 39S ribosomal protein L23, mitochondrial 1,46 -0,69
Rpe Ribulose-phosphate 3-epimerase 1,46 -0,52
Timm8b Mitochondrial import inner membrane translocase
subunit Tim8 B
1,46 -0,4
Ciapin1 Anamorsin 1,46 -0,39
Stx17 Syntaxin-17 1,46 -0,32
LII







Ipo7 Importin-7 1,46 -0,21
Yipf5 Protein YIPF5 1,45 -0,8
Asrgl1 Isoaspartyl peptidase/L-asparaginase 1,45 -0,73
Nr2f1 COUP transcription factor 1 1,45 -0,72
Rpl22l1 60S ribosomal protein L22-like 1 1,45 -0,61
Capns1 Calpain small subunit 1 1,45 -0,34
Ermp1 Endoplasmic reticulum metallopeptidase 1 1,45 -0,3
Clptm1l Cleft lip and palate transmembrane protein 1-like
protein
1,45 -0,25
Atrx Transcriptional regulator ATRX 1,44 -0,57
Mia3 Transport and Golgi organization protein 1 homolog 1,44 -0,48
Rpl19 60S ribosomal protein L19 1,44 -0,42
Ubl4a Ubiquitin-like protein 4A 1,44 -0,24
Rpl10a 60S ribosomal protein L10a 1,44 -0,23
Retreg2 Reticulophagy regulator 2 1,43 -1,08
Rbsn Rabenosyn-5 1,43 -0,66
Rpl13a 60S ribosomal protein L13a 1,43 -0,33
Rpl12 60S ribosomal protein L12 1,43 -0,3
Ppia Peptidyl-prolyl cis-trans isomerase A 1,43 -0,29
Upf1 Regulator of nonsense transcripts 1 1,43 -0,11
Hist1h1a Histone H1,1 1,42 -2,82
Cnot9 CCR4-NOT transcription complex subunit 9 1,42 -1,32
Rcc1 Regulator of chromosome condensation 1,42 -0,68
Trappc4 Tra"cking protein particle complex subunit 4 1,42 -0,52
Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 8, mitochondrial
1,42 -0,42
Htt Huntingtin 1,42 -0,29
Stat3 Signal transducer and activator of transcription 3 1,41 -1,3
Ublcp1 Ubiquitin-like domain-containing CTD phosphatase
1
1,41 -0,96
Kctd16 BTB/POZ domain-containing protein KCTD16 1,41 -0,87
Cpsf3 Cleavage and polyadenylation specificity factor sub-
unit 3
1,41 -0,57
Naa20 N-alpha-acetyltransferase 20 1,41 -0,5
Clpp ATP-dependent Clp protease proteolytic subunit,
mitochondrial
1,41 -0,24
Cers2 Ceramide synthase 2 1,4 -2,95
Myo16 Unconventional myosin-XVI 1,4 -1,72
Smc4 Structural maintenance of chromosomes protein 4 1,4 -1,11
Czib CXXC motif containing zinc binding protein 1,4 -0,47
LIII







Mif Macrophage migration inhibitory factor 1,4 -0,4
Gstp1 Glutathione S-transferase P 1 1,4 -0,31
Rac3 Ras-related C3 botulinum toxin substrate 3 1,4 -0,29
Hnrnpa0 Heterogeneous nuclear ribonucleoprotein A0 1,4 -0,29
Rab9a Ras-related protein Rab-9A 1,4 -0,28
Chtop Chromatin target of PRMT1 protein 1,4 -0,27
Lrrc47 Leucine-rich repeat-containing protein 47 1,4 -0,25
Qars Glutamine–tRNA ligase 1,4 -0,17
Rnf40 E3 ubiquitin-protein ligase BRE1B 1,39 -1,03
Epb41l3 Band 4,1-like protein 3 1,39 -0,44
Fndc3a Fibronectin type-III domain-containing protein 3A 1,39 -0,38
Pdhx Pyruvate dehydrogenase protein X component, mi-
tochondrial
1,39 -0,36
Snrpd2 Small nuclear ribonucleoprotein Sm D2 1,39 -0,32
Rcn2 Reticulocalbin-2 1,39 -0,31
Hmgb3 High mobility group protein B3 1,39 -0,26
Rps15a 40S ribosomal protein S15a 1,39 -0,2
Wbp11 WW domain-binding protein 11 1,38 -0,55
Prmt8 Protein arginine N-methyltransferase 8 1,38 -0,36
Ppif Peptidyl-prolyl cis-trans isomerase F, mitochondrial 1,38 -0,23
Hmgn2 Non-histone chromosomal protein HMG-17 1,37 -3,35
Ddx20 Probable ATP-dependent RNA helicase DDX20 1,37 -1,37




Cluh Clustered mitochondria protein homolog 1,37 -0,65
Tm9sf4 Transmembrane 9 superfamily member 4 1,37 -0,46
Pds5b Sister chromatid cohesion protein PDS5 homolog B 1,37 -0,44
Xkr4 XK-related protein 4 1,36 -2,29
Stat5b Signal transducer and activator of transcription 5B 1,36 -0,7
Iws1 Protein IWS1 homolog 1,36 -0,63
Aaas Aladin 1,36 -0,38
Nup210 Nuclear pore membrane glycoprotein 210 1,36 -0,31
Blvra Biliverdin reductase A 1,36 -0,29
Tcerg1 Transcription elongation regulator 1 1,36 -0,27
Ppp1r21 Protein phosphatase 1 regulatory subunit 21 1,36 -0,17
Csnk1e Casein kinase I isoform epsilon 1,35 -0,81
Cmc1 COX assembly mitochondrial protein homolog 1,35 -0,42
Ttl Tubulin–tyrosine ligase 1,35 -0,4
Mrpl45 39S ribosomal protein L45, mitochondrial 1,35 -0,36
LIV







Bclaf1 Bcl-2-associated transcription factor 1 1,35 -0,28
Lta4h Leukotriene A-4 hydrolase 1,35 -0,26
Trappc3 Tra"cking protein particle complex subunit 3 1,35 -0,24
Phactr1 Phosphatase and actin regulator 1 1,34 -0,69
Zw10 Centromere/kinetochore protein zw10 homolog 1,34 -0,63
Mtmr3 Myotubularin-related protein 3 1,34 -0,61
Nans Sialic acid synthase 1,34 -0,25
Rcor3 REST corepressor 3 1,33 -1,86
Penk Proenkephalin-A 1,33 -1,03
Camk4 Calcium/calmodulin-dependent protein kinase type
IV
1,33 -0,6
Atxn7l3b Ataxin-7-like protein 3B 1,33 -0,51
Rps5 40S ribosomal protein S5 1,33 -0,5
Hdac1 Histone deacetylase 1 1,33 -0,29
Dtd1 D-aminoacyl-tRNA deacylase 1 1,33 -0,24
Timm50 Mitochondrial import inner membrane translocase
subunit TIM50
1,33 -0,2
Snx27 Sorting nexin-27 1,33 -0,19
Psma5 Proteasome subunit alpha type-5 1,33 -0,18
Zdhhc17 Palmitoyltransferase ZDHHC17 1,33 -0,16
Chmp2b Charged multivesicular body protein 2b 1,32 -0,83
Pds5a Sister chromatid cohesion protein PDS5 homolog A 1,32 -0,6
Tbl2 Transducin beta-like protein 2 1,32 -0,27
Cab39 Calcium-binding protein 39 1,32 -0,24
Porcn Protein-serine O-palmitoleoyltransferase porcupine 1,31 -0,95
Atp5md ATP synthase membrane subunit DAPIT, mitochon-
drial
1,31 -0,76
Ndrg1 Protein NDRG1 1,31 -0,37
Fam160b1 Protein FAM160B1 1,31 -0,17
Haghl Hydroxyacylglutathione hydrolase-like protein 3,53 0,95
Cfap36 Cilia- and flagella-associated protein 36 3,45 0,79
Ndufc2 NADH dehydrogenase [ubiquinone] 1 subunit C2 3,11 0,6
Strn Striatin 2,95 0,18
Pten Phosphatidylinositol 3,4,5-trisphosphate 3-
phosphatase and dual-specificity protein phos-
phatase PTEN
2,89 0,59
Gnpda1 Glucosamine-6-phosphate isomerase 1 2,81 1,18











Ddi2 Protein DDI1 homolog 2 2,68 0,75
Ubr1 E3 ubiquitin-protein ligase UBR1 2,5 1,18
Dhodh Dihydroorotate dehydrogenase (quinone), mitochon-
drial
2,49 0,19
Mrpl44 39S ribosomal protein L44, mitochondrial 2,43 0,37
Cdkn1a Cyclin-dependent kinase inhibitor 1 2,41 1,92
Dmac2l ATP synthase subunit s, mitochondrial 2,38 0,21
Pik3ca Phosphatidylinositol 4,5-bisphosphate 3-kinase cat-
alytic subunit alpha isoform
2,35 0,76
Ergic3 Endoplasmic reticulum-Golgi intermediate compart-
ment protein 3
2,31 0,27
Afg3l1 AFG3-like protein 1 2,31 0,61
Syncrip Heterogeneous nuclear ribonucleoprotein Q 2,28 0,4
Prmt2 Protein arginine N-methyltransferase 2 2,28 1,04
Gnai2 Guanine nucleotide-binding protein G(i) subunit
alpha-2
2,23 0,32
Pelp1 Proline-, glutamic acid- and leucine-rich protein 1 2,22 0,27
Supv3l1 ATP-dependent RNA helicase SUPV3L1, mitochon-
drial
2,22 4,35
Tbl1xr1 F-box-like/WD repeat-containing protein TBL1XR1 2,19 0,84




Ptprj Receptor-type tyrosine-protein phosphatase eta 2,17 0,57
Bcs1l Mitochondrial chaperone BCS1 2,16 0,33
Pik3r1 Phosphatidylinositol 3-kinase regulatory subunit
alpha
2,16 1,59
Foxk2 Forkhead box protein K2 2,12 1,11
Vdac1 Voltage-dependent anion-selective channel protein 1 2,11 0,41
Ano10 Anoctamin-10 2,1 0,39
GOLGA7B Golgin subfamily A member 7B 2,09 0,61
Ndufa6 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 6
2,09 0,63
Cuedc1 CUE domain-containing protein 1 2,08 0,33
Hbb-b1 Hemoglobin subunit beta-1 2,08 3,94
Ttc9c Tetratricopeptide repeat protein 9C 2,07 0,15
Txndc15 Thioredoxin domain-containing protein 15 2,07 0,58











U2surp U2 snRNP-associated SURP motif-containing pro-
tein
2,07 1,29
Tmed3 Transmembrane emp24 domain-containing protein 3 2,01 1,08
Syn3 Synapsin-3 1,99 0,52
Sdcbp Syntenin-1 1,99 0,72
Prkaa2 5’-AMP-activated protein kinase catalytic subunit
alpha-2
1,97 0,16
Coro1c Coronin-1C 1,97 0,34
Prkar1a cAMP-dependent protein kinase type I-alpha regula-
tory subunit
1,97 0,35
Dhrs7b Dehydrogenase/reductase SDR family member 7B 1,97 0,39
Asic1 Acid-sensing ion channel 1 1,97 0,84
Immt MICOS complex subunit Mic60 1,96 0,23
Grk2 Beta-adrenergic receptor kinase 1 1,96 0,52
Brcc3 Lys-63-specific deubiquitinase BRCC36 1,95 0,26
Rab3gap1 Rab3 GTPase-activating protein catalytic subunit 1,95 0,3
Dmxl1 DmX-like protein 1 1,92 1,8
Nln Neurolysin, mitochondrial 1,91 0,19
Bcap29 B-cell receptor-associated protein 29 1,91 0,49
Ophn1 Oligophrenin-1 1,9 0,69
Hdac4 Histone deacetylase 4 1,89 0,61
Mrpl15 39S ribosomal protein L15, mitochondrial 1,88 0,21
Gtdc1 Glycosyltransferase-like domain-containing protein 1 1,87 1,18
Ddx39a ATP-dependent RNA helicase DDX39A 1,86 0,24
Sema3c Semaphorin-3C 1,86 1,1
Arxes1 Adipocyte-related X-chromosome expressed se-
quence 1
1,84 0,35
Timmdc1 Complex I assembly factor TIMMDC1, mitochon-
drial
1,83 4,8
Akap1 A-kinase anchor protein 1, mitochondrial 1,82 0,54
Mcm2 DNA replication licensing factor MCM2 1,82 5,54
Vps11 Vacuolar protein sorting-associated protein 11 ho-
molog
1,79 0,25
Ndufab1 Acyl carrier protein, mitochondrial 1,78 0,56
Hprt1 Hypoxanthine-guanine phosphoribosyltransferase 1,77 0,63
Kirrel3 Kin of IRRE-like protein 3 1,77 0,84
Jakmip1 Janus kinase and microtubule-interacting protein 1 1,76 1,92
Agk Acylglycerol kinase, mitochondrial 1,74 0,53
Rapgef2 Rap guanine nucleotide exchange factor 2 1,74 0,53
Ctnnb1 Catenin beta-1 1,73 0,27
LVII







Arid1a AT-rich interactive domain-containing protein 1A 1,73 0,58
Dynll2 Dynein light chain 2, cytoplasmic 1,72 0,27
Hspg2 Basement membrane-specific heparan sulfate pro-
teoglycan core protein
1,72 0,99
Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 10, mitochondrial
1,71 0,21
Pcdhb8 Protocadherin beta-8 1,71 1,02
Actb Actin, cytoplasmic 1 1,7 0,32
Exoc5 Exocyst complex component 5 1,69 0,37
Osbpl6 Oxysterol-binding protein-related protein 6 1,67 0,42
Ppm1l Protein phosphatase 1L 1,66 0,23
Dyrk1a Dual specificity tyrosine-phosphorylation-regulated
kinase 1A
1,65 2,3
Mrps15 28S ribosomal protein S15, mitochondrial 1,64 0,18
Fam114a2 Protein FAM114A2 1,63 0,48
Timp3 Metalloproteinase inhibitor 3 1,62 0,99
Ankib1 Ankyrin repeat and IBR domain-containing protein
1
1,6 2,65
Dgkz Diacylglycerol kinase zeta 1,59 0,61
Rad23a UV excision repair protein RAD23 homolog A 1,59 0,73
Mrpl46 39S ribosomal protein L46, mitochondrial 1,59 2,03
Ccdc88a Girdin 1,58 0,17
Gpr107 Protein GPR107 1,58 0,42
Hspd1 60 kDa heat shock protein, mitochondrial 1,57 0,42
Vdac2 Voltage-dependent anion-selective channel protein 2 1,56 0,51
Txn Thioredoxin 1,56 0,53
Nup160 Nuclear pore complex protein Nup160 1,56 0,74
Raf1 RAF proto-oncogene serine/threonine-protein kinase 1,55 0,22
Sptan1 Spectrin alpha chain, non-erythrocytic 1 1,55 0,23
Braf Serine/threonine-protein kinase B-raf 1,54 0,55
Sema7a Semaphorin-7A 1,54 1,65
Mecr Enoyl-[acyl-carrier-protein] reductase, mitochondrial 1,53 0,35
Ptp4a2 Protein tyrosine phosphatase type IVA 2 1,53 0,39
Lrrc8d Volume-regulated anion channel subunit LRRC8D 1,53 0,41




Prcp Lysosomal Pro-X carboxypeptidase 1,51 0,19











Mrpl11 39S ribosomal protein L11, mitochondrial 1,5 0,65
Ints14 Integrator complex subunit 14 1,5 0,98
Hras GTPase HRas 1,49 0,36
Thumpd3 THUMP domain-containing protein 3 1,49 0,7
Fkbp2 Peptidyl-prolyl cis-trans isomerase FKBP2 1,49 1,15
Herc4 Probable E3 ubiquitin-protein ligase HERC4 1,48 0,32
Kct2 Keratinocyte-associated transmembrane protein 2 1,48 1,63
Spry4 Protein sprouty homolog 4 1,47 0,92
Glrx2 Glutaredoxin-2, mitochondrial 1,47 2,27
Anapc7 Anaphase-promoting complex subunit 7 1,47 2,89
Extl3 Exostosin-like 3 1,43 0,97
Ptprm Receptor-type tyrosine-protein phosphatase mu 1,42 0,73
Dnajc11 DnaJ homolog subfamily C member 11 1,4 0,23
Nptx1 Neuronal pentraxin-1 1,4 0,33
Ppip5k2 Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 2
1,4 0,5
Ktn1 Kinectin 1,4 1,21
R3hdm2 R3H domain-containing protein 2 1,4 4,86
Eef1e1 Eukaryotic translation elongation factor 1 epsilon-1 1,39 0,29
Wdr48 WD repeat-containing protein 48 1,39 0,33
Drap1 Dr1-associated corepressor 1,39 0,35
Nup50 Nuclear pore complex protein Nup50 1,39 1,52
Slc44a3 Choline transporter-like protein 3 1,39 2,51
Gdpd5 Glycerophosphodiester phosphodiesterase domain-
containing protein 5
1,38 0,22
Gbe1 1,4-alpha-glucan-branching enzyme 1,38 0,95
Tgfbrap1 Transforming growth factor-beta receptor-associated
protein 1
1,37 0,28
Uba5 Ubiquitin-like modifier-activating enzyme 5 1,37 0,28
Lrp8 Low-density lipoprotein receptor-related protein 8 1,37 0,68
Adgrl2 Adhesion G protein-coupled receptor L2 1,36 0,18
Mrps17 28S ribosomal protein S17, mitochondrial 1,35 0,21
Prpf38b Pre-mRNA-splicing factor 38B 1,35 0,61
Smpdl3b Acid sphingomyelinase-like phosphodiesterase 3b 1,35 0,78
Rundc3b RUN domain-containing protein 3B 1,35 0,83
Abhd12 Lysophosphatidylserine lipase ABHD12 1,34 0,24
Actr1b Beta-centractin 1,34 0,28
Tmed8 Protein TMED8 1,34 0,36
Marcksl1 MARCKS-related protein 1,34 0,47
Vps13a Vacuolar protein sorting-associated protein 13A 1,34 0,48
LIX







Myo9b Unconventional myosin-IXb 1,34 1,15
Snrpg Small nuclear ribonucleoprotein G 1,33 0,33
Csnk2b Casein kinase II subunit beta 1,33 0,38
Ndst1 Bifunctional heparan sulfate N-deacetylase/N-
sulfotransferase 1
1,33 0,8
Mrto4 mRNA turnover protein 4 homolog 1,32 0,47
Smg1 Serine/threonine-protein kinase SMG1 1,32 2,85
Panx1 Pannexin-1 1,31 0,4
Table S2: Di!erentially expressed proteins in WT MNs after pyruvate treatment.
List of significantly changed proteins in WT MNs after pyruvate treatment (p < 0.05). Gene names,
protein names, p-values, and fold changes (FC) are listed. Proteins above the red line are down-regulated








Fam126b Protein FAM126B 2.74 -2.30
Astn2 Astrotactin-2 2.45 -1.27
Got2 Aspartate aminotransferase, mitochondrial 2.20 -0.42
Dnmt1 DNA (cytosine-5)-methyltransferase 1 2.15 -0.92
Vhl von Hippel-Lindau disease tumor suppressor 2.12 -0.83
Uevld Ubiquitin-conjugating enzyme E2 variant 3 2.03 -1.79
Esyt1 Extended synaptotagmin-1 1.93 -0.71
Gdap2 Ganglioside-induced di!erentiation-associated pro-
tein 2
1.91 -0.33
Acvr2a Activin receptor type-2A 1.80 -0.83
Ano8 Anoctamin-8 1.78 -1.37
Rb1cc1 RB1-inducible coiled-coil protein 1 1.77 -0.54
Kif1bp KIF1-binding protein 1.68 -0.21
Mrpl37 39S ribosomal protein L37, mitochondrial 1.66 -0.45
Gk Glycerol kinase 1.65 -0.30
Efnb3 Ephrin-B3 1.65 -0.83
Trpc3 Short transient receptor potential channel 3 1.60 -1.22
Enpp4 Bis(5’-adenosyl)-triphosphatase enpp4 1.56 -0.81
Cptp Ceramide-1-phosphate transfer protein 1.56 -1.59
Micu3 Calcium uptake protein 3, mitochondrial 1.54 -1.13
Sec11c Signal peptidase complex catalytic subunit SEC11C 1.49 -1.55
Slk STE20-like serine/threonine-protein kinase 1.44 -0.53
Ssh2 Protein phosphatase Slingshot homolog 2 1.40 -1.77
Dlgap1 Disks large-associated protein 1 1.38 -1.55
LX








Apc Adenomatous polyposis coli protein 1.37 -0.44
Cpsf1 Cleavage and polyadenylation specificity factor sub-
unit 1
1.36 -0.62
Pptc7 Protein phosphatase PTC7 homolog 1.33 -0.76
Borcs6 BLOC-1-related complex subunit 6 1.32 -1.31
Toe1 Target of EGR1 protein 1 1.31 -0.60
Pcsk2 Neuroendocrine convertase 2 1.31 -0.54
Gnpda1 Glucosamine-6-phosphate isomerase 1 3.94 1.57
Psme3 Proteasome activator complex subunit 3 3.41 0.19
Ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 8, mitochondrial
3.09 0.48
Asl Argininosuccinate lyase 2.87 0.44
Vps41 Vacuolar protein sorting-associated protein 41 ho-
molog
2.84 0.35
Itsn1 Intersectin-1 2.81 0.18
Smndc1 Survival of motor neuron-related-splicing factor 30 2.71 0.20
Canx Calnexin 2.68 0.17
Gpr107 Protein GPR107 2.61 0.35
Ctif CBP80/20-dependent translation initiation factor 2.47 0.81
Sdr39u1 Epimerase family protein SDR39U1 2.46 0.90
Epn1 Epsin-1 2.45 0.28
Cdh13 Cadherin-13 2.40 0.34
Hspe1 10 kDa heat shock protein, mitochondrial 2.33 0.27
Alpl Alkaline phosphatase, tissue-nonspecific isozyme 2.22 0.68
Atp5pf ATP synthase-coupling factor 6, mitochondrial 2.15 0.37
Skp1 S-phase kinase-associated protein 1 2.03 0.12
Zwint ZW10 interactor 2.03 0.63
Ndufs5 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 5
2.01 0.29
Txnrd1 Thioredoxin reductase 1, cytoplasmic 2.00 0.26
Farsb Phenylalanine–tRNA ligase beta subunit 1.93 0.26
Ccnt1 Cyclin-T1 1.91 0.49
Cstf1 Cleavage stimulation factor subunit 1 1.88 0.24
Spryd4 SPRY domain-containing protein 4 1.87 0.58
Ston1 Stonin-1 1.85 1.40
Rwdd1 RWD domain-containing protein 1 1.84 0.35
Rbm12 RNA-binding protein 12 1.82 0.57
Ccdc50 Coiled-coil domain-containing protein 50 1.82 0.34
LXI








Naa35 N-alpha-acetyltransferase 35, NatC auxiliary subunit 1.81 0.28
Afg3l1 AFG3-like protein 1 1.80 0.49
Jakmip1 Janus kinase and microtubule-interacting protein 1 1.77 1.44
Ica1 Islet cell autoantigen 1 1.75 0.91
Chp1 Calcineurin B homologous protein 1 1.75 0.27
Fat3 Protocadherin Fat 3 1.74 0.65
Capza2 F-actin-capping protein subunit alpha-2 1.74 0.19
Tmed4 Transmembrane emp24 domain-containing protein 4 1.73 0.31
Mrps7 28S ribosomal protein S7, mitochondrial 1.73 0.33
Ube2r2 Ubiquitin-conjugating enzyme E2 R2 1.72 0.29
Pdap1 28 kDa heat- and acid-stable phosphoprotein 1.71 0.30
Picalm Phosphatidylinositol-binding clathrin assembly pro-
tein
1.68 0.21
Rprd1b Regulation of nuclear pre-mRNA domain-containing
protein 1B
1.67 0.51
Ppih Peptidyl-prolyl cis-trans isomerase H 1.65 0.45
Mrpl12 39S ribosomal protein L12, mitochondrial 1.64 0.20
Mrrf Ribosome-recycling factor, mitochondrial 1.64 0.64
Ociad1 OCIA domain-containing protein 1 1.64 0.30
Skt Sickle tail protein 1.64 1.02
Sae1 SUMO-activating enzyme subunit 1 1.60 0.10
Selenof Selenoprotein F 1.59 0.52
Fundc2 FUN14 domain-containing protein 2 1.57 0.87
Ccny Cyclin-Y 1.57 0.28
Fkbp15 FK506-binding protein 15 1.57 1.58
Actr2 Actin-related protein 2 1.57 0.23
Srp68 Signal recognition particle subunit SRP68 1.56 0.21
Rap2c Ras-related protein Rap-2c 1.54 0.52
Tenm4 Teneurin-4 1.54 2.49
Naa10 N-alpha-acetyltransferase 10 1.53 0.25
Naa50 N-alpha-acetyltransferase 50 1.53 0.18
Dnajc2 DnaJ homolog subfamily C member 2 1.53 0.27
Robo1 Roundabout homolog 1 1.52 0.72
Lyar Cell growth-regulating nucleolar protein 1.51 0.33
Crebbp CREB-binding protein 1.51 0.82
Psmc4 26S proteasome regulatory subunit 6B 1.49 0.09
Cox6a1 Cytochrome c oxidase subunit 6A1, mitochondrial 1.49 0.55












Stub1 STIP1 homology and U box-containing protein 1 1.48 0.29
Trap1 Heat shock protein 75 kDa, mitochondrial 1.48 0.22
Ccdc22 Coiled-coil domain-containing protein 22 1.47 0.84
Ubl7 Ubiquitin-like protein 7 1.47 0.30
Mars Methionine–tRNA ligase, cytoplasmic 1.47 0.19
Col11a1 Collagen alpha-1(XI) chain 1.47 0.57
Vamp7 Vesicle-associated membrane protein 7 1.47 0.60
Mrps9 28S ribosomal protein S9, mitochondrial 1.46 0.43
Ubr4 E3 ubiquitin-protein ligase UBR4 1.46 0.36
Rad23a UV excision repair protein RAD23 homolog A 1.45 0.76
Gga3 ADP-ribosylation factor-binding protein GGA3 1.44 0.31
Lrpprc Leucine-rich PPR motif-containing protein, mito-
chondrial
1.44 0.21
Arxes1 Adipocyte-related X-chromosome expressed se-
quence 1
1.42 0.37
Cacna1e Voltage-dependent R-type calcium channel subunit
alpha-1E
1.42 0.60
Ubac1 Ubiquitin-associated domain-containing protein 1 1.41 0.38
Tfam Transcription factor A, mitochondrial 1.41 0.28
Prpf38b Pre-mRNA-splicing factor 38B 1.40 0.71
Slc33a1 Acetyl-coenzyme A transporter 1 1.38 0.55
Cnot1 CCR4-NOT transcription complex subunit 1 1.38 0.21
Plpp1 Phospholipid phosphatase 1 1.38 0.73
Mpdu1 Mannose-P-dolichol utilization defect 1 protein 1.37 0.41
Casc4 Protein CASC4 1.37 0.29
Sez6l Seizure 6-like protein 1.37 0.38
Mrps17 28S ribosomal protein S17, mitochondrial 1.37 0.22
Dnaja3 DnaJ homolog subfamily A member 3, mitochon-
drial
1.36 0.19
Sucla2 Succinate–CoA ligase [ADP-forming] subunit beta,
mitochondrial
1.35 0.18




Pcyox1 Prenylcysteine oxidase 1.35 0.11
Rtn4ip1 Reticulon-4-interacting protein 1, mitochondrial 1.35 0.82
Grsf1 G-rich sequence factor 1 1.35 0.24
Xpnpep1 Xaa-Pro aminopeptidase 1 1.35 0.25
LXIII








Ndufb11 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 11, mitochondrial
1.35 0.45
GOLGA7B Golgin subfamily A member 7B 1.34 0.35
Htatsf1 HIV Tat-specific factor 1 homolog 1.34 0.37
Rap2a Ras-related protein Rap-2a 1.34 0.27
Vac14 Protein VAC14 homolog 1.34 0.22
Nap1l4 Nucleosome assembly protein 1-like 4 1.34 0.14
Tpd52l1 Tumor protein D53 1.34 0.99
Csde1 Cold shock domain-containing protein E1 1.33 0.21
Mcm2 DNA replication licensing factor MCM2 1.33 4.48
Usp47 Ubiquitin carboxyl-terminal hydrolase 47 1.33 0.12
Eif5 Eukaryotic translation initiation factor 5 1.33 0.24
Ndufs6 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 6, mitochondrial
1.33 0.29
Calr Calreticulin 1.33 0.23
Hebp2 Heme-binding protein 2 1.32 0.85
Wdr91 WD repeat-containing protein 91 1.32 0.66
Nup62 Nuclear pore glycoprotein p62 1.32 0.36
Cdkn1a Cyclin-dependent kinase inhibitor 1 1.31 0.95
Rpl9 60S ribosomal protein L9 1.31 0.20
Ppia Peptidyl-prolyl cis-trans isomerase A 1.31 0.22
Table S3: Di!erentially expressed proteins in SMA MNs after pyruvate treatment.
List of significantly changed proteins in SMA MNs after pyruvate treatment (p < 0.05). Gene names,
protein names, p-values, and fold changes (FC) are listed. Proteins above the red line are down-regulated








Dclk1 Serine/threonine-protein kinase DCLK1 2.85 -0.23
Fxn Frataxin, mitochondrial 2.82 -0.27
Tspan4 Tetraspanin-4 2.74 -1.26
Ube2f NEDD8-conjugating enzyme UBE2F 2.66 -2.22
Cdk1 Cyclin-dependent kinase 1 2.65 -2.81
Ppil1 Peptidyl-prolyl cis-trans isomerase-like 1 2.51 -0.46
Trim67 Tripartite motif-containing protein 67 2.46 -0.36
Prxl2b Prostamide/prostaglandin F synthase 2.44 -0.41
Fry Protein furry homolog 2.39 -0.18
Cdr2l Cerebellar degeneration-related protein 2-like 2.24 -0.32
LXIV








Sh2d3c SH2 domain-containing protein 3C 2.19 -0.74
Ppp2r5c Serine/threonine-protein phosphatase 2A 56 kDa
regulatory subunit gamma isoform
1.97 -0.17
Pitpnm2 Membrane-associated phosphatidylinositol transfer
protein 2
1.94 -0.75
Snx16 Sorting nexin-16 1.93 -0.28
Rab39b Ras-related protein Rab-39B 1.89 -0.23
Slc4a3 Anion exchange protein 3 1.80 -1.61
Akap1 A-kinase anchor protein 1, mitochondrial 1.79 -0.33
Rpl35a 60S ribosomal protein L35a 1.79 -0.20
Slc23a2 Solute carrier family 23 member 2 1.73 -1.12
Dtd1 D-aminoacyl-tRNA deacylase 1 1.72 -0.33
Hpf1 Histone PARylation factor 1 1.69 -0.48
Srrt Serrate RNA e!ector molecule homolog 1.69 -0.12
Chga Chromogranin-A 1.68 -0.40
Myo5b Unconventional myosin-Vb 1.67 -0.58
Crmp1 Dihydropyrimidinase-related protein 1 1.66 -0.21
Grk2 Beta-adrenergic receptor kinase 1 1.63 -0.45




Acp1 Low molecular weight phosphotyrosine protein phos-
phatase
1.60 -0.09
Snap91 Clathrin coat assembly protein AP180 1.58 -0.20
Pabpc1 Polyadenylate-binding protein 1 1.56 -0.11
Gphn Gephyrin 1.56 -0.20
Wdr18 WD repeat-containing protein 18 1.55 -0.17
Gpsm1 G-protein-signaling modulator 1 1.55 -0.17
Ddx39a ATP-dependent RNA helicase DDX39A 1.54 -0.22
Rabif Guanine nucleotide exchange factor MSS4 1.54 -0.42
Epm2aip1 EPM2A-interacting protein 1 1.52 -0.33
Bdnf Brain-derived neurotrophic factor 1.51 -1.45
Ankle2 Ankyrin repeat and LEM domain-containing protein
2
1.50 -0.51
Ica1 Islet cell autoantigen 1 1.50 -0.16
Mrpl17 39S ribosomal protein L17, mitochondrial 1.50 -1.75
Hcn3 Potassium/sodium hyperpolarization-activated
cyclic nucleotide-gated channel 3
1.49 -0.28
Atp6v1h V-type proton ATPase subunit H 1.48 -0.18
LXV








Pcyt2 Ethanolamine-phosphate cytidylyltransferase 1.48 -0.26
Arhgap26 Rho GTPase-activating protein 26 1.47 -0.99
Arid1a AT-rich interactive domain-containing protein 1A 1.44 -0.74
Tmem11 Transmembrane protein 11, mitochondrial 1.43 -0.45
Dpysl4 Dihydropyrimidinase-related protein 4 1.43 -0.21
Pithd1 PITH domain-containing protein 1 1.43 -0.96
Snrpb Small nuclear ribonucleoprotein-associated protein
B
1.41 -0.21
Ttc39b Tetratricopeptide repeat protein 39B 1.40 -1.04
Stambp STAM-binding protein 1.36 -0.15
Amacr Alpha-methylacyl-CoA racemase 1.35 -0.34
Atf2 Cyclic AMP-dependent transcription factor ATF-2 1.35 -0.72
Atp6v0a1 V-type proton ATPase 116 kDa subunit a isoform 1 1.35 -0.17
Kif5c Kinesin heavy chain isoform 5C 1.34 -0.13
Rimklb Beta-citrylglutamate synthase B 1.34 -0.46
Dnm1l Dynamin-1-like protein 1.33 -0.21
Slc8a1 Sodium/calcium exchanger 1 1.33 -0.18
Naa25 N-alpha-acetyltransferase 25, NatB auxiliary subunit 1.32 -0.17
Gnl1 Guanine nucleotide-binding protein-like 1 1.32 -0.17
Syncrip Heterogeneous nuclear ribonucleoprotein Q 1.31 -0.19
Specc1 Cytospin-B 1.31 -0.90
Dlgap1 Disks large-associated protein 1 3.23 0.57
Dpf2 Zinc finger protein ubi-d4 2.94 1.69
Ppfibp1 Liprin-beta-1 2.66 1.04
Becn1 Beclin-1 2.63 1.62
Scaf1 Splicing factor, arginine/serine-rich 19 2.54 2.16
Rhog Rho-related GTP-binding protein RhoG 2.42 0.54
Slc8a2 Sodium/calcium exchanger 2 2.32 0.27
Tmem70 Transmembrane protein 70, mitochondrial 2.16 1.23
Acyp1 Acylphosphatase-1 1.96 0.34
Srek1 Splicing regulatory glutamine/lysine-rich protein 1 1.94 1.83
Plcd4 1-phosphatidylinositol 4,5-bisphosphate phosphodi-
esterase delta-4
1.91 0.48
Lypla1 Acyl-protein thioesterase 1 1.83 0.37
Nelfcd Negative elongation factor D 1.81 1.26
Spats2l SPATS2-like protein 1.77 0.38












Brix1 Ribosome biogenesis protein BRX1 homolog 1.77 1.35
Dock7 Dedicator of cytokinesis protein 7 1.74 0.26
Septin7 Septin-7 1.72 0.16
Ttc39c Tetratricopeptide repeat protein 39C 1.72 0.33
Cdc42ep1 Cdc42 e!ector protein 1 1.7 1.76
Tmem175 Endosomal/lysosomal potassium channel TMEM175 1.69 1.37
Xrcc5 X-ray repair cross-complementing protein 5 1.68 2.21
Stk24 Serine/threonine-protein kinase 24 1.66 0.19
Clpp ATP-dependent Clp protease proteolytic subunit,
mitochondrial
1.65 0.23




Stim2 Stromal interaction molecule 2 1.62 1.44
Tpm4 Tropomyosin alpha-4 chain 1.59 0.66
Lbr Delta(14)-sterol reductase LBR 1.56 1.39
Fam20b Glycosaminoglycan xylosylkinase 1.55 0.29
Map4k3 Mitogen-activated protein kinase kinase kinase ki-
nase 3
1.53 0.51
Tst Thiosulfate sulfurtransferase 1.52 0.44
Recql ATP-dependent DNA helicase Q1 1.51 1.91
Dhfr Dihydrofolate reductase 1.5 0.24
Commd1 COMM domain-containing protein 1 1.48 1.79
Gng4 Guanine nucleotide-binding protein G(I)/G(S)/G(O)
subunit gamma-4
1.47 0.6
Otud6b Deubiquitinase OTUD6B 1.46 0.46
Jup Junction plakoglobin 1.45 0.22
Psmg3 Proteasome assembly chaperone 3 1.42 1.67
Fnbp1 Formin-binding protein 1 1.41 0.25
Rcn1 Reticulocalbin-1 1.4 0.29
Stk38 Serine/threonine-protein kinase 38 1.4 0.43
Mrpl50 39S ribosomal protein L50, mitochondrial 1.39 0.31
Smc2 Structural maintenance of chromosomes protein 2 1.39 3.1
Timm13 Mitochondrial import inner membrane translocase
subunit Tim13
1.38 0.22
Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 8, mitochondrial
1.38 0.31
Bet1l BET1-like protein 1.37 0.37
Map3k12 Mitogen-activated protein kinase kinase kinase 12 1.37 0.8
LXVII








Micu1 Calcium uptake protein 1, mitochondrial 1.36 0.3
Gltp Glycolipid transfer protein 1.36 0.36
Plekha2 Pleckstrin homology domain-containing family A
member 2
1.36 0.45
Spg7 Paraplegin 1.36 0.57
Cul1 Cullin-1 1.35 0.16
Rbm26 RNA-binding protein 26 1.34 0.22
Cpeb3 Cytoplasmic polyadenylation element-binding pro-
tein 3
1.34 0.95
Limch1 LIM and calponin homology domains-containing
protein 1
1.33 0.32
Tppp3 Tubulin polymerization-promoting protein family
member 3
1.32 0.22
Sorbs1 Sorbin and SH3 domain-containing protein 1 1.32 0.37
Strn3 Striatin-3 1.31 0.16
Table S4: Di!erentially expressed proteins in WT MNs after NAC treatment.
List of significantly changed proteins in WT MNs after NAC treatment (p < 0.05). Gene names, protein
names, p-values, and fold changes (FC) are listed. Proteins above the red line are down-regulated and







Dusp12 Dual specificity protein phosphatase 12 3.17 -1.2
Wdr26 WD repeat-containing protein 26 2.53 -0.28
Dipk1b Divergent protein kinase domain 1B 2.39 -0.8
Cyp46a1 Cholesterol 24-hydroxylase 2.39 -0.98
Atg5 Autophagy protein 5 2.31 -0.42
Washc4 WASH complex subunit 4 2.27 -0.83
Stat3 Signal transducer and activator of transcription 3 2.17 -0.81
Ap1s1 AP-1 complex subunit sigma-1A 1.95 -0.56
Clcn3 H(+)/Cl(-) exchange transporter 3 1.93 -0.43
Elp2 Elongator complex protein 2 1.92 -0.26
Astn2 Astrotactin-2 1.9 -1.12
Rabl6 Rab-like protein 6 1.89 -0.35
Pid1 PTB-containing, cubilin and LRP1-interacting pro-
tein
1.85 -0.4
Rack1 Receptor of activated protein C kinase 1 1.77 -0.18
Rab9a Ras-related protein Rab-9A 1.76 -0.37
Slk STE20-like serine/threonine-protein kinase 1.75 -0.74
LXVIII







Smarcb1 SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily B member 1
1.73 -0.23
Ddx3x ATP-dependent RNA helicase DDX3X 1.7 -0.12
Pum2 Pumilio homolog 2 1.68 -0.69
Kctd16 BTB/POZ domain-containing protein KCTD16 1.67 -0.6
Smyd3 Histone-lysine N-methyltransferase SMYD3 1.67 -0.71
Fyttd1 UAP56-interacting factor 1.65 -0.24
Dhx36 ATP-dependent DNA/RNA helicase DHX36 1.65 -0.55
Ppp2r5b Serine/threonine-protein phosphatase 2A 56 kDa
regulatory subunit beta isoform
1.63 -0.52
Eif4a1 Eukaryotic initiation factor 4A-I 1.6 -0.07
Sec24a Protein transport protein Sec24A 1.58 -0.32
Ctnnd2 Catenin delta-2 1.57 -0.27
Pygl Glycogen phosphorylase, liver form 1.57 -0.45
Cdc16 Cell division cycle protein 16 homolog 1.54 -0.14
Acot8 Acyl-coenzyme A thioesterase 8 1.54 -1.15
Cyp51a1 Lanosterol 14-alpha demethylase 1.53 -0.43
Snrpb2 U2 small nuclear ribonucleoprotein B” 1.52 -0.44
Lrrc47 Leucine-rich repeat-containing protein 47 1.5 -0.22
Mrpl45 39S ribosomal protein L45, mitochondrial 1.48 -0.29
Otud6b Deubiquitinase OTUD6B 1.46 -0.58
Rpl7a 60S ribosomal protein L7a 1.45 -0.21
Icam5 Intercellular adhesion molecule 5 1.45 -0.77
Grip1 Glutamate receptor-interacting protein 1 1.43 -0.38
Usp9x Probable ubiquitin carboxyl-terminal hydrolase FAF-
X
1.4 -0.23
Slc25a16 Graves disease carrier protein homolog 1.4 -1.2
Fcho2 F-BAR domain only protein 2 1.39 -1.5
Kif1bp KIF1-binding protein 1.38 -0.29
Emc7 ER membrane protein complex subunit 7 1.37 -0.28
Sar1b GTP-binding protein SAR1b 1.37 -0.34
Golga7 Golgin subfamily A member 7 1.37 -0.56
Gkap1 G kinase-anchoring protein 1 1.36 -0.83
Kif1b Kinesin-like protein KIF1B 1.35 -0.34
Sin3a Paired amphipathic helix protein Sin3a 1.35 -2.23
Rpl27a 60S ribosomal protein L27a 1.34 -0.26
Eif4a3 Eukaryotic initiation factor 4A-III 1.34 -0.37
Epb41l3 Band 4.1-like protein 3 1.32 -0.34
Dpm3 Dolichol-phosphate mannosyltransferase subunit 3 2.7 2.15
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Cuedc1 CUE domain-containing protein 1 2.43 0.51
Smndc1 Survival of motor neuron-related-splicing factor 30 2.32 0.4
Commd8 COMM domain-containing protein 8 2.32 0.41
Afg3l1 AFG3-like protein 1 2.25 0.49
Cyth2 Cytohesin-2 2.19 0.47
Rnpep Aminopeptidase B 2.16 0.19
Hdac4 Histone deacetylase 4 2.05 0.66
Bcap29 B-cell receptor-associated protein 29 2.03 0.37
Tomm20 Mitochondrial import receptor subunit TOM20
homolog
1.87 1.3
Adnp Activity-dependent neuroprotector homeobox pro-
tein
1.85 0.27
Cdkn1b Cyclin-dependent kinase inhibitor 1B 1.85 0.39
Arxes1 Adipocyte-related X-chromosome expressed se-
quence 1
1.81 0.27
Hba Hemoglobin subunit alpha 1.81 1.35
Usp47 Ubiquitin carboxyl-terminal hydrolase 47 1.8 0.2
Dennd5b DENN domain-containing protein 5B 1.78 1.07
Rad23a UV excision repair protein RAD23 homolog A 1.76 0.8




Ppm1l Protein phosphatase 1L 1.68 0.25
Gga3 ADP-ribosylation factor-binding protein GGA3 1.66 0.17
Hnrnpu Heterogeneous nuclear ribonucleoprotein U 1.6 0.14
Gnai2 Guanine nucleotide-binding protein G(i) subunit
alpha-2
1.59 0.29
Gpalpp1 GPALPP motifs-containing protein 1 1.59 0.81
Itsn1 Intersectin-1 1.58 0.12
Ano10 Anoctamin-10 1.56 0.29
Bbc3 Bcl-2-binding component 3 1.54 1.19
Mrps7 28S ribosomal protein S7, mitochondrial 1.53 0.27
Hist1h1d Histone H1.3 1.53 0.32
Hopx Homeodomain-only protein 1.53 1.09
Mtss1 Protein MTSS 1 1.52 0.48
Ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 8, mitochondrial
1.49 0.3
Asic1 Acid-sensing ion channel 1 1.49 0.76
Ndufab1 Acyl carrier protein, mitochondrial 1.48 0.25
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Cpsf2 Cleavage and polyadenylation specificity factor sub-
unit 2
1.48 1.36
Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 10, mitochondrial
1.45 0.18
Cog2 Conserved oligomeric Golgi complex subunit 2 1.45 0.19
Xpnpep1 Xaa-Pro aminopeptidase 1 1.44 0.13
Rictor Rapamycin-insensitive companion of mTOR 1.44 0.67
Ubac1 Ubiquitin-associated domain-containing protein 1 1.43 0.24
Lamtor3 Ragulator complex protein LAMTOR3 1.4 0.11
Mrto4 mRNA turnover protein 4 homolog 1.4 0.44
Fam98b Protein FAM98B 1.39 0.13
Snap29 Synaptosomal-associated protein 29 1.38 0.26
Cacna1b Voltage-dependent N-type calcium channel subunit
alpha-1B
1.38 0.79
Clcc1 Chloride channel CLIC-like protein 1 1.37 0.73
Kpna6 Importin subunit alpha-7 1.36 0.22
Ergic3 Endoplasmic reticulum-Golgi intermediate compart-
ment protein 3
1.35 0.18
Hccs Cytochrome c-type heme lyase 1.35 0.22
Mtrex Exosome RNA helicase MTR4 1.35 0.24
Stk24 Serine/threonine-protein kinase 24 1.35 0.33
Ptpn11 Tyrosine-protein phosphatase non-receptor type 11 1.32 0.26
Gas1 Growth arrest-specific protein 1 1.32 0.9
Lyplal1 Lysophospholipase-like protein 1 1.31 0.65
Table S5: Di!erentially expressed proteins in SMA MNs after NAC treatment.
List of significantly changed proteins in SMA MNs after NAC treatment (p < 0.05). Gene names, protein
names, p-values, and fold changes (FC) are listed. Proteins above the red line are down-regulated and







Slc25a25 Calcium-binding mitochondrial carrier protein
SCaMC-2
3.32 -0.35
Chordc1 Cysteine and histidine-rich domain-containing pro-
tein 1
3.11 -0.17
Luc7l2 Putative RNA-binding protein Luc7-like 2 2.89 -0.17
Arf2 ADP-ribosylation factor 2 2.63 -0.54
Exosc7 Exosome complex exonuclease RRP42 2.59 -0.62
Dmxl1 DmX-like protein 1 2.54 -2.27
Vmp1 Vacuole membrane protein 1 2.19 -0.35
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Thumpd3 THUMP domain-containing protein 3 2.18 -0.55
Lsm6 U6 snRNA-associated Sm-like protein LSm6 2.01 -0.58
Mob4 MOB-like protein phocein 1.95 -0.3
Eef1akmt1 EEF1A lysine methyltransferase 1 1.91 -0.34
Cops6 COP9 signalosome complex subunit 6 1.88 -0.23
Nop2 Probable 28S rRNA (cytosine-C(5))-
methyltransferase
1.88 -0.38
Ttc9c Tetratricopeptide repeat protein 9C 1.87 -0.18
Ankle2 Ankyrin repeat and LEM domain-containing protein
2
1.87 -0.23
Csnk1a1 Casein kinase I isoform alpha 1.87 -0.31




cyclic nucleotide-gated channel 3
1.83 -0.47
Timm8b Mitochondrial import inner membrane translocase
subunit Tim8 B
1.8 -0.38
Gspt1 Eukaryotic peptide chain release factor GTP-binding
subunit ERF3A
1.78 -0.16
Mrpl14 39S ribosomal protein L14, mitochondrial 1.77 -0.36
Sart1 U4/U6.U5 tri-snRNP-associated protein 1 1.77 -0.46
Ndnf Protein NDNF 1.77 -2.02
Tmem65 Transmembrane protein 65 1.75 -0.22
Manba Beta-mannosidase 1.75 -0.65
Cog8 Conserved oligomeric Golgi complex subunit 8 1.73 -0.94
Sh2d3c SH2 domain-containing protein 3C 1.73 -1.48
Fut8 Alpha-(1,6)-fucosyltransferase 1.72 -0.21
Hip1 Huntingtin-interacting protein 1 1.72 -0.37
Clcn6 Chloride transport protein 6 1.71 -0.34
Scn2a Sodium channel protein type 2 subunit alpha 1.71 -0.36
Rab39b Ras-related protein Rab-39B 1.7 -0.19
Nlgn1 Neuroligin-1 1.7 -0.87
Pde12 2’,5’-phosphodiesterase 12 1.69 -0.21
Ube2r2 Ubiquitin-conjugating enzyme E2 R2 1.69 -0.47
Qrich1 Glutamine-rich protein 1 1.66 -0.29
Nptx1 Neuronal pentraxin-1 1.66 -0.31
Tnrc6c Trinucleotide repeat-containing gene 6C protein 1.63 -1.84
Fyn Tyrosine-protein kinase Fyn 1.61 -0.29
Mink1 Misshapen-like kinase 1 1.61 -0.41
G3bp2 Ras GTPase-activating protein-binding protein 2 1.6 -0.36
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Kiaa2013 Uncharacterized protein KIAA2013 1.59 -2.05
Ints14 Integrator complex subunit 14 1.56 -0.4
Atl1 Atlastin-1 1.56 -0.41
Foxk2 Forkhead box protein K2 1.56 -1.17
Map1lc3a Microtubule-associated proteins 1A/1B light chain
3A
1.55 -0.4
Snrpg Small nuclear ribonucleoprotein G 1.55 -0.53
Snrpb Small nuclear ribonucleoprotein-associated protein
B
1.53 -0.22
Snx12 Sorting nexin-12 1.53 -0.43
Grk2 Beta-adrenergic receptor kinase 1 1.53 -0.56
Ahsa1 Activator of 90 kDa heat shock protein ATPase
homolog 1
1.52 -0.12
Armc10 Armadillo repeat-containing protein 10 1.52 -0.21
Pax2 Paired box protein Pax-2 1.52 -1.4
Isyna1 Inositol-3-phosphate synthase 1 1.51 -0.67
Arl5a ADP-ribosylation factor-like protein 5A 1.5 -0.27
Mllt11 Protein AF1q 1.49 -0.4
Gphn Gephyrin 1.48 -0.32
Trmt10c tRNA methyltransferase 10 homolog C 1.48 -0.5
Oscp1 Protein OSCP1 1.48 -0.52
NA Protein C8orf37 homolog 1.47 -0.35
Scn3b Sodium channel subunit beta-3 1.46 -0.39
Rabif Guanine nucleotide exchange factor MSS4 1.45 -0.33
Ppip5k2 Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 2
1.44 -0.36
Ybx1 Nuclease-sensitive element-binding protein 1 1.43 -0.25
Rab6a Ras-related protein Rab-6A 1.42 -0.33
Mtg1 Mitochondrial ribosome-associated GTPase 1 1.42 -0.54
Psmd1 26S proteasome non-ATPase regulatory subunit 1 1.41 -0.26
Cpne1 Copine-1 1.41 -0.29
Nedd4 E3 ubiquitin-protein ligase NEDD4 1.41 -0.33
Ubqln1 Ubiquilin-1 1.4 -0.2
Gar1 H/ACA ribonucleoprotein complex subunit 1 1.4 -0.58
Ano8 Anoctamin-8 1.4 -0.82
Rab10 Ras-related protein Rab-10 1.39 -0.22
Ddx5 Probable ATP-dependent RNA helicase DDX5 1.39 -0.25
Trim32 E3 ubiquitin-protein ligase TRIM32 1.39 -0.31
Cdv3 Protein CDV3 1.38 -0.24
Arid1a AT-rich interactive domain-containing protein 1A 1.38 -0.25
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Pabpc1 Polyadenylate-binding protein 1 1.36 -0.11
L1cam Neural cell adhesion molecule L1 1.36 -0.26
Pithd1 PITH domain-containing protein 1 1.36 -1.7
Trim67 Tripartite motif-containing protein 67 1.35 -0.3
Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mito-
chondrial
1.34 -0.26
Pacs2 Phosphofurin acidic cluster sorting protein 2 1.34 -0.28
Dclk1 Serine/threonine-protein kinase DCLK1 1.33 -0.2
Ggps1 Geranylgeranyl pyrophosphate synthase 1.33 -0.56
Ddx39a ATP-dependent RNA helicase DDX39A 1.32 -0.32
Pcyt2 Ethanolamine-phosphate cytidylyltransferase 1.32 -0.34
Tac1 Protachykinin-1 1.32 -1.33
Tbcb Tubulin-folding cofactor B 1.31 -0.18
Erc1 ELKS/Rab6-interacting/CAST family member 1 1.31 -0.36
Slc39a6 Zinc transporter ZIP6 1.31 -0.48
Mrps21 28S ribosomal protein S21, mitochondrial 2.84 0.38
Ttc39c Tetratricopeptide repeat protein 39C 2.79 0.32
Dhfr Dihydrofolate reductase 2.46 0.29
Gatd3a Glutamine amidotransferase-like class 1 domain-
containing protein 3A, mitochondrial
2.42 0.3
Fbxo2 F-box only protein 2 2.36 0.27
Ppfibp1 Liprin-beta-1 2.34 0.93
Ube3a Ubiquitin-protein ligase E3A 2.18 0.17
Sumo3 Small ubiquitin-related modifier 3 2.14 0.71
Pbdc1 Protein PBDC1 2.08 0.18
Rpl32 60S ribosomal protein L32 2.05 0.13
Tm7sf3 Transmembrane 7 superfamily member 3 1.99 0.69
Tle5 TLE family member 5 1.93 0.5
Hnrnpul1 Heterogeneous nuclear ribonucleoprotein U-like
protein 1
1.9 0.23
Rexo2 Oligoribonuclease, mitochondrial 1.86 0.32
Plekha2 Pleckstrin homology domain-containing family A
member 2
1.85 0.73
Skt Sickle tail protein 1.82 0.72
Mmaa Methylmalonic aciduria type A homolog, mitochon-
drial
1.81 0.63
Wdr33 pre-mRNA 3’ end processing protein WDR33 1.81 0.78
Rab1b Ras-related protein Rab-1B 1.8 0.59
Mrps5 28S ribosomal protein S5, mitochondrial 1.71 0.28
LXXIV







Psmg3 Proteasome assembly chaperone 3 1.7 0.94
Ntmt1 N-terminal Xaa-Pro-Lys N-methyltransferase 1 1.65 0.36
Tmsb10 Thymosin beta-10 1.62 0.73
Atrx Transcriptional regulator ATRX 1.6 0.46
Scaf1 Splicing factor, arginine/serine-rich 19 1.6 2.02
Adck1 Uncharacterized aarF domain-containing protein
kinase 1
1.57 0.12
Otud6b Deubiquitinase OTUD6B 1.57 0.27
Prpf3 U4/U6 small nuclear ribonucleoprotein Prp3 1.54 0.36
Lbr Delta(14)-sterol reductase LBR 1.54 1.64
Uchl1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 1.52 0.19
Cdc73 Parafibromin 1.52 0.67
Adgrg1 Adhesion G-protein coupled receptor G1 1.5 0.26
Ndufaf4 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex assembly factor 4
1.48 0.41
Bet1l BET1-like protein 1.47 0.39
Scrib Protein scribble homolog 1.47 0.55
Fam91a1 Protein FAM91A1 1.41 0.15
Adpgk ADP-dependent glucokinase 1.4 0.22
Rnf2 E3 ubiquitin-protein ligase RING2 1.4 0.39
Dmd Dystrophin 1.4 0.86
Slc8a2 Sodium/calcium exchanger 2 1.39 0.33
Lztfl1 Leucine zipper transcription factor-like protein 1 1.38 0.66
Ctsl Cathepsin L1 1.37 0.23
Mturn Maturin 1.37 2.11
Ciapin1 Anamorsin 1.35 0.39
Brix1 Ribosome biogenesis protein BRX1 homolog 1.35 1.17
Dock7 Dedicator of cytokinesis protein 7 1.33 0.09
Usp39 U4/U6.U5 tri-snRNP-associated protein 2 1.33 0.28
Lemd3 Inner nuclear membrane protein Man1 1.33 0.36
Cdc42ep1 Cdc42 e!ector protein 1 1.33 1.52
Bcs1l Mitochondrial chaperone BCS1 1.32 0.23
Ndufa5 NADH dehydrogenase [ubiquinone] 1 alpha subcom-
plex subunit 5
1.31 0.12
Tst Thiosulfate sulfurtransferase 1.31 0.42
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Table S6: Di!erentially expressed proteins in WT MNs after menadione treatment.
List of significantly changed proteins in WT MNs after menadione treatment (p < 0.05). Gene names,
protein names, p-values, and fold changes (FC) are listed. Proteins above the red line are down-regulated







Ptges3 Prostaglandin E synthase 3 4.35 -0.63
Fads1 Acyl-CoA (8-3)-desaturase 4.32 -0.75
Mta1 Metastasis-associated protein MTA1 4.19 -0.63
Srrm2 Serine/arginine repetitive matrix protein 2 3.89 -1.07
Poldip3 Polymerase delta-interacting protein 3 3.49 -0.39
Adnp Activity-dependent neuroprotector homeobox pro-
tein
3.35 -0.73
Kpna1 Importin subunit alpha-5 3.32 -0.36
Psd PH and SEC7 domain-containing protein 1 3.19 -0.75
Raf1 RAF proto-oncogene serine/threonine-protein kinase 3.16 -0.33
Ehmt1 Histone-lysine N-methyltransferase EHMT1 3.11 -1.57
Phf6 PHD finger protein 6 3.06 -1.21
Ecpas Proteasome adapter and sca!old protein ECM29 3.02 -0.37
Mpst 3-mercaptopyruvate sulfurtransferase 2.99 -0.71
Pelo Protein pelota homolog 2.96 -0.63
Gatad2b Transcriptional repressor p66-beta 2.9 -0.81
Smad1 Mothers against decapentaplegic homolog 1 2.89 -0.54
Atg12 Ubiquitin-like protein ATG12 2.87 -0.6
Mllt11 Protein AF1q 2.86 -1.11
Toe1 Target of EGR1 protein 1 2.84 -0.9
Dhx30 ATP-dependent RNA helicase DHX30 2.83 -0.29
Klhl22 Kelch-like protein 22 2.83 -0.46
Pcbp2 Poly(rC)-binding protein 2 2.7 -0.42
Son Protein SON 2.62 -1.3
Scrib Protein scribble homolog 2.61 -0.95
Usp9x Probable ubiquitin carboxyl-terminal hydrolase FAF-
X
2.6 -0.42
Dtx3 Probable E3 ubiquitin-protein ligase DTX3 2.58 -0.53
Nifk MKI67 FHA domain-interacting nucleolar phospho-
protein
2.58 -1.16
Fgf13 Fibroblast growth factor 13 2.53 -2.58
Cnot2 CCR4-NOT transcription complex subunit 2 2.43 -0.32
Csde1 Cold shock domain-containing protein E1 2.4 -0.28
Eif5a Eukaryotic translation initiation factor 5A-1 2.38 -0.29
Arhgef9 Rho guanine nucleotide exchange factor 9 2.38 -2.31
Adar Double-stranded RNA-specific adenosine deaminase 2.36 -0.97
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Cnot3 CCR4-NOT transcription complex subunit 3 2.34 -0.14
Rnf14 E3 ubiquitin-protein ligase RNF14 2.34 -0.38
Moap1 Modulator of apoptosis 1 2.32 -2.15
Nsun2 tRNA (cytosine(34)-C(5))-methyltransferase 2.31 -0.65
Tnpo3 Transportin-3 2.28 -0.41
Arhgap21 Rho GTPase-activating protein 21 2.27 -0.45
Fkbp5 Peptidyl-prolyl cis-trans isomerase FKBP5 2.26 -0.72
Fip1l1 Pre-mRNA 3’-end-processing factor FIP1 2.25 -0.29
Hoxb6 Homeobox protein Hox-B6 2.25 -0.72
Usp22 Ubiquitin carboxyl-terminal hydrolase 22 2.24 -1.17
Lyar Cell growth-regulating nucleolar protein 2.23 -1.5
Specc1 Cytospin-B 2.19 -1.23
Wdr11 WD repeat-containing protein 11 2.14 -0.23
Dstn Destrin 2.14 -0.35
Srgap1 SLIT-ROBO Rho GTPase-activating protein 1 2.14 -0.48
Trappc9 Tra"cking protein particle complex subunit 9 2.13 -0.31
Vps41 Vacuolar protein sorting-associated protein 41 ho-
molog
2.13 -0.39
Cdc23 Cell division cycle protein 23 homolog 2.13 -0.43
Nelfb Negative elongation factor B 2.11 -0.41
Mlf2 Myeloid leukemia factor 2 2.11 -0.64
Gdap2 Ganglioside-induced di!erentiation-associated pro-
tein 2
2.09 -0.37
Tpgs1 Tubulin polyglutamylase complex subunit 1 2.09 -0.87
Bsn Protein bassoon 2.08 -1.17
Cdk9 Cyclin-dependent kinase 9 2.07 -0.37
Glyr1 Putative oxidoreductase GLYR1 2.07 -0.52
Elavl1 ELAV-like protein 1 2.05 -0.31
Edc4 Enhancer of mRNA-decapping protein 4 2.03 -0.66
Pcbp1 Poly(rC)-binding protein 1 2.02 -0.46
Nup133 Nuclear pore complex protein Nup133 1.98 -0.2
Prickle2 Prickle-like protein 2 1.98 -1.13
Gnl3l Guanine nucleotide-binding protein-like 3-like pro-
tein
1.96 -1.86
Grip1 Glutamate receptor-interacting protein 1 1.95 -0.37
Hnrnpm Heterogeneous nuclear ribonucleoprotein M 1.92 -0.62
Pelp1 Proline-, glutamic acid- and leucine-rich protein 1 1.91 -0.32
Irf2bp1 Interferon regulatory factor 2-binding protein 1 1.9 -0.77
Macf1 Microtubule-actin cross-linking factor 1 1.89 -0.45
Zmym3 Zinc finger MYM-type protein 3 1.89 -0.68
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Ppp6c Serine/threonine-protein phosphatase 6 catalytic
subunit
1.88 -0.27
Mon2 Protein MON2 homolog 1.88 -0.3
Srrt Serrate RNA e!ector molecule homolog 1.88 -0.6
Ntrk3 NT-3 growth factor receptor 1.87 -1.59
Prpf40a Pre-mRNA-processing factor 40 homolog A 1.86 -0.33
Ncbp1 Nuclear cap-binding protein subunit 1 1.85 -0.39
Pogz Pogo transposable element with ZNF domain 1.85 -0.99
Smarcc2 SWI/SNF complex subunit SMARCC2 1.84 -0.36
U2af1 Splicing factor U2AF 35 kDa subunit 1.84 -0.52
Smarca2 Probable global transcription activator SNF2L2 1.82 -0.32
Nup43 Nucleoporin Nup43 1.82 -0.35
Hcfc1 Host cell factor 1 1.81 -0.38
Hnrnpa0 Heterogeneous nuclear ribonucleoprotein A0 1.81 -0.51
Zdhhc17 Palmitoyltransferase ZDHHC17 1.8 -0.18
Rmc1 Regulator of MON1-CCZ1 complex 1.79 -0.42
Ptprs Receptor-type tyrosine-protein phosphatase S 1.79 -0.6
Gprasp1 G-protein coupled receptor-associated sorting pro-
tein 1
1.78 -0.33
Scyl1 N-terminal kinase-like protein 1.78 -0.34
Aida Axin interactor, dorsalization-associated protein 1.77 -0.54
Afdn Afadin 1.76 -0.47
Crppa D-ribitol-5-phosphate cytidylyltransferase 1.76 -1.72
Oga Protein O-GlcNAcase 1.75 -0.27
Dnmt3a DNA (cytosine-5)-methyltransferase 3A 1.75 -0.61
Eml1 Echinoderm microtubule-associated protein-like 1 1.75 -0.77
Polr2a DNA-directed RNA polymerase II subunit RPB1 1.74 -1.58
Heatr5b HEAT repeat-containing protein 5B 1.73 -0.51
Tsc1 Hamartin 1.73 -0.54
Zmat3 Zinc finger matrin-type protein 3 1.73 -1.28
Hook3 Protein Hook homolog 3 1.72 -0.19
Pde4dip Myomegalin 1.72 -0.38
Sugt1 Protein SGT1 homolog 1.71 -0.17
Xpo5 Exportin-5 1.71 -0.49
Smad4 Mothers against decapentaplegic homolog 4 1.71 -0.53
Celf4 CUGBP Elav-like family member 4 1.71 -0.8
Fbxl20 F-box/LRR-repeat protein 20 1.71 -1.11
Camk2b Calcium/calmodulin-dependent protein kinase type
II subunit beta
1.7 -0.48
Glrx3 Glutaredoxin-3 1.69 -0.3
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Arl3 ADP-ribosylation factor-like protein 3 1.68 -0.27
Eif3m Eukaryotic translation initiation factor 3 subunit M 1.68 -0.36
Las1l Ribosomal biogenesis protein LAS1L 1.68 -1.17
Elmo1 Engulfment and cell motility protein 1 1.68 -4.94
Uros Uroporphyrinogen-III synthase 1.66 -0.35
Ntm Neurotrimin 1.66 -0.82
Vps33a Vacuolar protein sorting-associated protein 33A 1.65 -0.39
Dlg3 Disks large homolog 3 1.65 -0.61
Hnrnph2 Heterogeneous nuclear ribonucleoprotein H2 1.65 -0.62
Pcm1 Pericentriolar material 1 protein 1.65 -0.65
Map3k12 Mitogen-activated protein kinase kinase kinase 12 1.65 -1.5
Sart3 Squamous cell carcinoma antigen recognized by
T-cells 3
1.64 -0.51
Wdr13 WD repeat-containing protein 13 1.63 -0.24
Fads2 Acyl-CoA 6-desaturase 1.63 -0.43
Syt11 Synaptotagmin-11 1.63 -0.48
NA UPF0600 protein C5orf51 homolog 1.63 -0.51
Znf512 Zinc finger protein 512 1.63 -0.74
Rdh11 Retinol dehydrogenase 11 1.62 -0.26
Fam126b Protein FAM126B 1.62 -2.12
Smyd5 SET and MYND domain-containing protein 5 1.61 -0.38
Gtf2i General transcription factor II-I 1.61 -0.8
Eif4enif1 Eukaryotic translation initiation factor 4E trans-
porter
1.61 -1.19
Stat3 Signal transducer and activator of transcription 3 1.61 -1.19
Anp32e Acidic leucine-rich nuclear phosphoprotein 32 family
member E
1.6 -0.42
Pcbp4 Poly(rC)-binding protein 4 1.6 -0.64
Mmaa Methylmalonic aciduria type A homolog, mitochon-
drial
1.6 -0.92
Prkaa2 5’-AMP-activated protein kinase catalytic subunit
alpha-2
1.59 -0.13
Cbx3 Chromobox protein homolog 3 1.59 -0.19
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1.59 -0.34
Tardbp TAR DNA-binding protein 43 1.58 -0.51
Vcpip1 Deubiquitinating protein VCIP135 1.58 -0.55
Golga4 Golgin subfamily A member 4 1.58 -1.06
Prmt1 Protein arginine N-methyltransferase 1 1.56 -0.23
Dmac2l ATP synthase subunit s, mitochondrial 1.56 -0.25
Ctnnd2 Catenin delta-2 1.56 -0.29
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Mbd3 Methyl-CpG-binding domain protein 3 1.56 -0.87
Mcoln1 Mucolipin-1 1.56 -1.46
Dhx57 Putative ATP-dependent RNA helicase DHX57 1.55 -0.27
Stk39 STE20/SPS1-related proline-alanine-rich protein
kinase
1.55 -0.62
Txndc17 Thioredoxin domain-containing protein 17 1.54 -0.32
Mark2 Serine/threonine-protein kinase MARK2 1.54 -0.61
Vim Vimentin 1.54 -2.1
Vps28 Vacuolar protein sorting-associated protein 28 ho-
molog
1.53 -0.36
Metap1 Methionine aminopeptidase 1 1.52 -0.2
Fndc3a Fibronectin type-III domain-containing protein 3A 1.52 -0.31
Camk2g Calcium/calmodulin-dependent protein kinase type
II subunit gamma
1.52 -0.37
Bcr Breakpoint cluster region protein 1.52 -0.45
Diaph1 Protein diaphanous homolog 1 1.51 -0.37
Prkar1a cAMP-dependent protein kinase type I-alpha regula-
tory subunit
1.5 -0.24
Park7 Protein/nucleic acid deglycase DJ-1 1.5 -0.27
Aarsd1 Alanyl-tRNA editing protein Aarsd1 1.49 -0.35
Sst Somatostatin 1.49 -0.35
Sh2b1 SH2B adapter protein 1 1.48 -0.56
Afap1 Actin filament-associated protein 1 1.48 -0.57
Syngap1 Ras/Rap GTPase-activating protein SynGAP 1.48 -0.64
Lrrc58 Leucine-rich repeat-containing protein 58 1.48 -0.93
Pclo Protein piccolo 1.48 -1.09
Fry Protein furry homolog 1.47 -0.39
Ltn1 E3 ubiquitin-protein ligase listerin 1.47 -0.43
Hnrnpll Heterogeneous nuclear ribonucleoprotein L-like 1.47 -0.48
Rims1 Regulating synaptic membrane exocytosis protein 1 1.47 -0.76
Vps18 Vacuolar protein sorting-associated protein 18 ho-
molog
1.46 -0.44
Snu13 NHP2-like protein 1 1.46 -0.51
Ppp1cc Serine/threonine-protein phosphatase PP1-gamma
catalytic subunit
1.45 -0.09
Tex10 Testis-expressed protein 10 1.45 -0.15
Agfg2 Arf-GAP domain and FG repeat-containing protein
2
1.45 -0.29
Camsap1 Calmodulin-regulated spectrin-associated protein 1 1.45 -0.48
Cep170b Centrosomal protein of 170 kDa protein B 1.45 -0.65
LXXX







Limk1 LIM domain kinase 1 1.45 -0.74
Sbf2 Myotubularin-related protein 13 1.45 -0.85
Tox4 TOX high mobility group box family member 4 1.45 -1.05
Mycbp2 E3 ubiquitin-protein ligase MYCBP2 1.44 -0.31
Apc Adenomatous polyposis coli protein 1.44 -0.42
Rasgrp2 RAS guanyl-releasing protein 2 1.44 -0.5
Spire1 Protein spire homolog 1 1.44 -1.28
Sae1 SUMO-activating enzyme subunit 1 1.43 -0.21
Camk2a Calcium/calmodulin-dependent protein kinase type
II subunit alpha
1.43 -0.32
Bcas3 Breast carcinoma-amplified sequence 3 homolog 1.43 -0.36
Fbll1 rRNA/tRNA 2’-O-methyltransferase fibrillarin-like
protein 1
1.43 -0.67
Arih1 E3 ubiquitin-protein ligase ARIH1 1.42 -0.32
Ethe1 Persulfide dioxygenase ETHE1, mitochondrial 1.42 -0.42
Eif2s3x Eukaryotic translation initiation factor 2 subunit 3,
X-linked
1.41 -0.27
Rell2 RELT-like protein 2 1.41 -1.19
Fbxw11 F-box/WD repeat-containing protein 11 1.4 -0.25
Reps1 RalBP1-associated Eps domain-containing protein 1 1.4 -0.29
Fahd1 Acylpyruvase FAHD1, mitochondrial 1.4 -0.35
Trim28 Transcription intermediary factor 1-beta 1.4 -0.39
Hnrnph1 Heterogeneous nuclear ribonucleoprotein H 1.4 -0.53
Ddx20 Probable ATP-dependent RNA helicase DDX20 1.4 -1.35
Cyp46a1 Cholesterol 24-hydroxylase 1.39 -0.56
Rtcb tRNA-splicing ligase RtcB homolog 1.38 -0.13
Srpk1 SRSF protein kinase 1 1.38 -0.22




Mtg1 Mitochondrial ribosome-associated GTPase 1 1.38 -1.16
Hnrnpu Heterogeneous nuclear ribonucleoprotein U 1.37 -0.2
Pdlim7 PDZ and LIM domain protein 7 1.37 -1.13
Ablim3 Actin-binding LIM protein 3 1.37 -1.59
Med22 Mediator of RNA polymerase II transcription sub-
unit 22
1.37 -2.97
Ctnnd1 Catenin delta-1 1.36 -0.48
Ppp2r5b Serine/threonine-protein phosphatase 2A 56 kDa
regulatory subunit beta isoform
1.36 -0.51
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Ankmy2 Ankyrin repeat and MYND domain-containing pro-
tein 2
1.36 -0.53
Slc30a1 Zinc transporter 1 1.35 -0.31
Sh3pxd2b SH3 and PX domain-containing protein 2B 1.35 -0.42
Zfand5 AN1-type zinc finger protein 5 1.35 -0.54
Dynlt3 Dynein light chain Tctex-type 3 1.34 -0.34
Dus3l tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-
like
1.34 -0.47
Iqsec1 IQ motif and SEC7 domain-containing protein 1 1.34 -0.48
Anp32b Acidic leucine-rich nuclear phosphoprotein 32 family
member B
1.34 -0.58
Trmt6 tRNA (adenine(58)-N(1))-methyltransferase non-
catalytic subunit TRM6
1.33 -0.2
Tra2a Transformer-2 protein homolog alpha 1.33 -0.28
Yy1 Transcriptional repressor protein YY1 1.33 -0.49
Ostf1 Osteoclast-stimulating factor 1 1.33 -0.53
Wasl Neural Wiskott-Aldrich syndrome protein 1.33 -1.08
Polr2c DNA-directed RNA polymerase II subunit RPB3 1.32 -0.3
Uba6 Ubiquitin-like modifier-activating enzyme 6 1.31 -0.29
Tbce Tubulin-specific chaperone E 1.31 -0.3
Aip AH receptor-interacting protein 1.31 -0.4
Actr1b Beta-centractin 3.09 0.46
Cox6b1 Cytochrome c oxidase subunit 6B1 2.9 0.24
Mrpl15 39S ribosomal protein L15, mitochondrial 2.9 0.27
Spcs2 Signal peptidase complex subunit 2 2.86 0.52
Arxes1 Adipocyte-related X-chromosome expressed se-
quence 1
2.85 0.44
Rbbp6 E3 ubiquitin-protein ligase RBBP6 2.64 1.23
Mrpl12 39S ribosomal protein L12, mitochondrial 2.43 0.25
Zdhhc5 Palmitoyltransferase ZDHHC5 2.41 1.54
Ckap4 Cytoskeleton-associated protein 4 2.32 0.3
Mtch2 Mitochondrial carrier homolog 2 2.28 0.29
Tmed10 Transmembrane emp24 domain-containing protein
10
2.17 0.23
Dnajc11 DnaJ homolog subfamily C member 11 2.16 0.28
Adgrb1 Adhesion G protein-coupled receptor B1 2.16 0.8
Ganab Neutral alpha-glucosidase AB 2.15 0.23












Slc25a20 Mitochondrial carnitine/acylcarnitine carrier protein 2.09 0.22
Vti1a Vesicle transport through interaction with t-
SNAREs homolog 1A
2.08 0.33
Hspe1 10 kDa heat shock protein, mitochondrial 2.07 0.19
Ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 8, mitochondrial
2.05 0.36
Cttn Src substrate cortactin 2.04 0.3
Canx Calnexin 2.02 0.2
Thtpa Thiamine-triphosphatase 2.0 0.6
Tfam Transcription factor A, mitochondrial 1.97 0.25




Fh Fumarate hydratase, mitochondrial 1.96 0.27
Arg2 Arginase-2, mitochondrial 1.96 0.87
Cpd Carboxypeptidase D 1.92 0.33
Nufip2 Nuclear fragile X mental retardation-interacting
protein 2
1.91 0.22
Tmed4 Transmembrane emp24 domain-containing protein 4 1.91 0.36
Dhodh Dihydroorotate dehydrogenase (quinone), mitochon-
drial
1.86 0.21
Rps7 40S ribosomal protein S7 1.84 0.19
Kpnb1 Importin subunit beta-1 1.83 0.19
Spcs3 Signal peptidase complex subunit 3 1.83 0.2
Grpel1 GrpE protein homolog 1, mitochondrial 1.79 0.19
Rps19 40S ribosomal protein S19 1.78 0.21
Emc7 ER membrane protein complex subunit 7 1.77 0.28
Mars Methionine–tRNA ligase, cytoplasmic 1.76 0.18
Lzic Protein LZIC 1.76 0.32
Impa1 Inositol monophosphatase 1 1.75 0.2
Snrpd3 Small nuclear ribonucleoprotein Sm D3 1.74 0.16
Gpr107 Protein GPR107 1.72 0.59
Svop Synaptic vesicle 2-related protein 1.72 0.77
Eif2s1 Eukaryotic translation initiation factor 2 subunit 1 1.71 0.17
Rwdd1 RWD domain-containing protein 1 1.7 0.24
Sec11a Signal peptidase complex catalytic subunit SEC11A 1.7 0.34
Uqcrb Cytochrome b-c1 complex subunit 7 1.69 0.28
Pcyox1 Prenylcysteine oxidase 1.69 0.31
Afg3l1 AFG3-like protein 1 1.69 0.33
Afg3l2 AFG3-like protein 2 1.67 0.1
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Vdac1 Voltage-dependent anion-selective channel protein 1 1.66 0.18
Ppm1f Protein phosphatase 1F 1.66 0.51
Chmp2a Charged multivesicular body protein 2a 1.65 0.27
Atp5mg ATP synthase subunit g, mitochondrial 1.65 0.35
Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 1.65 0.49
Fgd5 FYVE, RhoGEF and PH domain-containing protein
5
1.64 0.79
Lrrc59 Leucine-rich repeat-containing protein 59 1.63 0.17
Ndufc2 NADH dehydrogenase [ubiquinone] 1 subunit C2 1.63 0.23
Usp39 U4/U6.U5 tri-snRNP-associated protein 2 1.63 0.33
Glg1 Golgi apparatus protein 1 1.61 0.26
Crkl Crk-like protein 1.61 0.29
M6pr Cation-dependent mannose-6-phosphate receptor 1.61 0.36
Ergic3 Endoplasmic reticulum-Golgi intermediate compart-
ment protein 3
1.6 0.25
Slc4a3 Anion exchange protein 3 1.6 1.1
Pdia3 Protein disulfide-isomerase A3 1.58 0.2
Ndufs6 NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 6, mitochondrial
1.57 0.23
Ndufb10 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 10
1.55 0.23
Kif5b Kinesin-1 heavy chain 1.54 0.17
Nap1l4 Nucleosome assembly protein 1-like 4 1.51 0.16
Pdia6 Protein disulfide-isomerase A6 1.51 0.17
Pgm1 Phosphoglucomutase-1 1.51 0.2
Cdkn1a Cyclin-dependent kinase inhibitor 1 1.51 0.91
Cpsf2 Cleavage and polyadenylation specificity factor sub-
unit 2
1.51 1.35
Wdr1 WD repeat-containing protein 1 1.5 0.18




Rpl12 60S ribosomal protein L12 1.49 0.18
Snap29 Synaptosomal-associated protein 29 1.49 0.25
Sod2 Superoxide dismutase [Mn], mitochondrial 1.48 0.24
Ano10 Anoctamin-10 1.48 0.27
Mrpl22 39S ribosomal protein L22, mitochondrial 1.48 0.34
Timm44 Mitochondrial import inner membrane translocase
subunit TIM44
1.47 0.19
Arpc5 Actin-related protein 2/3 complex subunit 5 1.47 0.26
LXXXIV







Atp5f1c ATP synthase subunit gamma, mitochondrial 1.46 0.24
Prpsap2 Phosphoribosyl pyrophosphate synthase-associated
protein 2
1.46 0.24
Mpc1 Mitochondrial pyruvate carrier 1 1.45 0.52
Atp1a1 Sodium/potassium-transporting ATPase subunit
alpha-1
1.44 0.24




Lemd2 LEM domain-containing protein 2 1.43 0.32
Micos10 MICOS complex subunit Mic10 1.43 0.36
Timm13 Mitochondrial import inner membrane translocase
subunit Tim13
1.42 0.22
Bclaf1 Bcl-2-associated transcription factor 1 1.42 0.25
Alg9 Alpha-1,2-mannosyltransferase ALG9 1.42 0.33
Cacnb1 Voltage-dependent L-type calcium channel subunit
beta-1
1.42 1.31
Cops4 COP9 signalosome complex subunit 4 1.41 0.16
Ppm1l Protein phosphatase 1L 1.4 0.27
Abcb10 ATP-binding cassette sub-family B member 10,
mitochondrial
1.4 0.9
Gpaa1 Glycosylphosphatidylinositol anchor attachment 1
protein
1.38 0.47
Rack1 Receptor of activated protein C kinase 1 1.37 0.15
Rpl5 60S ribosomal protein L5 1.37 0.18
Reep5 Receptor expression-enhancing protein 5 1.37 0.3
Ociad1 OCIA domain-containing protein 1 1.37 0.32
Zpr1 Zinc finger protein ZPR1 1.36 0.06
Rap1a Ras-related protein Rap-1A 1.35 0.18
Os9 Protein OS-9 1.35 0.34
Adpgk ADP-dependent glucokinase 1.35 0.36
Ndufb5 NADH dehydrogenase [ubiquinone] 1 beta subcom-
plex subunit 5, mitochondrial
1.34 0.31




transferase 48 kDa subunit
1.33 0.32
Srsf1 Serine/arginine-rich splicing factor 1 1.33 0.33
Prkcsh Glucosidase 2 subunit beta 1.32 0.18
Phb2 Prohibitin-2 1.32 0.22
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Sppl2b Signal peptide peptidase-like 2B 1.32 1.37
Pa2g4 Proliferation-associated protein 2G4 1.31 0.13
Por NADPH–cytochrome P450 reductase 1.31 0.24
Atp5f1d ATP synthase subunit delta, mitochondrial 1.31 0.28
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